<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacotherapy for social anxiety disorder (SAnD) - Williams, T - 2017 | Cochrane Library</title> <meta content="Pharmacotherapy for social anxiety disorder (SAnD) - Williams, T - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001206.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacotherapy for social anxiety disorder (SAnD) - Williams, T - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001206.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001206.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacotherapy for social anxiety disorder (SAnD)" name="citation_title"/> <meta content="Taryn Williams" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Coenie J Hattingh" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Catherine M Kariuki" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Sean A Tromp" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Anton J van Balkom" name="citation_author"/> <meta content="VU‐University Medical Centre and GGZ inGeest" name="citation_author_institution"/> <meta content="Jonathan C Ipser" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="Dan J Stein" name="citation_author"/> <meta content="University of Cape Town" name="citation_author_institution"/> <meta content="dan.stein@uct.ac.za" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD001206.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/10/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001206.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001206.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001206.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [therapeutic use]; Chronic Disease; Monoamine Oxidase Inhibitors [therapeutic use]; Phobia, Social [*drug therapy]; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors [therapeutic use]; Serotonin and Noradrenaline Reuptake Inhibitors [therapeutic use]; Venlafaxine Hydrochloride [therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001206.pub3&amp;doi=10.1002/14651858.CD001206.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="STpJR8yz";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001206\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001206\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","pt","ms","hr","fr","zh_HANS","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001206.pub3",title:"Pharmacotherapy for social anxiety disorder (SAnD)",firstPublishedDate:"Oct 19, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Common Mental Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001206.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001206.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001206.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001206.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001206.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001206.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pt&quot;,&quot;title&quot;:&quot;Resumo para leigos&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001206.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001206.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001206.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001206.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>15388 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001206.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-abs-0003"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-sec-0147"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-sec-0015"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-sec-0016"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-sec-0022"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-sec-0064"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-sec-0139"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/appendices#CD001206-sec-0152"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/table_n/CD001206StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/table_n/CD001206StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacotherapy for social anxiety disorder (SAnD)</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information#CD001206-cr-0002">Taryn Williams</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information#CD001206-cr-0003">Coenie J Hattingh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information#CD001206-cr-0004">Catherine M Kariuki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information#CD001206-cr-0005">Sean A Tromp</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information#CD001206-cr-0006">Anton J van Balkom</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information#CD001206-cr-0007">Jonathan C Ipser</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information#CD001206-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Dan J Stein</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information/en#CD001206-sec-0172">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 October 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001206.pub3">https://doi.org/10.1002/14651858.CD001206.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001206-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001206-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001206-abs-0002">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001206-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001206-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001206-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001206-abs-0001" lang="en"> <section id="CD001206-sec-0001"> <h3 class="title" id="CD001206-sec-0001">Background</h3> <p>Recognition is growing that social anxiety disorder (SAnD) is a chronic and disabling disorder, and data from early trials demonstrate that medication may be effective in its treatment. This systematic review is an update of an earlier review of pharmacotherapy of SAnD. </p> </section> <section id="CD001206-sec-0002"> <h3 class="title" id="CD001206-sec-0002">Objectives</h3> <p>To assess the effects of pharmacotherapy for social anxiety disorder in adults and identify which factors (methodological or clinical) predict response to treatment. </p> </section> <section id="CD001206-sec-0003"> <h3 class="title" id="CD001206-sec-0003">Search methods</h3> <p>We searched the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR‐Studies and CCMDCTR‐References) to 17 August 2015. The CCMDCTR contains reports of relevant RCTs from MEDLINE (1950‐), Embase (1974‐), PsycINFO (1967‐) and CENTRAL (all years). We scanned the reference lists of articles for additional studies. We updated the search in August 2017 and placed additional studies in Awaiting Classification, these will be incorporated in the next version of the review, as appropriate. </p> </section> <section id="CD001206-sec-0004"> <h3 class="title" id="CD001206-sec-0004">Selection criteria</h3> <p>We restricted studies to randomised controlled trials (RCTs) of pharmacotherapy versus placebo in the treatment of SAnD in adults. </p> </section> <section id="CD001206-sec-0005"> <h3 class="title" id="CD001206-sec-0005">Data collection and analysis</h3> <p>Two authors (TW and JI) assessed trials for eligibility and inclusion for this review update. We extracted descriptive, methodological and outcome information from each trial, contacting investigators for missing information where necessary. We calculated summary statistics for continuous and dichotomous variables (if provided) and undertook subgroup and sensitivity analyses. </p> </section> <section id="CD001206-sec-0006"> <h3 class="title" id="CD001206-sec-0006">Main results</h3> <p>We included 66 RCTs in the review (&gt; 24 weeks; 11,597 participants; age range 18 to 70 years) and 63 in the meta‐analysis. For the primary outcome of treatment response, we found very low‐quality evidence of treatment response for selective serotonin reuptake inhibitors (SSRIs) compared with placebo (number of studies (k) = 24, risk ratio (RR) 1.65; 95% confidence interval (CI) 1.48 to 1.85, N = 4984). On this outcome there was also evidence of benefit for monoamine oxidase inhibitors (MAOIs) (k = 4, RR 2.36; 95% CI 1.48 to 3.75, N = 235), reversible inhibitors of monoamine oxidase A (RIMAs) (k = 8, RR 1.83; 95% CI 1.32 to 2.55, N = 1270), and the benzodiazepines (k = 2, RR 4.03; 95% CI 2.45 to 6.65, N = 132), although the evidence was low quality. We also found clinical response for the anticonvulsants with gamma‐amino butyric acid (GABA) analogues (k = 3, RR 1.60; 95% CI 1.16 to 2.20, N = 532; moderate‐quality evidence). The SSRIs were the only medication proving effective in reducing relapse based on moderate‐quality evidence. We assessed the SSRIs and the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine on the basis of treatment withdrawal; this was higher for medication than placebo (SSRIs: k = 24, RR 2.59; 95% CI 1.97 to 3.39, N = 5131, low‐quality evidence; venlafaxine: k = 4, RR 3.23; 95% CI 2.15 to 4.86, N = 1213, moderate‐quality evidence), but there were low absolute rates of withdrawal for both these medications classes compared to placebo. We did not find evidence of a benefit for the rest of the medications compared to placebo. </p> <p>For the secondary outcome of SAnD symptom severity, there was benefit for the SSRIs, the SNRI venlafaxine, MAOIs, RIMAs, benzodiazepines, the antipsychotic olanzapine, and the noradrenergic and specific serotonergic antidepressant (NaSSA) atomoxetine in the reduction of SAnD symptoms, but most of the evidence was of very low quality. Treatment with SSRIs and RIMAs was also associated with a reduction in depression symptoms. The SSRIs were the only medication class that demonstrated evidence of reduction in disability across a number of domains. </p> <p>We observed a response to long‐term treatment with medication for the SSRIs (low‐quality evidence), for the MAOIs (very low‐quality evidence) and for the RIMAs (moderate‐quality evidence). </p> </section> <section id="CD001206-sec-0007"> <h3 class="title" id="CD001206-sec-0007">Authors' conclusions</h3> <p>We found evidence of treatment efficacy for the SSRIs, but it is based on very low‐ to moderate‐quality evidence. Tolerability of SSRIs was lower than placebo, but absolute withdrawal rates were low. </p> <p>While a small number of trials did report treatment efficacy for benzodiazepines, anticonvulsants, MAOIs, and RIMAs, readers should consider this finding in the context of potential for abuse or unfavourable side effects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001206-abs-0003" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001206-abs-0003">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001206-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001206-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001206-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001206-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001206-abs-0005">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pt#CD001206-abs-0004">Português</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001206-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001206-abs-0003" lang="en"> <h3>Medication for social anxiety disorder (SAnD): a review of the evidence</h3> <p><b>Why is this review important?</b> </p> <p>Individuals with SAnD often experience intense fear, avoidance, and distress in unfamiliar social situations. There is evidence that medications are useful in minimising these symptoms. </p> <p><b>Who will be interested in this review?</b> </p> <p>‐ People with SAnD.</p> <p>‐ Families and friends of people who suffer from anxiety disorders.</p> <p>‐ General practitioners, psychiatrists, psychologists, and pharmacists.</p> <p><b>What questions does this review aim to answer?</b> </p> <p>‐ Is pharmacotherapy an effective form of treatment for SAnD in adults?</p> <p>‐ Is medication effective and tolerable for people in terms of side effects?</p> <p>‐ Which factors (methodological or clinical) predict response to pharmacotherapy?</p> <p><b>Which studies were included in the review?</b> </p> <p>We included studies comparing medication with placebo for the treatment of SAnD in adults. </p> <p>We included 66 trials in the review, with a total of 11,597 participants.</p> <p><b>What does the evidence from the review tell us?</b> </p> <p>There was evidence of benefit that selective serotonin reuptake inhibitors (SSRIs) were more effective than placebo, although the evidence was of very low quality. There was also evidence of benefit for monoamine oxidase inhibitors (MAOIs), reversible inhibitors of monoamine oxidase A (RIMAs), and benzodiazepines, even though the evidence was low in quality. The anticonvulsants gabapentin and pregabalin also showed moderate‐quality evidence of a clinical response. We did not observe this effect for the remaining medication classes. The SSRIs were the only medication proving effective in reducing relapse based on moderate‐quality evidence. There was low‐quality evidence that more people taking SSRIs and SNRIs dropped out due to side effects than those taking placebo, but absolute withdrawal rates were low. </p> <p>For the outcome of SAnD symptom severity, there was evidence of benefit for SSRIs, the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine, MAOIs, RIMAs, benzodiazepines, the antipsychotic olanzapine, and the noradrenergic and specific serotonergic antidepressant (NaSSA) atomoxetine, but most of the evidence was of very low quality. SSRIs and RIMAs reduced depression symptoms, and SSRIs reduced functional disability across all domains. </p> <p>We also observed response to long‐term treatment with SSRIs (based on low‐quality evidence), MAOIs (based on very low‐quality evidence), and RIMAs (based on moderate‐quality evidence). </p> <p><b>What should happen next?</b> </p> <p>Most evidence for treatment efficacy is related to SSRIs. Nevertheless, SSRI trials were associated with very low‐quality evidence and high risk of publication bias. It would be useful for future studies to evaluate the treatment of SAnD in people with comorbid disorders, including substance use disorders. Trials that provide adequate information on randomisation and allocation concealment are needed. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001206-sec-0147" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001206-sec-0147"></div> <h3 class="title" id="CD001206-sec-0148">Implications for practice</h3> <section id="CD001206-sec-0148"> <p>Medication can be effective for the treatment of SAnD, with higher rates of treatment response compared to placebo, as well as reductions in core SAnD symptoms and associated disability. Most evidence of efficacy in this review was for the SSRIs. Although there was evidence that treatment with SSRIs was less tolerable than placebo, the absolute proportions of participants withdrawing due to drug‐related adverse events after treatment with these agents were small (&lt; 17%). Moreover, the SSRIs were the only medication class that demonstrated consistent evidence of reductions in functional disability across a number of domains. The possible influence of publication bias on the validity of conclusions regarding the efficacy overall, and the SSRIs in particular, in treating SAnD, as well as the potential risk of bias for this outcome, needs to be acknowledged. This review also found preliminary evidence to support the use of the anticonvulsants/GABAs in treating SAnD. Readers should exercise great caution in making any inferences about the experimental agents GW876008 and NK1 receptor antagonist GR205171; more trials with each of these agents in the future may allow better comparison of classes of medication. </p> <p>Treatment efficacy of medication was significantly larger in trials conducted at single centres than multiple centres, as well as when administered to participants described as being diagnosed with generalised SAnD. The findings that both RIMAs and benzodiazepines were efficacious and tolerable in treating SAnD therefore needs to be interpreted in light of the observation that none of the included trials for these medications reported restricting inclusion to the generalised SAnD subtype. Moreover, the RIMAs are not available in clinical practice, while findings from the small number of trials of benzodiazepines must be weighed against concerns regarding their adverse effects and their lack efficacy for common comorbid conditions that occur with SAnD (<a href="./references#CD001206-bbs2-0189" title="FordC , LawF . Guidance for the use and reduction of misuse of benzodiazepines and other hypnotics and anxiolytics in general practice. www.emcdda.europa.eu/attachements.cfm/att_248926_EN_UK59_benzos (accessed prior to 26 July 2017). ">Ford 2014</a>; <a href="./references#CD001206-bbs2-0207" title="LicataSC , RowlettJK . Abuse and dependence liability of benzodiazepine‐type drugs: GABAA receptor modulation and beyond. Pharmacology Biochemistry &amp; Behavior2008;90(1):74–89. ">Licata 2008</a>). </p> <p>Trials took place in a diverse range of settings and with heterogenous samples and should therefore currently be considered in a broad spectrum of SAnD participants. Nevertheless, we recognise that certain forms of the disorder, such as those consisting of 'pure' public speaking fears, were not well represented in this review. We observed continued response to medication in trials extending beyond 12 weeks in duration, supporting the consensus that medication responders should continue to be treated over the long term. Although beta‐blockers are often recommended for the treatment of performance anxiety, there was insufficient evidence in this review to support the use of this medication class for people without the generalised type of SAnD. </p> </section> <h3 class="title" id="CD001206-sec-0149">Implications for research</h3> <section id="CD001206-sec-0149"> <p>Differences in the efficacy of different medications deserve more attention; there are few studies directly comparing modern agents with one another. In addition, there is a paucity of RCTs evaluating the efficacy of medications for treating SAnD in people with comorbid disorders, including substance use disorders, and in people in general psychiatric and medical settings. Studies of these populations could address the question of whether early and robust pharmacotherapy of SAnD can prevent subsequent morbidity and comorbidity. Further attention should also be paid to people who fall on a putative SAnD spectrum of disorders, including people with performance anxiety. Finally, commonly used symptom outcomes in SAnD have limitations, with more refined measures of response to treatment warranting further investigation. This would help inform the concept of remission in SAnD. </p> <p>Additional work is also needed to determine the best approach to people who fail to respond to pharmacotherapy; there are relatively few studies of treatment augmentation (<a href="./references#CD001206-bbs2-0201" title="IpserJC , SanderC , SeifanA , SteinDJ . Augmentation of psychotherapy with d‐cycloserine for anxiety disorders. Cochrane Database of Systematic Reviews2009, Issue 2. [DOI: 10.1002/14651858.CD007803] ">Ipser 2009b</a>; <a href="./references#CD001206-bbs2-0119" title="PecknoldJC , McClureDJ , AppeltauerL , AllanT , WrzesinskiL . Does tryptophan potentiate clomipramine in the treatment of agoraphobic and agoraphobic and social phobic patients. British Journal of Psychiatry1982;140:484‐90. ">Pecknold 1982</a>; <a href="./references#CD001206-bbs2-0232" title="VanAmeringenM , ManciniC , WilsonC . Busiprone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. Journal of Affective Disorders1996;39(2):115‐21. ">Van Ameringen 1996</a>; <a href="./references#CD001206-bbs2-0224" title="SteinMB , SareenJ , HamiS , ChaoJ . Pindolol potentiation of paroxetine for generalized social phobia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(10):1725‐7. ">Stein 2001</a>; <a href="./references#CD001206-bbs2-0155" title="AarreTF . Phenelzine efficacy in refractory social anxiety disorder: a case series. Nordic Journal of Psychiatry2003;57(4):313‐5. ">Aarre 2003</a>) or pharmacotherapy switching (<a href="./references#CD001206-bbs2-0203" title="KelseyJE . Venalafaxine in social phobia. Psychopharmacology Bulletin1995;31(4):767‐71. ">Kelsey 1995</a>). The current review also does not directly address the question of whether pharmacotherapy or psychotherapy has a larger effect size in SAnD (<a href="./references#CD001206-bbs2-0193" title="GouldRA , BuckministerS , PollackMH , OttoMW , YapL . Cognitive‐behavioral and pharmacological treatments of social phobia. Clinical Psychology ‐ Science &amp; Practice1997;4(4):291‐306. ">Gould 1997</a>). In clinical practice, clinicians often use exposure instructions (<a href="./references#CD001206-bbs2-0089" title="GelernterCS , UhdeTW , CimbolicP , ArnkoffDB , VittoneBJ , TancerME , et al. Cognitive‐behavioural and pharmacological treatments of social phobia: a controlled study. Archives of General Psychiatry1991;48(10):938‐45. ">Gelernter 1991</a>), while theoretically, modern understanding of SAnD as involving psychobiological dysfunctions would indicate that it is unnecessary to institute false dichotomies between brain and mind, and that both kinds of intervention might be useful (<a href="./references#CD001206-bbs2-0190" title="FurmarkT , TillforsM , MarteinsdottirI , FischerH , PissiotaA , LångströmB , et al. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive‐behavioral therapy. Archives of General Psychiatry2002;59(5):425‐33. ">Furmark 2002</a>). Therefore, another research priority revolves around the combined use of pharmacotherapy with psychotherapy and when and if these treatments should be combined or sequenced. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001206-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001206-sec-0015"></div> <div class="table" id="CD001206-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Comparison 1: 5HT1A partial agonists versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 1: 5HT1A partial agonists versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : 5HT1A partial agonists<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With 5HT1A partial agonists</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.00</b> <br/> (0.07 to 14.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the 5HT1A partial agonist group compared to the placebo group who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 1.00). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b><br/> (5 to 970) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b><br/> (5 to 975) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.00</b> <br/> (0.13 to 68.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dropout rates due to adverse events were low in the 5HT1A partial agonist group (1/30, 3%). No participants withdrew from the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 24.3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>1.4 points lower</b> (11.61 lower to 8.81 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the 5HT1A partial agonist intervention group was 22.9 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (small sample size, few events and wide confidence interval).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (small sample size and wide confidence interval).<br/> <sup>d</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Comparison 2: anticonvulsants/GABAs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 2: anticonvulsants/GABAs versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : anticonvulsants/GABAs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With anticonvulsants/GABAs </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.60</b> <br/> (1.16 to 2.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>532<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of benefit on the number of participants with SAnD who responded to treatment (P = 0.004). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the anticonvulsant/GABA groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>221 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>353 per 1000</b><br/> (256 to 486) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b><br/> (252 to 477) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.90</b> <br/> (0.92 to 9.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>532<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dropout rates due to adverse events were high in the anticonvulsant/GABA groups (64/369, 17%) relative to placebo (9/163, 6%). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b><br/> (51 to 505) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>252 per 1000</b><br/> (80 to 795) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 71.8</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>11.50 lower</b><br/> (25.20 lower to 2.20 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the anticonvulsant/GABA intervention group was 60.3 which suggests 'moderate' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 33.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>4.60 points lower</b> (11.88 lower to 2.68 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the anticonvulsant/GABA intervention group was 29.3 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 37.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>6.90 points lower</b> (13.65 lower to 0.15 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the anticonvulsant/GABA intervention group was 31.0 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to moderate heterogeneity (I<sup>2</sup> of 56%).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>d</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>e</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Comparison 3: anticonvulsant levetiracetam versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 3: levetiracetam versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : other anticonvulsants<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Wtih levetiracetam</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/> (0.70 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>228<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the anticonvulsant levetiracetam groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.90). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>373 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b><br/> (261 to 511) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>266 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>261 per 1000</b><br/> (186 to 364) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.00</b> <br/> (0.81 to 4.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>235<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The proportion of dropouts due to adverse events was high in participants receiving the anticonvulsant levetiracetam (15/122, 12%) relative to placebo (6/113, 5%). There was no evidence of a difference between the number of participants that dropped out due to adverse events (P = 0.14). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>106 per 1000</b><br/> (43 to 262) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b><br/> (23 to 138) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 62.4 to 75.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>0.24 points lower</b> (15.69 lower to 15.21 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the anticonvulsant levetiracetam intervention groups ranged from 55 to 65 which suggests 'moderate' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 36.71</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>9.15 points lower</b><br/> (26.86 lower to 8.56 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the anticonvulsant levetiracetam intervention group was 27.56 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 38.71</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was<br/> <b>8.71 points lower</b> (26.02 lower to 8.60 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the anticonvulsant levetiracetam intervention group was 30.0 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>d</sup>Downgraded two levels due to very serious imprecision (small sample size, few events and wide confidence interval).<br/> <sup>e</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Comparison 4: antipsychotics versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 4: antipsychotics versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : antipsychotics<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With antipsychotics </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 7.00</b> <br/> (0.45 to 108.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>10<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the antipsychotic group compared to the placebo group who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.16). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.71</b> <br/> (0.06 to 8.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no difference on the number of participants who withdrew due to adverse events (P = 0.79). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>142 per 1000</b><br/> (12 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>142 per 1000</b><br/> (12 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 86.0</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>37.80 points lower</b><br/> (74.22 lower to 1.38 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the antipsychotic intervention group was 48.2 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (small sample size, few events, and wide confidence interval).<br/> <sup>d</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Comparison 5: benzodiazepines versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 5: benzodiazepines versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : inpatient and outpatient settings<br/> <b>Intervention</b> : benzodiazepines<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With benzodiazepines</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.03</b> <br/> (2.45 to 6.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>132<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of a large effect on the number of participants with SAnD who responded to treatment (P &lt; 0.00001). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the benzodiazepine groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>806 per 1000</b><br/> (490 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>806 per 1000</b><br/> (490 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Relapse rate ‐ no. relapsed</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.12</b> <br/> (0.01 to 2.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>36<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence on the number of treatment responders who subsequently relapsed (P = 0.15). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>211 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>25 per 1000</b><br/> (2 to 451) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>211 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>25 per 1000</b><br/> (2 to 452) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.68</b> <br/> (0.21 to 13.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>96<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dropout rates due to adverse events were low in the benzodiazepine groups (2/47; 4%) and did not differ from the placebo groups (P = 0.62). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/> (4 to 268) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b><br/> (4 to 223) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 61.7 to 82.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>39.75 points lower</b><br/> (71.11 lower to 8.39 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the benzodiazepine intervention groups ranged from 26.6 to 38.1 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 30.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>10.40 points lower</b> (16.08 lower to 4.72 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the benzodiazepine intervention group was 19.8 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 31.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>10.80 points lower</b> (16.62 lower to 4.98 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the benzodiazepine intervention group was 21.1 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (small sample size and wide confidence interval).<br/> <sup>d</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>e</sup>Downgraded two levels due to considerable heterogeneity (I<sup>2</sup> of 94%).<br/> <sup>f</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Comparison 6: beta‐blockers versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 6: beta‐blockers versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : inpatient and outpatient settings<br/> <b>Intervention</b> : beta‐blockers<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With beta‐blockers </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.09</b> <br/> (0.63 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>97<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the beta‐blocker groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.75). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>341 per 1000</b><br/> (197 to 587) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>332 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>362 per 1000</b><br/> (209 to 624) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>c</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Comparison 7: MAOIs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 7: MAOIs versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : inpatient and outpatient settings<br/> <b>Intervention</b> : MAOIs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With MAOIs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.36</b> <br/> (1.48 to 3.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>235<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of an effect on the number of participants with SAnD who responded to treatment (P = 0.0003). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the MAOI groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>621 per 1000</b><br/> (389 to 987) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>274 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>647 per 1000</b><br/> (406 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 4.05 to 63.29</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>16.39 points lower</b><br/> (32.27 lower to 0.51 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the MAOI intervention groups ranged from 14.0 to 47.8 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 24.54</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>5.42 points lower</b><br/> (14.69 lower to 3.85 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the MAOI intervention group was 19.12 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 27.31</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>5.23 points lower</b> (13.97 lower to 3.51 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the MAOI intervention group was 22.08 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinical Global Impressions scale change item (CGI‐I)</b> :<b>no. of responders (long term)</b> </p> <p>Post‐treatment: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.84</b> <br/> (1.02 to 3.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>113<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was data indicating greater efficacy over the long term on the number of participants with SAnD who responded to treatment (P = 0.04). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the MAOI groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>264 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>486 per 1000</b><br/> (269 to 880) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>484 per 1000</b><br/> (268 to 876) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to moderate heterogeneity (I<sup>2</sup> of 44%).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>d</sup>Downgraded two levels due to considerable heterogeneity (I<sup>2</sup> of 93%).<br/> <sup>e</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Comparison 8: NARIs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 8: NARIs versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : NARIs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With NARIs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.70</b> <br/> (0.19 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the NARI group compared to the placebo group who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.58). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>215 per 1000</b><br/> (58 to 782) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>216 per 1000</b><br/> (59 to 782) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.80</b> <br/> (0.12 to 63.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Only 1 of 14 (7%) participants withdrew during 10 weeks of NARI treatment. There was no evidence for a difference in the number of participants who withdrew due to adverse events (P = 0.52). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 70.8</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>2.60 points higher</b> (15.43 lower to 20.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the NARI intervention group was 73.4 which suggests 'marked' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (small sample size and wide confidence interval).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (small sample size, few events and wide confidence interval).<br/> <sup>d</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Comparison 9: NaSSAs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 9: NaSSAs compared to placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : NaSSAs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With NaSSAs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.00</b> <br/> (0.28 to 3.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>An equal number of participants (4/30, 13%) responded to treatment in both the NaSSA and placebo groups, however this difference was not statistically significant (P = 1.00). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b><br/> (37 to 484) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b><br/> (37 to 483) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 5.00</b> <br/> (0.25 to 99.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>A small proportion of participants receiving NaSSAs dropped out due to adverse events (2/30, 7%). Although, the difference was not statistically significant (P = 0.29). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 62.4 to 67.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>15.37 points lower</b><br/> (28.10 lower to 2.63 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the NaSSA intervention groups ranged from 46.3 to 54.8 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 28.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>3.90 points lower</b> (9.90 lower to 2.10 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the NaSSA intervention group was 25.0 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 33.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>3.70 points lower</b> (9.42 lower to 2.02 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the NaSSA intervention group was 29.8 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>d</sup>Downgraded two levels due to substantial heterogeneity (I<sup>2</sup> of 79%).<br/> <sup>e</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Comparison 10: RIMAs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 10: RIMAs versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : inpatient and outpatient settings<br/> <b>Intervention</b> : RIMAs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With RIMAs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.83</b> <br/> (1.32 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1270<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of benefit on the number of participants with SAnD who responded to treatment (P = 0.0003). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the RIMA groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>254 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b><br/> (335 to 647) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>207 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>379 per 1000</b><br/> (273 to 528) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.42</b> <br/> (0.86 to 2.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1305<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dropout rates due to adverse events were low in the RIMA groups and equivalent to those observed in the placebo groups (72/83; 9%). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b><br/> (42 to 114) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b><br/> (28 to 75) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 54.4 to 79.3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>12.17 points lower</b> (23.51 lower to 0.84 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1163<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the RIMA intervention groups ranged from 27.0 to 62.6 which suggests low to 'moderate' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 23.3 to 39.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was<br/> <b>5.05 points lower</b> (7.91 lower to 2.18 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>695<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the RIMA intervention groups ranged from 15.3 to 30.7 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 29.4 to 40.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>5.40 points lower</b> (8.92 lower to 1.88 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>724<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the RIMA intervention groups ranged from 19.1 to 33.3 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinical Global Impressions scale change item (CGI‐I): no. of responders (long term)</b> </p> <p>Post‐treatment: 1‐15 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.50</b> <br/> (1.12 to 2.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>90<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of a long‐term effect on treatment efficacy in participants with SAnD who responded to treatment (P = 0.006). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the RIMA group compared to the placebo group who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>575 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>862 per 1000</b><br/> (644 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>575 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>862 per 1000</b><br/> (644 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to substantial heterogeneity (I<sup>2</sup> of 70%).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>d</sup>Downgraded two levels due to considerable heterogeneity (I<sup>2</sup> of 94%).<br/> <sup>e</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>f</sup>Downgraded two levels due to moderate heterogeneity (I<sup>2</sup> of 55%).<br/> <sup>g</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0011"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Comparison 11: SARIs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 11: SARIs versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : SARIs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With SARIs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 71.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>6.10 points lower</b> (16.55 lower to 4.35 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the SARI intervention group was 65.1 which suggests 'marked' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (wide confidence interval). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0012"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Comparison 12: SNRIs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 12: SNRIs compared to placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : SNRIs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With SNRIs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.30</b> <br/> (0.85 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1173<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the SNRI groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.22). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>486 per 1000</b><br/> (460 to 610) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>451 per 1000</b><br/> (465 to 617) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.23</b> <br/> (2.15 to 4.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1213<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The proportion of dropouts due to adverse events was more than three times as high in participants receiving SNRIs (109/663, 16%) compared to placebo (27/550, 5%), a statistically significant difference (P &lt; 0.00001). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>159 per 1000</b><br/> (106 to 239) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>158 per 1000</b><br/> (105 to 238) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from ‐22.2 to 66.0</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>11.91 points lower</b> (16.06 lower to 7.76 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>902<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the SNRI intervention groups ranged from ‐35.0 to 57.7 which suggests 'low' to 'moderate' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 32.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>4.30 points lower</b> (8.14 lower to 0.46 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the SNRI intervention group was 27.8 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 33.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>4.00 points lower</b> (7.68 lower to 0.32 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the SNRI intervention group was 29.9 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to considerable heterogeneity (I<sup>2</sup> of 89%).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>d</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0013"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Comparison 13: SSRIs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 13: SSRIs versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : inpatient and outpatient settings<br/> <b>Intervention</b> : SSRIs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With SSRIs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.65</b> <br/> (1.48 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4984<br/> (24 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of benefit on the number of participants with SAnD who responded to treatment (P &lt; 0.00001). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the SSRI groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>317 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>523 per 1000</b><br/> (469 to 587) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>290 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>476 per 1000</b><br/> (478 to 537) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Relapse rate ‐ no. relapsed</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.34</b> <br/> (0.22 to 0.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>389<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence that SSRIs prevented relapse compared to placebo (P &lt; 0.00001).</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>397 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>135 per 1000</b><br/> (87 to 198) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>391 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>133 per 1000</b><br/> (86 to 195) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.59</b> <br/> (1.97 to 3.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>5131<br/> (24 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The proportion of dropouts due to adverse events was approximately three times higher amongst participants receiving SSRIs compared to placebo ((P &lt; 0.00001). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b><br/> (80 to 137) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b><br/> (73 to 125) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from ‐7.8 to 69.88</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>10.14 points lower</b> (14.05 to 6.22 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1990<br/> (14 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the SSRI intervention groups ranged from 14.7 to 60.3 which suggests 'low' to 'moderate' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 24.2 to 34.8</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>7.01 points lower</b> (10.21 to 3.80 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1173<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the SSRI intervention groups ranged from 17.09 to 26.11 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 29.83 to 37.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>7.28 points lower</b> (10.86 to 3.71 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1173<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the SSRI intervention groups ranged from 19.84 to 32.79 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinical Global Impressions scale change item (CGI‐I): no. of responders (long term)</b> </p> <p>Post‐treatment: 1‐4 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.27</b> <br/> (1.07 to 1.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>806<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence for a response to long‐term treatment compared to placebo in participants with SAnD (P = 0.007). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the SSRI groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>579 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>735 per 1000</b><br/> (619 to 874) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>584 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>742 per 1000</b><br/> (625 to 882) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (long term)</b> </p> <p>Post‐treatment: 1‐4 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.17</b> <br/> (0.43 to 3.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1274<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,h,i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>We found no difference in dropout rates due to adverse events between the SSRI and control groups (P = 0.76). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b><br/> (23 to 166) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b><br/> (22 to 159) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to moderate heterogeneity (I<sup>2</sup> of 50%).<br/> <sup>c</sup>Downgraded two levels due to very serious publication bias (t = 2.6426, df = 22, p = 0.015).<br/> <sup>d</sup>Downgraded two levels due to substantial heterogeneity (I<sup>2</sup> of 67%).<br/> <sup>e</sup>Downgraded two levels due to substantial heterogeneity (I<sup>2</sup> of 65%).<br/> <sup>f</sup>Downgraded two levels due to substantial heterogeneity (I<sup>2</sup> of 75%).<br/> <sup>g</sup>Downgraded two levels due to moderate heterogeneity (I<sup>2</sup> of 60%).<br/> <sup>h</sup>Downgraded two levels due to moderate heterogeneity (I<sup>2</sup> of 57%).<br/> <sup>i</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>j</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0014"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Comparison 14: GW876008 versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 14: GW876008 versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : GW876008<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Comparison 14: GW876008 versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.83</b> <br/> (0.58 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>250<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the GW876008 group compared to the placebo group who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.32). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>302 per 1000</b><br/> (211 to 433) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>302 per 1000</b><br/> (211 to 433) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.95</b> <br/> (0.67 to 13.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>252<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The proportion of dropouts due to adverse events was approximately three times higher amongst participants receiving GW876008 (11/164, 7%) compared to placebo (2/88, 2%), though this difference was not statistically significant (P = 0.15). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b><br/> (15 to 296) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b><br/> (15 to 299) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup> Downgraded one level due to serious imprecision (wide confidence intervals). </p> <p><sup>c</sup> Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0015"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Comparison 15: NK1 receptor antagonist GR205171 versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 15: NK1 receptor antagonist GR205171 versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : NK1 receptor antagonist GR205171<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Comparison 15: NK1 receptor antagonist GR205171 versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 5</b> <br/> (0.68 to 36.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the NK1 receptor antagonist GR205171 group compared to the placebo group who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.11). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>417 per 1000</b><br/> (57 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>415 per 1000</b><br/> (56 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participants withdrew due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 4.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinician‐rated: liebowitz social anxiety scale (lsas): reduction of anxiety symptoms ‐ lsas total score in the intervention groups was <b>0.5 points lower</b> (1.35 lower to 0.35 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the NK1 receptor antagonist GR205171 intervention group was 3.6 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup> Downgraded two levels due to very serious imprecision (small sample size and wide confidence intervals). </p> <p><sup>c</sup> Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001206-tbl-0016"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 16.</span> <span class="table-title">Comparison 16: LY686017 versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 16: LY686017 versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : LY686017<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Comparison 16: LY686017 versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was ‐22.59</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinician‐rated: liebowitz social anxiety scale (lsas): reduction of anxiety symptoms ‐ lsas total score in the intervention groups was <b>1.8 points higher</b> (6.92 lower to 10.52 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the LY686017 intervention group was ‐20.79 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup> Downgraded one level due to serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001206-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001206-sec-0016"></div> <section id="CD001206-sec-0017"> <h3 class="title" id="CD001206-sec-0017">Description of the condition</h3> <p>Although the symptoms of social anxiety disorder (SAnD) have long been recognised (<a href="./references#CD001206-bbs2-0210" title="MarksIM , GelderMG . Different ages of onset in varieties of phobias. American Journal of Psychiatry1966;123(2):218‐21. ">Marks 1966</a>), the disorder only appeared within the official psychiatric nomenclature relatively recently (<a href="./references#CD001206-bbs2-0183" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. Washington, DC: American Psychiatric Press, 1980. ">DSM‐III 1980</a>). Diagnostic criteria for SAnD in the third edition of the <i>Diagnostic and Statistical Manual of Mental Disorders</i> (DSM‐III) encouraged research on its epidemiology, psychobiology, and treatment. Subsequent epidemiological research determined that the disorder is highly prevalent in a wide range of settings, that it is characterised by significant chronicity and comorbidity, and that it is associated with marked functional impairment, including academic, occupational, marital, and social dysfunction (<a href="./references#CD001206-bbs2-0228" title="SteinMB , SteinDJ . Social anxiety disorder. Lancet2008;271(9618):1115‐25. ">Stein 2008</a>). Such data allay skepticism about whether SAnD is really a medical disorder and support the importance of pharmacotherapy for its treatment. </p> <p>SAnD usually begins in childhood or adolescence, with studies reporting lifetime prevalence rates of between 3% and 16% (<a href="./references#CD001206-bbs2-0204" title="KesslerRC , McGonagleKA , ZhaoS , NelsonCB , HughesM , EhslemanS , et al. Lifetime and 12‐month prevalence of DSM III‐R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry1994;51(1):8‐19. ">Kessler 1994</a>; <a href="./references#CD001206-bbs2-0205" title="KesslerRC , BerglundP , DemlerO , JinR , MerikangasKR , WaltersEE . Lifetime prevalence and age‐of‐onset distributions of DSM‐IV disorders in the National Comorbidity Survey Replication. Archives of General Psychiatry2005;62(6):593‐602. ">Kessler 2005</a>). Some European studies describe a one‐year prevalence of 2% to 5% (<a href="./references#CD001206-bbs2-0236" title="WancataJ , FridlM , FriedrichF . Social phobia: epidemiology and health care. Psychiatrica Danubina2009;21(4):520‐4. ">Wancata 2009</a>). Typically, individuals with SAnD experience severe, intense fear of drawing attention to themselves in unfamiliar social situations or negative evaluation in situations that are potentially embarrassing or humiliating. This in turn results in avoiding the phobic situation or tolerating it with extreme distress. The affected individual recognises this fear as unreasonable, excessive, and more than mere shyness. These symptoms may take the form of a situationally predisposed panic attack and always impair functioning on a number of levels (<a href="./references#CD001206-bbs2-0184" title="American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. Washington, DC: American Psychiatric Association, 1994. ">DSM‐IV 2004</a>). </p> <p>There is a growing body of work demonstrating that SAnD is mediated by specific neurocircuitry, with serotonergic and dopaminergic systems particularly relevant (<a href="./references#CD001206-bbs2-0226" title="SteinDJ , HunterB , RolfeT , Oakes , R . Paroxetine in social anxiety disorder: a remission analysis. European College of Neuropsychopharmacology (ECNP) Congress; Oct. Barcelona, Spain, 2002. ">Stein 2002d</a>), providing a rationale for the use of pharmacotherapy. The glutamatergic and noradrenergic systems, as well as substance P, may also be implicated in the neurological basis of SAnD, suggesting a role for agents such as gabapentin, pregabalin, and neurokinin‐1 receptor antagonists (<a href="./references#CD001206-bbs2-0039" title="PandeAC , DavidsonJR , JeffersonJW , JanneyCA , KatzelnickDJ , WeislerRH , GreistJH , SutherlandSM . Treatment of social phobia with gabapentin: a placebo‐controlled study. Journal of Clinical Psychopharmacology1999;19(4):341‐8. ">Pande 1999</a>; <a href="./references#CD001206-bbs2-0040" title="FeltnerDE , DavidsonJR , PollackMH , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social anxiety disorder: outcome and predictors of response. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14. San Juan, Puerto Rico, 2000. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled study of pregabalin in social phobia (social anxiety disorder) [abstract]. International Journal of Neuropsychopharmacology2000;3(Suppl 1):284. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererRA , JeffersonJW , et al. Pregabalin treatment of social phobia. New Research Abstracts. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000. FeltnerDE , PollackMH , DavidsonJRT , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social phobia: outcome and predictors of response [abstract]. European Neuropsychopharmacology2000;10(Suppl 3):S345. PandeAC , FeltnerDE , JeffersonJW , DavidsonJRT , PollackM , SteinMB , et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo‐controlled, multicenter study. Journal of Clinical Psychopharmacology2004;24(2):141‐9. ">Pande 2004</a>, <a href="./references#CD001206-bbs2-0054" title="TauscherJ , KielbasaW , IyengarS , VandenhendeF , PengX , MozleyD , et al. Development of the 2nd generation neurokinin‐1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology2010;20(2):80‐7. ">Tauscher 2010</a>). Indeed there is accumulating evidence that particular medications are effective in the management of SAnD (<a href="./references#CD001206-bbs2-0227" title="SteinDJ , IpserJC , BalkomAJ . Pharmacotherapy for social phobia. Cochrane Database of Systematic Reviews2004, Issue 4. [DOI: 10.1002/14651858.CD001206.pub2] ">Stein 2004</a>). </p> <p>The effectiveness of cognitive‐behavioural therapy (CBT) in managing SAnD is also receiving increasing empirical support (<a href="./references#CD001206-bbs2-0182" title="DorrepaalE , ThomaesK , HoogendoornAW , VeltmanDJ , DraijerN , VanBalkomAJLM . Evidence‐based treatment for adult women with child abuse‐related Complex PTSD: a quantitative review. European Journal of Psychotraumatology2014;14(5):236‐413. ">Dorrepaal 2014</a>; <a href="./references#CD001206-bbs2-0188" title="FedoroffIC , TaylorS . Psychological and pharmacological treatments of social phobia. Journal of Clinical Psychopharmacology2001;21(3):311‐24. ">Fedoroff 2001</a>; <a href="./references#CD001206-bbs2-0193" title="GouldRA , BuckministerS , PollackMH , OttoMW , YapL . Cognitive‐behavioral and pharmacological treatments of social phobia. Clinical Psychology ‐ Science &amp; Practice1997;4(4):291‐306. ">Gould 1997</a>), and current expert consensus is that both pharmacotherapy and psychotherapy have a role in the management of this disorder (<a href="./references#CD001206-bbs2-0160" title="BallengerJC , DavidsonJR , LecrubierY , NuttDJ , BobesJ , BeidelDC , et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry1998;59(Suppl 17):54–60. ">Ballenger 1998</a>; <a href="./references#CD001206-bbs2-0161" title="BandelowB , ZoharJ , HollanderE , KasperS , MollerHJ . WFSBP Task Force on Treatment Guidelines for Anxiety O‐CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive‐compulsive and posttraumatic stress disorders. World Journal of Biological Psychiatry2002;3(4):171‐99. ">Bandelow 2002</a>; <a href="./references#CD001206-bbs2-0162" title="BandelowB , SherL , BuneviciusR , HollanderE , KasperS , ZoharJ , et al. WFSBP Task Force on Mental Disorders in Primary Care, WFSBP Task Force on Anxiety Disorders, OCD , PTSD . Guidelines for the pharmacological treatment of anxiety disorders, obsessive – compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice2012;16:77–84. [DOI: 10.3109/13651501.2012.667114] ">Bandelow 2012</a>; <a href="./references#CD001206-bbs2-0163" title="BandelowB , MichaelisS . Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical Neuroscience2015;17(3):327‐35. ">Bandelow 2015</a>). Interestingly, both CBT and pharmacotherapy are able to normalise functional neuroanatomical abnormalities in SAnD (<a href="./references#CD001206-bbs2-0190" title="FurmarkT , TillforsM , MarteinsdottirI , FischerH , PissiotaA , LångströmB , et al. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive‐behavioral therapy. Archives of General Psychiatry2002;59(5):425‐33. ">Furmark 2002</a>). Nevertheless, this review focuses exclusively on pharmacotherapy interventions. </p> </section> <section id="CD001206-sec-0018"> <h3 class="title" id="CD001206-sec-0018">Description of the intervention</h3> <p>Research has evaluated a range of medications for SAnD. Early reports noted the potential value of irreversible monoamine oxidase inhibitors (MAOIs) (<a href="./references#CD001206-bbs2-0013" title="FahlenT , HumbleM , KoczkasC , NilssonH . Social phobia and its treatment with brofaromine, efficacy regarding social phobia symptoms and personality traits. Clinical Neuropharmacology1992;15(1 Pt B):64. FahlenT , NilssonHl , BorgK , HumbleM , PauliU . Social phobia: the clinical efficacy and tolerability of the monoamine oxidase‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study. Acta Psychiatrica Scandinavica1995;92(5):351‐8. ">Fahlen 1995</a>; <a href="./references#CD001206-bbs2-0059" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO‐A inhibitor. European Neuropsychopharmacology1992;2(1):21‐9. ">Van Vliet 1992</a>), beta‐blockers (<a href="./references#CD001206-bbs2-0191" title="GormanJM , GormanLK . Drug treatment of social phobia. Journal of Affective Disorders1987;13(2):183‐92. ">Gorman 1987</a>; <a href="./references#CD001206-bbs2-0055" title="TurnerS , BeidelDC , JacobRG . Social phobia: a comparison of behaviour therapy and atenolol. Journal of Consulting and Clinical Psychology1994;62(2):350‐8. ">Turner 1994</a>), reversible inhibitors of monoamine oxidase A (RIMAs) (<a href="./references#CD001206-bbs2-0135" title="TyrerP , CandyJ , KellyD . A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologica1973;32(3):237‐54. ">Tyrer 1973</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>), and high potency benzodiazepines (<a href="./references#CD001206-bbs2-0171" title="DavidsonJR , FordSM , SmithRD , PottsNL . Long‐term treatment of social phobia with clonazepam. Journal of Clinical Psychiatry1991;52(Suppl 1):16‐20. ">Davidson 1991</a>). More recent studies have focused on the selective serotonin reuptake inhibitors (SSRIs) (<a href="./references#CD001206-bbs2-0233" title="Van derLindenGJ , SteinDJ , vanBalkomAJ . The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta‐analysis of randomized controlled trials. International Clinical Psychopharmacology2000;15(Suppl 2):15‐24. ">Van der Linden 2000</a>), plus other newer agents such as GW876008 (<a href="./references#CD001206-bbs2-0033" title="NCT00397722 . Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [Treatment of patients with social anxiety disorder]. clinicaltrials.gov/ct2/show/results/NCT00397722 (first received 8 November 2006). ">NCT00397722</a>). Randomised controlled trials (RCTs) have also assessed buspirone (<a href="./references#CD001206-bbs2-0010" title="DavidsonJR , PottsN , RichichiE , KrishnanR , FordSM , SmithR , et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology1993;13(6):423‐8. SutherlandSM , TuplerLA , ColketJT , DavidsonJR . A 2‐year follow‐up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease1996;184(12):731‐8. ">Davidson 1993</a>), the noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazepine (<a href="./references#CD001206-bbs2-0030" title="MuehlbacherM , NickelMK , NickelC , KettlerC , LahmannC , GilFP , et al. Mirtazapine treatment of social phobia in women. A randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychopharmacology2005;25(6):580‐3. ">Muehlbacher 2005</a>), the new generation antipsychotic olanzapine (<a href="./references#CD001206-bbs2-0005" title="BarnettSD , KramerML , CasatCD , ConnorKM , DavidsonJR . Efficacy of olanzapine in social anxiety disorder: a pilot study. Journal of Psychopharmacology2002;16(4):365‐8. ">Barnett 2002</a>), the highly selective noradrenaline reuptake inhibitor (NARI) atomoxetine (<a href="./references#CD001206-bbs2-0042" title="RavindranLN , KimDS , LetamendiAM , SteinMB . A randomized controlled trial of atomoxetine in generalized social anxiety disorder. Journal of Clinical Psychopharmacology2009;29(6):561‐4. ">Ravindran 2009</a>), the serotonin antagonist and reuptake inhibitor (SARI) nefazodone (<a href="./references#CD001206-bbs2-0058" title="VanAmeringenM , ManciniC , OakmanJ , WalkerJ , KjernistedK , ChokkaP , et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(2):288‐95. VanAmeringenMA , ManciniCL , PipeB , OakmanJ , WalkerJR , KjernistedKD , et al. Not all serotonergic agents are created equal in social phobia: nefazodone, a placebo‐controlled trial. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR789. ">Van Ameringen 2007</a>), the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine (<a href="./references#CD001206-bbs2-0043" title="RickelsK , ManganoR , KhanA . A double‐blind, placebo‐controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(5):488‐96. ">Rickels 2004</a>), and certain anticonvulsants/gamma‐amino butyric acids (GABAs) (<a href="./references#CD001206-bbs2-0039" title="PandeAC , DavidsonJR , JeffersonJW , JanneyCA , KatzelnickDJ , WeislerRH , GreistJH , SutherlandSM . Treatment of social phobia with gabapentin: a placebo‐controlled study. Journal of Clinical Psychopharmacology1999;19(4):341‐8. ">Pande 1999</a>; <a href="./references#CD001206-bbs2-0040" title="FeltnerDE , DavidsonJR , PollackMH , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social anxiety disorder: outcome and predictors of response. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14. San Juan, Puerto Rico, 2000. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled study of pregabalin in social phobia (social anxiety disorder) [abstract]. International Journal of Neuropsychopharmacology2000;3(Suppl 1):284. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererRA , JeffersonJW , et al. Pregabalin treatment of social phobia. New Research Abstracts. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000. FeltnerDE , PollackMH , DavidsonJRT , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social phobia: outcome and predictors of response [abstract]. European Neuropsychopharmacology2000;10(Suppl 3):S345. PandeAC , FeltnerDE , JeffersonJW , DavidsonJRT , PollackM , SteinMB , et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo‐controlled, multicenter study. Journal of Clinical Psychopharmacology2004;24(2):141‐9. ">Pande 2004</a>). </p> </section> <section id="CD001206-sec-0019"> <h3 class="title" id="CD001206-sec-0019">How the intervention might work</h3> <p>Although the pathophysiology of SAnD is incompletely understood, various mono‐aminergic systems, such as the serotonergic, dopaminergic, and noradrenergic systems, may play a role in mediating SAnD symptoms. Strongly serotonergic drugs such as SSRIs have specific activity in the inhibition of serotonin reuptake, with minimal direct effects on norepinephrine and dopamine reuptake. This inhibition of reuptake increases the bio‐available concentration of serotonin, which then binds to and activates various receptors. Clinical efficacy is observed with 70% to 80% occupancy of serotonin transporters (<a href="./references#CD001206-bbs2-0223" title="StahlSM . Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd Edition. Cambridge University Press, 2008. ">Stahl 2008</a>). SNRIs are potent inhibitors of the reuptake of catecholamines but weak inhibitors of dopamine reuptake (<a href="./references#CD001206-bbs2-0043" title="RickelsK , ManganoR , KhanA . A double‐blind, placebo‐controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(5):488‐96. ">Rickels 2004</a>; <a href="./references#CD001206-bbs2-0223" title="StahlSM . Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd Edition. Cambridge University Press, 2008. ">Stahl 2008</a>). The putative effects of the selective NARI atomoxetine on the noradrenergic neurotransmitter system in adults and children with attention‐deficit/hyperactivity disorder (ADHD), reported by <a href="./references#CD001206-bbs2-0168" title="ChamberlainSR , DelCampoN , DowsonJ , MüllerU , ClarkL , RobbinsTW , et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biological Psychiatry2007;62(9):977–84. ">Chamberlain 2007</a> and <a href="./references#CD001206-bbs2-0211" title="MichelsonD , FariesD , WernickeJ , KelseyD , KendrickK , SalleeFR , et al. the Atomoxetine ADHD Study Group. Atomoxetine in the treatment of children and adolescents with attention‐deficit/hyperactivity disorder: a randomized, placebo‐controlled, dose‐response study. Pediatrics2001;108(5):1‐9. ">Michelson 2001</a>, suggest potential use for anxiety and mood disorders (<a href="./references#CD001206-bbs2-0042" title="RavindranLN , KimDS , LetamendiAM , SteinMB . A randomized controlled trial of atomoxetine in generalized social anxiety disorder. Journal of Clinical Psychopharmacology2009;29(6):561‐4. ">Ravindran 2009</a>). There is evidence to suggest that some serotonin‐dopamine antagonists (SDAs) such as quetiapine and olanzapine may possess anxiolytic properties, and they may potentially have a role in treatment‐resistant SAnD (<a href="./references#CD001206-bbs2-0005" title="BarnettSD , KramerML , CasatCD , ConnorKM , DavidsonJR . Efficacy of olanzapine in social anxiety disorder: a pilot study. Journal of Psychopharmacology2002;16(4):365‐8. ">Barnett 2002</a>; <a href="./references#CD001206-bbs2-0056" title="VaishnaviS , AlamyS , ZhangW , ConnorKM , DavidsonJRT . Quetiapine as monotherapy for social anxiety disorder: a placebo‐controlled study. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007;31(7):1464‐9. ">Vaishnavi 2007</a>). Nefazodone is an agent with both pre‐ and postsynaptic serotonin reuptake inhibition, but concerns about hepatotoxicity limit its use in clinical practice (<a href="./references#CD001206-bbs2-0058" title="VanAmeringenM , ManciniC , OakmanJ , WalkerJ , KjernistedK , ChokkaP , et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(2):288‐95. VanAmeringenMA , ManciniCL , PipeB , OakmanJ , WalkerJR , KjernistedKD , et al. Not all serotonergic agents are created equal in social phobia: nefazodone, a placebo‐controlled trial. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR789. ">Van Ameringen 2007</a>). </p> <p>MAOIs increase biogenic amine neurotransmitter levels by inhibiting their degradation, facilitating presynaptic reuptake of these chemicals through specific transporter molecules and inhibiting their de‐amination in mitochondria by the enzyme MAO. This inhibition may be either reversible or irreversible (<a href="./references#CD001206-bbs2-0223" title="StahlSM . Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd Edition. Cambridge University Press, 2008. ">Stahl 2008</a>). RIMAs are generally safer and better tolerated than MAOIs and have shown efficacy in treating SAnD (<a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>). The drug functions by selectively binding to a specific isoenzyme of monoamine oxidase (<a href="./references#CD001206-bbs2-0173" title="DavidsonJR . Pharmacotherapy of social anxiety disorder: what does the evidence tell us?. Journal of Clinical Psychiatry2006;67(Suppl 12):20–6. ">Davidson 2006</a>). </p> <p>Beta‐adrenoreceptor antagonists block catecholamines released in the stress response, thus potentially reducing the physiological symptoms associated with SAnD. This may then enable the individual to function with fewer objective signs of anxiety (<a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>; <a href="./references#CD001206-bbs2-0223" title="StahlSM . Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd Edition. Cambridge University Press, 2008. ">Stahl 2008</a>; <a href="./references#CD001206-bbs2-0055" title="TurnerS , BeidelDC , JacobRG . Social phobia: a comparison of behaviour therapy and atenolol. Journal of Consulting and Clinical Psychology1994;62(2):350‐8. ">Turner 1994</a>). The NaSSA mirtazepine has potent action on central adrenergic receptors, leading to a net increase in noradrenaline and serotonin, without the unwanted activation of cholinergic receptors (<a href="./references#CD001206-bbs2-0030" title="MuehlbacherM , NickelMK , NickelC , KettlerC , LahmannC , GilFP , et al. Mirtazapine treatment of social phobia in women. A randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychopharmacology2005;25(6):580‐3. ">Muehlbacher 2005</a>). </p> <p>The efficacy of benzodiazepines in the treatment of many anxiety disorders is consistent with the hypothesized role of GABA in these conditions. In low doses, benzodiazepines act as anxiolytic agents and may be especially useful in providing rapid control of anxiety symptoms (<a href="./references#CD001206-bbs2-0192" title="GormanJM . Treating generalized anxiety disorder. Journal of Clinical Psychiatry2003;64(Suppl 2):24‐9. ">Gorman 2003</a>; <a href="./references#CD001206-bbs2-0216" title="PecknoldJC . A risk‐benefit assessment of buspirone in the treatment of anxiety disorders. Drug Safety1997;16(2):118–32. ">Pecknold 1997</a>; <a href="./references#CD001206-bbs2-0223" title="StahlSM . Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd Edition. Cambridge University Press, 2008. ">Stahl 2008</a>). Repeated buspirone treatment may desensitise inhibitory 5‐HT1A receptors and this, together with its modest postsynaptic 5‐HT1A receptor agonist actions, could lead to an overall increase in 5‐HT neurotransmission as well (<a href="./references#CD001206-bbs2-0169" title="CowenPJ . Pharmacotherapy for anxiety disorders: drugs available. Advances in Psychiatric Treatment1997;3:66‐71. ">Cowen 1997</a>). </p> <p>The anticonvulsant pregabalin reduces the release of norepinephrine, glutamate, and substance P from the brain and spinal cord and may have a benefit in anxiety reduction (<a href="./references#CD001206-bbs2-0040" title="FeltnerDE , DavidsonJR , PollackMH , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social anxiety disorder: outcome and predictors of response. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14. San Juan, Puerto Rico, 2000. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled study of pregabalin in social phobia (social anxiety disorder) [abstract]. International Journal of Neuropsychopharmacology2000;3(Suppl 1):284. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererRA , JeffersonJW , et al. Pregabalin treatment of social phobia. New Research Abstracts. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000. FeltnerDE , PollackMH , DavidsonJRT , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social phobia: outcome and predictors of response [abstract]. European Neuropsychopharmacology2000;10(Suppl 3):S345. PandeAC , FeltnerDE , JeffersonJW , DavidsonJRT , PollackM , SteinMB , et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo‐controlled, multicenter study. Journal of Clinical Psychopharmacology2004;24(2):141‐9. ">Pande 2004</a>). Gabapentin may be similarly effective for these conditions (<a href="./references#CD001206-bbs2-0229" title="StahlM , MooreBA . Anxiety Disorders: A Guide for Integrating Psychopharmacology and Psychotherapy (Clinical Topics in Psychology and Psychiatry). 1st edition. Routledge, 2013. ">Stephen 2013</a>). </p> <p>Newer medications such as GW876008 have corticotropin‐releasing factors (CRFs) that target behavioural, autonomic, and neurochemical responses linked to a variety of anxiety and stress‐related disorders (<a href="./references#CD001206-bbs2-0199" title="HubbardCS , LabusJS , BuellerJ , StainsJ , SuyenobuB , DukesGE , et al. Corticotropin‐releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional arousal circuit during expectation of abdominal pain. Journal of Neuroscience2011;31(35):12491–500. ">Hubbard 2011</a>). GW876008 also plays a role in the activation of the hypothalamus in patients with anxiety (<a href="./references#CD001206-bbs2-0199" title="HubbardCS , LabusJS , BuellerJ , StainsJ , SuyenobuB , DukesGE , et al. Corticotropin‐releasing factor receptor 1 antagonist alters regional activation and effective connectivity in an emotional arousal circuit during expectation of abdominal pain. Journal of Neuroscience2011;31(35):12491–500. ">Hubbard 2011</a>). </p> </section> <section id="CD001206-sec-0020"> <h3 class="title" id="CD001206-sec-0020">Why it is important to do this review</h3> <p>A systematic review of pharmacotherapy studies may be useful in tackling several questions for the field. First, is pharmacotherapy in fact an effective form of treatment in SAnD? Given scepticism about SAnD diagnosis and the importance of psychological models and psychotherapy studies for the disorder, the role of pharmacotherapy remains moot for some. For those who accept the role of pharmacotherapy, questions remain about the appropriate dose and duration of treatments. Although in the late 1990s expert consensus suggested continuing pharmacotherapy for at least a year, there was arguably relatively little data to support this conclusion at the time (<a href="./references#CD001206-bbs2-0160" title="BallengerJC , DavidsonJR , LecrubierY , NuttDJ , BobesJ , BeidelDC , et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry1998;59(Suppl 17):54–60. ">Ballenger 1998</a>). </p> <p>Second, are particular medication classes more effective in treating symptoms, more tolerable to the patient in terms of adverse events, or both? The use of recently introduced antidepressants (e.g. SSRIs) for SAnD has raised the question of how these agents compare with older medications (e.g. MAOIs). Current expert consensus has suggested that in view of their efficacy and tolerability, SSRIs should be considered as first‐line medications for the treatment of SAnD, while beta‐blockers have a role in the management of performance anxiety (<a href="./references#CD001206-bbs2-0160" title="BallengerJC , DavidsonJR , LecrubierY , NuttDJ , BobesJ , BeidelDC , et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry1998;59(Suppl 17):54–60. ">Ballenger 1998</a>; <a href="./references#CD001206-bbs2-0161" title="BandelowB , ZoharJ , HollanderE , KasperS , MollerHJ . WFSBP Task Force on Treatment Guidelines for Anxiety O‐CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive‐compulsive and posttraumatic stress disorders. World Journal of Biological Psychiatry2002;3(4):171‐99. ">Bandelow 2002</a>; <a href="./references#CD001206-bbs2-0162" title="BandelowB , SherL , BuneviciusR , HollanderE , KasperS , ZoharJ , et al. WFSBP Task Force on Mental Disorders in Primary Care, WFSBP Task Force on Anxiety Disorders, OCD , PTSD . Guidelines for the pharmacological treatment of anxiety disorders, obsessive – compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice2012;16:77–84. [DOI: 10.3109/13651501.2012.667114] ">Bandelow 2012</a>; <a href="./references#CD001206-bbs2-0163" title="BandelowB , MichaelisS . Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical Neuroscience2015;17(3):327‐35. ">Bandelow 2015</a>); it is important to determine whether such recommendations are supported by evidence from RCTs. </p> <p>Third, can a systematic review of RCTs provide information about the most important variables affecting pharmacotherapy response? Methodological factors such as the number of participating centres or the duration of the trial may affect treatment outcomes (<a href="./references#CD001206-bbs2-0225" title="SteinDJ , SteinMB , PittsCD , KumarR , HunterB . Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo‐controlled paroxetine trials. Journal of Clinical Psychiatry2002;63(2):152‐5. ">Stein 2002c</a>). Some authors have also suggested that clinical factors such as the nature of the SAnD sub‐type present (e.g. generalised versus non‐generalised), and the severity of baseline symptoms, may play a role (<a href="./references#CD001206-bbs2-0225" title="SteinDJ , SteinMB , PittsCD , KumarR , HunterB . Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo‐controlled paroxetine trials. Journal of Clinical Psychiatry2002;63(2):152‐5. ">Stein 2002c</a>). The body of evidence from RCTs may provide more conclusive information about the predictors of pharmacotherapy response in this disorder. </p> <p>Indeed, a series of reviews of the pharmacotherapy of SAnD has been published (<a href="./references#CD001206-bbs2-0165" title="BlancoC , AntiaSX , LiebowitzMR . Pharmacotherapy of social anxiety disorder. Biological Psychiatry2002;51(1):109‐20. ">Blanco 2002</a>; <a href="./references#CD001206-bbs2-0167" title="BlancoC , BragdonLB , SchneierFR , LiebowitzMR . The evidence‐based pharmacotherapy of social anxiety disorder. International Journal of Neuropsychopharmacology2013;16(1):235‐49. ">Blanco 2013</a>; <a href="./references#CD001206-bbs2-0170" title="CurtissJ , AndrewsL , DavisM , SmitsJ , HofmannSG . A meta‐analysis of pharmacotherapy for social anxiety disorder: anexamination of efficacy, moderators, and mediators. Expert Opinion on Pharmacotherapy2017;18(3):243‐51. [hdl.handle.net/2144/21703] ">Curtiss 2017</a>; <a href="./references#CD001206-bbs2-0176" title="DeMenezesGB , CoutinhoESF , FontenelleLF , VigneP , FigueiraI , VersianiMá . Second‐generation antidepressants in social anxiety disorder: meta‐analysis of controlled clinical trials. Psychopharmacology2011;215(1):1‐11. ">De Menezes 2011</a>). These reviews have been useful in summarising the existing research, pointing to methodological flaws, and outlining areas for future research. A number of systematic reviews also exist (<a href="./references#CD001206-bbs2-0166" title="BlancoC , SchneierFR , SchmidtA , Blanco‐JerezC , MarshallRD , Sanchez‐LacayA , et al. Pharmalogical treatment of social anxiety disorder: a meta‐analysis. Depression and Anxiety2003;18(1):29‐40. ">Blanco 2003</a>; <a href="./references#CD001206-bbs2-0175" title="DavisML , SmitsJAJ , HofmannSG . Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta‐analysis. Expert Opinion on Pharmacotherapy2014;15(16):2281‐91. ">Davis 2014</a>; <a href="./references#CD001206-bbs2-0188" title="FedoroffIC , TaylorS . Psychological and pharmacological treatments of social phobia. Journal of Clinical Psychopharmacology2001;21(3):311‐24. ">Fedoroff 2001</a>; <a href="./references#CD001206-bbs2-0193" title="GouldRA , BuckministerS , PollackMH , OttoMW , YapL . Cognitive‐behavioral and pharmacological treatments of social phobia. Clinical Psychology ‐ Science &amp; Practice1997;4(4):291‐306. ">Gould 1997</a>; <a href="./references#CD001206-bbs2-0233" title="Van derLindenGJ , SteinDJ , vanBalkomAJ . The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta‐analysis of randomized controlled trials. International Clinical Psychopharmacology2000;15(Suppl 2):15‐24. ">Van der Linden 2000</a>), and these have provided useful lessons for both clinicians and researchers. Further reviews in this area, from Cochrane or elsewhere, need to adhere to guidelines for the systematic identification of trials, investigation of sources of heterogeneity, measurement of methodological quality, and estimation of the effects of intervention (<a href="./references#CD001206-bbs2-0212" title="MoherD , CookDJ , EastwoodS , OlkinI , RennieD , StroupDF . Improving the quality of reports of meta‐analyses of randomized controlled trials: the QUOROM statement. Lancet1999;354(9193):1896‐900. ">Moher 1999</a>; <a href="./references#CD001206-bbs2-0213" title="MulrowCD , OxmanAD . Cochrane Collaboration Handbook. Oxford: Update Software, 1997. ">Mulrow 1997</a>). </p> <p>The authors updated the systematic review of RCTs of the pharmacotherapy of SAnD, following Cochrane guidelines and software (<a href="./references#CD001206-bbs2-0198" title="HigginsJPT , GreensS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>; <a href="./references#CD001206-bbs2-0218" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001206-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001206-sec-0021"></div> <p>To assess the effects of pharmacotherapy for social anxiety disorder in adults and identify which factors (methodological or clinical) predict response to treatment. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001206-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001206-sec-0022"></div> <section id="CD001206-sec-0023"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001206-sec-0024"> <h4 class="title">Types of studies</h4> <p>We considered all RCTs, irrespective of publication status, methodological differences, or language. We only included trials comparing multiple forms of medication if one of the comparison groups was a placebo group. Because publication is not necessarily related to study quality and indeed may imply certain biases (<a href="./references#CD001206-bbs2-0181" title="DickersinK , MinYI , MeinertCL . Factors influencing the publication of research results: follow‐up of applications submitted to two substantial review boards. JAMA1992;267(3):374‐8. ">Dickersin 1992</a>; <a href="./references#CD001206-bbs2-0185" title="EasterbrookPJ , BerlineJA , GopalanR , MathewsDR . Publication bias in clinical research. Lancet1991;337(8746):867‐72. ">Easterbrook 1991</a>; <a href="./references#CD001206-bbs2-0220" title="SchererRW , DickersinK , LangenbergP . Full publication of results initially presented in abstracts. A meta‐analysis. JAMA1994;272(2):158‐62. ">Scherer 1994</a>), we also considered unpublished reports, abstracts, and brief and preliminary reports. We also included cluster‐randomised controlled trials, cross‐over trials and multiple treatment trials in the analysis. </p> </section> <section id="CD001206-sec-0025"> <h4 class="title">Types of participants</h4> <section id="CD001206-sec-0026"> <h5 class="title">Participant characteristics</h5> <p>We included adult participants diagnosed with SAnD irrespective of diagnostic criteria and measure, duration and severity of SAnD symptoms, age, and sex. We did, however, tabulate these descriptors in order to address the question of their possible impact on the effects of medication. </p> </section> <section id="CD001206-sec-0027"> <h5 class="title">Comorbidities</h5> <p>We placed no restrictions on comorbid psychopathological disorders secondary to SAnD.</p> </section> <section id="CD001206-sec-0028"> <h5 class="title">Setting</h5> <p>We placed no restrictions on setting.</p> </section> <section id="CD001206-sec-0029"> <h5 class="title">Subsets of participants</h5> <p>We did not include trials that only included a subset of participants that met the review inclusion criteria in the analysis. None of the trials provided such information, so randomisation was preserved. </p> </section> </section> <section id="CD001206-sec-0030"> <h4 class="title">Types of interventions</h4> <p>We considered any medication administered to treat SAnD versus an active or non‐active placebo. We also included trials with multiple treatment arms if the comparator was a placebo, as well as placebo‐controlled trials studying multimodal treatments (cognitive behavioural therapy), if an active drug was a comparator. </p> <section id="CD001206-sec-0031"> <h5 class="title">Experimental interventions</h5> <p>We grouped specific pharmacological interventions according to medication class. We added anticonvulsants/GABAs, the anticonvulsant levetiracetam, NARIs, NaSSAs, and SARIs post hoc (see <a href="#CD001206-sec-0176">Differences between protocol and review</a>). The medication classes are listed below. </p> <p> <ul id="CD001206-list-0001"> <li> <p>5HT1A partial agonists (e.g. buspirone).</p> </li> <li> <p>Anticonvulsants/gamma‐amino butyric acids (GABAs, e.g. gabapentin and pregabalin).</p> </li> <li> <p>The anticonvulsant levetiracetam.</p> </li> <li> <p>Antipsychotics (e.g. olanzapine).</p> </li> <li> <p>Benzodiazepines (e.g. clonazepam and bromazepam).</p> </li> <li> <p>Beta‐blockers (e.g. atenolol).</p> </li> <li> <p>Mono‐amine oxidase inhibitors (MAOIs, e.g. brofaromine and moclobemide).</p> </li> <li> <p>Noradrenaline reuptake inhibitors (NARIs, e.g. atomoxetine and mirtazepine).</p> </li> <li> <p>Noradrenergic and specific serotonergic antidepressants (NaSSAs, e.g. mirtazepine).</p> </li> <li> <p>Reversible inhibitors of monoamine oxidase A (RIMAs, e.g. phenelzine).</p> </li> <li> <p>Serotonin antagonist and reuptake inhibitors (SARIs, e.g. nefazodone).</p> </li> <li> <p>Serotonin and norepinephrine reuptake inhibitors (SNRIs, e.g. venlafaxine).</p> </li> <li> <p>Selective serotonin reuptake inhibitors (SSRIs, e.g. paroxetine, fluvoxamine, sertraline, fluoxetine and citalopram). </p> </li> <li> <p>Other medications (e.g. GW876008, GR205171 and LY686017).</p> </li> </ul> </p> </section> <section id="CD001206-sec-0032"> <h5 class="title">Comparator interventions</h5> <p> <ul id="CD001206-list-0002"> <li> <p>Placebo (active or non‐active).</p> </li> </ul> </p> <p>We placed no restrictions on timing, dose, duration, or co‐interventions.</p> </section> </section> <section id="CD001206-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD001206-sec-0034"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD001206-list-0003"> <li> <p><b>Treatment efficacy</b>: </p> </li> </ol> <ul id="CD001206-list-0004"> <li> <p>Clinical Global Impressions Improvement scale or similar: we determined treatment efficacy from the number of participants with SAnD who responded to treatment, as assessed by the Clinical Global Impressions Improvement scale (CGI‐I) or a closely related measure or definition (<a href="./references#CD001206-bbs2-0195" title="GuyW . ECDEU Assessment Manual for Psychopharmacology. Washington, DC: US National Institute of Health, 1976. ">Guy 1976</a>). The CGI ranges from 1 (normal, not at all ill) to 7 (among the most extremely ill patients). We defined responders as having a change item score of 1 ('very much') improved and 2 ('much') improved. Given its wide use and its reliability as a robust measure of the clinical value of treatment in SAnD, the CGI‐I served as a primary outcome measure for comparisons of both short‐ and long‐term trials in this review. </p> </li> </ul> <ul id="CD001206-list-0005"> <li> <p>Relapse rate: The number of treatment responders who subsequently relapsed, according to investigator‐defined criteria, was compared between the medication and control groups. </p> </li> </ul> </p> <p>2.<b>Treatment tolerability</b>: we included the total proportion of participants who withdrew from the RCTs due to treatment‐emergent side effects in the analysis as a surrogate measure of treatment tolerability, in the absence of other more direct indicators. </p> </section> <section id="CD001206-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD001206-list-0006"> <li> <p><b>Reduction in SAnD symptoms</b>: we assessed symptom severity and, where available, symptom cluster response, using the Liebowitz Social Anxiety Scale (LSAS), a validated, commonly used, and psychometrically sound instrument (<a href="./references#CD001206-bbs2-0208" title="LiebowitzMR . Social Phobia. Modern Problems in Pharmacopsychiatry1987;22:141‐73. ">Liebowitz 1987</a>). The LSAS is a 24‐item scale that provides separate scores for fear and avoidance in social and performance situations, with higher scores representing increased social anxiety. The LSAS contains three total scores: total fear score (0 to 72), total avoidance score (0 to 72), and total overall score (0 to 144). Suggested interpretations are that total scores of 55 to 65 indicate moderate social phobia; 65 to 80, marked social phobia; 80 to 95, severe social phobia; and greater than 95, very severe social phobia. </p> </li> <li> <p><b>Reduction in depressive symptoms</b>: we determined comorbid depressive symptoms using standardised scales such as the Hamilton Depression scale (HAM‐D) (<a href="./references#CD001206-bbs2-0196" title="HamiltonM . The assessment of anxiety states by rating. British Journal of Medical Psychology1959;32(1):50‐5. ">Hamilton 1959</a>) or Hamilton Rating Scale for Depression (HDRS), the Beck Depression Inventory (BDI) (<a href="./references#CD001206-bbs2-0164" title="BeckAT , WardCH , MendelsonM , MockJ , ErbaughJ . An inventory for measuring depression. Archives of General Psychiartry1961;4(6):561‐71. ">Beck 1961</a>), the Montgomery–Åsberg Depression Rating Scale (MADRS) or similar. The Hamilton Depression scale (HAM‐D) is a multiple item questionnaire with 17 to 29 items (depending on the version). Patients are rated on a 3 or 5 point scale. A score of 0‐7 is considered to be normal and a score of 20 or higher moderate, severe, or very severe. The Beck Depression Inventory (BDI) is a 21‐question multiple‐choice self‐report, one of the most widely used psychometric tests for measuring the severity of depression. A score of 0–9 indicates minimal depression, 10–18 mild depression, 19–29 moderate depression and 30–63 severe depression. The MADRS is a ten‐item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders. A higher MADRS score indicates more severe depression, and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. Usual cutoff points are 0 to 6 – normal/symptom absent; 7 to 19 – mild depression; 20 to 34 – moderate depression; and &gt; 34 – severe depression. </p> </li> <li> <p><b>Functional disability</b>: we considered measures such as the Sheehan Disability Scale (SDS) (<a href="./references#CD001206-bbs2-0221" title="SheehanDV , Harnett‐SheehanK , RajBA . The measurement of disability. International Clinical Psychopharmacology1996;11(Suppl 3):89‐95. ">Sheehan 1996</a>). The Sheehan Disability Scale is a composite of three self‐rated items designed to measure the extent to which three major sectors in the patient’s life are impaired by panic, anxiety, phobic, or depressive symptoms. The patient rates the extent to which his or her 1) work, 2) social life or leisure activities, and 3) home life or family responsibilities are impaired by his or her symptoms on a 10‐point visual analogue scale. The numerical ratings of 0‐10 can be translated into a percentage if desired. The three items may be summed into a single dimensional measure of global functional impairment that ranges from 0 (unimpaired) to 30 (highly impaired). </p> </li> <li> <p><b>Dropout rates</b>: we compared all‐cause dropout rates for both short‐ and long‐term trials in order to provide some indication of treatment effectiveness. </p> </li> </ol> </p> <section id="CD001206-sec-0036"> <h6 class="title">Timing of outcome assessment</h6> <p>For studies that assessed outcomes at multiple time points (e.g. <a href="./references#CD001206-bbs2-0004" title="29060/502 . Randomised, double‐blind study of paroxetine and placebo in the treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/502#rs (first received 30 September 2005). BaldwinD , BobesJ , SteinDJ , ScharwaechterI , FaureM . Paroxetine in social phobia/social anxiety disorder. Randomised, double‐blind, placebo‐controlled study. British Journal of Psychiatry1999;175(2):120‐6. SteinDJ , BerkM , ElsC , EmsleyRA , GittelsonL , WilsonD , et al. A double‐blind placebo‐controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. South African Medical Journal1999;89(4):402‐6. ">Baldwin 1999</a>; <a href="./references#CD001206-bbs2-0007" title="BlomhoffS , HaugTT , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry2001;179(1):23‐30. BlomhoffS , HaugTT , HumbleM , HallstromK , MadsbuHP , WoldJE , et al. Treatment of generalized social phobia. New Research Abstracts. 152nd Annual Meeting of the American Psychiatric Association; May 15‐20. Washington DC, 1999:NR650. HaugTT , BlomhoffS , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Exposure therapy and sertraline in social phobia: 1‐year follow‐up of a randomised controlled trial. British Journal of Psychiatry2003;182(4):312‐8. WalkerJR . The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia. Evidence‐based Mental Health2003;6(3):90. ">Blomhoff 2001</a>; <a href="./references#CD001206-bbs2-0014" title="FeltnerD , BielskiR , Liu‐DumawM . Efficacy of pregabalin in generalised social anxiety disorder: results of a placebo‐controlled, fixed‐dose study. European Neuropsychopharmacology2010;20(Suppl 3):S525–6. FeltnerDE , Liu‐DumawM , SchweizerE , BielskiR . Efficacy of pregabalin in generalized social anxiety disorder: results of a double‐blind, placebo‐controlled, fixed‐dose study. International Clinical Psychopharmacology2011;26(4):213–20. ">Feltner 2011</a>), we synthesised data from the last assessment within a 16‐week, postbaseline period to estimate the acute effects of medication, with the final assessment in longer trials providing data for the assessment of maintenance effects (20 to 24 weeks). </p> </section> <section id="CD001206-sec-0037"> <h6 class="title">Hierarchy of outcome measures</h6> <p> <ol id="CD001206-list-0007"> <li> <p>If several measures for one outcome were reported, we selected the measures or scales laid out in the Methods. We used both clinician‐rated scales and self‐reported scales. </p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD001206-sec-0038"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001206-sec-0039"> <h4 class="title">Cochrane Specialised Register (CCMDCTR)</h4> <p>The Cochrane Common Mental Disorders Group maintained a comprehensive, specialised register of randomized controlled trials, the CCMDCTR (to June 2016). The register contains over 39,000 reference records (reports of RCTs) for anxiety disorders, depression, bipolar disorder, eating disorders, self‐harm and other mental disorders within the scope of this Group. The CCMDCTR is a partially studies based register with &gt;50% of reference records tagged to c12,500 individually PICO coded study records. Reports of trials for inclusion in the register were collated from (weekly) generic searches of Medline (1950‐), Embase (1974‐) and PsycINFO (1967‐), quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review specific searches of additional databases. Reports of trials were also sourced from international trial registries, drug companies, the hand‐searching of key journals, conference proceedings and other (non‐Cochrane) systematic reviews and meta‐analyses. Details of <a href="http://www.cmd.cochrane.org" target="_blank">CCMD's core search strategies</a> (used to identify RCTs) can be found on the Group's website with an example of the core Medline search displayed in <a href="./appendices#CD001206-sec-0153">Appendix 1</a>. </p> </section> <section id="CD001206-sec-0040"> <h4 class="title">Electronic searches</h4> <p>The CCMD Group's information specialist searched the CCMDCTR (studies and references) registers on condition alone, due to concerns regarding multiple searches, change of authorship, and broad scope of this review. The latest version of the review incorporates results of searches to 17 August 2015 (<a href="./appendices#CD001206-sec-0154">Appendix 2</a>). The information specialist ran a pre‐publication search (2 August 2017) (<a href="./appendices#CD001206-sec-0155">Appendix 3</a>) and we have placed two additional studies in Awaiting Classification. These will be incorporated in the next version of the review, as appropriate. </p> <p>The review author team also conducted earlier searches on PubMed, PsycINFO and clinicaltrials.gov (1966 to 2011), using terms 'social phobia OR social anxiety disorder' and 'medication OR pharmacotherapy OR treatment'. We undertook an initial broad search to find RCTs and open‐label trials, as well as journal and chapter reviews of the pharmacotherapy of SAnD. </p> <p>The review authors also searched the ICTRP (<a href="http://apps.who.int/trialsearch" target="_blank">apps.who.int/trialsearch</a>) using the terms 'social phobia' or 'social anxiety' as search queries for this database (August 2012). We repeated this search on 4 November 2015 and 15 March 2017. </p> <p>A 2016 Google Scholar search also yielded an additional included study by <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a>. We repeated this search on 15 March 2017. </p> </section> <section id="CD001206-sec-0041"> <h4 class="title">Searching other resources</h4> <section id="CD001206-sec-0042"> <h5 class="title">Reference lists</h5> <p>We scanned the bibliographies of all identified trials for additional studies.</p> </section> <section id="CD001206-sec-0043"> <h5 class="title">Personal communication</h5> <p>We obtained published and unpublished trials from key researchers, who we identified by the frequency with which they were cited in the bibliographies of RCTs and open‐label studies. </p> </section> </section> </section> <section id="CD001206-sec-0044"> <h3 class="title" id="CD001206-sec-0044">Data collection and analysis</h3> <p>With the exception of the Egger test of funnel plot asymmetry, and generation of the contour enhanced funnel plots (created using the metafor package of the R statistical computing platform (<a href="./references#CD001206-bbs2-0235" title="ViechtbauerW . Conducting meta‐analyses in R with the metafor package. Journal of Statistical Software2010;36(3):1‐48. ">Viechtbauer 2010</a>), we used Review Manager 5 (RevMan 5) to perform all analyses reported in this review (<a href="./references#CD001206-bbs2-0218" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). </p> <section id="CD001206-sec-0045"> <h4 class="title">Selection of studies</h4> <p>Two authors (TW and JI) independently assessed the title and abstract of RCTs identified from the search. We subsequently scanned full‐text articles agreed upon as potentially eligible. The authors independently collated the data listed under <a href="#CD001206-sec-0046">Data extraction and management</a> that satisfied the inclusion criteria specified in the <a href="#CD001206-sec-0023">Criteria for considering studies for this review</a> section. We listed studies for which we need additional information to determine eligibility in the <a href="./references#CD001206-bbs1-0003" title="">Studies awaiting classification</a> table, pending the availability of this information. We resolved any disagreements in the trial assessment and data collation procedures by discussion with a third review author (DS). </p> </section> <section id="CD001206-sec-0046"> <h4 class="title">Data extraction and management</h4> <p>We obtained the following information from each trial.</p> <p> <ol id="CD001206-list-0008"> <li> <p>Description of the trials, including the year of publication, diagnostic instrument used (e.g. the Structured Clinical Interview for DSM‐IV (SCID)), use of placebo run‐in, use of a minimal severity criterion, number of participating centres, presence of support from the pharmaceutical industry, and methodological quality. </p> </li> <li> <p>Characteristics of participants, including the diagnostic criteria met (e.g. DSM‐IV), subtype of SAnD (e.g. generalised SAnD), duration of symptoms, presence of comorbid depression, mean age, age range, and sex distribution. </p> </li> <li> <p>Characteristics of the intervention, including its duration, the class of medication used, and the doses employed. </p> </li> <li> <p>Outcome measures employed (primary and secondary), and summary continuous (means and standard deviations) and dichotomous (number of responders) data. We included additional information, such as the number of dropouts per group as well as the number that dropped out due to treatment‐emergent side effects. </p> </li> </ol> </p> <section id="CD001206-sec-0047"> <h5 class="title">Main comparisons</h5> <p>We planned to compare the following medications (grouped according to medication class) against placebo for treating SAnD. </p> <p> <ul id="CD001206-list-0009"> <li> <p>5HT1A partial agonists.</p> </li> <li> <p>Anticonvulsants/GABAs.</p> </li> <li> <p>The anticonvulsant levetiracetam.</p> </li> <li> <p>Antipsychotics.</p> </li> <li> <p>Benzodiazepines.</p> </li> <li> <p>Beta‐blockers.</p> </li> <li> <p>MAOIs.</p> </li> <li> <p>NARIs.</p> </li> <li> <p>NaSSAs.</p> </li> <li> <p>RIMAs.</p> </li> <li> <p>SARIs.</p> </li> <li> <p>SNRIs.</p> </li> <li> <p>SSRIs.</p> </li> <li> <p>Other medications.</p> </li> </ul> </p> <p>Subgroup analyses included the following comparisons.</p> <p> <ul id="CD001206-list-0010"> <li> <p>Multicentre compared to single‐centre trials.</p> </li> <li> <p>Generalised SAnD compared to inclusive SAnD.</p> </li> <li> <p>Industry funding compared to no industry funding.</p> </li> <li> <p>Inclusion versus exclusion of participants diagnosed with major depressive disorder (MDD). </p> </li> </ul> </p> </section> </section> <section id="CD001206-sec-0048"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias of each included study using the Cochrane 'Risk of bias' tool (<a href="./references#CD001206-bbs2-0198" title="HigginsJPT , GreensS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>). We considered the following six domains. </p> <p> <ol id="CD001206-list-0011"> <li> <p>Random sequence generation: did investigators use a random number table or a computerised random number generator? </p> </li> <li> <p>Allocation concealment: was the medication sequentially numbered, sealed, and placed in opaque envelopes? </p> </li> <li> <p>Blinding of participants, personnel, and outcome assessors for each main outcome or class of outcomes: was knowledge of the allocated treatment or assessment adequately prevented during the study? </p> </li> <li> <p>Incomplete outcome data for each main outcome or class of outcomes: were missing or excluded outcome data adequately addressed? </p> </li> <li> <p>Selective outcome reporting: were the reports of the study free of suggestion of selective outcome reporting? We could only make such a judgement based on the availability of the protocol. </p> </li> <li> <p>Other sources of bias: was the study apparently free of other problems that could put it at a high risk of bias? </p> </li> </ol> </p> <p>We extracted relevant information from each study report, where provided. We made a judgement on the risk of bias for each domain within and across studies, based on the following three categories: 'low' risk of bias, 'unclear' risk of bias, and 'high' risk of bias. Two independent review authors (TW and JI) assessed the risk of bias for the included studies. We discussed any disagreements with a third review author (DS). Where necessary, we contacted the authors of the studies for further information. We present all risk of bias data graphically and describe them in the text. </p> </section> <section id="CD001206-sec-0049"> <h4 class="title">Measures of treatment effect</h4> <section id="CD001206-sec-0050"> <h5 class="title">Categorical data</h5> <p>We calculated the risk ratio (RR) of response to treatment for the dichotomous outcomes of interest. We used RR instead of odds ratio (OR), as ORs are more difficult to interpret. ORs also tend to overestimate the size of the treatment effect relative to RRs, especially when the occurrence of the outcome of interest is common (as anticipated in this review, with an expected response greater than 20%) (<a href="./references#CD001206-bbs2-0180" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: EggerM , DaveySG , AltmanDG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. BMJ Publication Group, 2008:285‐312. ">Deeks 2011</a>). </p> </section> <section id="CD001206-sec-0051"> <h5 class="title">Continuous data</h5> <p>In cases in which studies used a range of scales for each outcome, such as the assessment of comorbid depressive symptoms on the Hamilton Depression scale (HAM‐D) and the Beck Depression Inventory (BDI), we calculated treatment outcome using the standardised mean difference (SMD). The SMD standardises the differences between the means of the treatment and control groups in terms of the variability observed across all participants in the trial. </p> </section> </section> <section id="CD001206-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <section id="CD001206-sec-0053"> <h5 class="title">Cluster‐randomised trials</h5> <p>In cluster‐randomised trials, groups of individuals are randomised to different interventions rather than individuals themselves. Analysing treatment response in cluster‐randomised trials without taking these groupings into account is potentially problematic, as participants within any one cluster often tend to respond in a similar manner, and thus analyses cannot assume that participants' data are independent of the rest of the cluster. Cluster‐randomised trials also face additional risk of bias issues including recruitment bias, baseline imbalance, loss of clusters, and non‐comparability with trials randomising individuals (<a href="./references#CD001206-bbs2-0198" title="HigginsJPT , GreensS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>). No cluster‐randomised trials were eligible for inclusion in this review. To prevent unit of analysis errors in future updates of this review, we plan to divide the effective sample size of each comparison group in trials that do not adjust for clustering by the design effect metric (<a href="./references#CD001206-bbs2-0198" title="HigginsJPT , GreensS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>). For these analyses the intraclass correlation coefficient (ICC) that is incorporated within the design effect will be set equivalent to the median ICC from published cluster‐randomised pharmacotherapy RCTs for anxiety disorders. </p> </section> <section id="CD001206-sec-0054"> <h5 class="title">Cross‐over trials</h5> <p>We only included cross‐over trials in the calculation of summary statistics when it was possible to extract medication and placebo/comparator data from the first treatment period or when the inclusion of these data from both treatment periods was justified by a washout period of sufficient duration that minimised the risk of carry‐over effects. In the latter case, we included data from both periods only when it was possible to determine the correlation between participants' responses to the interventions in the different phases (<a href="./references#CD001206-bbs2-0187" title="ElbourneDR , AltmanDG , HigginsJPT , CurtinF , WorthingtonHV , VailA . Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology2002;31(1):140‐9. ">Elbourne 2002</a>). A washout period of at least two weeks was necessary in the case of trials assessing the efficacy of agents with extended half‐lives, such as the SSRI fluoxetine (<a href="./references#CD001206-bbs2-0194" title="GuryC , CousinF . Pharmacokinetics of SSRI antidepressants: half‐life and clinical applicability. Encephale1999;25(5):470‐6. ">Gury 1999</a>). </p> </section> <section id="CD001206-sec-0055"> <h5 class="title">Multiple treatment groups</h5> <p>A number of the trials included in this review compared more than two intervention groups or multiple doses of the same medication against placebo. Including data from the same placebo group for these studies repeatedly in the same comparison would result in a unit of analysis error (<a href="./references#CD001206-bbs2-0198" title="HigginsJPT , GreensS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>). To prevent these errors for trials comparing multiple dosages of the same agent to placebo, we averaged the mean and standard deviation of the outcome of interest across dosage groups. We included outcome data from multiple treatment arms in the same comparison if the agents tested were from different medication classes. We turned off the subtotals of the outcome if the placebo group appeared twice in the analysis to accommodate for the second medication. In the case of trials testing multiple agents from the same classes, and in calculating the total effect across all medication classes, we restricted data from multi‐arm RCTs to the agent that was least represented in the database. </p> <p>We will circumvent unit‐of‐analysis bias resulting from the simultaneous comparison of multiple arms from the same trial in future updates of this review by means of a multiple‐treatments meta‐analysis (MTM) (<a href="./references#CD001206-bbs2-0209" title="Lumley , T . Network meta‐analysis for indirect treatment comparisons. Statistics in Medicine2002;21(16):2313‐24. ">Lumley 2002</a>). An MTM allows the assessment of treatment efficacy through the combination of both direct and indirect comparisons of all interventions on a specific outcome. We can subsequently assess potential unit‐of‐analysis bias in a sensitivity analysis in which we compare the results obtained with those from a meta‐analysis restricted to data from direct comparisons of interventions. </p> </section> </section> <section id="CD001206-sec-0056"> <h4 class="title">Dealing with missing data</h4> <p>All analyses of dichotomous data were intention‐to‐treat (ITT). We only included data from trials providing information on the original group size (prior to dropouts) in the analyses of treatment efficacy. We gave preference within studies to the inclusion of summary statistics for continuous outcome measures derived from mixed‐effects models, followed by last observation carried forward (LOCF) and observed cases (OC) summary statistics (in that order). This is in line with evidence that mixed‐effects methods are more robust to bias than LOCF analyses (<a href="./references#CD001206-bbs2-0234" title="VerbekeM , MolenberghsG . Linear Mixed Models for Longitudinal Data. New York: Springer, 2000. ">Verbeke 2000</a>). </p> </section> <section id="CD001206-sec-0057"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by means of the Chi<sup>2</sup> test for heterogeneity to assess whether observed differences in results were compatible with chance alone. A low P value (or a large Chi<sup>2</sup> test relative to its degree of freedom (df)) provides evidence of heterogeneity of intervention effects (variation in effect estimates beyond chance). If the Chi<sup>2</sup> test had a P value of less than 0.10, we interpreted it as evidence of heterogeneity, given the low power of the Chi<sup>2</sup> test when the number of trials is small (<a href="./references#CD001206-bbs2-0180" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: EggerM , DaveySG , AltmanDG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. BMJ Publication Group, 2008:285‐312. ">Deeks 2011</a>). We also used the Deeks' stratified test of heterogeneity (<a href="./references#CD001206-bbs2-0178" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: EggerM , DaveySG , AltmanDG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. BMJ Publication Group, 2008:285‐312. ">Deeks 200</a>), as implemented in RevMan 5, to assess differences by means of the Q<sub>b</sub> metric in treatment response between subgroups, by subtracting the sum of the Chi<sup>2</sup> statistic for the subgroups from the total Chi<sup>2</sup> statistic for those subgroups. </p> <p>In addition, we used the I<sup>2</sup> statistic reported by RevMan 5 to quantify the inconsistency of the trial results within each analysis (<a href="./references#CD001206-bbs2-0197" title="HigginsJT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(6):557‐60. ">Higgins 2003</a>). Thresholds for the interpretation of I<sup>2</sup> can be misleading, since the importance of inconsistency depends on several factors. We followed a rough guide for interpretation. </p> <p> <ul id="CD001206-list-0012"> <li> <p>0% to 40%: might not be important.</p> </li> <li> <p>30% to 60%: may represent moderate heterogeneity.</p> </li> <li> <p>50% to 90%: may represent substantial heterogeneity.</p> </li> <li> <p>75% to 100%: considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD001206-sec-0058"> <h4 class="title">Assessment of reporting biases</h4> <p>Funnel plots provide a graphic illustration of the effect estimates of an intervention from individual studies against some measure of the precision of that estimate. We visually inspected publication bias from the funnel plot for treatment efficacy, with the consideration of confounding selection bias, poor methodological quality, true heterogeneity, artefact, and chance. We also calculated Eggers' regression tests as a more objective quantitative measure of funnel plot asymmetry using the Dersimonian and Laird estimator of heterogeneity (<a href="./references#CD001206-bbs2-0186" title="EggerM , SmithGD , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;13(315(7109)):629–34. ">Egger 1997</a>). Given that both tests are dependent on having 10 trials per outcome, we could only calculate this for SSRIs. <a href="./references#CD001206-bbs2-0202" title="IrwigL , MacaskillP , BerryG , GlasziouP . Bias in meta‐analysis detected by a simple, graphical test. Graphical test is itself biased. BMJ1998;316(7109):470‐1. ">Irwig 1998</a> and others have voiced concerns that the statistical phenomenon increasing the likelihood of falsely detecting publication bias when applying the Egger test to odds ratio effect estimates may extend to risk ratio effect estimates (<a href="./references#CD001206-bbs2-0230" title="SterneJAC , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Sterne 2011</a>). Accordingly, we generated contour enhanced funnel plots, which explicitly illustrate the relationship between missing studies and the statistical significance of study findings at various statistical thresholds (e.g. alpha = 0.1, 0.05, and 0.01) (<a href="./references#CD001206-bbs2-0217" title="PetersJL , SuttonAJ , JonesDR , AbramsKR , RushtonL . Contour‐enhanced meta‐analysis funnel plots help distinguish publication bias from other causes of asymmetry. Journal of Clinical Epidemiology2008;61(10):991‐6. ">Peters 2008</a>). We estimated the position of missing studies in these plots using the trim and fill method. </p> </section> <section id="CD001206-sec-0059"> <h4 class="title">Data synthesis</h4> <p>We obtained binary and continuous treatment effects from a random‐effects model. Random‐effects analytic models include both within‐study sampling error and between‐study variation in determining the precision of the confidence interval around the overall effect size, whereas fixed‐effect modelling approaches take only within‐study variation into account. In recognition of the possibility of differential effects for different types of medication, such as the SSRIs and the MAOIs, we stratified all of the comparisons by medication class. We expressed the outcomes of these comparisons in terms of an average effect and 95% confidence interval (CI) for each subgroup. </p> </section> <section id="CD001206-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We conducted the following subgroup analyses to assess the degree to which methodological differences between trials might have systematically influenced differences observed in the primary treatment outcomes (<a href="./references#CD001206-bbs2-0231" title="ThompsonSG . Why sources of heterogeneity in meta‐analysis should be investigated. BMJ1994;309(6965):1351‐15. ">Thompson 1994</a>). </p> <p> <ul id="CD001206-list-0013"> <li> <p>We compared multicentre versus single‐centre trials. The latter are more likely to be associated with lower sample size but will tend to have less variability in clinician ratings. </p> </li> <li> <p>We compared trials including only participants diagnosed with the generalised form of SAnD versus those including both the generalised and specific subtypes of SAnD. Specialists recognise generalised SAnD as often representing a more severe form of the disorder. </p> </li> </ul> </p> <p>In addition, we assessed the following.</p> <p> <ul id="CD001206-list-0014"> <li> <p>Whether or not trials were industry funded. In general, published trials sponsored by pharmaceutical companies appear more likely to report positive findings than trials that are not supported by profit companies (<a href="./references#CD001206-bbs2-0156" title="Als‐NielsenB , ChenW , GluudC , KjaergardLL . Association of funding and conclusions in randomized drug trials ‐ a reflection of treatment effect or adverse events?. JAMA2003;290(7):921‐8. ">Als‐Nielsen 2003</a>; <a href="./references#CD001206-bbs2-0158" title="BakerCB , JohnsrudMT , CrismonML , RosenheckRA , WoodsSW . Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry2003;183(6):498‐506. ">Baker 2003</a>). </p> </li> <li> <p>Whether or not the sample included patients diagnosed with major depression. Such an analysis might assist in determining the extent to which the efficacy of a medication agent in treating SAnD is independent of its ability to reduce symptoms of depression, an important consideration given the classification of many of these medications as anti‐depressants. </p> </li> </ul> </p> </section> <section id="CD001206-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses determine the robustness of the review authors' conclusion to methodological assumptions made in conducting the meta‐analysis. We planned to compare the effect of assessing interventions in terms of clinical treatment response versus non‐response in light of evidence that treatment response may result in less consistent outcome statistics than non‐response (<a href="./references#CD001206-bbs2-0179" title="DeeksJJ . Issues in the selection of a summary statistic for meta‐analysis of clinical trials with binary outcomes. Statistics in Medicine2002;21(11):1575‐600. ">Deeks 2002</a>). However, reports on this potential difference in outcome consistency have arisen only when the control group event rate was above 50%, far higher than the baseline proportion of response observed across trials in this review (30%). Accordingly, we did not conduct this analysis. </p> <p>In addition, we performed a 'worst case/best case' analysis to determine whether the the coding of participants who were lost to follow‐up influenced the findings of treatment efficacy (<a href="./references#CD001206-bbs2-0180" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: EggerM , DaveySG , AltmanDG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. BMJ Publication Group, 2008:285‐312. ">Deeks 2011</a>). In this analysis, we recorded all the missing data for the treatment group as responders in the worst case scenario, whereas in the best case, we coded all missing data for the control group as responders. If the conclusions regarding treatment efficacy did not differ between these two comparisons, we assumed that missing data in trial reports did not have a significant influence on this outcome. </p> <section id="CD001206-sec-0062"> <h5 class="title">Summary of findings tables</h5> <p>We compiled 'Summary of findings' tables to summarise the best evidence for all relevant outcomes (i.e. experimental versus comparator interventions), reporting the following six elements according to a fixed format (<a href="./references#CD001206-bbs2-0198" title="HigginsJPT , GreensS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. The Cochrane Collaboration. Available from www.cochrane‐handbook.org, 2011. ">Higgins 2011</a>). </p> <p> <ul id="CD001206-list-0015"> <li> <p>A list of all important outcomes, both desirable and undesirable.</p> </li> <li> <p>A measure of the typical burden of these outcomes (e.g. illustrative risk, or illustrative mean, on control intervention). </p> </li> <li> <p>Absolute and relative magnitude of effect (if both are appropriate).</p> </li> <li> <p>Numbers of participants and studies addressing these outcomes.</p> </li> <li> <p>A grade of the overall quality of the body of evidence for each outcome.</p> </li> <li> <p>Space for comments.</p> </li> </ul> </p> <p>We based downgrading of the evidence rating for outcomes on five factors. We classified reasons for downgrading the evidence as 'serious' (downgrading the quality rating by one level) or 'very serious' (downgrading the quality grade by two levels). </p> <p> <ul id="CD001206-list-0016"> <li> <p>Limitations in the design and implementation of the trial.</p> </li> <li> <p>Indirectness of evidence.</p> </li> <li> <p>Unexplained heterogeneity or inconsistency of results.</p> </li> <li> <p>Imprecision of results.</p> </li> <li> <p>High probability of publication bias.</p> </li> </ul> </p> <p>We classified the quality of evidence for each outcome according to the following categories. </p> <p> <ul id="CD001206-list-0017"> <li> <p>High quality: further research is very unlikely to change our confidence in the estimate of effect. </p> </li> <li> <p>Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. </p> </li> <li> <p>Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. </p> </li> <li> <p>Very low quality: we are very uncertain about the estimate.</p> </li> </ul> </p> </section> <section id="CD001206-sec-0063"> <h5 class="title">Main comparisons</h5> <p>We planned the following outcomes and grouped specific pharmacological interventions according to medication class. </p> <p> <ul id="CD001206-list-0018"> <li> <p>5HT1A partial agonists versus placebo.</p> </li> <li> <p>Anticonvulsants/GABAs versus placebo.</p> </li> <li> <p>The anticonvulsant levetiracetam versus placebo.</p> </li> <li> <p>Antipsychotics versus placebo.</p> </li> <li> <p>Benzodiazepines versus placebo.</p> </li> <li> <p>Beta‐blockers versus placebo.</p> </li> <li> <p>MAOIs versus placebo.</p> </li> <li> <p>NARIs versus placebo.</p> </li> <li> <p>NaSSAs versus placebo.</p> </li> <li> <p>RIMAs versus placebo.</p> </li> <li> <p>SARIs versus placebo.</p> </li> <li> <p>SNRIs versus placebo.</p> </li> <li> <p>SSRIs versus placebo.</p> </li> <li> <p>Other medication versus placebo.</p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001206-sec-0064" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001206-sec-0064"></div> <section id="CD001206-sec-0065"> <h3 class="title">Description of studies</h3> <section id="CD001206-sec-0066"> <h4 class="title">Results of the search</h4> <p>We found a total of 2611 study reports through the search process (CCMDCTR 2162; ICTRP 449). We scanned each title and abstract (if provided) for eligibility. Three hundred and two studies initially seemed relevant, but after further inspection we excluded 166 of these, leaving 136 studies that potentially met the inclusion criteria (we found the additional study by <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a> from a search conducted in 2016). After independent review of the full‐text studies, we found that 70 failed to meet inclusion criteria, leaving 66 RCTs eligible for inclusion in the review (see <a href="./references#CD001206-sec-0178" title="">Characteristics of included studies</a> and <a href="#CD001206-fig-0001">Figure 1</a>). Of the 66 trials, we included 63 RCTs in the meta‐analysis. Eleven studies are awaiting classification, and five studies are ongoing (see <a href="./references#CD001206-bbs1-0003" title="">Studies awaiting classification</a> and <a href="./references#CD001206-bbs1-0004" title="">Ongoing studies</a>). </p> <div class="figure" id="CD001206-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001206-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The update search performed by CCMD's information specialist retrieved 754 records (de‐duplicated), and after screening the abstracts, we identified an addition two studies which we have added to awaiting classification. We will incorporate these into the next version of the review as appropriate. </p> </section> <section id="CD001206-sec-0067"> <h4 class="title">Included studies</h4> <section id="CD001206-sec-0068"> <h5 class="title">Design</h5> <p>The review includes 66 RCTs treating participants for SAnD from 1 to 24 weeks. Of these, 56 of the trials were short term (14 weeks or less), while 7 trials included a maintenance component, and 4 trials a relapse component (14 to 24 weeks or less). This update includes 29 new studies. All trials included a placebo comparison group, with eight studies having two medication arms (i.e. two trials assessing paroxetine and venlafaxine, and one trial each assessing citalopram and NK1 antagonist GR205171, paroxetine and escitalopram, phenelzine and atenolol, paroxetine and neurokinin‐1 (NK‐1) antagonist LY686017, phenelzine and moclobemide, and GW876008 and paroxetine) (<a href="./references#CD001206-bbs2-0002" title="AllgulanderC , ManganoR , ZhangJ , DahlAA , LepolaU , SjödinI , EmilienG . Efficacy of venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine. Human Psychopharmacology2004;19(6):387‐96. ManganoR , LiebowitzMR , AllgulanderC . Comparison of venlafaxine extended release and paroxetine in short‐term treatment of SAD. New Research Abstracts. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22. San Francisco (CA), 2003. ">Allgulander 2004</a>; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0021" title="LaderM , StenderK , BurgerV , NilR . Efficacy and tolerability of escitalopram in 12‐ and 24‐week treatment of social anxiety disorder: randomised, double‐blind, placebo‐controlled, fixed dose study. Depression and Anxiety2004;19:241‐8. ">Lader 2004</a>; <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>; <a href="./references#CD001206-bbs2-0027" title="Liebow3149018itzMR , GelenbergAJ , MunjackD . Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry2005;62(2):190‐8. ">Liebowitz 2005b</a>; <a href="./references#CD001206-bbs2-0033" title="NCT00397722 . Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [Treatment of patients with social anxiety disorder]. clinicaltrials.gov/ct2/show/results/NCT00397722 (first received 8 November 2006). ">NCT00397722</a>; <a href="./references#CD001206-bbs2-0054" title="TauscherJ , KielbasaW , IyengarS , VandenhendeF , PengX , MozleyD , et al. Development of the 2nd generation neurokinin‐1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology2010;20(2):80‐7. ">Tauscher 2010</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>). <a href="./references#CD001206-bbs2-0019" title="KatzelnickDJ , KobakKA , GreistJH , JeffersonJW , MantleJM , SerlinRC . Sertraline for social phobia: a double‐blind, placebo‐controlled crossover study. American Journal of Psychiatry1995;152(9):1368‐71. ">Katzelnick 1995</a> employed a a cross‐over design in testing the efficacy of sertraline. All trials were published in English, and pharmaceutical companies contributed funding for 41. </p> </section> <section id="CD001206-sec-0069"> <h5 class="title">Participants</h5> <p>The 66 eligible trials included 11,597 participants aged 18 to 70, most of whom were outpatients. The average sample size was 176 and ranged from 12 in <a href="./references#CD001206-bbs2-0005" title="BarnettSD , KramerML , CasatCD , ConnorKM , DavidsonJR . Efficacy of olanzapine in social anxiety disorder: a pilot study. Journal of Psychopharmacology2002;16(4):365‐8. ">Barnett 2002</a> and <a href="./references#CD001206-bbs2-0019" title="KatzelnickDJ , KobakKA , GreistJH , JeffersonJW , MantleJM , SerlinRC . Sertraline for social phobia: a double‐blind, placebo‐controlled crossover study. American Journal of Psychiatry1995;152(9):1368‐71. ">Katzelnick 1995</a> to 839 in <a href="./references#CD001206-bbs2-0021" title="LaderM , StenderK , BurgerV , NilR . Efficacy and tolerability of escitalopram in 12‐ and 24‐week treatment of social anxiety disorder: randomised, double‐blind, placebo‐controlled, fixed dose study. Depression and Anxiety2004;19:241‐8. ">Lader 2004</a>. Sixty trials involved both men and women, while <a href="./references#CD001206-bbs2-0030" title="MuehlbacherM , NickelMK , NickelC , KettlerC , LahmannC , GilFP , et al. Mirtazapine treatment of social phobia in women. A randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychopharmacology2005;25(6):580‐3. ">Muehlbacher 2005</a> included only women and <a href="./references#CD001206-bbs2-0029" title="MoghadamMNM , Atef‐VahidMK , Asgharnejad‐FaridAA , ShabaniA , LavasniF . Effectiveness of short‐term dynamic psychotherapy versus sertraline in treatment of social phobia. Iranian Journal of Psychiatry and Behavioral Sciences2015;9(2):e228. ">Moghadam 2015</a> only men. Adult participants were diagnosed with SAnD according to DSM criteria (DSM‐IV‐TR, DSM‐IV, DSM‐III‐R), assessed by means of a variety of instruments, including the Structured Clinical Interview for DSM (SCID/SCID‐I) (e.g. <a href="./references#CD001206-bbs2-0029" title="MoghadamMNM , Atef‐VahidMK , Asgharnejad‐FaridAA , ShabaniA , LavasniF . Effectiveness of short‐term dynamic psychotherapy versus sertraline in treatment of social phobia. Iranian Journal of Psychiatry and Behavioral Sciences2015;9(2):e228. ">Moghadam 2015</a>; <a href="./references#CD001206-bbs2-0035" title="NCT00470483 . A Double‐Blind, Randomized, Placebo‐Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge‐induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects With Social Anxiety Disorder [A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/results/NCT00470483 (first received 3 May 2007). ">NCT00470483</a>), the Mini International Neuropsychiatric Interview (MINI) (e.g. <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0022" title="LepolaU , BergtholdtB , LambertJS , DavyKL , RuggieroL . Controlled‐release paroxetine in the treatment of patients with social anxiety disorder. Journal of Clinical Psychiatry2004;65:222‐9. ">Lepola 2004</a>; <a href="./references#CD001206-bbs2-0034" title="NCT00403962 . A Randomised, Double‐Blind, Parallel‐Group, Placebo‐Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD) [A Combination Therapy In Patients With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/NCT00403962 (first received 29 August 2005). ">NCT00403962</a>; <a href="./references#CD001206-bbs2-0050" title="29060/595 . A study of the maintained efficacy and safety of paroxetine versus placebo in the long‐term treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/595#rs (first received 28 September 2008). SteinDJ , VersianiM , HairT , KumarR . Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24‐week study. Archives of General Psychiatry2002;59(12):1111‐8. ">Stein 2002b</a>; <a href="./references#CD001206-bbs2-0066" title="ZhangW , ConnorKM , DavidsonJRT . Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology2005;19(5):551‐3. ">Zhang 2005</a>), and the Initial Evaluation Form and the Anxiety Disorders Interview Schedule‐Revised (ADIS‐R) (e.g. <a href="./references#CD001206-bbs2-0055" title="TurnerS , BeidelDC , JacobRG . Social phobia: a comparison of behaviour therapy and atenolol. Journal of Consulting and Clinical Psychology1994;62(2):350‐8. ">Turner 1994</a>). </p> <p>Twenty‐one studies included individuals with major depressive disorder (MDD), while MDD was an exclusion criterion for 41. Four studies did not specify, so we were unable to determine whether or not individuals with MDD could take part (<a href="./references#CD001206-bbs2-0029" title="MoghadamMNM , Atef‐VahidMK , Asgharnejad‐FaridAA , ShabaniA , LavasniF . Effectiveness of short‐term dynamic psychotherapy versus sertraline in treatment of social phobia. Iranian Journal of Psychiatry and Behavioral Sciences2015;9(2):e228. ">Moghadam 2015</a>; <a href="./references#CD001206-bbs2-0035" title="NCT00470483 . A Double‐Blind, Randomized, Placebo‐Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge‐induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects With Social Anxiety Disorder [A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/results/NCT00470483 (first received 3 May 2007). ">NCT00470483</a>; <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a>; <a href="./references#CD001206-bbs2-0054" title="TauscherJ , KielbasaW , IyengarS , VandenhendeF , PengX , MozleyD , et al. Development of the 2nd generation neurokinin‐1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology2010;20(2):80‐7. ">Tauscher 2010</a>). We also reported other comorbidities related to functional disability and avoidant personality where provided. </p> </section> <section id="CD001206-sec-0070"> <h5 class="title">Setting</h5> <p>Most eligible RCTs took place in the USA (number of studies (k) = 58), while others were in Europe (k = 10), Japan (k = 2), South Africa (k = 6), and Iran (k = 1). Of the trials included in the analysis, 24 studies were single‐centre trials, and 42 studies took place in multiple centres. Participants were recruited via telephone, newspaper, radio, or clinical referral. Recruitment settings included university‐based hospitals and centres, medical centres, and research and private clinics. </p> </section> <section id="CD001206-sec-0071"> <h5 class="title">Interventions</h5> <p>Approximately half of the included RCTs tested the efficacy of selective serotonin reuptake inhibitors (SSRIs; k = 34), including 19 studies of paroxetine, of which two studies had a third arm investigating venlafaxine, one study had a third arm investigating escitalopram, one had a third arm investigating LY686017 and another a third arm investigating GW876008 (<a href="./references#CD001206-bbs2-0001" title="AllgulanderC . Efficacy of paroxetine in social phobia ‐ a single‐center double‐blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20‐50 mg or placebo for 3 months. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4. Paris, France, 1998:P.3.005. AllgulanderC . Paroxetine in social anxiety disorder: a randomised placebo‐controlled study. Acta Psychiatrica Scandinavica1999;100(3):193‐8. ">Allgulander 1999</a>; <a href="./references#CD001206-bbs2-0002" title="AllgulanderC , ManganoR , ZhangJ , DahlAA , LepolaU , SjödinI , EmilienG . Efficacy of venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine. Human Psychopharmacology2004;19(6):387‐96. ManganoR , LiebowitzMR , AllgulanderC . Comparison of venlafaxine extended release and paroxetine in short‐term treatment of SAD. New Research Abstracts. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22. San Francisco (CA), 2003. ">Allgulander 2004;</a><a href="./references#CD001206-bbs2-0004" title="29060/502 . Randomised, double‐blind study of paroxetine and placebo in the treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/502#rs (first received 30 September 2005). BaldwinD , BobesJ , SteinDJ , ScharwaechterI , FaureM . Paroxetine in social phobia/social anxiety disorder. Randomised, double‐blind, placebo‐controlled study. British Journal of Psychiatry1999;175(2):120‐6. SteinDJ , BerkM , ElsC , EmsleyRA , GittelsonL , WilsonD , et al. A double‐blind placebo‐controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. South African Medical Journal1999;89(4):402‐6. ">Baldwin 1999</a>; <a href="./references#CD001206-bbs2-0008" title="BookSW , ThomasSE , RandallPK , RandallCL . Paroxetine reduces social anxiety in individuals with a co‐occurring alcohol use disorder. Journal of Anxiety Disorders2008;22(2):310‐8. ThomasSE , RandallPK , BookSW , RandallCL . A complex relationship between co‐occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research2008;32(1):77‐84. ">Book 2008</a>; <a href="./references#CD001206-bbs2-0021" title="LaderM , StenderK , BurgerV , NilR . Efficacy and tolerability of escitalopram in 12‐ and 24‐week treatment of social anxiety disorder: randomised, double‐blind, placebo‐controlled, fixed dose study. Depression and Anxiety2004;19:241‐8. ">Lader 2004</a>; <a href="./references#CD001206-bbs2-0022" title="LepolaU , BergtholdtB , LambertJS , DavyKL , RuggieroL . Controlled‐release paroxetine in the treatment of patients with social anxiety disorder. Journal of Clinical Psychiatry2004;65:222‐9. ">Lepola 2004</a>; <a href="./references#CD001206-bbs2-0024" title="LiebowitzMR , SteinMB , TancerM , CarpenterD , OakesR , PittsCD . A randomized, double‐blind, fixed‐dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry2002;63(1):66‐74. ">Liebowitz 2002</a>; <a href="./references#CD001206-bbs2-0027" title="Liebow3149018itzMR , GelenbergAJ , MunjackD . Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry2005;62(2):190‐8. ">Liebowitz 2005b</a>; <a href="./references#CD001206-bbs2-0031" title="NCT00273039 . A Study Of A New Medicine (GW679769) For The Treatment Of Social Anxiety Disorder [A Randomized, Double‐Blind, Parallel Group, Placebo‐Controlled, Forced Dose Titration Study Evaluating the Efficacy and Safety of GW679769 and Paroxetine in Subjects With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/record/NCT00273039 (first received 5 January 2006). ">NCT00273039</a>; <a href="./references#CD001206-bbs2-0032" title="NCT00318669 . Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) ‐A Double‐blind, Placebo‐controlled Study‐ &lt;Phase III Study&gt; [Social Anxiety Disorder Study Of Paroxetine]. clinicaltrials.gov/ct2/show/NCT00318669 (first received 24 April 2006). ">NCT00318669</a>; <a href="./references#CD001206-bbs2-0034" title="NCT00403962 . A Randomised, Double‐Blind, Parallel‐Group, Placebo‐Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD) [A Combination Therapy In Patients With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/NCT00403962 (first received 29 August 2005). ">NCT00403962</a>; <a href="./references#CD001206-bbs2-0033" title="NCT00397722 . Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [Treatment of patients with social anxiety disorder]. clinicaltrials.gov/ct2/show/results/NCT00397722 (first received 8 November 2006). ">NCT00397722</a>; <a href="./references#CD001206-bbs2-0035" title="NCT00470483 . A Double‐Blind, Randomized, Placebo‐Controlled, Parallel Group, fMRI and PET Study Comparing Emotional Challenge‐induced Regional Cerebral Blood Flow Changes Before and After 8 Weeks of Treatment With Placebo and Paroxetine in Subjects With Social Anxiety Disorder [A Study To Compare Emotional Changes In Subjects With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/results/NCT00470483 (first received 3 May 2007). ">NCT00470483</a>; <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a>; <a href="./references#CD001206-bbs2-0041" title="RandallCL , JohnsonMR , ThevosAK , SonneSC , ThomasSE , WillardSL , et al. Paroxetine for social anxiety and alcohol use in dual‐diagnosed patients. Depression &amp; Anxiety2001;14(4):255‐62. RandallCL , JohnsonMR , ThevosAK , SonneSC , WillardSL , ThomasSE , et al. Paroxetine improves both social anxiety and alcohol use in dual‐diagnosed patients. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. ">Randall 2001</a>; <a href="./references#CD001206-bbs2-0046" title="SteinMB , ChartierMJ , HazenAL , KroftCD , ChaleRA , CotéD , et al. Paroxetine in the treatment of generalized social phobia: open‐label treatment and double‐blind placebo‐controlled discontinuation. Journal of Clinical Psychopharmacology1996;16(3):218‐22. ">Stein 1996</a>; <a href="./references#CD001206-bbs2-0047" title="SteinMB , LiebowitzMR , LydiardRB , PittsCD , BushnellW , GergelI . Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA1998;280(8):708‐13. ">Stein 1998</a>; <a href="./references#CD001206-bbs2-0051" title="SteinDJ , WestenbergHGM , YangH , LiD , BarbatoLM . Fluvoxamine CR in the long‐term treatment of social anxiety disorder: the 12‐ to 24‐week extension phase of a multicentre, randomized, placebo‐controlled trial. International Journal of Neuropsychopharmacology2003;6(4):317‐23. ">Stein 2003</a>; <a href="./references#CD001206-bbs2-0054" title="TauscherJ , KielbasaW , IyengarS , VandenhendeF , PengX , MozleyD , et al. Development of the 2nd generation neurokinin‐1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology2010;20(2):80‐7. ">Tauscher 2010</a>). In addition, the SSRI RCTs included five trials of fluvoxamine (<a href="./references#CD001206-bbs2-0003" title="AsakuraS , TajimaO , KoyamaT . Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized, double‐blind, placebo‐controlled study. International Journal of Neuropsychopharmacology2007;10(2):263‐74. ">Asakura 2007</a>; <a href="./references#CD001206-bbs2-0011" title="DavidsonJ , Yaryura‐TobiasJ , DuPontR , StallingsL , BarbatoLM , Van derHoopRG , et al. Fluvoxamine‐controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(2):118‐25. DavidsonJR , HembyLW , BarbatoL , Van derHoopRG . Fluvoxamine controlled release for the treatment of generalized social anxiety disorder. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14;. San Juan, Puerto Rico, 2000:161. ">Davidson 2004a</a>; <a href="./references#CD001206-bbs2-0048" title="SteinMB , FyerAJ , DavidsonJR , PollackMH , WiitaB . Fluvoxamine treatment of social phobia (social anxiety disorder): a double‐blind, placebo‐controlled study. American Journal of Psychiatry1999;156(5):756‐60. ">Stein 1999</a>; <a href="./references#CD001206-bbs2-0060" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology1994;115(1‐2):128‐34. ">Van Vliet 1994</a>; <a href="./references#CD001206-bbs2-0065" title="WestenbergHGM , SteinDJ , YangH , LiD , BarbatoLM . A double‐blind placebo‐controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(1):49‐55. ">Westenberg 2004</a>), six trials of sertraline (<a href="./references#CD001206-bbs2-0007" title="BlomhoffS , HaugTT , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry2001;179(1):23‐30. BlomhoffS , HaugTT , HumbleM , HallstromK , MadsbuHP , WoldJE , et al. Treatment of generalized social phobia. New Research Abstracts. 152nd Annual Meeting of the American Psychiatric Association; May 15‐20. Washington DC, 1999:NR650. HaugTT , BlomhoffS , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Exposure therapy and sertraline in social phobia: 1‐year follow‐up of a randomised controlled trial. British Journal of Psychiatry2003;182(4):312‐8. WalkerJR . The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia. Evidence‐based Mental Health2003;6(3):90. ">Blomhoff 2001</a>; <a href="./references#CD001206-bbs2-0019" title="KatzelnickDJ , KobakKA , GreistJH , JeffersonJW , MantleJM , SerlinRC . Sertraline for social phobia: a double‐blind, placebo‐controlled crossover study. American Journal of Psychiatry1995;152(9):1368‐71. ">Katzelnick 1995</a>; <a href="./references#CD001206-bbs2-0025" title="LiebowitzMR , DeMartinisNA , WeihsKL , LondborgPD , SmithWT , ChungH , et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64(7):785‐92. ">Liebowitz 2003</a>; <a href="./references#CD001206-bbs2-0029" title="MoghadamMNM , Atef‐VahidMK , Asgharnejad‐FaridAA , ShabaniA , LavasniF . Effectiveness of short‐term dynamic psychotherapy versus sertraline in treatment of social phobia. Iranian Journal of Psychiatry and Behavioral Sciences2015;9(2):e228. ">Moghadam 2015</a>; <a href="./references#CD001206-bbs2-0057" title="LaneR , WalkerJ , SwinsonR , VanAmeringenM . Sertraline in generalised social phobia. 11th World Congress of Psychiatry; Aug 6‐11. Hamburg, Germany, 1999. PietersG . Sertraline was effective and well tolerated for generalised social phobia. Evidence‐based Mental Health2001;4(3):91. VanAmeringenM , OakmanJM , FarvoldenPG , ManciniC , WalkerJR , LaneRM . Predictors of sertraline response in social phobia. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14. San Juan, Puerto Rico, 2000:163. VanAmeringenMA , LaneRM , WalkerJR , BowenRC , ChokkaPR , GoldnerEM , et al. Sertraline treatment of generalised social phobia: a 20‐week, double‐blind, placebo‐controlled study. American Journal of Psychiatry2001;158(2):275‐81. VanAmeringenMA , SwinsonR , WalkerJR , LaneRM . A placebo‐controlled study of sertraline in generalized social phobia [abstract]. European Neuropsychopharmacology2000;10(Suppl 3):S335. ">Van Ameringen 2001a</a>; <a href="./references#CD001206-bbs2-0064" title="WalkerJR , VanAmeringenMA , SwinsonR , BowenRC , ChokkaPR , GoldnerE , et al. Prevention of relapse in generalized social phobia: results of a 24‐week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology2000;20(6):636‐44. WalkerJR , VanAmeringenMA , SwinsonRP , LaneRM . A 24‐week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000:NR259. ">Walker 2000</a>), two trials of fluoxetine (<a href="./references#CD001206-bbs2-0012" title="AderkaIM , McLeanCP , HuppertJD , DavidsonJRT , FoaEB . Fear, avoidance and physiological symptoms during cognitive‐behavioral therapy for social anxiety disorder. Behaviour Research and Therapy2013;51(7):352‐8. DavidsonJRT , FoaEB , HuppertJD , KeefeFJ , FranklinME , ComptonJS , et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry2004;61(10):1005‐13. HuppertJD , SchultzLT , FoaEB , BarlowDH , DavidsonJR , GormanJM , et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive‐compulsive disorder. American Journal of Psychiatry2004;161(8):1485‐7. LedleyDR , HuppertJD , FoaEB , DavidsonJRT , KeefeFJ , PottsNLS . Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depression and Anxiety2005;22(4):161‐7. ">Davidson 2004b</a>; <a href="./references#CD001206-bbs2-0020" title="KobakKA , GreistJH , JeffersonJW , KatzelnickDJ . Fluoxetine in social phobia: a double‐blind, placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2002;22(3):257‐62. ">Kobak 2002</a>), and single RCTs of citalopram (<a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>, with a third arm investigating NK1 antagonist GR205171) and escitalopram (<a href="./references#CD001206-bbs2-0017" title="KasperS , LoftH , NilR . Escitalopram in the treatment of social anxiety disorder. XII World Congress of Psychiatry; Aug 24‐9. Yokohama, Japan, 2002. KasperS , LoftH , SmithJR . Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder. New Research Abstracts. 155th Annual Meeting of the American Psychiatric Association; May 18‐23;. Philadelphia (PA), 2002. KasperS , SteinDJ , LoftH , Nil , R . Escitalopram in the treatment of social anxiety disorder: randomised, placebo‐controlled, flexible‐dosage study. British Journal of Psychiatry2005;186(3):222‐6. ">Kasper 2005</a>). The lowest and highest dosage for paroxetine ranged from 7.5 mg/d (<a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-NCT00403962" target="_blank">NCT00403962</a>) to 60 mg/d (<a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Book-2008" target="_blank">Book 2008</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-NCT00397722" target="_blank">NCT00397722</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Nordahl-2016" target="_blank">Nordahl 2016</a>); for sertraline from 50 mg/d (<a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Blomhoff-2001" target="_blank">Blomhoff 2001</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Katzelnick-1995" target="_blank">Katzelnick 1995</a>) to 200 mg/d (<a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Katzelnick-1995" target="_blank">Katzelnick 1995</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Liebowitz-2003" target="_blank">Liebowitz 2003</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Van-Ameringen-2001a" target="_blank">Van Ameringen 2001a</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Walker-2000" target="_blank">Walker 2000</a>); for fluoxetine from 20 mg/d to 60 mg/d (<a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Davidson-2004b" target="_blank">Davidson 2004b</a>); for fluvoxamine from 50 mg/d (<a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Asakura-2007" target="_blank">Asakura 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Stein-1999" target="_blank">Stein 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-van-Vliet-1997" target="_blank">van Vliet 1997</a>) to 300 mg/d (<a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Asakura-2007" target="_blank">Asakura 2007</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Davidson-2004a" target="_blank">Davidson 2004a</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Stein-1999" target="_blank">Stein 1999</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Stein-2003" target="_blank">Stein 2003</a>; <a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Westenberg-2004" target="_blank">Westenberg 2004</a>); for citalopram from 20 mg/d to 40 mg/d (<a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Furmark-2005" target="_blank">Furmark 2005</a>); and for escitalopram from 10 mg/d to 20 mg/d (<a href="https://archie.cochrane.org/sections/documents/view?document=715499102709384187%26format=REVMAN#STD-Kasper-2005" target="_blank">Kasper 2005</a>). </p> <p>Eight trials studied reversible inhibitors of monoamine oxidase A (RIMAs), including three RCTs of brofaromine (<a href="./references#CD001206-bbs2-0013" title="FahlenT , HumbleM , KoczkasC , NilssonH . Social phobia and its treatment with brofaromine, efficacy regarding social phobia symptoms and personality traits. Clinical Neuropharmacology1992;15(1 Pt B):64. FahlenT , NilssonHl , BorgK , HumbleM , PauliU . Social phobia: the clinical efficacy and tolerability of the monoamine oxidase‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study. Acta Psychiatrica Scandinavica1995;92(5):351‐8. ">Fahlen 1995</a>; <a href="./references#CD001206-bbs2-0028" title="LottM , GreistJH , JeffersonJW , KobakKA , KatzelnickDJ , KatzRJ , SchaettleSC . Brofaromine for social phobia: a multicenter, placebo‐controlled, double‐blind study. Journal of Clinical Psychopharmacology1997;17(4):255‐60. ">Lott 1997</a>; <a href="./references#CD001206-bbs2-0059" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO‐A inhibitor. European Neuropsychopharmacology1992;2(1):21‐9. ">Van Vliet 1992</a>), plus five of moclobemide (<a href="./references#CD001206-bbs2-0018" title="KatschnigK , SteinMB , BullerR . Moclobemide in social phobia. A double‐blind, placebo‐controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience1997;247(2):71‐80. ">Katschnig 1997</a>; <a href="./references#CD001206-bbs2-0037" title="NoyesRJr , MorozG , DavidsonJR , LiebowitzMR , DavidsonA , SiegelJ , et al. Moclobemide in social phobia: a controlled dose response trial. Journal of Clinical Psychopharmacology1997;17(4):247‐54. ">Noyes 1997</a>; <a href="./references#CD001206-bbs2-0038" title="OosterbaanDB , VanBalkomAJLM , SpinhovenP , vanOppenP , vanDyckR . Cognitive therapy versus moclobemide in social phobia: a controlled study. Clinical Pscyhology and Psychotherapy2001;8(4):263‐73. ">Oosterbaan 2001</a>; <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>; <a href="./references#CD001206-bbs2-0049" title="SteinDJ , CameronA , AmreinR , MontgomerySA . Moclobemide is effective and well tolerated in the long‐term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology2002;17(4):161‐70. ">Stein 2002a</a>). For brofaromine, the daily dosage ranged from 50 mg/d to 150 mg/d in both <a href="./references#CD001206-bbs2-0028" title="LottM , GreistJH , JeffersonJW , KobakKA , KatzelnickDJ , KatzRJ , SchaettleSC . Brofaromine for social phobia: a multicenter, placebo‐controlled, double‐blind study. Journal of Clinical Psychopharmacology1997;17(4):255‐60. ">Lott 1997</a> and <a href="./references#CD001206-bbs2-0059" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO‐A inhibitor. European Neuropsychopharmacology1992;2(1):21‐9. ">Van Vliet 1992</a>, and for moclobemide, it ranged from 75 mg/d in <a href="./references#CD001206-bbs2-0037" title="NoyesRJr , MorozG , DavidsonJR , LiebowitzMR , DavidsonA , SiegelJ , et al. Moclobemide in social phobia: a controlled dose response trial. Journal of Clinical Psychopharmacology1997;17(4):247‐54. ">Noyes 1997</a> to 750 mg/d in <a href="./references#CD001206-bbs2-0049" title="SteinDJ , CameronA , AmreinR , MontgomerySA . Moclobemide is effective and well tolerated in the long‐term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology2002;17(4):161‐70. ">Stein 2002a</a>. </p> <p>Four trials evaluated the mono‐amine oxidase inhibitor (MAOI) phenelzine, one of which had a third arm investigating atenolol and another investigating moclobemide (<a href="./references#CD001206-bbs2-0006" title="BlancoC , HeimbergRG , SchneierFR , FrescoDM , ChenH , TurkCL , et al. A placebo‐controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry2010;67(3):286‐95. ">Blanco 2010</a>; <a href="./references#CD001206-bbs2-0016" title="HeimbergRG , LiebowitzMR , HopeDA , SchneierFR , HoltCS , WelkowitzLA , et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry1998;55(12):1133‐41. ">Heimberg 1998</a>; <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>). Dosage for the phenelzine ranged from 15 mg/d in <a href="./references#CD001206-bbs2-0006" title="BlancoC , HeimbergRG , SchneierFR , FrescoDM , ChenH , TurkCL , et al. A placebo‐controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry2010;67(3):286‐95. ">Blanco 2010</a> and <a href="./references#CD001206-bbs2-0016" title="HeimbergRG , LiebowitzMR , HopeDA , SchneierFR , HoltCS , WelkowitzLA , et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry1998;55(12):1133‐41. ">Heimberg 1998</a> to 100 mg/d in <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>. </p> <p>There were four trials of the serotonin and norepinephrine reuptake inhibitor (SNRI) venlafaxine (<a href="./references#CD001206-bbs2-0026" title="LiebowitzMR , ManganoRM , BradwejnJ , AsnisG . A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. Journal of Clinical Psychiatry2005;66(2):238‐47. ">Liebowitz 2005a</a>; <a href="./references#CD001206-bbs2-0027" title="Liebow3149018itzMR , GelenbergAJ , MunjackD . Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry2005;62(2):190‐8. ">Liebowitz 2005b</a>; <a href="./references#CD001206-bbs2-0052" title="SteinMB , PollackMH , BystritskyA , KelseyJE , ManganoRM . Efficacy of low and higher dose extended‐release venlafaxine in generalized social anxiety disorder: a 6‐month randomized controlled trial. Psychopharmacology2005;177(3):280‐8. SteinMB , PollackMH , ManganoR . Long‐term treatment of generalized SAD with venlafaxine extended release. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR251. ">Stein 2005</a>; <a href="./references#CD001206-bbs2-0043" title="RickelsK , ManganoR , KhanA . A double‐blind, placebo‐controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(5):488‐96. ">Rickels 2004</a>). Dosage ranged from 75 mg/d to 225 mg/d in all of these trials. </p> <p>Three trials focused on anticonvulsants comprising gamma‐amino butyric acid (GABA) analogues (including two studies of pregabalin, <a href="./references#CD001206-bbs2-0014" title="FeltnerD , BielskiR , Liu‐DumawM . Efficacy of pregabalin in generalised social anxiety disorder: results of a placebo‐controlled, fixed‐dose study. European Neuropsychopharmacology2010;20(Suppl 3):S525–6. FeltnerDE , Liu‐DumawM , SchweizerE , BielskiR . Efficacy of pregabalin in generalized social anxiety disorder: results of a double‐blind, placebo‐controlled, fixed‐dose study. International Clinical Psychopharmacology2011;26(4):213–20. ">Feltner 2011</a> and <a href="./references#CD001206-bbs2-0040" title="FeltnerDE , DavidsonJR , PollackMH , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social anxiety disorder: outcome and predictors of response. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14. San Juan, Puerto Rico, 2000. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled study of pregabalin in social phobia (social anxiety disorder) [abstract]. International Journal of Neuropsychopharmacology2000;3(Suppl 1):284. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererRA , JeffersonJW , et al. Pregabalin treatment of social phobia. New Research Abstracts. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000. FeltnerDE , PollackMH , DavidsonJRT , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social phobia: outcome and predictors of response [abstract]. European Neuropsychopharmacology2000;10(Suppl 3):S345. PandeAC , FeltnerDE , JeffersonJW , DavidsonJRT , PollackM , SteinMB , et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo‐controlled, multicenter study. Journal of Clinical Psychopharmacology2004;24(2):141‐9. ">Pande 2004</a>, and one of gabapentin, <a href="./references#CD001206-bbs2-0039" title="PandeAC , DavidsonJR , JeffersonJW , JanneyCA , KatzelnickDJ , WeislerRH , GreistJH , SutherlandSM . Treatment of social phobia with gabapentin: a placebo‐controlled study. Journal of Clinical Psychopharmacology1999;19(4):341‐8. ">Pande 1999</a>). Two trials investigated levetiracetam, another anticonvulsant (<a href="./references#CD001206-bbs2-0053" title="SteinMB , RavindranLN , SimonNM , LiebowitzMR , KhanA , Brawman‐MintzerO , et al. Levetiracetam in generalized social anxiety disorder: a double‐blind, randomized controlled trial. Journal of Clinical Psychiatry2010;71(5):627‐31. ">Stein 2010</a>; <a href="./references#CD001206-bbs2-0066" title="ZhangW , ConnorKM , DavidsonJRT . Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology2005;19(5):551‐3. ">Zhang 2005</a>). </p> <p>Three trials studied benzodiazepines, including two studies of clonazepam in doses ranging from 0.25 mg/d in both <a href="./references#CD001206-bbs2-0009" title="ConnorKM , DavidsonJR , PottsNL , TuplerLA , MinerCM , MalikML , et al. Discontinuation of clonazepam in the treatment of social phobia. Journal of Clinical Psychopharmacology1998;18(5):373‐8. ">Connor 1998</a> and <a href="./references#CD001206-bbs2-0010" title="DavidsonJR , PottsN , RichichiE , KrishnanR , FordSM , SmithR , et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology1993;13(6):423‐8. SutherlandSM , TuplerLA , ColketJT , DavidsonJR . A 2‐year follow‐up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease1996;184(12):731‐8. ">Davidson 1993</a> to 2.5 mg/d in <a href="./references#CD001206-bbs2-0009" title="ConnorKM , DavidsonJR , PottsNL , TuplerLA , MinerCM , MalikML , et al. Discontinuation of clonazepam in the treatment of social phobia. Journal of Clinical Psychopharmacology1998;18(5):373‐8. ">Connor 1998</a>, and one of bromazepam (<a href="./references#CD001206-bbs2-0063" title="VersianiM , NardiAE , FigueiraI , MendlowiczM , MarquesC . Double‐blind placebo controlled trial with bromazepam in social phobia. Jornal Brasileiro de Psiquiatria1997;46(3):167‐71. ">Versiani 1997</a>), administered in doses of 3 mg/d to 9 mg/d. </p> <p>There were two trials on antipsychotics, including one study of olanzapine, with dosage ranging from 5 mg/d to 20 mg/d (<a href="./references#CD001206-bbs2-0005" title="BarnettSD , KramerML , CasatCD , ConnorKM , DavidsonJR . Efficacy of olanzapine in social anxiety disorder: a pilot study. Journal of Psychopharmacology2002;16(4):365‐8. ">Barnett 2002</a>), and another study on quetiapine, with dosage of 25 mg/d to 300 mg/d (<a href="./references#CD001206-bbs2-0056" title="VaishnaviS , AlamyS , ZhangW , ConnorKM , DavidsonJRT . Quetiapine as monotherapy for social anxiety disorder: a placebo‐controlled study. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007;31(7):1464‐9. ">Vaishnavi 2007</a>). </p> <p>Two trials evaluated the noradrenergic and specific serotonergic antidepressant (NaSSA) mirtazepine, in doses ranging from 30 mg/d in <a href="./references#CD001206-bbs2-0030" title="MuehlbacherM , NickelMK , NickelC , KettlerC , LahmannC , GilFP , et al. Mirtazapine treatment of social phobia in women. A randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychopharmacology2005;25(6):580‐3. ">Muehlbacher 2005</a> and <a href="./references#CD001206-bbs2-0045" title="SchuttersSIJ , VanMegenHJGM , VanVeenJF , DenysDAJP , WestenbergHGM . Mirtazapine in generalized social anxiety disorder: a randomized, double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2010;25(5):302–4. ">Schutters 2010</a> to 45 mg/d in <a href="./references#CD001206-bbs2-0045" title="SchuttersSIJ , VanMegenHJGM , VanVeenJF , DenysDAJP , WestenbergHGM . Mirtazapine in generalized social anxiety disorder: a randomized, double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2010;25(5):302–4. ">Schutters 2010</a>. </p> <p><a href="./references#CD001206-bbs2-0055" title="TurnerS , BeidelDC , JacobRG . Social phobia: a comparison of behaviour therapy and atenolol. Journal of Consulting and Clinical Psychology1994;62(2):350‐8. ">Turner 1994</a> assessed the beta‐blocker atenolol, administered in doses of 25 mg/d to 100 mg/d; <a href="./references#CD001206-bbs2-0042" title="RavindranLN , KimDS , LetamendiAM , SteinMB . A randomized controlled trial of atomoxetine in generalized social anxiety disorder. Journal of Clinical Psychopharmacology2009;29(6):561‐4. ">Ravindran 2009</a> assessed the noradrenaline reuptake inhibitor (NARI) atomoxetine, administered in doses of 20 mg/d to 100 mg/d; <a href="./references#CD001206-bbs2-0058" title="VanAmeringenM , ManciniC , OakmanJ , WalkerJ , KjernistedK , ChokkaP , et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(2):288‐95. VanAmeringenMA , ManciniCL , PipeB , OakmanJ , WalkerJR , KjernistedKD , et al. Not all serotonergic agents are created equal in social phobia: nefazodone, a placebo‐controlled trial. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR789. ">Van Ameringen 2007</a> looked at the serotonin antagonist and reuptake inhibitor (SARI) nefazodone, with dosage of 100 mg/d to 600 mg/d; <a href="./references#CD001206-bbs2-0033" title="NCT00397722 . Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [Treatment of patients with social anxiety disorder]. clinicaltrials.gov/ct2/show/results/NCT00397722 (first received 8 November 2006). ">NCT00397722</a> studied GW876008, at doses of 25 mg/d to 50 mg/d; <a href="./references#CD001206-bbs2-0054" title="TauscherJ , KielbasaW , IyengarS , VandenhendeF , PengX , MozleyD , et al. Development of the 2nd generation neurokinin‐1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology2010;20(2):80‐7. ">Tauscher 2010</a> studied LY686017 at 50 mg/d; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a> investigated the NK1 antagonist GR205171, at 4 mL to 100 mL; and <a href="./references#CD001206-bbs2-0061" title="VanVlietI , DenBoerJ , WestenbergH , Ho PianK . Clinical effects of buspirone in social phobia, a double‐blind placebo controlled study. 9th European College of Neuropsychopharmacology Congress; Sept 21‐25. Amsterdam, Netherlands, 1996. VanVlietIM , DenBoerJA , WestenbergHG , PianKL . Clinical effects of buspirone in social phobia: a double‐blind placebo‐controlled study. Journal of Clinical Psychiatry1997;58(4):164‐8. ">Van Vliet 1997</a> the 5HT1A partial agonist buspirone, at doses of 15 mg/d to 30 mg/d. </p> <p>Psychiatrists, pharmacists, mental health professionals, and multi‐disciplinary teams of investigators administered the interventions. </p> </section> <section id="CD001206-sec-0072"> <h5 class="title">Outcomes</h5> <p>Twenty‐three trials assessed the primary efficacy outcome – number of participants with SAnD who responded to treatment – using the Clinical Global Impression – Global Improvement (CGI–I) Scale, whilst 27 other trials assessed this outcome as a secondary measure using the same scale. Forty‐two trials used the Liebowitz Social Anxiety Scale (LSAS) to assess the reduction of SAnD symptoms, while eight used the Clinical Global Impression ‐ Severity scale (CGI‐S). The most common measures used to assess depression were the Beck Depression Inventory (BDI; k = 2), the the Hamilton Rating Scale for Depression (HAM‐D; k = 12), and the Montgomery–Åsberg Depression Rating Scale (MADRS) (k = 10). Thirty trials assessed functional disability using the Sheehan Disability Scale (SDS). Post‐treatment follow‐up assessments ranged from two weeks in <a href="./references#CD001206-bbs2-0054" title="TauscherJ , KielbasaW , IyengarS , VandenhendeF , PengX , MozleyD , et al. Development of the 2nd generation neurokinin‐1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology2010;20(2):80‐7. ">Tauscher 2010</a> to 15 months in <a href="./references#CD001206-bbs2-0038" title="OosterbaanDB , VanBalkomAJLM , SpinhovenP , vanOppenP , vanDyckR . Cognitive therapy versus moclobemide in social phobia: a controlled study. Clinical Pscyhology and Psychotherapy2001;8(4):263‐73. ">Oosterbaan 2001</a>. See <a href="./references#CD001206-sec-0178" title="">Characteristics of included studies</a> for more details. </p> </section> </section> <section id="CD001206-sec-0073"> <h4 class="title">Excluded studies</h4> <p>We excluded 70 studies from the review (see <a href="./references#CD001206-sec-0179" title="">Characteristics of excluded studies</a>). The most common reason we considered trials ineligible was the absence of a placebo comparator (<a href="./references#CD001206-bbs2-0069" title="AllsoppLF , CooperGL , PoolePH . Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Current Medical Research and Opinion1984;9(1):64‐70. ">Allsopp 1984</a>; <a href="./references#CD001206-bbs2-0067" title="ACTRN12608000363381 . Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants [Dopaminergic challenges in social anxiety disorder: evidence for dopamine D3 desensitisation following successful treatment with serotonergic antidepressants]. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12608000363381 (first received 9 July 2008). ">ACTRN12608000363381</a>; <a href="./references#CD001206-bbs2-0071" title="AtmacaM , KulogluM , TezcanE , UnalA . Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Human Psychopharmacology2002;2002(8):401‐5. ">Atmaca 2002</a>; <a href="./references#CD001206-bbs2-0072" title="BlankS , LenzeEJ , MulsantBH , DewMA , KarpJF , ShearMK , et al. Outcomes of late‐life anxiety disorders during 32 weeks of citalopram treatment. Journal of Clinical Psychiatry2006;67(3):468‐72. ">Blank 2006</a>; <a href="./references#CD001206-bbs2-0074" title="BystritskyA , KerwinL , EidusonS , VapnikT . A pilot controlled trial of bupropion vs. escitalopram in generalized anxiety disorder (GAD). Neuropsychopharmacology2005;30 Suppl(1):S101. ">Bystritsky 2005</a>; <a href="./references#CD001206-bbs2-0075" title="ClarkDM , EhlersA , McManusF , HackmannA , FennellM , CampbellH , et al. Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo‐controlled trial. Journal of Consulting and Clinical Psychology2003;71(6):1058‐67. ">Clark 2003</a>; <a href="./references#CD001206-bbs2-0081" title="DunlopBW , PappL , GarlowSJ , WeissPS , KnightBT , NinanPT . Tiagabine for social anxiety disorder. Human Psychopharmacology: Clinical and Experimental2007;22(4):241‐4. ">Dunlop 2007</a>; <a href="./references#CD001206-bbs2-0083" title="FalloonIR , LlodyGG , HarpinRE . The treatment of social phobia: real‐life rehearsal with nonprofessional therapists. Journal of Nervous and Mental Disease1981;169(3):180‐4. ">Falloon 1981</a>; <a href="./references#CD001206-bbs2-0089" title="GelernterCS , UhdeTW , CimbolicP , ArnkoffDB , VittoneBJ , TancerME , et al. Cognitive‐behavioural and pharmacological treatments of social phobia: a controlled study. Archives of General Psychiatry1991;48(10):938‐45. ">Gelernter 1991</a>; <a href="./references#CD001206-bbs2-0082" title="EUCTR2004‐001894‐24‐DE . A randomised, double‐blind, parallel‐group, placebo‐controlled fixed dose study comparing the efficacy and safety of GW597599/paroxetine combination or paroxetine monotherapy to placebo in patients with social anxiety disorder (SAD). apps.who.int/trialsearch/Trial2.aspx?TrialID=EUCTR2004‐001894‐24‐DE2012. ">EUCTR2004‐001894‐24‐DE</a>; <a href="./references#CD001206-bbs2-0093" title="GuastellaAJ , HowardAL , DaddsMR , MitchellP , CarsonDS . A randomized controlled trial of intranasal oxytocin as an adjunct to exposure therapy for social anxiety disorder. Psychoneuroendocrinology2009;34(6):917‐23. ">Guastella 2009</a>; <a href="./references#CD001206-bbs2-0097" title="HofmannSG , MeuretAE , SmitsJAJ , SimonNM , PollackMH , EisenmengerK , et al. Augmentation of exposure therapy with D‐cycloserine for social anxiety disorder. Archives of General Psychiatry2006;63(3):298‐304. ">Hofmann 2006</a>; <a href="./references#CD001206-bbs2-0102" title="KrishmanG . Oxprenolol in the treatment of examination stress. Current Medical Research and Opinion1976;4(3):241‐3. ">Krishman 1976</a>; <a href="./references#CD001206-bbs2-0103" title="LiappasJ , PaparrigopoulosT , TzavellasE , ChristodoulouG . Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazepine administration. Journal of Affective Disorders2003;76(1‐3):279‐84. ">Liappas 2003</a>; <a href="./references#CD001206-bbs2-0105" title="LiebowitzMR , HeimbergRG , SchneierFR , HopeDA , DaviesS , HoltCS , et al. Cognitive‐behavioral group therapy versus phenelzine in social phobia: long‐term outcome. Depression and Anxiety1999;10(3):89‐98. ">Liebowitz 1999</a>; <a href="./references#CD001206-bbs2-0117" title="OosterbaanD , VanBalkomA , Spinhoven , VanDykR . Cognitive behavior therapy versus moclobemide in social phobia. The World Psychiatric Association's (WPA) Thematic Congress; Nov. Jerusalem, 1997. ">Oosterbaan 1997</a>; <a href="./references#CD001206-bbs2-0118" title="OttoMW , PollackMH , GouldRA , WorthingtonJJ , McArdleET , RosenbaumJF . A comparison of the efficacy of clonazepam and cognitive‐behavioural group therapy for the treatment of social phobia. Journal of Anxiety Disorders2000;14(4):345‐8. ">Otto 2000</a>; <a href="./references#CD001206-bbs2-0119" title="PecknoldJC , McClureDJ , AppeltauerL , AllanT , WrzesinskiL . Does tryptophan potentiate clomipramine in the treatment of agoraphobic and agoraphobic and social phobic patients. British Journal of Psychiatry1982;140:484‐90. ">Pecknold 1982</a>; <a href="./references#CD001206-bbs2-0043" title="RickelsK , ManganoR , KhanA . A double‐blind, placebo‐controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(5):488‐96. ">Rickels 2004</a>; <a href="./references#CD001206-bbs2-0127" title="SeedatS , SteinM . Pindolol potentiation of paroxetine for generalized social phobia: a double‐blind, placebo‐controlled, crossover study. American Journal of Psychiatry2001;158(10):1725‐7. ">Seedat 2003</a>; <a href="./references#CD001206-bbs2-0131" title="SimonNM , WorthingtonJJ , MoshierSJ , MarksEH , HogeEA , BrandesM , et al. Duloxetine for the treatment of generalized social anxiety disorder: a preliminary randomized trial of increased dose to optimize response. CNS Spectrums2010;15(7):436‐43. ">Simon 2010</a>; <a href="./references#CD001206-bbs2-0134" title="TubakiBR , ChandrashekarCR , SudhakarD , PrabhaTN , LavekarGS , KuttyBM . Clinical efficacy of manasamitra vataka (an Ayurveda Medication) on generalized anxiety disorder with comorbid generalized social phobia: a randomized controlled study. Journal of Alternative &amp; Complementary Medicine2012;18(6):612‐21. ">Tubaki 2012</a>; <a href="./references#CD001206-bbs2-0068" title="ACTRN12609000091202 . The use of tiagabine and gabapentin in the treatment of social anxiety disorder in 8 patients [Gabapentin and tiagabine for treatment of social anxiety disorder in 8 patients in a random double blind crossover study with outcome measured as changes in the Leibowitz Social Anxiety Scale]. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12609000091202 (first received 18 December 2008). ">ACTRN12609000091202</a>). We also excluded studies with participants under the age of 18 and those with combined populations and certain comorbidities (<a href="./references#CD001206-bbs2-0078" title="DempseyJP , RandallPK , ThomasSE , BookSW , CarriganMH . Treatment of social anxiety with paroxetine: mediation of changes in anxiety and depression symptoms. Comprehensive Psychiatry2009;50(2):135‐41. ">Dempsey 2009</a>; <a href="./references#CD001206-bbs2-0092" title="GrosserB , Monti‐BlochL , Jennings‐WhiteC . Rapid anti‐anxiety effects in women of picogram quantities of a 19‐carbon steroid [abstract]. International Journal of Neuropsychopharmacology2012:230‐1. ">Grosser 2012</a>; <a href="./references#CD001206-bbs2-0098" title="IonescuD . Clinical study on the efficacy and tolerability of escitalopram in patients diagnosed with social anxiety [abstract]. European Psychiatry2013;28(1):1. ">Ionescu 2013</a>). We excluded <a href="./references#CD001206-bbs2-0078" title="DempseyJP , RandallPK , ThomasSE , BookSW , CarriganMH . Treatment of social anxiety with paroxetine: mediation of changes in anxiety and depression symptoms. Comprehensive Psychiatry2009;50(2):135‐41. ">Dempsey 2009</a>, <a href="./references#CD001206-bbs2-0087" title="GaleC . Escitalopram 10 mg daily is more effective than paroxetine and placebo for generalised anxiety disorder. Evidence Based Mental Health2007;10(2):45. ">Gale 2007</a>, and <a href="./references#CD001206-bbs2-0108" title="ManganoR , LiebowitzMR , AllgulanderC . Comparison of venlafaxine extended release and paroxetine in short‐term treatment of SAD. 156th Annual Meeting of the American Psychiatric Association, May 17‐22. San Francisco (CA), 2003. ">Mangano 2003</a> because these trials were secondary analyses of previous studies. We also excluded open‐label studies that did not employ a randomised double‐blind placebo‐control study design (<a href="./references#CD001206-bbs2-0070" title="AngeliniG , BichisaoE , CatapanoF , CerretaA , Ferini StrambiL , MajM , et al. Ketazolam, a new long‐acting benzodiazepine, in the treatment of anxious patients. A multicenter study of 2,056 patients. Current Therapeutic Research, Clinical and Experimental1989;45(2):294‐304. ">Angelini 1989</a>). Twelve early trials with anxiety disorders did not report data separately for patients with SAnD, so we could not include them (<a href="./references#CD001206-bbs2-0070" title="AngeliniG , BichisaoE , CatapanoF , CerretaA , Ferini StrambiL , MajM , et al. Ketazolam, a new long‐acting benzodiazepine, in the treatment of anxious patients. A multicenter study of 2,056 patients. Current Therapeutic Research, Clinical and Experimental1989;45(2):294‐304. ">Angelini 1989</a>; <a href="./references#CD001206-bbs2-0077" title="CouplandNJ , BellC , PotokarJP , DorkinsE , NuttDJ . Flumazenil challenge in social phobia. Depression and Anxiety2000;11(1):27‐30. ">Coupland 2000</a>; <a href="./references#CD001206-bbs2-0112" title="NCT00248612 . Psychosocial and Medication Treatment for Anxiety in Alcoholism. clinicaltrials.gov/ct2/show/results/NCT00248612 (first received 2 November 2005). ">NCT00248612</a>; <a href="./references#CD001206-bbs2-0091" title="GreenhillLL . A multisite treatment of anxiety disorders. 152nd Annual Meeting of the American Psychiatric Association; May 15‐20;. Washington DC, 1999. ">Greenhill 1999</a>; <a href="./references#CD001206-bbs2-0096" title="HeunR , CorralRM , AhokasA , NicoliniH , TeixeiraJM , DeheleanP . Efficacy of agomelatine in more anxious elderly depressed patients. A randomized, double‐blind study vs placebo. European Psychiatry2013;28(Suppl 1):1. ">Heun 2013</a>; <a href="./references#CD001206-bbs2-0107" title="MalcolmR , AntonRF , RandallCL , JohnstonA , BradyK , ThevosA . A placebo‐controlled trial of buspirone in anxious inpatient alcoholics. Alcoholism Clinical and Experimental Research1992;16(6):1007‐13. ">Malcolm 1992</a>; <a href="./references#CD001206-bbs2-0110" title="MountjoyCQ , RothM , GarsideRF , LeitchIM . A clinical trial of phenelzine in anxiety depressive and phobic neuroses. British Journal of Psychiatry1977;131:486‐92. ">Mountjoy 1977</a>; <a href="./references#CD001206-bbs2-0121" title="PineDS , WalkupJT , LabellarteMJ , RiddleMA , GreenhillL , KleinR , et al. Research Unit on Pediatric Psychopharmacology Anxiety Study Group. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. New England Journal of Medicine2001;344(17):1279‐85. ">Pine 2001</a>; <a href="./references#CD001206-bbs2-0126" title="SchuurmansJ , ComijsHC , EmmelkampPM , VanDyckR . A randomized controlled trial of the effectiveness of cognitive‐behavioral therapy and sertraline versus a waiting list control group for anxiety disorders in older adults. 32nd Congress of the British Association for Behavioural and Cognitive Psychotherapies (jointly with the European Association of Behavioural and Cognitive Therapies); Sept 7‐11. Manchester, UK, 2004. ">Schuurmans 2004</a>; <a href="./references#CD001206-bbs2-0132" title="SolyomL , HeseltineGF , McClureDJ , SolyomC , LedwidgeB , SteinbergG . Behaviour therapy versus drug therapy in the treatment of phobic neurosis. Canadian Psychiatric Association Journal1973;18(1):25‐32. ">Solyom 1973</a>; <a href="./references#CD001206-bbs2-0133" title="SolyomC , SolyomL , LaPierreY , PecknoldJ , MortonL . Phenelzine and exposure in the treatment of phobias. Biological Psychiatry1981;16(3):239‐47. ">Solyom 1981</a>; <a href="./references#CD001206-bbs2-0135" title="TyrerP , CandyJ , KellyD . A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologica1973;32(3):237‐54. ">Tyrer 1973</a>). One study focused on neuroendocrine and behavioural responses of SAnD (<a href="./references#CD001206-bbs2-0128" title="ShlikJ , MaronE , AluojaA , VasarV , ToruI . Citalopram challenge in social anxiety disorder. European Neuropsychopharmacology2002;12(Suppl 3):S339. ">Shlik 2002</a>). Four studies on brain functioning, with specific reference to the modulation of amygdala‐frontal reactivity and connectivity, were ineligible for inclusion (<a href="./references#CD001206-bbs2-0079" title="DodhiaS , HosanagarA , FitzgeraldDA , LabuschagneI , WoodAG , NathanPJ , et al. Modulation of resting‐state amygdala‐frontal functional connectivity by oxytocin in generalized social anxiety disorder. Neuropsychopharmacology2014;39(9):2061‐9. ">Dodhia 2014</a>; <a href="./references#CD001206-bbs2-0090" title="GorkaSM , FitzgeraldDA , LabuschagneI , HosanagarA , WoodAG , NathanPJ , et al. Oxytocin modulation of amygdala functional connectivity to fearful faces in generalized social anxiety disorder. Neuropsychopharmacology2015;40(2):278‐86. [] ">Gorka 2015</a>; <a href="./references#CD001206-bbs2-0114" title="NCT00332046 . fMRI Study Comparing BOLD Activation Patterns Using GW679769 In Subjects With Social Anxiety Disorder [A Double‐Blind, Randomized, Placebo‐Controlled, Double‐Dummy, Parallel Group, fMRI Study Comparing BOLD Activation Patterns Before and After 12 Weeks of Treatment With Placebo, Comparator and GW679769 in Subjects With Social Anxiety Disorder (SAD)]. clinicaltrials.gov/ct2/show/NCT00332046 (first received 30 May 2006). ">NCT00332046</a>; <a href="./references#CD001206-bbs2-0120" title="PhanKL . Oxytocin modulation of amygdala‐frontal reactivity and connectivity to threat and at rest in social anxiety disorder [abstract]. Biological Psychiatry2015;75(9 Suppl 1):27S. ">Phan 2015</a>). A number of trials assessed the effect of medication on individuals with performance anxiety who were not diagnosed with SAnD (<a href="./references#CD001206-bbs2-0073" title="BrantiganCO , BrantiganTA , JosephN . Effects of beta‐blockade and beta‐stimulation on stage fright. American Journal of Medicine1982;72(1):88‐94. ">Brantigan 1982</a>; <a href="./references#CD001206-bbs2-0076" title="Clark‐ElfordR , NathanPJ , AuyeungB , MoggK , Bradley , BP , SuleA , et al. Effects of oxytocin on attention to emotional faces in healthy volunteers and highly socially anxious males. International Journal of Neuropsychopharmacology2014;18(2):1–7. ">Clark‐Elford 2015</a>; <a href="./references#CD001206-bbs2-0084" title="FangA , HogeEA , HeinrichsM , HofmannSG . Attachment style moderates the effects of oxytocin on social behaviors and cognitions during social rejection: applying a research domain criteria framework to social anxiety. Clinical Psychological Science2014;2(6):740‐7. ">Fang 2014</a>; <a href="./references#CD001206-bbs2-0088" title="GatesGA , SaegertJ , WilsonN , JohnsonL , ShepherdA , HearneEM3rd . Effect of beta‐blockage on singing performance. Annals of Otology, Rhinology and Laryngology1985;94(6 Pt 1):570‐4. ">Gates 1985</a>; <a href="./references#CD001206-bbs2-0090" title="GorkaSM , FitzgeraldDA , LabuschagneI , HosanagarA , WoodAG , NathanPJ , et al. Oxytocin modulation of amygdala functional connectivity to fearful faces in generalized social anxiety disorder. Neuropsychopharmacology2015;40(2):278‐86. [] ">Gorka 2015</a>; <a href="./references#CD001206-bbs2-0094" title="HartleyLR , UngapenS , DavieI , SpencerDJ . The effect of beta adrenergic blockade on speaker's performance and memory. British Journal of Psychiatry1983;142(5):512‐7. ">Hartley 1983</a>; <a href="./references#CD001206-bbs2-0099" title="JamesIM , GriffithDN , PearsonRM , NewburyP . Effect of oxprenolol on stage‐fright in musicians. Lancet1977;2(8045):952‐4. ">James 1977</a>; <a href="./references#CD001206-bbs2-0101" title="JamesI , SavageI . Beneficial effect of nadolol on anxiety‐induced disturbances of performance in musicians: a comparison with diazepam and placebo. American Heart Journal1984;108(4 Pt 2):1150‐5. ">James 1984</a>; <a href="./references#CD001206-bbs2-0100" title="JamesIM , BurgoyneW , SavageIT . Effect on pindolol on stress‐related disturbances of musical performance: preliminary communication. Journal of the Royal Society of Medicine1983;76(3):194‐6. ">James 1983</a>; <a href="./references#CD001206-bbs2-0106" title="LiebowitzMR , SalmanE , NicoliniH , RosenthalN , HanoverR , MontiL . Effect of an acute intranasal aerosol dose of PH94B on social and performance anxiety in women with social anxiety disorder. American Journal of Psychiatry2014;171(6):675‐82. ">Liebowitz 2014</a>; <a href="./references#CD001206-bbs2-0104" title="LidenS , GottfriesCG . Beta‐blocking agents in the treatment of catecholamine‐induced symptoms in musicians. Lancet1974;2(7879):529. ">Liden 1974</a>; <a href="./references#CD001206-bbs2-0113" title="NCT00308724 . Treating Late‐Life Generalized Anxiety Disorder (GAD) in Primary Care. clinicaltrials.gov/ct2/show/NCT00308724 (first received 28 March 2006). ">NCT00308724</a>; <a href="./references#CD001206-bbs2-0115" title="NCT00343707 . PET (Positron Emission Tomography)/Public Speaking Study With A Combination Of 2 Medications In Social Anxiety Patients [A Double‐blind, Triple Dummy, Placebo‐controlled, Randomised, Parallel Group Positron Emission Tomography Study to Investigate the Effects of a 8 Week Administration of GW597599 and Paroxetine Either Alone or in Combination on Regional Cerebral Blood Flow During a Public Speaking Test in Subjects Affected by Social Phobia]. clinicaltrials.gov/ct2/show/NCT00343707 (first received 21 June 2006). ">NCT00343707</a>; <a href="./references#CD001206-bbs2-0116" title="NeftelKA , AdlerRH , KappeliL , RossiM , DolderM , KaserHE , et al. Stage fright in musicians: a model illustrating the effect of beta blockers. Psychosomatic Medicine1982;44(5):461‐9. ">Neftel 1982</a>; <a href="./references#CD001206-bbs2-0129" title="SiitonenL , JanneJ . Effect of beta‐blockade during bowling competition. Annals of Clinical Research1976;8(6):393‐8. ">Siitonen 1976</a>; <a href="./references#CD001206-bbs2-0136" title="WardleMC , FryeCG , DeWitH . MDMA buffers against cues of social rejection [abstract]. Neuropsychopharmacology2012:S414‐5. ">Wardle 2012</a>). One excluded study only measured treatment‐emergent side effects (<a href="./references#CD001206-bbs2-0125" title="RynnM , RussellJ , EricksonJ , DetkeMJ , BallS , DinkelJ , et al. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible‐dose, progressive‐titration, placebo‐controlled trial. Depression and Anxiety2008;25(3):182‐9. ">Rynn 2008</a>). Finally, we excluded studies that combined pharmacotherapy and psychotherapy (<a href="./references#CD001206-bbs2-0080" title="DonahueCB , KushnerMG , ThurasPD , MurphyTG , VanDemarkJB , AdsonDE . Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia. Journal of Anxiety Disorders2009;23(3):362‐8. ">Donahue 2009</a>; <a href="./references#CD001206-bbs2-0086" title="FeifelD , MacdonaldK , McKinneyR , HeissereN , SerranoV . A randomized, placebo controlled investigation of intranasal oxytocin in patients with anxiety. Neuropsychopharmacology2011;36:S421. ">Feifel 2011</a>; <a href="./references#CD001206-bbs2-0095" title="HaugTT , BlomhoffS , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Exposure therapy and sertraline in social phobia: 1‐year follow up of a randomised controlled trial. British Journal of Psychiatry2003;182:312‐8. ">Haug 2003</a>; <a href="./references#CD001206-bbs2-0109" title="MortbergE , ClarkDM , SundinO , Aberg WistedtA . Intensive group cognitive treatment and individual cognitive therapy vs treatment as usual in social phobia: a randomized controlled trial. Acta Psychiatrica Scandinavica2007;115(2):142‐54. ">Mortberg 2007</a>; <a href="./references#CD001206-bbs2-0113" title="NCT00308724 . Treating Late‐Life Generalized Anxiety Disorder (GAD) in Primary Care. clinicaltrials.gov/ct2/show/NCT00308724 (first received 28 March 2006). ">NCT00308724</a>; <a href="./references#CD001206-bbs2-0122" title="PraskoJ . Moclobemide and/or cognitive‐behavior therapy in the treatment of social phobia. 157th Annual Meeting of the American Psychiatric Association; May 1‐6. New York (NY), 2004. ">Prasko 2004</a>; <a href="./references#CD001206-bbs2-0123" title="RavindranAV , AbrahamG , JohnsonS , ChandrasenaR . Randomized, placebo‐controlled effectiveness study of quetiapine XR in co‐morbid depressive and anxiety disorders [abstract]. International Journal of Neuropsychopharmacology2014;46(1):91. ">Ravindran 2014</a>; <a href="./references#CD001206-bbs2-0130" title="SilverstoneJT , SalkindMR . Controlled evaluation of intravenous drugs in the specific desensitization of phobias. Canadian Psychiatric Association Journal1973;18(1):47‐53. ">Silverstone 1973</a>; <a href="./references#CD001206-bbs2-0136" title="WardleMC , FryeCG , DeWitH . MDMA buffers against cues of social rejection [abstract]. Neuropsychopharmacology2012:S414‐5. ">Wardle 2012</a>), as well as studies using herbal treatments (<a href="./references#CD001206-bbs2-0111" title="NCT00118833 . St. John's Wort for the Treatment of Generalized Social Anxiety Disorder (GSAD) [Placebo‐Controlled Trial of Hypericum Perforatum in the Treatment of Generalized Social Anxiety Disorder (GSAD)]. clinicaltrials.gov/ct2/show/NCT00118833 (first received 7 July 2005). ">NCT00118833</a>). See <a href="./references#CD001206-sec-0179" title="">Characteristics of excluded studies</a> for more details. </p> <section id="CD001206-sec-0074"> <h5 class="title">Studies awaiting classification</h5> <p>Thirteen trials are awaiting classification (<a href="./references#CD001206-bbs2-0137" title="AsakuraS , HayanoT , HaginoA , KoyamaT . A randomized, double‐blind, placebo‐controlled study of escitalopram in patients with social anxiety disorder in Japan. Current Medical Research and Opinion2016;32(4):749‐57. [DOI: 10.1185/03007995.2016.1146663] ">Asakura 2016</a>; <a href="./references#CD001206-bbs2-0138" title="CareriJM , DraineAE , HanoverR , LiebowitzMR . A 12‐Week Double‐Blind, Placebo‐Controlled, Flexible‐Dose Trial of Vilazodone in Generalized Social Anxiety Disorder. The Primary Care Companion for CNS Disorders2015;17(6):e1‐e6. [DOI: 10.4088/PCC.15m01831] ">Careri 2015</a>; <a href="./references#CD001206-bbs2-0139" title="De laBarqueraJAOS . Double‐blind controlled study with clonazepam and placebo in social anxiety disorder. Salud Mental2008;31(4):299‐306. ">De la Barquera 2008</a>; <a href="./references#CD001206-bbs2-0140" title="FrickA , AhsF , AppelL , JonassonM , LinnmanC , FariaV , et al. Reduced serotonin synthesis after pharmacological treatment of social anxiety disorder [abstract]. Biological Psychiatry2015;77(9):236. ">Frick 2015</a>; <a href="./references#CD001206-bbs2-0141" title="KrylovV . Pharmacological treatment of social phobia: a controlled study with alprazolam and buspirone. 9th European College of Neuropsychopharmacology (ECNP) Congress. Amsterdam, Netherlands, 1996. ">Krylov 1996</a>; <a href="./references#CD001206-bbs2-0142" title="NCT00114127 . Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome [Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome]. clinicaltrials.gov/ct2/show/NCT00114127 (first received 13 June 2005). ">NCT00114127</a>; <a href="./references#CD001206-bbs2-0143" title="NCT00208741 . Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder [A 12‐Week Open‐Label Study Followed By A 24‐Week Double‐Blind Discontinuation Exploratory Study To Evaluate The Effects Of Gabitril™ (Tiagabine Hydrochloride) In Patients With Social Anxiety Disorder (SAD)]. clinicaltrials.gov/ct2/show/NCT00208741 (first received 13 September 2005). ">NCT00208741</a>; <a href="./references#CD001206-bbs2-0144" title="NCT00215254 . Quetiapine in Social Anxiety Disorder [A Randomized, Double‐Blind, Placebo‐Controlled Pilot Study of Quetiapine in Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/NCT00215254 (first received 20 September 2005). ">NCT00215254</a>; <a href="./references#CD001206-bbs2-0145" title="NCT00246441 . Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism [Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism]. clinicaltrials.gov/ct2/show/NCT00246441 (first received 28 October 2005). ">NCT00246441</a>; <a href="./references#CD001206-bbs2-0146" title="NCT00294346 . Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder [A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/NCT00294346 17 February 2006). ">NCT00294346</a>; <a href="./references#CD001206-bbs2-0147" title="NCT00485888 . Flushing in Social Anxiety Disorder on Cipralex [Changes in the Vasodilatory Response to Methyl‐nicotinate in Response to S‐citalopram Treatment in Social Phobia Patients]. clinicaltrials.gov/ct2/show/NCT00485888 (first received 12 June 2007). ">NCT00485888</a>; <a href="./references#CD001206-bbs2-0148" title="NCT00612859 . Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type) [A Multicenter, Randomized, Double‐Blind, PBO‐Controlled, Parallel Group Study to Assess the Efficacy and Safety of Levetiracetam Versus PBO for the Treatment of Social Anxiety Disorder (Generalized Type)]. clinicaltrials.gov/ct2/show/NCT00612859 (first received 14 January 2008). ">NCT00612859</a>; <a href="./references#CD001206-bbs2-0149" title="NCT01316302 . 12‐Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder [A 12‐Week Double‐Blind, Placebo‐Controlled, Flexible‐Dose Trial of Pristiq® (Desvenlafaxine) Extended‐Release Tablets in Generalized Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/NCT01316302 (first received 14 March 2011). ">NCT01316302</a>). <a href="./references#CD001206-bbs2-0146" title="NCT00294346 . Safety and Efficacy Study of AV608 in Subjects With Social Anxiety Disorder [A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/NCT00294346 17 February 2006). ">NCT00294346</a> conducted a study on the effectiveness of an investigational drug AV608 in subjects with social anxiety disorder (SAnD), using the Liebowitz Social Anxiety Scale (LSAS) to assess reductions of anxiety symptoms. <a href="./references#CD001206-bbs2-0139" title="De laBarqueraJAOS . Double‐blind controlled study with clonazepam and placebo in social anxiety disorder. Salud Mental2008;31(4):299‐306. ">De la Barquera 2008</a> assessed clonazepam compared to placebo in patients with social phobia, and <a href="./references#CD001206-bbs2-0140" title="FrickA , AhsF , AppelL , JonassonM , LinnmanC , FariaV , et al. Reduced serotonin synthesis after pharmacological treatment of social anxiety disorder [abstract]. Biological Psychiatry2015;77(9):236. ">Frick 2015</a> citalopram, GR205171, or placebo. <a href="./references#CD001206-bbs2-0140" title="FrickA , AhsF , AppelL , JonassonM , LinnmanC , FariaV , et al. Reduced serotonin synthesis after pharmacological treatment of social anxiety disorder [abstract]. Biological Psychiatry2015;77(9):236. ">Frick 2015</a> involved 18 SAnD patients and used the Liebowitz Social Anxiety Scale (LSAS) to assess symptom severity and positron emission tomography (PET) imaging to assess brain function. <a href="./references#CD001206-bbs2-0141" title="KrylovV . Pharmacological treatment of social phobia: a controlled study with alprazolam and buspirone. 9th European College of Neuropsychopharmacology (ECNP) Congress. Amsterdam, Netherlands, 1996. ">Krylov 1996</a> assessed alprazolam, buspirone, or placebo in 66 patients with social phobia. <a href="./references#CD001206-bbs2-0147" title="NCT00485888 . Flushing in Social Anxiety Disorder on Cipralex [Changes in the Vasodilatory Response to Methyl‐nicotinate in Response to S‐citalopram Treatment in Social Phobia Patients]. clinicaltrials.gov/ct2/show/NCT00485888 (first received 12 June 2007). ">NCT00485888</a> investigated the effects of cipralex on the reduction of social phobia, as measured by the LSAS and various other secondary scales, in 71 outpatients aged 18 to 75 years and diagnosed with social phobia. <a href="./references#CD001206-bbs2-0149" title="NCT01316302 . 12‐Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder [A 12‐Week Double‐Blind, Placebo‐Controlled, Flexible‐Dose Trial of Pristiq® (Desvenlafaxine) Extended‐Release Tablets in Generalized Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/NCT01316302 (first received 14 March 2011). ">NCT01316302</a> studied desvenlafaxine (Pristiq) compared to matching placebo over 12 weeks. Sixty‐three patients enrolled, and the primary outcome of symptom severity was measured with the LSAS. Similarly, <a href="./references#CD001206-bbs2-0143" title="NCT00208741 . Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder [A 12‐Week Open‐Label Study Followed By A 24‐Week Double‐Blind Discontinuation Exploratory Study To Evaluate The Effects Of Gabitril™ (Tiagabine Hydrochloride) In Patients With Social Anxiety Disorder (SAD)]. clinicaltrials.gov/ct2/show/NCT00208741 (first received 13 September 2005). ">NCT00208741</a> investigated Gabitril compared to placebo over 24 weeks with 50 patients using the LSAS and CGI‐C scales as primary outcome measures; <a href="./references#CD001206-bbs2-0145" title="NCT00246441 . Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism [Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism]. clinicaltrials.gov/ct2/show/NCT00246441 (first received 28 October 2005). ">NCT00246441</a> compared paroxetine to placebo over 16 weeks with 42 patients; and <a href="./references#CD001206-bbs2-0142" title="NCT00114127 . Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome [Duloxetine for Social Anxiety Disorder: Prediction of Long Term Outcome]. clinicaltrials.gov/ct2/show/NCT00114127 (first received 13 June 2005). ">NCT00114127</a> compared duloxetine to placebo for 18 weeks with 28 patients whose symptoms were assessed with the LSAS. The additional trial by <a href="./references#CD001206-bbs2-0148" title="NCT00612859 . Study to Assess the Efficacy and Safety of Levetiracetam for the Treatment of Social Anxiety Disorder (Generalized Type) [A Multicenter, Randomized, Double‐Blind, PBO‐Controlled, Parallel Group Study to Assess the Efficacy and Safety of Levetiracetam Versus PBO for the Treatment of Social Anxiety Disorder (Generalized Type)]. clinicaltrials.gov/ct2/show/NCT00612859 (first received 14 January 2008). ">NCT00612859</a> assessed the efficacy and safety of levetiracetam versus placebo for the treatment of generalised SAnD measured by the LSAS. See <a href="./references#CD001206-sec-0180" title="">Characteristics of studies awaiting classification</a> and <a href="#CD001206-fig-0001">Figure 1</a> for more details. </p> <p>We identified two studies from the update search performed by CCMD's information specialist (<a href="./references#CD001206-bbs2-0137" title="AsakuraS , HayanoT , HaginoA , KoyamaT . A randomized, double‐blind, placebo‐controlled study of escitalopram in patients with social anxiety disorder in Japan. Current Medical Research and Opinion2016;32(4):749‐57. [DOI: 10.1185/03007995.2016.1146663] ">Asakura 2016</a>; <a href="./references#CD001206-bbs2-0138" title="CareriJM , DraineAE , HanoverR , LiebowitzMR . A 12‐Week Double‐Blind, Placebo‐Controlled, Flexible‐Dose Trial of Vilazodone in Generalized Social Anxiety Disorder. The Primary Care Companion for CNS Disorders2015;17(6):e1‐e6. [DOI: 10.4088/PCC.15m01831] ">Careri 2015</a>). We will incorporate these into the next version of the review as appropriate. </p> </section> <section id="CD001206-sec-0075"> <h5 class="title">Ongoing studies</h5> <p>Five studies are ongoing (<a href="./references#CD001206-bbs2-0150" title="NCT00182533 . Sertraline in Generalized Social Phobia With Co‐Occurring Anxiety and Mood Disorders [Sertraline in the Treatment of Generalized Social Phobia With Comorbidity]. clinicaltrials.gov/ct2/show/NCT00182533 (first received 14 September 2005). ">NCT00182533</a>; <a href="./references#CD001206-bbs2-0151" title="NCT01712321 . Study of Vilazodone to Treat Social Anxiety Disorder [Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study]. clinicaltrials.gov/ct2/show/NCT01712321 (first received 18 October 2012). ">NCT01712321</a>; <a href="./references#CD001206-bbs2-0152" title="NCT02083926 . Ketamine Infusion for Social Anxiety Disorder [Ketamine Infusion for Social Anxiety Disorder]. clinicaltrials.gov/show/NCT02083926 (first received 5 March 2014). ">NCT02083926</a>; <a href="./references#CD001206-bbs2-0153" title="NCT02294305 . ortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder. clinicaltrials.gov/show/NCT02294305 (first received 11 November 2014). ">NCT02294305</a>; <a href="./references#CD001206-bbs2-0154" title="NCT02432703 . A Safety and Efficacy Study of JNJ‐42165279 in Participants With Social Anxiety Disorder [A Phase 2a Randomized, Double‐blind, Placebo‐Controlled, Parallel‐Group, Multi‐center Study Investigating the Efficacy, Safety, and Tolerability of JNJ‐42165279 in Subjects With Social Anxiety Disorder]. clinicaltrials.gov/show/NCT02432703 (first received 29 April 2015). ">NCT02432703</a>). <a href="./references#CD001206-bbs2-0152" title="NCT02083926 . Ketamine Infusion for Social Anxiety Disorder [Ketamine Infusion for Social Anxiety Disorder]. clinicaltrials.gov/show/NCT02083926 (first received 5 March 2014). ">NCT02083926</a> will compare ketamine compared placebo (saline) using the Beck Anxiety Inventory (BAI), the CGI scale, and the LSAS to determine levels of anxiety severity in SAnD patients, whereas <a href="./references#CD001206-bbs2-0154" title="NCT02432703 . A Safety and Efficacy Study of JNJ‐42165279 in Participants With Social Anxiety Disorder [A Phase 2a Randomized, Double‐blind, Placebo‐Controlled, Parallel‐Group, Multi‐center Study Investigating the Efficacy, Safety, and Tolerability of JNJ‐42165279 in Subjects With Social Anxiety Disorder]. clinicaltrials.gov/show/NCT02432703 (first received 29 April 2015). ">NCT02432703</a> will compare JNJ‐42165279 to placebo for 12 weeks on the LSAS. <a href="./references#CD001206-bbs2-0150" title="NCT00182533 . Sertraline in Generalized Social Phobia With Co‐Occurring Anxiety and Mood Disorders [Sertraline in the Treatment of Generalized Social Phobia With Comorbidity]. clinicaltrials.gov/ct2/show/NCT00182533 (first received 14 September 2005). ">NCT00182533</a> will assess the efficacy of sertraline, and <a href="./references#CD001206-bbs2-0151" title="NCT01712321 . Study of Vilazodone to Treat Social Anxiety Disorder [Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study]. clinicaltrials.gov/ct2/show/NCT01712321 (first received 18 October 2012). ">NCT01712321</a> and <a href="./references#CD001206-bbs2-0153" title="NCT02294305 . ortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder. clinicaltrials.gov/show/NCT02294305 (first received 11 November 2014). ">NCT02294305</a> will compare vortioxetine to placebo for treating generalised social anxiety disorder in outpatients. The most common secondary outcome measures include the assessment of depression (<a href="./references#CD001206-bbs2-0150" title="NCT00182533 . Sertraline in Generalized Social Phobia With Co‐Occurring Anxiety and Mood Disorders [Sertraline in the Treatment of Generalized Social Phobia With Comorbidity]. clinicaltrials.gov/ct2/show/NCT00182533 (first received 14 September 2005). ">NCT00182533</a>; <a href="./references#CD001206-bbs2-0151" title="NCT01712321 . Study of Vilazodone to Treat Social Anxiety Disorder [Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study]. clinicaltrials.gov/ct2/show/NCT01712321 (first received 18 October 2012). ">NCT01712321</a>; <a href="./references#CD001206-bbs2-0153" title="NCT02294305 . ortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder. clinicaltrials.gov/show/NCT02294305 (first received 11 November 2014). ">NCT02294305</a>), anxiety (<a href="./references#CD001206-bbs2-0151" title="NCT01712321 . Study of Vilazodone to Treat Social Anxiety Disorder [Vilazodone in the Treatment of Social Anxiety Disorder: A Double Blind Study]. clinicaltrials.gov/ct2/show/NCT01712321 (first received 18 October 2012). ">NCT01712321</a>; <a href="./references#CD001206-bbs2-0153" title="NCT02294305 . ortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder. clinicaltrials.gov/show/NCT02294305 (first received 11 November 2014). ">NCT02294305</a>), functional disability, and quality of life (<a href="./references#CD001206-bbs2-0150" title="NCT00182533 . Sertraline in Generalized Social Phobia With Co‐Occurring Anxiety and Mood Disorders [Sertraline in the Treatment of Generalized Social Phobia With Comorbidity]. clinicaltrials.gov/ct2/show/NCT00182533 (first received 14 September 2005). ">NCT00182533</a>). See <a href="./references#CD001206-sec-0181" title="">Characteristics of ongoing studies</a> and <a href="#CD001206-fig-0001">Figure 1</a> for more details. </p> </section> </section> </section> <section id="CD001206-sec-0076"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias using the Cochrane 'Risk of bias' tool for allocation concealment, blinding, incomplete outcome data, selective reporting and other potential sources of bias. We classified twelve of the included studies as being at high risk for at least one type of bias (see <a href="#CD001206-fig-0002">Figure 2</a> and <a href="#CD001206-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD001206-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001206-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD001206-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001206-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001206-sec-0077"> <h4 class="title">Allocation</h4> <section id="CD001206-sec-0078"> <h5 class="title">Randomisation</h5> <p>Seventeen of the included studies described the sequence generation as randomised. <a href="./references#CD001206-bbs2-0001" title="AllgulanderC . Efficacy of paroxetine in social phobia ‐ a single‐center double‐blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20‐50 mg or placebo for 3 months. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4. Paris, France, 1998:P.3.005. AllgulanderC . Paroxetine in social anxiety disorder: a randomised placebo‐controlled study. Acta Psychiatrica Scandinavica1999;100(3):193‐8. ">Allgulander 1999</a>, <a href="./references#CD001206-bbs2-0006" title="BlancoC , HeimbergRG , SchneierFR , FrescoDM , ChenH , TurkCL , et al. A placebo‐controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry2010;67(3):286‐95. ">Blanco 2010</a>, <a href="./references#CD001206-bbs2-0016" title="HeimbergRG , LiebowitzMR , HopeDA , SchneierFR , HoltCS , WelkowitzLA , et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry1998;55(12):1133‐41. ">Heimberg 1998</a>, <a href="./references#CD001206-bbs2-0030" title="MuehlbacherM , NickelMK , NickelC , KettlerC , LahmannC , GilFP , et al. Mirtazapine treatment of social phobia in women. A randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychopharmacology2005;25(6):580‐3. ">Muehlbacher 2005</a>, and <a href="./references#CD001206-bbs2-0064" title="WalkerJR , VanAmeringenMA , SwinsonR , BowenRC , ChokkaPR , GoldnerE , et al. Prevention of relapse in generalized social phobia: results of a 24‐week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology2000;20(6):636‐44. WalkerJR , VanAmeringenMA , SwinsonRP , LaneRM . A 24‐week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000:NR259. ">Walker 2000</a> used tabulated random numbers to randomly assign participants to two groups. In other studies, group assignment was via a computer‐generated urn program (<a href="./references#CD001206-bbs2-0008" title="BookSW , ThomasSE , RandallPK , RandallCL . Paroxetine reduces social anxiety in individuals with a co‐occurring alcohol use disorder. Journal of Anxiety Disorders2008;22(2):310‐8. ThomasSE , RandallPK , BookSW , RandallCL . A complex relationship between co‐occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research2008;32(1):77‐84. ">Book 2008</a>; <a href="./references#CD001206-bbs2-0056" title="VaishnaviS , AlamyS , ZhangW , ConnorKM , DavidsonJRT . Quetiapine as monotherapy for social anxiety disorder: a placebo‐controlled study. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007;31(7):1464‐9. ">Vaishnavi 2007</a>), block program or randomisation (<a href="./references#CD001206-bbs2-0004" title="29060/502 . Randomised, double‐blind study of paroxetine and placebo in the treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/502#rs (first received 30 September 2005). BaldwinD , BobesJ , SteinDJ , ScharwaechterI , FaureM . Paroxetine in social phobia/social anxiety disorder. Randomised, double‐blind, placebo‐controlled study. British Journal of Psychiatry1999;175(2):120‐6. SteinDJ , BerkM , ElsC , EmsleyRA , GittelsonL , WilsonD , et al. A double‐blind placebo‐controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. South African Medical Journal1999;89(4):402‐6. ">Baldwin 1999</a>; <a href="./references#CD001206-bbs2-0012" title="AderkaIM , McLeanCP , HuppertJD , DavidsonJRT , FoaEB . Fear, avoidance and physiological symptoms during cognitive‐behavioral therapy for social anxiety disorder. Behaviour Research and Therapy2013;51(7):352‐8. DavidsonJRT , FoaEB , HuppertJD , KeefeFJ , FranklinME , ComptonJS , et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry2004;61(10):1005‐13. HuppertJD , SchultzLT , FoaEB , BarlowDH , DavidsonJR , GormanJM , et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive‐compulsive disorder. American Journal of Psychiatry2004;161(8):1485‐7. LedleyDR , HuppertJD , FoaEB , DavidsonJRT , KeefeFJ , PottsNLS . Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depression and Anxiety2005;22(4):161‐7. ">Davidson 2004b</a>; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a>; <a href="./references#CD001206-bbs2-0047" title="SteinMB , LiebowitzMR , LydiardRB , PittsCD , BushnellW , GergelI . Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA1998;280(8):708‐13. ">Stein 1998</a>), or a computer‐generated randomisation list (<a href="./references#CD001206-bbs2-0007" title="BlomhoffS , HaugTT , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry2001;179(1):23‐30. BlomhoffS , HaugTT , HumbleM , HallstromK , MadsbuHP , WoldJE , et al. Treatment of generalized social phobia. New Research Abstracts. 152nd Annual Meeting of the American Psychiatric Association; May 15‐20. Washington DC, 1999:NR650. HaugTT , BlomhoffS , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Exposure therapy and sertraline in social phobia: 1‐year follow‐up of a randomised controlled trial. British Journal of Psychiatry2003;182(4):312‐8. WalkerJR . The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia. Evidence‐based Mental Health2003;6(3):90. ">Blomhoff 2001</a>; <a href="./references#CD001206-bbs2-0010" title="DavidsonJR , PottsN , RichichiE , KrishnanR , FordSM , SmithR , et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology1993;13(6):423‐8. SutherlandSM , TuplerLA , ColketJT , DavidsonJR . A 2‐year follow‐up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease1996;184(12):731‐8. ">Davidson 1993</a>; <a href="./references#CD001206-bbs2-0050" title="29060/595 . A study of the maintained efficacy and safety of paroxetine versus placebo in the long‐term treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/595#rs (first received 28 September 2008). SteinDJ , VersianiM , HairT , KumarR . Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24‐week study. Archives of General Psychiatry2002;59(12):1111‐8. ">Stein 2002b</a>). <a href="./references#CD001206-bbs2-0003" title="AsakuraS , TajimaO , KoyamaT . Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized, double‐blind, placebo‐controlled study. International Journal of Neuropsychopharmacology2007;10(2):263‐74. ">Asakura 2007</a> used a randomisation scheme by double‐dummy method, whereas <a href="./references#CD001206-bbs2-0011" title="DavidsonJ , Yaryura‐TobiasJ , DuPontR , StallingsL , BarbatoLM , Van derHoopRG , et al. Fluvoxamine‐controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(2):118‐25. DavidsonJR , HembyLW , BarbatoL , Van derHoopRG . Fluvoxamine controlled release for the treatment of generalized social anxiety disorder. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14;. San Juan, Puerto Rico, 2000:161. ">Davidson 2004a</a> and <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a> determined randomisation through the sponsor of the central source (e.g. pharmacy) or through a data manager with no patient contact. We classified all these studies as being at low risk for selection bias, while we designated the risk of bias as unclear in the remaining studies. </p> </section> <section id="CD001206-sec-0079"> <h5 class="title">Allocation concealment</h5> <p>We could only classify 17 of the 66 trials included in the review as being at low risk for allocation concealment from their description of the method of allocation. A pharmacist or sponsor who prepared and supplied the study medication maintained allocation concealment in nine trials (<a href="./references#CD001206-bbs2-0001" title="AllgulanderC . Efficacy of paroxetine in social phobia ‐ a single‐center double‐blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20‐50 mg or placebo for 3 months. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4. Paris, France, 1998:P.3.005. AllgulanderC . Paroxetine in social anxiety disorder: a randomised placebo‐controlled study. Acta Psychiatrica Scandinavica1999;100(3):193‐8. ">Allgulander 1999</a>; <a href="./references#CD001206-bbs2-0002" title="AllgulanderC , ManganoR , ZhangJ , DahlAA , LepolaU , SjödinI , EmilienG . Efficacy of venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine. Human Psychopharmacology2004;19(6):387‐96. ManganoR , LiebowitzMR , AllgulanderC . Comparison of venlafaxine extended release and paroxetine in short‐term treatment of SAD. New Research Abstracts. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22. San Francisco (CA), 2003. ">Allgulander 2004</a>; <a href="./references#CD001206-bbs2-0003" title="AsakuraS , TajimaO , KoyamaT . Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized, double‐blind, placebo‐controlled study. International Journal of Neuropsychopharmacology2007;10(2):263‐74. ">Asakura 2007</a>; <a href="./references#CD001206-bbs2-0004" title="29060/502 . Randomised, double‐blind study of paroxetine and placebo in the treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/502#rs (first received 30 September 2005). BaldwinD , BobesJ , SteinDJ , ScharwaechterI , FaureM . Paroxetine in social phobia/social anxiety disorder. Randomised, double‐blind, placebo‐controlled study. British Journal of Psychiatry1999;175(2):120‐6. SteinDJ , BerkM , ElsC , EmsleyRA , GittelsonL , WilsonD , et al. A double‐blind placebo‐controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. South African Medical Journal1999;89(4):402‐6. ">Baldwin 1999</a>; <a href="./references#CD001206-bbs2-0007" title="BlomhoffS , HaugTT , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry2001;179(1):23‐30. BlomhoffS , HaugTT , HumbleM , HallstromK , MadsbuHP , WoldJE , et al. Treatment of generalized social phobia. New Research Abstracts. 152nd Annual Meeting of the American Psychiatric Association; May 15‐20. Washington DC, 1999:NR650. HaugTT , BlomhoffS , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Exposure therapy and sertraline in social phobia: 1‐year follow‐up of a randomised controlled trial. British Journal of Psychiatry2003;182(4):312‐8. WalkerJR . The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia. Evidence‐based Mental Health2003;6(3):90. ">Blomhoff 2001</a>; <a href="./references#CD001206-bbs2-0008" title="BookSW , ThomasSE , RandallPK , RandallCL . Paroxetine reduces social anxiety in individuals with a co‐occurring alcohol use disorder. Journal of Anxiety Disorders2008;22(2):310‐8. ThomasSE , RandallPK , BookSW , RandallCL . A complex relationship between co‐occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research2008;32(1):77‐84. ">Book 2008</a>; <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a>; <a href="./references#CD001206-bbs2-0041" title="RandallCL , JohnsonMR , ThevosAK , SonneSC , ThomasSE , WillardSL , et al. Paroxetine for social anxiety and alcohol use in dual‐diagnosed patients. Depression &amp; Anxiety2001;14(4):255‐62. RandallCL , JohnsonMR , ThevosAK , SonneSC , WillardSL , ThomasSE , et al. Paroxetine improves both social anxiety and alcohol use in dual‐diagnosed patients. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. ">Randall 2001</a>; <a href="./references#CD001206-bbs2-0064" title="WalkerJR , VanAmeringenMA , SwinsonR , BowenRC , ChokkaPR , GoldnerE , et al. Prevention of relapse in generalized social phobia: results of a 24‐week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology2000;20(6):636‐44. WalkerJR , VanAmeringenMA , SwinsonRP , LaneRM . A 24‐week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000:NR259. ">Walker 2000</a>). Other studies maintained concealment with the use of sealed envelopes (<a href="./references#CD001206-bbs2-0007" title="BlomhoffS , HaugTT , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry2001;179(1):23‐30. BlomhoffS , HaugTT , HumbleM , HallstromK , MadsbuHP , WoldJE , et al. Treatment of generalized social phobia. New Research Abstracts. 152nd Annual Meeting of the American Psychiatric Association; May 15‐20. Washington DC, 1999:NR650. HaugTT , BlomhoffS , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Exposure therapy and sertraline in social phobia: 1‐year follow‐up of a randomised controlled trial. British Journal of Psychiatry2003;182(4):312‐8. WalkerJR . The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia. Evidence‐based Mental Health2003;6(3):90. ">Blomhoff 2001</a>; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>), double‐blind packaging (<a href="./references#CD001206-bbs2-0003" title="AsakuraS , TajimaO , KoyamaT . Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized, double‐blind, placebo‐controlled study. International Journal of Neuropsychopharmacology2007;10(2):263‐74. ">Asakura 2007</a>; <a href="./references#CD001206-bbs2-0012" title="AderkaIM , McLeanCP , HuppertJD , DavidsonJRT , FoaEB . Fear, avoidance and physiological symptoms during cognitive‐behavioral therapy for social anxiety disorder. Behaviour Research and Therapy2013;51(7):352‐8. DavidsonJRT , FoaEB , HuppertJD , KeefeFJ , FranklinME , ComptonJS , et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry2004;61(10):1005‐13. HuppertJD , SchultzLT , FoaEB , BarlowDH , DavidsonJR , GormanJM , et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive‐compulsive disorder. American Journal of Psychiatry2004;161(8):1485‐7. LedleyDR , HuppertJD , FoaEB , DavidsonJRT , KeefeFJ , PottsNLS . Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depression and Anxiety2005;22(4):161‐7. ">Davidson 2004b</a>; <a href="./references#CD001206-bbs2-0050" title="29060/595 . A study of the maintained efficacy and safety of paroxetine versus placebo in the long‐term treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/595#rs (first received 28 September 2008). SteinDJ , VersianiM , HairT , KumarR . Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24‐week study. Archives of General Psychiatry2002;59(12):1111‐8. ">Stein 2002b</a>; <a href="./references#CD001206-bbs2-0051" title="SteinDJ , WestenbergHGM , YangH , LiD , BarbatoLM . Fluvoxamine CR in the long‐term treatment of social anxiety disorder: the 12‐ to 24‐week extension phase of a multicentre, randomized, placebo‐controlled trial. International Journal of Neuropsychopharmacology2003;6(4):317‐23. ">Stein 2003</a>; <a href="./references#CD001206-bbs2-0064" title="WalkerJR , VanAmeringenMA , SwinsonR , BowenRC , ChokkaPR , GoldnerE , et al. Prevention of relapse in generalized social phobia: results of a 24‐week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology2000;20(6):636‐44. WalkerJR , VanAmeringenMA , SwinsonRP , LaneRM . A 24‐week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000:NR259. ">Walker 2000</a>), label coding for each participant or numbered box (<a href="./references#CD001206-bbs2-0012" title="AderkaIM , McLeanCP , HuppertJD , DavidsonJRT , FoaEB . Fear, avoidance and physiological symptoms during cognitive‐behavioral therapy for social anxiety disorder. Behaviour Research and Therapy2013;51(7):352‐8. DavidsonJRT , FoaEB , HuppertJD , KeefeFJ , FranklinME , ComptonJS , et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry2004;61(10):1005‐13. HuppertJD , SchultzLT , FoaEB , BarlowDH , DavidsonJR , GormanJM , et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive‐compulsive disorder. American Journal of Psychiatry2004;161(8):1485‐7. LedleyDR , HuppertJD , FoaEB , DavidsonJRT , KeefeFJ , PottsNLS . Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depression and Anxiety2005;22(4):161‐7. ">Davidson 2004b</a>; <a href="./references#CD001206-bbs2-0030" title="MuehlbacherM , NickelMK , NickelC , KettlerC , LahmannC , GilFP , et al. Mirtazapine treatment of social phobia in women. A randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychopharmacology2005;25(6):580‐3. ">Muehlbacher 2005</a>; <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>; <a href="./references#CD001206-bbs2-0052" title="SteinMB , PollackMH , BystritskyA , KelseyJE , ManganoRM . Efficacy of low and higher dose extended‐release venlafaxine in generalized social anxiety disorder: a 6‐month randomized controlled trial. Psychopharmacology2005;177(3):280‐8. SteinMB , PollackMH , ManganoR . Long‐term treatment of generalized SAD with venlafaxine extended release. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR251. ">Stein 2005</a>; <a href="./references#CD001206-bbs2-0051" title="SteinDJ , WestenbergHGM , YangH , LiD , BarbatoLM . Fluvoxamine CR in the long‐term treatment of social anxiety disorder: the 12‐ to 24‐week extension phase of a multicentre, randomized, placebo‐controlled trial. International Journal of Neuropsychopharmacology2003;6(4):317‐23. ">Stein 2003</a>), and cohorts of patients randomly intermixed (<a href="./references#CD001206-bbs2-0016" title="HeimbergRG , LiebowitzMR , HopeDA , SchneierFR , HoltCS , WelkowitzLA , et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry1998;55(12):1133‐41. ">Heimberg 1998</a>). </p> </section> </section> <section id="CD001206-sec-0080"> <h4 class="title">Blinding</h4> <section id="CD001206-sec-0081"> <h5 class="title">Blinding of participants and personnel</h5> <p>We classified 13 studies included in the review as being at low risk of performance bias, as participants and personnel were explicitly described as blinded in the study report (<a href="./references#CD001206-bbs2-0003" title="AsakuraS , TajimaO , KoyamaT . Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized, double‐blind, placebo‐controlled study. International Journal of Neuropsychopharmacology2007;10(2):263‐74. ">Asakura 2007</a>; <a href="./references#CD001206-bbs2-0004" title="29060/502 . Randomised, double‐blind study of paroxetine and placebo in the treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/502#rs (first received 30 September 2005). BaldwinD , BobesJ , SteinDJ , ScharwaechterI , FaureM . Paroxetine in social phobia/social anxiety disorder. Randomised, double‐blind, placebo‐controlled study. British Journal of Psychiatry1999;175(2):120‐6. SteinDJ , BerkM , ElsC , EmsleyRA , GittelsonL , WilsonD , et al. A double‐blind placebo‐controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. South African Medical Journal1999;89(4):402‐6. ">Baldwin 1999</a>; <a href="./references#CD001206-bbs2-0010" title="DavidsonJR , PottsN , RichichiE , KrishnanR , FordSM , SmithR , et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology1993;13(6):423‐8. SutherlandSM , TuplerLA , ColketJT , DavidsonJR . A 2‐year follow‐up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease1996;184(12):731‐8. ">Davidson 1993</a>; <a href="./references#CD001206-bbs2-0011" title="DavidsonJ , Yaryura‐TobiasJ , DuPontR , StallingsL , BarbatoLM , Van derHoopRG , et al. Fluvoxamine‐controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(2):118‐25. DavidsonJR , HembyLW , BarbatoL , Van derHoopRG . Fluvoxamine controlled release for the treatment of generalized social anxiety disorder. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14;. San Juan, Puerto Rico, 2000:161. ">Davidson 2004a</a>; <a href="./references#CD001206-bbs2-0012" title="AderkaIM , McLeanCP , HuppertJD , DavidsonJRT , FoaEB . Fear, avoidance and physiological symptoms during cognitive‐behavioral therapy for social anxiety disorder. Behaviour Research and Therapy2013;51(7):352‐8. DavidsonJRT , FoaEB , HuppertJD , KeefeFJ , FranklinME , ComptonJS , et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry2004;61(10):1005‐13. HuppertJD , SchultzLT , FoaEB , BarlowDH , DavidsonJR , GormanJM , et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive‐compulsive disorder. American Journal of Psychiatry2004;161(8):1485‐7. LedleyDR , HuppertJD , FoaEB , DavidsonJRT , KeefeFJ , PottsNLS . Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depression and Anxiety2005;22(4):161‐7. ">Davidson 2004b</a>; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0016" title="HeimbergRG , LiebowitzMR , HopeDA , SchneierFR , HoltCS , WelkowitzLA , et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry1998;55(12):1133‐41. ">Heimberg 1998</a>; <a href="./references#CD001206-bbs2-0030" title="MuehlbacherM , NickelMK , NickelC , KettlerC , LahmannC , GilFP , et al. Mirtazapine treatment of social phobia in women. A randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychopharmacology2005;25(6):580‐3. ">Muehlbacher 2005</a>; <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a>; <a href="./references#CD001206-bbs2-0038" title="OosterbaanDB , VanBalkomAJLM , SpinhovenP , vanOppenP , vanDyckR . Cognitive therapy versus moclobemide in social phobia: a controlled study. Clinical Pscyhology and Psychotherapy2001;8(4):263‐73. ">Oosterbaan 2001</a>; <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>; <a href="./references#CD001206-bbs2-0052" title="SteinMB , PollackMH , BystritskyA , KelseyJE , ManganoRM . Efficacy of low and higher dose extended‐release venlafaxine in generalized social anxiety disorder: a 6‐month randomized controlled trial. Psychopharmacology2005;177(3):280‐8. SteinMB , PollackMH , ManganoR . Long‐term treatment of generalized SAD with venlafaxine extended release. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR251. ">Stein 2005</a>; <a href="./references#CD001206-bbs2-0064" title="WalkerJR , VanAmeringenMA , SwinsonR , BowenRC , ChokkaPR , GoldnerE , et al. Prevention of relapse in generalized social phobia: results of a 24‐week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology2000;20(6):636‐44. WalkerJR , VanAmeringenMA , SwinsonRP , LaneRM . A 24‐week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000:NR259. ">Walker 2000</a>). In <a href="./references#CD001206-bbs2-0038" title="OosterbaanDB , VanBalkomAJLM , SpinhovenP , vanOppenP , vanDyckR . Cognitive therapy versus moclobemide in social phobia: a controlled study. Clinical Pscyhology and Psychotherapy2001;8(4):263‐73. ">Oosterbaan 2001</a> and <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>, participants and therapists or independent evaluators guessed post‐test whether medication or placebo had been administered. Correct classifications did not differ from chance. We classified one trial as being at high risk because it provided no information on blinding participants or personnel, nor did investigators describe the study as double‐blind (<a href="./references#CD001206-bbs2-0029" title="MoghadamMNM , Atef‐VahidMK , Asgharnejad‐FaridAA , ShabaniA , LavasniF . Effectiveness of short‐term dynamic psychotherapy versus sertraline in treatment of social phobia. Iranian Journal of Psychiatry and Behavioral Sciences2015;9(2):e228. ">Moghadam 2015</a>). We classified risk of bias for the remaining trials as unclear, despite investigators describing them in the study reports as double‐blinded, as they did not specify the actual parties blinded. </p> </section> <section id="CD001206-sec-0082"> <h5 class="title">Blinding of outcome assessors</h5> <p>We classified 13 of the studies included in the review as being at low risk of detection bias, as the study reports explicitly described outcome assessors as blinded in the study report (<a href="./references#CD001206-bbs2-0002" title="AllgulanderC , ManganoR , ZhangJ , DahlAA , LepolaU , SjödinI , EmilienG . Efficacy of venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine. Human Psychopharmacology2004;19(6):387‐96. ManganoR , LiebowitzMR , AllgulanderC . Comparison of venlafaxine extended release and paroxetine in short‐term treatment of SAD. New Research Abstracts. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22. San Francisco (CA), 2003. ">Allgulander 2004</a>; <a href="./references#CD001206-bbs2-0003" title="AsakuraS , TajimaO , KoyamaT . Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized, double‐blind, placebo‐controlled study. International Journal of Neuropsychopharmacology2007;10(2):263‐74. ">Asakura 2007</a>; <a href="./references#CD001206-bbs2-0006" title="BlancoC , HeimbergRG , SchneierFR , FrescoDM , ChenH , TurkCL , et al. A placebo‐controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry2010;67(3):286‐95. ">Blanco 2010</a>; <a href="./references#CD001206-bbs2-0008" title="BookSW , ThomasSE , RandallPK , RandallCL . Paroxetine reduces social anxiety in individuals with a co‐occurring alcohol use disorder. Journal of Anxiety Disorders2008;22(2):310‐8. ThomasSE , RandallPK , BookSW , RandallCL . A complex relationship between co‐occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research2008;32(1):77‐84. ">Book 2008</a>; <a href="./references#CD001206-bbs2-0010" title="DavidsonJR , PottsN , RichichiE , KrishnanR , FordSM , SmithR , et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology1993;13(6):423‐8. SutherlandSM , TuplerLA , ColketJT , DavidsonJR . A 2‐year follow‐up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease1996;184(12):731‐8. ">Davidson 1993</a>; <a href="./references#CD001206-bbs2-0012" title="AderkaIM , McLeanCP , HuppertJD , DavidsonJRT , FoaEB . Fear, avoidance and physiological symptoms during cognitive‐behavioral therapy for social anxiety disorder. Behaviour Research and Therapy2013;51(7):352‐8. DavidsonJRT , FoaEB , HuppertJD , KeefeFJ , FranklinME , ComptonJS , et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry2004;61(10):1005‐13. HuppertJD , SchultzLT , FoaEB , BarlowDH , DavidsonJR , GormanJM , et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive‐compulsive disorder. American Journal of Psychiatry2004;161(8):1485‐7. LedleyDR , HuppertJD , FoaEB , DavidsonJRT , KeefeFJ , PottsNLS . Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depression and Anxiety2005;22(4):161‐7. ">Davidson 2004b</a>; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0016" title="HeimbergRG , LiebowitzMR , HopeDA , SchneierFR , HoltCS , WelkowitzLA , et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry1998;55(12):1133‐41. ">Heimberg 1998</a>; <a href="./references#CD001206-bbs2-0030" title="MuehlbacherM , NickelMK , NickelC , KettlerC , LahmannC , GilFP , et al. Mirtazapine treatment of social phobia in women. A randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychopharmacology2005;25(6):580‐3. ">Muehlbacher 2005</a>; <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a>; <a href="./references#CD001206-bbs2-0038" title="OosterbaanDB , VanBalkomAJLM , SpinhovenP , vanOppenP , vanDyckR . Cognitive therapy versus moclobemide in social phobia: a controlled study. Clinical Pscyhology and Psychotherapy2001;8(4):263‐73. ">Oosterbaan 2001</a>; <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>; <a href="./references#CD001206-bbs2-0064" title="WalkerJR , VanAmeringenMA , SwinsonR , BowenRC , ChokkaPR , GoldnerE , et al. Prevention of relapse in generalized social phobia: results of a 24‐week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology2000;20(6):636‐44. WalkerJR , VanAmeringenMA , SwinsonRP , LaneRM . A 24‐week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000:NR259. ">Walker 2000</a>). We classified <a href="./references#CD001206-bbs2-0007" title="BlomhoffS , HaugTT , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry2001;179(1):23‐30. BlomhoffS , HaugTT , HumbleM , HallstromK , MadsbuHP , WoldJE , et al. Treatment of generalized social phobia. New Research Abstracts. 152nd Annual Meeting of the American Psychiatric Association; May 15‐20. Washington DC, 1999:NR650. HaugTT , BlomhoffS , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Exposure therapy and sertraline in social phobia: 1‐year follow‐up of a randomised controlled trial. British Journal of Psychiatry2003;182(4):312‐8. WalkerJR . The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia. Evidence‐based Mental Health2003;6(3):90. ">Blomhoff 2001</a>, <a href="./references#CD001206-bbs2-0052" title="SteinMB , PollackMH , BystritskyA , KelseyJE , ManganoRM . Efficacy of low and higher dose extended‐release venlafaxine in generalized social anxiety disorder: a 6‐month randomized controlled trial. Psychopharmacology2005;177(3):280‐8. SteinMB , PollackMH , ManganoR . Long‐term treatment of generalized SAD with venlafaxine extended release. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR251. ">Stein 2005</a>, and <a href="./references#CD001206-bbs2-0058" title="VanAmeringenM , ManciniC , OakmanJ , WalkerJ , KjernistedK , ChokkaP , et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(2):288‐95. VanAmeringenMA , ManciniCL , PipeB , OakmanJ , WalkerJR , KjernistedKD , et al. Not all serotonergic agents are created equal in social phobia: nefazodone, a placebo‐controlled trial. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR789. ">Van Ameringen 2007</a> as being at high risk, as these studies reported that outcome assessors were not blinded to treatment, and <a href="./references#CD001206-bbs2-0029" title="MoghadamMNM , Atef‐VahidMK , Asgharnejad‐FaridAA , ShabaniA , LavasniF . Effectiveness of short‐term dynamic psychotherapy versus sertraline in treatment of social phobia. Iranian Journal of Psychiatry and Behavioral Sciences2015;9(2):e228. ">Moghadam 2015</a> because authors provided no information to determine if outcome assessors were blinded, nor if the study was double blind. We classified the remaining studies as being at unclear risk. </p> </section> </section> <section id="CD001206-sec-0083"> <h4 class="title">Incomplete outcome data</h4> <p>Fourteen studies failed to provide sufficient information to determine whether the medication and placebo groups were comparable with respect to dropout proportions, or in terms of the demographic and clinical characteristics of those who withdrew (<a href="./references#CD001206-bbs2-0009" title="ConnorKM , DavidsonJR , PottsNL , TuplerLA , MinerCM , MalikML , et al. Discontinuation of clonazepam in the treatment of social phobia. Journal of Clinical Psychopharmacology1998;18(5):373‐8. ">Connor 1998</a>; <a href="./references#CD001206-bbs2-0011" title="DavidsonJ , Yaryura‐TobiasJ , DuPontR , StallingsL , BarbatoLM , Van derHoopRG , et al. Fluvoxamine‐controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(2):118‐25. DavidsonJR , HembyLW , BarbatoL , Van derHoopRG . Fluvoxamine controlled release for the treatment of generalized social anxiety disorder. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14;. San Juan, Puerto Rico, 2000:161. ">Davidson 2004a</a>; <a href="./references#CD001206-bbs2-0018" title="KatschnigK , SteinMB , BullerR . Moclobemide in social phobia. A double‐blind, placebo‐controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience1997;247(2):71‐80. ">Katschnig 1997</a>; <a href="./references#CD001206-bbs2-0027" title="Liebow3149018itzMR , GelenbergAJ , MunjackD . Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry2005;62(2):190‐8. ">Liebowitz 2005b</a>; <a href="./references#CD001206-bbs2-0040" title="FeltnerDE , DavidsonJR , PollackMH , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social anxiety disorder: outcome and predictors of response. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14. San Juan, Puerto Rico, 2000. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled study of pregabalin in social phobia (social anxiety disorder) [abstract]. International Journal of Neuropsychopharmacology2000;3(Suppl 1):284. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererRA , JeffersonJW , et al. Pregabalin treatment of social phobia. New Research Abstracts. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000. FeltnerDE , PollackMH , DavidsonJRT , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social phobia: outcome and predictors of response [abstract]. European Neuropsychopharmacology2000;10(Suppl 3):S345. PandeAC , FeltnerDE , JeffersonJW , DavidsonJRT , PollackM , SteinMB , et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo‐controlled, multicenter study. Journal of Clinical Psychopharmacology2004;24(2):141‐9. ">Pande 2004</a>; <a href="./references#CD001206-bbs2-0041" title="RandallCL , JohnsonMR , ThevosAK , SonneSC , ThomasSE , WillardSL , et al. Paroxetine for social anxiety and alcohol use in dual‐diagnosed patients. Depression &amp; Anxiety2001;14(4):255‐62. RandallCL , JohnsonMR , ThevosAK , SonneSC , WillardSL , ThomasSE , et al. Paroxetine improves both social anxiety and alcohol use in dual‐diagnosed patients. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. ">Randall 2001</a>; <a href="./references#CD001206-bbs2-0043" title="RickelsK , ManganoR , KhanA . A double‐blind, placebo‐controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(5):488‐96. ">Rickels 2004</a>; <a href="./references#CD001206-bbs2-0046" title="SteinMB , ChartierMJ , HazenAL , KroftCD , ChaleRA , CotéD , et al. Paroxetine in the treatment of generalized social phobia: open‐label treatment and double‐blind placebo‐controlled discontinuation. Journal of Clinical Psychopharmacology1996;16(3):218‐22. ">Stein 1996</a>; <a href="./references#CD001206-bbs2-0048" title="SteinMB , FyerAJ , DavidsonJR , PollackMH , WiitaB . Fluvoxamine treatment of social phobia (social anxiety disorder): a double‐blind, placebo‐controlled study. American Journal of Psychiatry1999;156(5):756‐60. ">Stein 1999</a>; <a href="./references#CD001206-bbs2-0049" title="SteinDJ , CameronA , AmreinR , MontgomerySA . Moclobemide is effective and well tolerated in the long‐term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology2002;17(4):161‐70. ">Stein 2002a</a>; <a href="./references#CD001206-bbs2-0051" title="SteinDJ , WestenbergHGM , YangH , LiD , BarbatoLM . Fluvoxamine CR in the long‐term treatment of social anxiety disorder: the 12‐ to 24‐week extension phase of a multicentre, randomized, placebo‐controlled trial. International Journal of Neuropsychopharmacology2003;6(4):317‐23. ">Stein 2003</a>; <a href="./references#CD001206-bbs2-0054" title="TauscherJ , KielbasaW , IyengarS , VandenhendeF , PengX , MozleyD , et al. Development of the 2nd generation neurokinin‐1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology2010;20(2):80‐7. ">Tauscher 2010</a>; <a href="./references#CD001206-bbs2-0055" title="TurnerS , BeidelDC , JacobRG . Social phobia: a comparison of behaviour therapy and atenolol. Journal of Consulting and Clinical Psychology1994;62(2):350‐8. ">Turner 1994</a>; <a href="./references#CD001206-bbs2-0056" title="VaishnaviS , AlamyS , ZhangW , ConnorKM , DavidsonJRT . Quetiapine as monotherapy for social anxiety disorder: a placebo‐controlled study. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007;31(7):1464‐9. ">Vaishnavi 2007</a>). We rated the risk of attrition bias as unclear for these trials. We observed substantial differences in the proportion of study dropouts between the medication and placebo groups in <a href="./references#CD001206-bbs2-0001" title="AllgulanderC . Efficacy of paroxetine in social phobia ‐ a single‐center double‐blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20‐50 mg or placebo for 3 months. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4. Paris, France, 1998:P.3.005. AllgulanderC . Paroxetine in social anxiety disorder: a randomised placebo‐controlled study. Acta Psychiatrica Scandinavica1999;100(3):193‐8. ">Allgulander 1999</a>, <a href="./references#CD001206-bbs2-0019" title="KatzelnickDJ , KobakKA , GreistJH , JeffersonJW , MantleJM , SerlinRC . Sertraline for social phobia: a double‐blind, placebo‐controlled crossover study. American Journal of Psychiatry1995;152(9):1368‐71. ">Katzelnick 1995</a>, <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>, <a href="./references#CD001206-bbs2-0029" title="MoghadamMNM , Atef‐VahidMK , Asgharnejad‐FaridAA , ShabaniA , LavasniF . Effectiveness of short‐term dynamic psychotherapy versus sertraline in treatment of social phobia. Iranian Journal of Psychiatry and Behavioral Sciences2015;9(2):e228. ">Moghadam 2015</a>; <a href="./references#CD001206-bbs2-0052" title="SteinMB , PollackMH , BystritskyA , KelseyJE , ManganoRM . Efficacy of low and higher dose extended‐release venlafaxine in generalized social anxiety disorder: a 6‐month randomized controlled trial. Psychopharmacology2005;177(3):280‐8. SteinMB , PollackMH , ManganoR . Long‐term treatment of generalized SAD with venlafaxine extended release. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR251. ">Stein 2005</a>, <a href="./references#CD001206-bbs2-0058" title="VanAmeringenM , ManciniC , OakmanJ , WalkerJ , KjernistedK , ChokkaP , et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(2):288‐95. VanAmeringenMA , ManciniCL , PipeB , OakmanJ , WalkerJR , KjernistedKD , et al. Not all serotonergic agents are created equal in social phobia: nefazodone, a placebo‐controlled trial. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR789. ">Van Ameringen 2007</a>, and in the maintenance treatment design that <a href="./references#CD001206-bbs2-0064" title="WalkerJR , VanAmeringenMA , SwinsonR , BowenRC , ChokkaPR , GoldnerE , et al. Prevention of relapse in generalized social phobia: results of a 24‐week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology2000;20(6):636‐44. WalkerJR , VanAmeringenMA , SwinsonRP , LaneRM . A 24‐week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000:NR259. ">Walker 2000</a> and <a href="./references#CD001206-bbs2-0066" title="ZhangW , ConnorKM , DavidsonJRT . Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology2005;19(5):551‐3. ">Zhang 2005</a> employed, justifying a rating of high risk. We rated the remaining 44 studies as being at low risk for this domain, on the basis of comparable dropout rates in each comparison group and no difference in the demographic characteristics. Overall, the total dropout rate was 25% across all medications compared to placebo (with the exclusion of one trial of paroxetine, to give preference to the experimental drug that is least represented in the data set). We assessed intention‐to‐treat data for all outcomes in 11 studies and used LOCF (k = 46), observed cases (k = 9) and mixed‐effect models (k = 3) to account for missing data in the rest of the trials. Thirteen studies did not specify how they addressed the issue of missing data. </p> </section> <section id="CD001206-sec-0084"> <h4 class="title">Selective reporting</h4> <p>It was unclear whether selective reporting took place in 55 trials because the study protocols were not available for the study. We rated eight studies as being at low risk for selective reporting because authors reported on all outcomes as specified in their respective trial protocols (<a href="./references#CD001206-bbs2-0002" title="AllgulanderC , ManganoR , ZhangJ , DahlAA , LepolaU , SjödinI , EmilienG . Efficacy of venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine. Human Psychopharmacology2004;19(6):387‐96. ManganoR , LiebowitzMR , AllgulanderC . Comparison of venlafaxine extended release and paroxetine in short‐term treatment of SAD. New Research Abstracts. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22. San Francisco (CA), 2003. ">Allgulander 2004</a>; <a href="./references#CD001206-bbs2-0022" title="LepolaU , BergtholdtB , LambertJS , DavyKL , RuggieroL . Controlled‐release paroxetine in the treatment of patients with social anxiety disorder. Journal of Clinical Psychiatry2004;65:222‐9. ">Lepola 2004</a>; <a href="./references#CD001206-bbs2-0029" title="MoghadamMNM , Atef‐VahidMK , Asgharnejad‐FaridAA , ShabaniA , LavasniF . Effectiveness of short‐term dynamic psychotherapy versus sertraline in treatment of social phobia. Iranian Journal of Psychiatry and Behavioral Sciences2015;9(2):e228. ">Moghadam 2015</a>; <a href="./references#CD001206-bbs2-0032" title="NCT00318669 . Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) ‐A Double‐blind, Placebo‐controlled Study‐ &lt;Phase III Study&gt; [Social Anxiety Disorder Study Of Paroxetine]. clinicaltrials.gov/ct2/show/NCT00318669 (first received 24 April 2006). ">NCT00318669</a>; <a href="./references#CD001206-bbs2-0042" title="RavindranLN , KimDS , LetamendiAM , SteinMB . A randomized controlled trial of atomoxetine in generalized social anxiety disorder. Journal of Clinical Psychopharmacology2009;29(6):561‐4. ">Ravindran 2009</a>; <a href="./references#CD001206-bbs2-0047" title="SteinMB , LiebowitzMR , LydiardRB , PittsCD , BushnellW , GergelI . Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA1998;280(8):708‐13. ">Stein 1998</a>; <a href="./references#CD001206-bbs2-0053" title="SteinMB , RavindranLN , SimonNM , LiebowitzMR , KhanA , Brawman‐MintzerO , et al. Levetiracetam in generalized social anxiety disorder: a double‐blind, randomized controlled trial. Journal of Clinical Psychiatry2010;71(5):627‐31. ">Stein 2010</a>; <a href="./references#CD001206-bbs2-0056" title="VaishnaviS , AlamyS , ZhangW , ConnorKM , DavidsonJRT . Quetiapine as monotherapy for social anxiety disorder: a placebo‐controlled study. Progress in Neuro‐Psychopharmacology and Biological Psychiatry2007;31(7):1464‐9. ">Vaishnavi 2007</a>). In <a href="./references#CD001206-bbs2-0008" title="BookSW , ThomasSE , RandallPK , RandallCL . Paroxetine reduces social anxiety in individuals with a co‐occurring alcohol use disorder. Journal of Anxiety Disorders2008;22(2):310‐8. ThomasSE , RandallPK , BookSW , RandallCL . A complex relationship between co‐occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research2008;32(1):77‐84. ">Book 2008</a>, <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a>, and <a href="./references#CD001206-bbs2-0054" title="TauscherJ , KielbasaW , IyengarS , VandenhendeF , PengX , MozleyD , et al. Development of the 2nd generation neurokinin‐1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology2010;20(2):80‐7. ">Tauscher 2010</a>, the pre‐specified secondary outcomes in the protocol did not appear in the study report, meriting a classification of high risk. </p> </section> <section id="CD001206-sec-0085"> <h4 class="title">Other potential sources of bias</h4> <p>We classified 11 studies as being at low risk for other potential sources of bias (<a href="./references#CD001206-bbs2-0006" title="BlancoC , HeimbergRG , SchneierFR , FrescoDM , ChenH , TurkCL , et al. A placebo‐controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry2010;67(3):286‐95. ">Blanco 2010</a>; <a href="./references#CD001206-bbs2-0010" title="DavidsonJR , PottsN , RichichiE , KrishnanR , FordSM , SmithR , et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology1993;13(6):423‐8. SutherlandSM , TuplerLA , ColketJT , DavidsonJR . A 2‐year follow‐up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease1996;184(12):731‐8. ">Davidson 1993</a>; <a href="./references#CD001206-bbs2-0029" title="MoghadamMNM , Atef‐VahidMK , Asgharnejad‐FaridAA , ShabaniA , LavasniF . Effectiveness of short‐term dynamic psychotherapy versus sertraline in treatment of social phobia. Iranian Journal of Psychiatry and Behavioral Sciences2015;9(2):e228. ">Moghadam 2015</a>; <a href="./references#CD001206-bbs2-0030" title="MuehlbacherM , NickelMK , NickelC , KettlerC , LahmannC , GilFP , et al. Mirtazapine treatment of social phobia in women. A randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychopharmacology2005;25(6):580‐3. ">Muehlbacher 2005</a>; <a href="./references#CD001206-bbs2-0043" title="RickelsK , ManganoR , KhanA . A double‐blind, placebo‐controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(5):488‐96. ">Rickels 2004</a>; <a href="./references#CD001206-bbs2-0046" title="SteinMB , ChartierMJ , HazenAL , KroftCD , ChaleRA , CotéD , et al. Paroxetine in the treatment of generalized social phobia: open‐label treatment and double‐blind placebo‐controlled discontinuation. Journal of Clinical Psychopharmacology1996;16(3):218‐22. ">Stein 1996</a>; <a href="./references#CD001206-bbs2-0049" title="SteinDJ , CameronA , AmreinR , MontgomerySA . Moclobemide is effective and well tolerated in the long‐term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology2002;17(4):161‐70. ">Stein 2002a</a>; <a href="./references#CD001206-bbs2-0059" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO‐A inhibitor. European Neuropsychopharmacology1992;2(1):21‐9. ">Van Vliet 1992</a>; <a href="./references#CD001206-bbs2-0060" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology1994;115(1‐2):128‐34. ">Van Vliet 1994</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>; <a href="./references#CD001206-bbs2-0063" title="VersianiM , NardiAE , FigueiraI , MendlowiczM , MarquesC . Double‐blind placebo controlled trial with bromazepam in social phobia. Jornal Brasileiro de Psiquiatria1997;46(3):167‐71. ">Versiani 1997</a>). We rated the risk of other bias for the remaining studies as unclear due to industry involvement, whether through funding or provision of study medication. </p> </section> </section> <section id="CD001206-sec-0086"> <h3 class="title" id="CD001206-sec-0086">Effects of interventions</h3> <p>See: <a href="./full#CD001206-tbl-0001"><b>Summary of findings for the main comparison</b> Comparison 1: 5HT1A partial agonists versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0002"><b>Summary of findings 2</b> Comparison 2: anticonvulsants/GABAs versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0003"><b>Summary of findings 3</b> Comparison 3: anticonvulsant levetiracetam versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0004"><b>Summary of findings 4</b> Comparison 4: antipsychotics versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0005"><b>Summary of findings 5</b> Comparison 5: benzodiazepines versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0006"><b>Summary of findings 6</b> Comparison 6: beta‐blockers versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0007"><b>Summary of findings 7</b> Comparison 7: MAOIs versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0008"><b>Summary of findings 8</b> Comparison 8: NARIs versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0009"><b>Summary of findings 9</b> Comparison 9: NaSSAs versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0010"><b>Summary of findings 10</b> Comparison 10: RIMAs versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0011"><b>Summary of findings 11</b> Comparison 11: SARIs versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0012"><b>Summary of findings 12</b> Comparison 12: SNRIs versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0013"><b>Summary of findings 13</b> Comparison 13: SSRIs versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0014"><b>Summary of findings 14</b> Comparison 14: GW876008 versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0015"><b>Summary of findings 15</b> Comparison 15: NK1 receptor antagonist GR205171 versus placebo for social anxiety disorder (SAnD)</a>; <a href="./full#CD001206-tbl-0016"><b>Summary of findings 16</b> Comparison 16: LY686017 versus placebo for social anxiety disorder (SAnD)</a> </p> <p>See 'Summary of findings' tables for the main comparisons of medication classes compared to placebo for treating SAnD (where provided): <a href="./full#CD001206-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD001206-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD001206-tbl-0003">summary of findings Table 3</a>; <a href="./full#CD001206-tbl-0004">summary of findings Table 4</a>; <a href="./full#CD001206-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD001206-tbl-0006">summary of findings Table 6</a>; <a href="./full#CD001206-tbl-0007">summary of findings Table 7</a>; <a href="./full#CD001206-tbl-0008">summary of findings Table 8</a>; <a href="./full#CD001206-tbl-0009">summary of findings Table 9</a>; <a href="./full#CD001206-tbl-0010">summary of findings Table 10</a>; <a href="./full#CD001206-tbl-0011">summary of findings Table 11</a>; <a href="./full#CD001206-tbl-0012">summary of findings Table 12</a>; <a href="./full#CD001206-tbl-0013">summary of findings Table 13</a>; <a href="./full#CD001206-tbl-0014">summary of findings Table 14</a>; <a href="./full#CD001206-tbl-0015">summary of findings Table 15</a>; <a href="./full#CD001206-tbl-0016">summary of findings Table 16</a>. Please refer to <a href="#CD001206-sec-0033">Types of outcome measures</a> for a description of the scoring systems used in included studies. </p> <section id="CD001206-sec-0087"> <h4 class="title">Comparison 1: 5HT1A partial agonists versus placebo</h4> <section id="CD001206-sec-0088"> <h5 class="title">Primary outcome measures</h5> <p>There was no evidence of an effect of buspirone on treatment efficacy in participants with SAnD compared to placebo (k = 1, risk ratio (RR) 1.00, 95% confidence interval (CI) 0.07 to 14.55, N = 30; see <a href="./references#CD001206-fig-0006" title="">Analysis 1.1;</a><a href="./references#CD001206-bbs2-0061" title="VanVlietI , DenBoerJ , WestenbergH , Ho PianK . Clinical effects of buspirone in social phobia, a double‐blind placebo controlled study. 9th European College of Neuropsychopharmacology Congress; Sept 21‐25. Amsterdam, Netherlands, 1996. VanVlietIM , DenBoerJA , WestenbergHG , PianKL . Clinical effects of buspirone in social phobia: a double‐blind placebo‐controlled study. Journal of Clinical Psychiatry1997;58(4):164‐8. ">Van Vliet 1997</a>). In addition, the quality of the evidence for this outcome is very low. Dropout rates due to adverse events were low in the medication arm of one RCT of buspirone (1/30, 3%) (see <a href="./references#CD001206-fig-0007" title="">Analysis 1.2</a>); again, however, this conclusion is based on very low‐quality evidence. </p> </section> <section id="CD001206-sec-0089"> <h5 class="title">Secondary outcomes measures</h5> <p>Buspirone was not superior to placebo on the avoidance subscale of the LSAS for the reduction of anxiety symptoms (k = 1, mean difference (MD) <b>−</b> 1.40 points, 95% CI <b>−</b>11.61 to 8.81; N = 30; <a href="./references#CD001206-fig-0008" title="">Analysis 1.3</a>; <a href="./references#CD001206-bbs2-0061" title="VanVlietI , DenBoerJ , WestenbergH , Ho PianK . Clinical effects of buspirone in social phobia, a double‐blind placebo controlled study. 9th European College of Neuropsychopharmacology Congress; Sept 21‐25. Amsterdam, Netherlands, 1996. VanVlietIM , DenBoerJA , WestenbergHG , PianKL . Clinical effects of buspirone in social phobia: a double‐blind placebo‐controlled study. Journal of Clinical Psychiatry1997;58(4):164‐8. ">Van Vliet 1997</a>).The evidence that was available for this outcome was of very low quality. There was no evidence of an effect of buspirone on depression symptoms on the HAM‐D scale in participants with SAnD compared to placebo (k = 1, MD −0.60 points, 95% CI −2.86 to 1.66, N = 27; see <a href="./references#CD001206-fig-0009" title="">Analysis 1.4</a>; <a href="./references#CD001206-bbs2-0061" title="VanVlietI , DenBoerJ , WestenbergH , Ho PianK . Clinical effects of buspirone in social phobia, a double‐blind placebo controlled study. 9th European College of Neuropsychopharmacology Congress; Sept 21‐25. Amsterdam, Netherlands, 1996. VanVlietIM , DenBoerJA , WestenbergHG , PianKL . Clinical effects of buspirone in social phobia: a double‐blind placebo‐controlled study. Journal of Clinical Psychiatry1997;58(4):164‐8. ">Van Vliet 1997</a>). </p> <p>More participants withdrew from the placebo group (3/15; 20%) compared to the buspirone group (0/15; 0%). Nevertheless, the total proportion of dropouts (20%) is relatively low and is confirmed by the lack of evidence of a difference between the two groups (k = 1, RR 0.14; 95% CI 0.01 to 2.55, N = 30; see <a href="./references#CD001206-fig-0010" title="">Analysis 1.5</a>). </p> </section> </section> <section id="CD001206-sec-0090"> <h4 class="title">Comparison 2: anticonvulsants/GABAs versus placebo</h4> <section id="CD001206-sec-0091"> <h5 class="title">Primary outcome measures</h5> <p>There was evidence of benefit for gabapentin and pregabalin compared to placebo on the number of participants with SAnD who responded to treatment (k = 3, RR 1.60 ; 95% CI 1.16 to 2.20, N = 532; see <a href="./references#CD001206-fig-0011" title="">Analysis 2.1</a>; <a href="./references#CD001206-bbs2-0014" title="FeltnerD , BielskiR , Liu‐DumawM . Efficacy of pregabalin in generalised social anxiety disorder: results of a placebo‐controlled, fixed‐dose study. European Neuropsychopharmacology2010;20(Suppl 3):S525–6. FeltnerDE , Liu‐DumawM , SchweizerE , BielskiR . Efficacy of pregabalin in generalized social anxiety disorder: results of a double‐blind, placebo‐controlled, fixed‐dose study. International Clinical Psychopharmacology2011;26(4):213–20. ">Feltner 2011</a>; <a href="./references#CD001206-bbs2-0040" title="FeltnerDE , DavidsonJR , PollackMH , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social anxiety disorder: outcome and predictors of response. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14. San Juan, Puerto Rico, 2000. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled study of pregabalin in social phobia (social anxiety disorder) [abstract]. International Journal of Neuropsychopharmacology2000;3(Suppl 1):284. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererRA , JeffersonJW , et al. Pregabalin treatment of social phobia. New Research Abstracts. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000. FeltnerDE , PollackMH , DavidsonJRT , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social phobia: outcome and predictors of response [abstract]. European Neuropsychopharmacology2000;10(Suppl 3):S345. PandeAC , FeltnerDE , JeffersonJW , DavidsonJRT , PollackM , SteinMB , et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo‐controlled, multicenter study. Journal of Clinical Psychopharmacology2004;24(2):141‐9. ">Pande 2004</a>; <a href="./references#CD001206-bbs2-0039" title="PandeAC , DavidsonJR , JeffersonJW , JanneyCA , KatzelnickDJ , WeislerRH , GreistJH , SutherlandSM . Treatment of social phobia with gabapentin: a placebo‐controlled study. Journal of Clinical Psychopharmacology1999;19(4):341‐8. ">Pande 1999</a>), with moderate‐quality evidence. The proportion of dropouts due to adverse events was approximately three times as high in participants receiving gabapentin or pregabalin (64/369, 17%) relative to placebo (9/163, 6%) (k = 3, RR 2.90; 95% CI 0.92 to 9.14; see <a href="./references#CD001206-fig-0012" title="">Analysis 2.2</a>). The higher dropout rate associated with medication was particularly apparent in the <a href="./references#CD001206-bbs2-0014" title="FeltnerD , BielskiR , Liu‐DumawM . Efficacy of pregabalin in generalised social anxiety disorder: results of a placebo‐controlled, fixed‐dose study. European Neuropsychopharmacology2010;20(Suppl 3):S525–6. FeltnerDE , Liu‐DumawM , SchweizerE , BielskiR . Efficacy of pregabalin in generalized social anxiety disorder: results of a double‐blind, placebo‐controlled, fixed‐dose study. International Clinical Psychopharmacology2011;26(4):213–20. ">Feltner 2011</a> trial of pregabalin, with the proportion of discontinuations due to adverse events ranging between 14% and 20.5% for the three dosages tested (300 mg/d, 450 mg/d, 600 mg/d), versus 1.2% in the placebo group (RR 14.00; 95% CI 1.96 to 100.12). </p> <p>The GABA anticonvulsants were significantly more efficacious than the anticonvulsant levetiracetam (Chi<sup>2</sup> = 4.25, df = 1, P = 0.04; I<sup>2</sup> = 76.5%). </p> </section> <section id="CD001206-sec-0092"> <h5 class="title">Secondary outcomes measures</h5> <p>There was no evidence that gabapentin reduced total SAnD symptom severity scores on the LSAS (k = 1, MD −11.50 points, 95% CI −25.20 to 2.20, N = 69; see <a href="./references#CD001206-fig-0013" title="">Analysis 2.3</a>; <a href="./references#CD001206-bbs2-0039" title="PandeAC , DavidsonJR , JeffersonJW , JanneyCA , KatzelnickDJ , WeislerRH , GreistJH , SutherlandSM . Treatment of social phobia with gabapentin: a placebo‐controlled study. Journal of Clinical Psychopharmacology1999;19(4):341‐8. ">Pande 1999</a>). In addition, there was no evidence of a difference on either the avoidance (MD −4.60 points, 95% CI −11.88 to 2.68, see <a href="./references#CD001206-fig-0013" title="">Analysis 2.3</a>) or fear subscale of the LSAS (MD −6.90 points, 95% CI −13.65 to −0.15, see <a href="./references#CD001206-fig-0013" title="">Analysis 2.3</a>). The evidence for the three outcomes was low in quality. We did not find an effect for medication in reducing depression symptoms on the HAM‐D scale in a single RCT of gabapentin compared to placebo (MD −2.30 points, 95% CI −4.78 to 0.18, N = 69; see <a href="./references#CD001206-fig-0014" title="">Analysis 2.4</a>; <a href="./references#CD001206-bbs2-0039" title="PandeAC , DavidsonJR , JeffersonJW , JanneyCA , KatzelnickDJ , WeislerRH , GreistJH , SutherlandSM . Treatment of social phobia with gabapentin: a placebo‐controlled study. Journal of Clinical Psychopharmacology1999;19(4):341‐8. ">Pande 1999</a>). </p> <p>Three studies with 488 participants reported similar proportions of dropouts due to any cause in the medication and placebo groups (RR 1.16; 95% CI 0.78 to 1.70; see <a href="./references#CD001206-fig-0015" title="">Analysis 2.5</a>; <a href="./references#CD001206-bbs2-0014" title="FeltnerD , BielskiR , Liu‐DumawM . Efficacy of pregabalin in generalised social anxiety disorder: results of a placebo‐controlled, fixed‐dose study. European Neuropsychopharmacology2010;20(Suppl 3):S525–6. FeltnerDE , Liu‐DumawM , SchweizerE , BielskiR . Efficacy of pregabalin in generalized social anxiety disorder: results of a double‐blind, placebo‐controlled, fixed‐dose study. International Clinical Psychopharmacology2011;26(4):213–20. ">Feltner 2011</a>; <a href="./references#CD001206-bbs2-0040" title="FeltnerDE , DavidsonJR , PollackMH , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social anxiety disorder: outcome and predictors of response. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14. San Juan, Puerto Rico, 2000. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled study of pregabalin in social phobia (social anxiety disorder) [abstract]. International Journal of Neuropsychopharmacology2000;3(Suppl 1):284. FeltnerDE , PollackMH , DavidsonJR , SteinMB , FuttererRA , JeffersonJW , et al. Pregabalin treatment of social phobia. New Research Abstracts. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000. FeltnerDE , PollackMH , DavidsonJRT , SteinMB , FuttererR , JeffersonJW , et al. A placebo‐controlled, double‐blind study of pregabalin treatment of social phobia: outcome and predictors of response [abstract]. European Neuropsychopharmacology2000;10(Suppl 3):S345. PandeAC , FeltnerDE , JeffersonJW , DavidsonJRT , PollackM , SteinMB , et al. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo‐controlled, multicenter study. Journal of Clinical Psychopharmacology2004;24(2):141‐9. ">Pande 2004</a>; <a href="./references#CD001206-bbs2-0039" title="PandeAC , DavidsonJR , JeffersonJW , JanneyCA , KatzelnickDJ , WeislerRH , GreistJH , SutherlandSM . Treatment of social phobia with gabapentin: a placebo‐controlled study. Journal of Clinical Psychopharmacology1999;19(4):341‐8. ">Pande 1999</a>). </p> </section> </section> <section id="CD001206-sec-0093"> <h4 class="title">Comparison 3: anticonvulsant levetiracetam versus placebo</h4> <section id="CD001206-sec-0094"> <h5 class="title">Primary outcome measures</h5> <p>There was no evidence of an effect of levetiracetam on treatment efficacy in participants with SAnD compared to placebo (k = 2, RR 0.98; 95% CI 0.70 to 1.37, N = 228; see <a href="./references#CD001206-fig-0016" title="">Analysis 3.1</a>; <a href="./references#CD001206-bbs2-0053" title="SteinMB , RavindranLN , SimonNM , LiebowitzMR , KhanA , Brawman‐MintzerO , et al. Levetiracetam in generalized social anxiety disorder: a double‐blind, randomized controlled trial. Journal of Clinical Psychiatry2010;71(5):627‐31. ">Stein 2010</a>; <a href="./references#CD001206-bbs2-0066" title="ZhangW , ConnorKM , DavidsonJRT . Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology2005;19(5):551‐3. ">Zhang 2005</a>). The evidence that was available for this outcome was of moderate quality. There was evidence of a response to treatment with the anticonvulsant levetiracetam compared to anticonvulsants with gamma‐amino butyric acid (GABA) analogues (Chi<sup>2</sup> = 4.25, df = 1, P = 0.04; I<sup>2</sup> = 76.5%), the benzodiazepines (Chi<sup>2</sup> = 21.10, df = 1, P &lt; 0.00001; I<sup>2</sup> = 95.3%), the MAOIs (Chi<sup>2</sup> = 5.86, df = 1, P = 0.02; I<sup>2</sup> = 82.9%), the RIMAs (Chi<sup>2</sup> = 6.76, df = 1, P = 0.009; I<sup>2</sup> = 85.2%), and the SSRIs (Chi<sup>2</sup> = 8.02, df = 1, P = 0.005; I<sup>2</sup> = 87.5%). </p> <p>The proportion of dropouts due to adverse events was more than twice as high in participants receiving levetiracetam (15/122, 12%) relative to placebo (6/113, 5%). There was no evidence of a difference between the number of participants that dropped out due to treatment‐emergent side effects (k = 2, RR 2.00; 95% CI 0.81 to 4.94; see <a href="./references#CD001206-fig-0017" title="">Analysis 3.2</a>), but the quality of the evidence is very low. </p> </section> <section id="CD001206-sec-0095"> <h5 class="title">Secondary outcome measures</h5> <p>There was no evidence of a difference for a reduction of SAnD symptom severity in participants treated with levetiracetam compared to placebo on the LSAS (k = 2, MD −0.24 points, 95% CI −15.69 to 15.21, N = 228; <a href="./references#CD001206-fig-0018" title="">Analysis 3.3</a>; <a href="./references#CD001206-bbs2-0053" title="SteinMB , RavindranLN , SimonNM , LiebowitzMR , KhanA , Brawman‐MintzerO , et al. Levetiracetam in generalized social anxiety disorder: a double‐blind, randomized controlled trial. Journal of Clinical Psychiatry2010;71(5):627‐31. ">Stein 2010</a>; <a href="./references#CD001206-bbs2-0066" title="ZhangW , ConnorKM , DavidsonJRT . Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology2005;19(5):551‐3. ">Zhang 2005</a>). In addition, there was no evidence of a difference between these groups in <a href="./references#CD001206-bbs2-0066" title="ZhangW , ConnorKM , DavidsonJRT . Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology2005;19(5):551‐3. ">Zhang 2005</a> (N = 16) on either the avoidance (MD −9.15 points, 95% CI −26.86 to 8.56, <a href="./references#CD001206-fig-0018" title="">Analysis 3.3</a>) or fear subscale of the LSAS (MD −8.71 points, 95% CI −26.02 to 8.60, <a href="./references#CD001206-fig-0018" title="">Analysis 3.3</a>). The evidence that was available for the three outcomes was of very low quality. We found no evidence of an effect for levetiracetam of a reduction in depression symptoms on the HDRS compared to placebo (k = 1, MD 0.20 points, 95% CI −1.33 to 1.73, N = 212; <a href="./references#CD001206-fig-0019" title="">Analysis 3.4</a>; <a href="./references#CD001206-bbs2-0053" title="SteinMB , RavindranLN , SimonNM , LiebowitzMR , KhanA , Brawman‐MintzerO , et al. Levetiracetam in generalized social anxiety disorder: a double‐blind, randomized controlled trial. Journal of Clinical Psychiatry2010;71(5):627‐31. ">Stein 2010</a>). </p> <p>The proportion of participants dropping out due to any cause from the anticonvulsants and placebo groups was comparable (31% in both groups). We found no evidence of a difference for levetiracetam compared to placebo (k = 2, RR 1.42; 95% CI 0.30 to 6.76, N = 235; see <a href="./references#CD001206-fig-0020" title="">Analysis 3.5</a>; <a href="./references#CD001206-bbs2-0053" title="SteinMB , RavindranLN , SimonNM , LiebowitzMR , KhanA , Brawman‐MintzerO , et al. Levetiracetam in generalized social anxiety disorder: a double‐blind, randomized controlled trial. Journal of Clinical Psychiatry2010;71(5):627‐31. ">Stein 2010</a>; <a href="./references#CD001206-bbs2-0066" title="ZhangW , ConnorKM , DavidsonJRT . Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology2005;19(5):551‐3. ">Zhang 2005</a>). </p> </section> </section> <section id="CD001206-sec-0096"> <h4 class="title">Comparison 4: antipsychotics versus placebo</h4> <section id="CD001206-sec-0097"> <h5 class="title">Primary outcome measures</h5> <p>In a small RCT with 10 participants, there was no evidence of an effect for olanzapine compared to placebo on the number of participants who responded to treatment (k = 1, RR 7.00; 95% CI 0.45 to 108.26, <a href="./references#CD001206-fig-0021" title="">Analysis 4.1</a>; <a href="./references#CD001206-bbs2-0005" title="BarnettSD , KramerML , CasatCD , ConnorKM , DavidsonJR . Efficacy of olanzapine in social anxiety disorder: a pilot study. Journal of Psychopharmacology2002;16(4):365‐8. ">Barnett 2002</a>). The data provided for this outcome was of very low quality. </p> <p>Of the 12 participants randomised to 8 weeks of treatment with olanzapine or placebo, there was no difference in the number of participants who withdrew due to treatment‐emergent side effects (k = 1, RR 0.71; 95% CI 0.06 to 8.90; see <a href="./references#CD001206-fig-0022" title="">Analysis 4.2</a>). The evidence that was available for this outcome was of very low quality. </p> </section> <section id="CD001206-sec-0098"> <h5 class="title">Secondary outcome measures</h5> <p>There was evidence of benefit for olanzapine compared to placebo in the reduction of SAnD symptoms on the LSAS (k = 1, MD −37.80 points, 95% CI −74.22 to −1.38, N = 9; see <a href="./references#CD001206-fig-0023" title="">Analysis 4.3</a>; <a href="./references#CD001206-bbs2-0005" title="BarnettSD , KramerML , CasatCD , ConnorKM , DavidsonJR . Efficacy of olanzapine in social anxiety disorder: a pilot study. Journal of Psychopharmacology2002;16(4):365‐8. ">Barnett 2002</a>), though the evidence is of very low quality. </p> <p>A similar proportion of participants withdrew from the olanzapine group (43%) compared to the placebo group (40%) (k = 1, RR 1.07; 95% CI 0.27 to 4.23, N = 12; see <a href="./references#CD001206-fig-0024" title="">Analysis 4.4</a>; <a href="./references#CD001206-bbs2-0005" title="BarnettSD , KramerML , CasatCD , ConnorKM , DavidsonJR . Efficacy of olanzapine in social anxiety disorder: a pilot study. Journal of Psychopharmacology2002;16(4):365‐8. ">Barnett 2002</a>). </p> </section> </section> <section id="CD001206-sec-0099"> <h4 class="title">Comparison 5: benzodiazepines versus placebo</h4> <section id="CD001206-sec-0100"> <h5 class="title">Primary outcome measures</h5> <p>There was evidence of a large effect of clonazepam and bromazepam on treatment efficacy in participants with SAnD compared to placebo (k = 2, RR 4.03; 95% CI 2.45 to 6.65, N = 132; see <a href="./references#CD001206-fig-0025" title="">Analysis 5.1</a>; <a href="./references#CD001206-bbs2-0010" title="DavidsonJR , PottsN , RichichiE , KrishnanR , FordSM , SmithR , et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology1993;13(6):423‐8. SutherlandSM , TuplerLA , ColketJT , DavidsonJR . A 2‐year follow‐up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease1996;184(12):731‐8. ">Davidson 1993</a>; <a href="./references#CD001206-bbs2-0063" title="VersianiM , NardiAE , FigueiraI , MendlowiczM , MarquesC . Double‐blind placebo controlled trial with bromazepam in social phobia. Jornal Brasileiro de Psiquiatria1997;46(3):167‐71. ">Versiani 1997</a>), although the evidence was of low quality. The benzodiazepines demonstrated superiority with respect to treatment response relative to all the other medication classes that contained data from more than a single study, with the exception of the MAOI phenelzine (Chi<sup>2</sup> = 1.67, df = 1, P = 0.20; I<sup>2</sup> = 40.3%). </p> <p>There was no evidence that clonazepam prevented relapse in SAnD participants more than placebo (k = 1, RR 0.12; 95% CI 0.01 to 2.14, N = 36; see <a href="./references#CD001206-fig-0026" title="">Analysis 5.2</a>; <a href="./references#CD001206-bbs2-0009" title="ConnorKM , DavidsonJR , PottsNL , TuplerLA , MinerCM , MalikML , et al. Discontinuation of clonazepam in the treatment of social phobia. Journal of Clinical Psychopharmacology1998;18(5):373‐8. ">Connor 1998</a>). </p> <p>The dropout rate due to adverse events was low in RCTs of clonazepam and bromazepam (2/47; 4%) and did not differ appreciably from that observed in the placebo groups (k = 2, RR 1.68; 95% CI 0.21, 13.13, N = 96; see <a href="./references#CD001206-fig-0027" title="">Analysis 5.3</a>; <a href="./references#CD001206-bbs2-0009" title="ConnorKM , DavidsonJR , PottsNL , TuplerLA , MinerCM , MalikML , et al. Discontinuation of clonazepam in the treatment of social phobia. Journal of Clinical Psychopharmacology1998;18(5):373‐8. ">Connor 1998</a>; <a href="./references#CD001206-bbs2-0063" title="VersianiM , NardiAE , FigueiraI , MendlowiczM , MarquesC . Double‐blind placebo controlled trial with bromazepam in social phobia. Jornal Brasileiro de Psiquiatria1997;46(3):167‐71. ">Versiani 1997</a>). The evidence that was available for this outcome was of very low quality. </p> </section> <section id="CD001206-sec-0101"> <h5 class="title">Secondary outcome measures</h5> <p>There was evidence of a reduction of SAnD symptoms following treatment with benzodiazepines compared to placebo on the LSAS (k = 2, MD −39.75 points, 95% CI −71.11 to −8.39, N = 135, see <a href="./references#CD001206-fig-0028" title="">Analysis 5.4</a>; <a href="./references#CD001206-bbs2-0010" title="DavidsonJR , PottsN , RichichiE , KrishnanR , FordSM , SmithR , et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology1993;13(6):423‐8. SutherlandSM , TuplerLA , ColketJT , DavidsonJR . A 2‐year follow‐up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease1996;184(12):731‐8. ">Davidson 1993</a>; <a href="./references#CD001206-bbs2-0063" title="VersianiM , NardiAE , FigueiraI , MendlowiczM , MarquesC . Double‐blind placebo controlled trial with bromazepam in social phobia. Jornal Brasileiro de Psiquiatria1997;46(3):167‐71. ">Versiani 1997</a>) although the evidence was very low in quality. There was considerable heterogeneity in effect size estimates for this outcome (P &lt; 0.001; I<sup>2</sup> = 94%), while effect estimates from both of the included RCTs demonstrated a beneficial effect of benzodiazepines relative to placebo. Clonazepam was superior to placebo on both the avoidance (MD −10.40 points, 95% CI −16.08 to −4.72, see <a href="./references#CD001206-fig-0028" title="">Analysis 5.4</a>) and fear subscale of the LSAS (MD −10.80 points, 95% CI −16.62 to −4.98, see <a href="./references#CD001206-fig-0028" title="">Analysis 5.4</a>) in one trial with 75 participants (<a href="./references#CD001206-bbs2-0010" title="DavidsonJR , PottsN , RichichiE , KrishnanR , FordSM , SmithR , et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology1993;13(6):423‐8. SutherlandSM , TuplerLA , ColketJT , DavidsonJR . A 2‐year follow‐up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease1996;184(12):731‐8. ">Davidson 1993</a>). The quality of evidence was very low for both outcomes, however. We found no evidence for an effect of clonazepam compared to placebo (k = 1, MD −1.60 points, 95% CI −3.96 to 0.76, N = 75; see <a href="./references#CD001206-fig-0029" title="">Analysis 5.5</a>; <a href="./references#CD001206-bbs2-0010" title="DavidsonJR , PottsN , RichichiE , KrishnanR , FordSM , SmithR , et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology1993;13(6):423‐8. SutherlandSM , TuplerLA , ColketJT , DavidsonJR . A 2‐year follow‐up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease1996;184(12):731‐8. ">Davidson 1993</a>) on the HDRS for depression symptoms. </p> <p>There was evidence of an effect of clonazepam and bromazepam compared to placebo on the reduction of associated disability on the work (MD −3.58 points, 95% CI −6.39 to −0.78, N = 135; see <a href="./references#CD001206-fig-0030" title="">Analysis 5.6</a>) and social subscale of the SDS (MD −2.31 points, 95% CI 3.79 to −0.83, N = 135; see <a href="./references#CD001206-fig-0030" title="">Analysis 5.6</a>) in two trials (<a href="./references#CD001206-bbs2-0010" title="DavidsonJR , PottsN , RichichiE , KrishnanR , FordSM , SmithR , et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology1993;13(6):423‐8. SutherlandSM , TuplerLA , ColketJT , DavidsonJR . A 2‐year follow‐up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease1996;184(12):731‐8. ">Davidson 1993</a>; <a href="./references#CD001206-bbs2-0063" title="VersianiM , NardiAE , FigueiraI , MendlowiczM , MarquesC . Double‐blind placebo controlled trial with bromazepam in social phobia. Jornal Brasileiro de Psiquiatria1997;46(3):167‐71. ">Versiani 1997</a>). We found no evidence of an overall effect for the benzodiazepines in reducing levels of associated disability on the family subscale of the SDS (k = 2, MD −2.02 points, 95% CI −4.26 to 0.22, N = 135; see <a href="./references#CD001206-fig-0030" title="">Analysis 5.6</a>). There was considerable heterogeneity in effect size estimates for the outcomes of disability (P &lt; 0.001, I<sup>2</sup> = 93%; P = 0.07, I<sup>2</sup> = 69%; P = 0.04, I<sup>2</sup> = 77%, respectively). </p> <p>Similar dropout rates were observed in the medication and placebo arms for the benzodiazepines (k = 3, RR 0.79; 95% CI 0.41 to 1.52, N = 171; see <a href="./references#CD001206-fig-0031" title="">Analysis 5.7</a>; <a href="./references#CD001206-bbs2-0010" title="DavidsonJR , PottsN , RichichiE , KrishnanR , FordSM , SmithR , et al. Treatment of social phobia with clonazepam and placebo. Journal of Clinical Psychopharmacology1993;13(6):423‐8. SutherlandSM , TuplerLA , ColketJT , DavidsonJR . A 2‐year follow‐up of social phobia. Status after a brief medication trial. Journal of Nervous and Mental Disease1996;184(12):731‐8. ">Davidson 1993</a>; <a href="./references#CD001206-bbs2-0009" title="ConnorKM , DavidsonJR , PottsNL , TuplerLA , MinerCM , MalikML , et al. Discontinuation of clonazepam in the treatment of social phobia. Journal of Clinical Psychopharmacology1998;18(5):373‐8. ">Connor 1998</a>; <a href="./references#CD001206-bbs2-0063" title="VersianiM , NardiAE , FigueiraI , MendlowiczM , MarquesC . Double‐blind placebo controlled trial with bromazepam in social phobia. Jornal Brasileiro de Psiquiatria1997;46(3):167‐71. ">Versiani 1997</a>). </p> </section> </section> <section id="CD001206-sec-0102"> <h4 class="title">Comparison 6: beta‐blockers versus placebo</h4> <section id="CD001206-sec-0103"> <h5 class="title">Primary outcome measures</h5> <p>There was no evidence of an effect of atenolol on treatment efficacy in participants with SAnD compared to placebo (k = 2, RR 1.09; 95% CI 0.63 to 1.88, N = 97; see <a href="./references#CD001206-fig-0032" title="">Analysis 6.1</a>; <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>; <a href="./references#CD001206-bbs2-0055" title="TurnerS , BeidelDC , JacobRG . Social phobia: a comparison of behaviour therapy and atenolol. Journal of Consulting and Clinical Psychology1994;62(2):350‐8. ">Turner 1994</a>). The evidence that was available for this outcome was of very low quality. We observed a treatment response for the beta‐blockers compared to the benzodiazepines, in favour of the benzodiazepines (Chi<sup>2</sup> = 12.02, df = 1, P = 0.0005; I<sup>2</sup> = 91.7%). </p> </section> <section id="CD001206-sec-0104"> <h5 class="title">Secondary outcome measures</h5> <p>We found no evidence of an effect for atenolol versus placebo in the single trial that provided data for the reduction of depression symptoms (MD 1.82 points, 95% CI −1.38 to 5.02, N = 46; <a href="./references#CD001206-fig-0033" title="">Analysis 6.2</a>; <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>) on the HDRS. There was also no evidence of an effect of atenolol compared to placebo on the reduction of associated disability on the work (k = 1, MD −0.05 points, 95% CI −1.80 to 1.70, N = 42; see <a href="./references#CD001206-fig-0034" title="">Analysis 6.3</a>), social (k = 1, MD 0.07 points, 95% CI −1.71 to 1.85, N = 42; see <a href="./references#CD001206-fig-0034" title="">Analysis 6.3</a>) and family subscales of the SDS (MD −0.11 points, 95% CI −1.74 to 1.52, N = 42; see <a href="./references#CD001206-fig-0034" title="">Analysis 6.3</a>) in one trial that reported this outcome (<a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>). </p> <p>The proportion of dropouts was more than three times higher in participants receiving atenolol (4/25, 16%) than placebo (1,21, 5%) in a single trial, though this difference was not statistically significant (RR 3.36; 95% CI 0.41 to 27.80; N = 46; <a href="./references#CD001206-fig-0035" title="">Analysis 6.4</a>; <a href="./references#CD001206-bbs2-0055" title="TurnerS , BeidelDC , JacobRG . Social phobia: a comparison of behaviour therapy and atenolol. Journal of Consulting and Clinical Psychology1994;62(2):350‐8. ">Turner 1994</a>). </p> </section> </section> <section id="CD001206-sec-0105"> <h4 class="title">Comparison 7: MAOIs versus placebo</h4> <section id="CD001206-sec-0106"> <h5 class="title">Primary outcome measures</h5> <p>There was evidence of an effect of phenelzine on acute treatment efficacy in participants with SAnD compared to placebo (k = 4, RR 2.36; 95% CI 1.48 to 3.75, N = 235; see <a href="./references#CD001206-fig-0036" title="">Analysis 7.1</a>; <a href="./references#CD001206-bbs2-0006" title="BlancoC , HeimbergRG , SchneierFR , FrescoDM , ChenH , TurkCL , et al. A placebo‐controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry2010;67(3):286‐95. ">Blanco 2010</a>; <a href="./references#CD001206-bbs2-0016" title="HeimbergRG , LiebowitzMR , HopeDA , SchneierFR , HoltCS , WelkowitzLA , et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry1998;55(12):1133‐41. ">Heimberg 1998</a>; <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>), though the evidence was low in quality. There were data indicating greater efficacy over the long term for phenelzine compared to placebo in participants with SAnD (k = 2, RR 1.84; 95% CI 1.02 to 3.33, N = 113; see <a href="./references#CD001206-fig-0041" title="">Analysis 7.6</a>; <a href="./references#CD001206-bbs2-0006" title="BlancoC , HeimbergRG , SchneierFR , FrescoDM , ChenH , TurkCL , et al. A placebo‐controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry2010;67(3):286‐95. ">Blanco 2010</a>; <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>). This conclusion was based on very low‐quality evidence, however. Treatment efficacy was greater for the MAOIs compared to the anticonvulsant levetiracetam (Chi<sup>2</sup> = 5.86, df = 1, P = 0.02; I<sup>2</sup> = 82.9%) and the GW876008 (Chi<sup>2</sup> = 7.97, df = 1, P = 0.005; I<sup>2</sup> = 87.5%). </p> </section> <section id="CD001206-sec-0107"> <h5 class="title">Secondary outcome measures</h5> <p>We assessed data on the reduction of SAnD symptoms, measured by the LSAS, in four studies comparing phenelzine to placebo (MD −16.39 points, 95% CI −32.27 to −0.51, N = 218; see <a href="./references#CD001206-fig-0037" title="">Analysis 7.2</a>; <a href="./references#CD001206-bbs2-0006" title="BlancoC , HeimbergRG , SchneierFR , FrescoDM , ChenH , TurkCL , et al. A placebo‐controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry2010;67(3):286‐95. ">Blanco 2010</a>; <a href="./references#CD001206-bbs2-0016" title="HeimbergRG , LiebowitzMR , HopeDA , SchneierFR , HoltCS , WelkowitzLA , et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry1998;55(12):1133‐41. ">Heimberg 1998</a>; <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>). There was evidence of benefit even though the data were based on low‐quality evidence. Considerable heterogeneity on this outcome (Chi<sup>2</sup> = 45.00, df = 3, P &lt; 0.001; I<sup>2</sup> = 93%) partially reflected the unusually large medication effect observed in <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a> (MD −42.20 points, 95% CI −55.66 to −28.74). Removing this trial resulted in a substantially reduced and statistically non‐significant treatment effect (MD −7.39 points, 95% CI −16.77 to 1.99), with considerable heterogeneity still evident across the effects for the remaining trials (Chi<sup>2</sup> = 8.94, df = 2, P = 0.01; I<sup>2</sup> = 78%). Phenelzine was not superior to placebo on either the avoidance (MD −5.42 points, 95% CI −14.69 to 3.85; see <a href="./references#CD001206-fig-0037" title="">Analysis 7.2</a>) or fear subscale of the LSAS (MD −5.23 points, 95% CI −13.97 to 3.51; see <a href="./references#CD001206-fig-0037" title="">Analysis 7.2</a>) in one trial with 51 participants (<a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>). These outcomes were also based on very low‐quality evidence, however. </p> <p>There was no evidence of an effect of phenelzine in the reduction of depression symptoms compared to placebo (k = 4, SMD −0.40 ; 95% CI −1.11 to 0.31, N = 216; see <a href="./references#CD001206-fig-0038" title="">Analysis 7.3</a>; <a href="./references#CD001206-bbs2-0006" title="BlancoC , HeimbergRG , SchneierFR , FrescoDM , ChenH , TurkCL , et al. A placebo‐controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry2010;67(3):286‐95. ">Blanco 2010</a>; <a href="./references#CD001206-bbs2-0016" title="HeimbergRG , LiebowitzMR , HopeDA , SchneierFR , HoltCS , WelkowitzLA , et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry1998;55(12):1133‐41. ">Heimberg 1998</a>; <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>) on the HAM‐D. Moreover, there was considerable heterogeneity in effect size estimates for this outcome (Chi<sup>2</sup> = 33.26, df = 3, P &lt; 0.001; I<sup>2</sup> = 85%). This was partly due to large medication effects of one study (<a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>). However, after the removal of this study from the analysis, no evidence for efficacy of the MAOIs was still apparent (k = 3, SMD −0.51; 95% CI −1.49 to 0.47, N = 167). There was an effect of phenelzine in the reduction of associated disability compared to placebo on the work subscale of the SDS (MD −2.84 points, 95% CI −4.40 to −1.28; see <a href="./references#CD001206-fig-0039" title="">Analysis 7.4</a>) in two trials with 95 participants (<a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>). There was no evidence that phenelzine reduced associated disability on the social (MD −3.26 points, 95% CI −7.25 to 0.72, N = 94; see <a href="./references#CD001206-fig-0039" title="">Analysis 7.4</a>) or family subscale of the SDS (k = 2, MD −2.20 points, 95% CI −5.34 to 0.95, N = 95; see <a href="./references#CD001206-fig-0039" title="">Analysis 7.4</a>) in these trials. There was also considerable heterogeneity in effect size estimates for the outcomes of disability (P = 0.06, I<sup>2</sup> = 72%; P &lt; 0.001, I<sup>2</sup> = 92%; P = 0.002, I<sup>2</sup> = 90%, respectively). </p> <p>Similar dropout rates were observed in the medication and placebo arms for the MAOIs (RR 1.33; 95% CI 0.71 to 2.48; see <a href="./references#CD001206-fig-0040" title="">Analysis 7.5</a>) in four trials with 235 participants (<a href="./references#CD001206-bbs2-0006" title="BlancoC , HeimbergRG , SchneierFR , FrescoDM , ChenH , TurkCL , et al. A placebo‐controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Archives of General Psychiatry2010;67(3):286‐95. ">Blanco 2010</a>; <a href="./references#CD001206-bbs2-0016" title="HeimbergRG , LiebowitzMR , HopeDA , SchneierFR , HoltCS , WelkowitzLA , et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry1998;55(12):1133‐41. ">Heimberg 1998</a>; <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>). </p> </section> </section> <section id="CD001206-sec-0108"> <h4 class="title">Comparison 8: NARIs versus placebo</h4> <section id="CD001206-sec-0109"> <h5 class="title">Primary outcome measures</h5> <p>There was no evidence of an effect for atomoxetine on treatment efficacy in participants with SAnD compared to placebo (RR 0.70; 95% CI 0.19 to 2.54, see <a href="./references#CD001206-fig-0042" title="">Analysis 8.1</a>) in one trial with 27 participants (<a href="./references#CD001206-bbs2-0042" title="RavindranLN , KimDS , LetamendiAM , SteinMB . A randomized controlled trial of atomoxetine in generalized social anxiety disorder. Journal of Clinical Psychopharmacology2009;29(6):561‐4. ">Ravindran 2009</a>). The evidence that was available for this outcome was of very low quality. There was evidence of an effect for the NARIs compared to the benzodiazepines, in favour of the benzodiazepines (Chi<sup>2</sup> = 6.17, df = 1, P = 0.01; I<sup>2</sup> = 83.8%). </p> <p>Only 1 of 14 (7%) participants withdrew during 10 weeks of treatment with atomoxetine (see <a href="./references#CD001206-fig-0043" title="">Analysis 8.2</a>); there was no evidence for a difference in the number of participants who withdrew due to treatment‐emergent side effects. The evidence that was available for this outcome was of very low quality. </p> </section> <section id="CD001206-sec-0110"> <h5 class="title">Secondary outcome measures</h5> <p>We found no evidence for an effect of the single trial that provided data for the reduction of SAnD symptoms (i.e. LSAS total symptom severity) when comparing atomoxetine to placebo (MD 2.60 points, 95% CI −15.43 to 20.63, N = 26; see <a href="./references#CD001206-fig-0044" title="">Analysis 8.3</a>). The evidence that was available for this outcome was of very low quality. Furthermore, we found no evidence of an effect for the reduction of depression symptoms on the HAM‐D when comparing atomoxetine to placebo (k = 1, MD −0.10 points, 95% CI −2.73 to 2.53, N = 26; see <a href="./references#CD001206-fig-0045" title="">Analysis 8.4</a>). </p> <p>Similar dropout rates were observed in the medication and placebo arms for the NARIs (k = 1, RR 0.93; 95% CI 0.23 to 3.81, N = 27; see <a href="./references#CD001206-fig-0046" title="">Analysis 8.5</a>; <a href="./references#CD001206-bbs2-0042" title="RavindranLN , KimDS , LetamendiAM , SteinMB . A randomized controlled trial of atomoxetine in generalized social anxiety disorder. Journal of Clinical Psychopharmacology2009;29(6):561‐4. ">Ravindran 2009</a>). </p> </section> </section> <section id="CD001206-sec-0111"> <h4 class="title">Comparison 9: NaSSAs versus placebo</h4> <section id="CD001206-sec-0112"> <h5 class="title">Primary outcome measures</h5> <p>An equal number of participants (4/30, 13%) responded to treatment in both the medication and placebo arms of a trial of mirtazepine (k = 1, RR 1.00; 95% CI 0.28 to 3.63; N = 60, see <a href="./references#CD001206-fig-0047" title="">Analysis 9.1</a>; <a href="./references#CD001206-bbs2-0045" title="SchuttersSIJ , VanMegenHJGM , VanVeenJF , DenysDAJP , WestenbergHGM . Mirtazapine in generalized social anxiety disorder: a randomized, double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2010;25(5):302–4. ">Schutters 2010</a>). The evidence that was available for this outcome was of very low quality. </p> <p>A small proportion of participants receiving mirtazepine dropped out due to adverse events (2/30, 7%) in one trial with 60 participants (<a href="./references#CD001206-bbs2-0045" title="SchuttersSIJ , VanMegenHJGM , VanVeenJF , DenysDAJP , WestenbergHGM . Mirtazapine in generalized social anxiety disorder: a randomized, double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2010;25(5):302–4. ">Schutters 2010</a>). Although this proportion was larger than that observed for placebo (0/30, 0%), the difference was not statistically significant (P = 0.29, see <a href="./references#CD001206-fig-0048" title="">Analysis 9.2</a>). The evidence that was available for this outcome was of very low quality. </p> </section> <section id="CD001206-sec-0113"> <h5 class="title">Secondary outcome measures</h5> <p>Evidence of an effect was found for mirtazepine compared to placebo in the reduction of total SAnD symptom severity on the LSAS (k = 2, MD −15.37 points, 95% CI −28.10 to −2.63, N = 126; see <a href="./references#CD001206-fig-0049" title="">Analysis 9.3</a>; <a href="./references#CD001206-bbs2-0045" title="SchuttersSIJ , VanMegenHJGM , VanVeenJF , DenysDAJP , WestenbergHGM . Mirtazapine in generalized social anxiety disorder: a randomized, double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2010;25(5):302–4. ">Schutters 2010</a>; <a href="./references#CD001206-bbs2-0030" title="MuehlbacherM , NickelMK , NickelC , KettlerC , LahmannC , GilFP , et al. Mirtazapine treatment of social phobia in women. A randomized, double‐blind, placebo‐controlled study. Journal of Clinical Psychopharmacology2005;25(6):580‐3. ">Muehlbacher 2005</a>), even though the evidence was very low in quality. Mirtazepine was not superior to placebo on either the avoidance (MD −3.90 points, 95% CI −9.90 to 2.10, see <a href="./references#CD001206-fig-0049" title="">Analysis 9.3</a>) or fear subscale of the LSAS (MD −3.70 points, 95% CI −9.42 to 2.02, see <a href="./references#CD001206-fig-0049" title="">Analysis 9.3</a>) in one trial with 60 participants (<a href="./references#CD001206-bbs2-0045" title="SchuttersSIJ , VanMegenHJGM , VanVeenJF , DenysDAJP , WestenbergHGM . Mirtazapine in generalized social anxiety disorder: a randomized, double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2010;25(5):302–4. ">Schutters 2010</a>). This conclusion was based on low‐quality evidence. </p> <p>A low proportion of participants withdrew for any cause during 12 weeks of treatment with mirtazepine (2/30, 7%), with overall dropout rates similar to those observed following treatment with placebo (1/30, 3%) (k = 1, RR 2.00; 95% CI 0.19 to 20.90; see <a href="./references#CD001206-fig-0050" title="">Analysis 9.4</a>; <a href="./references#CD001206-bbs2-0045" title="SchuttersSIJ , VanMegenHJGM , VanVeenJF , DenysDAJP , WestenbergHGM . Mirtazapine in generalized social anxiety disorder: a randomized, double‐blind, placebo‐controlled study. International Clinical Psychopharmacology2010;25(5):302–4. ">Schutters 2010</a>). </p> </section> </section> <section id="CD001206-sec-0114"> <h4 class="title">Comparison 10: RIMAs versus placebo</h4> <section id="CD001206-sec-0115"> <h5 class="title">Primary outcome measures</h5> <p>There was evidence of benefit for brofaromine and moclobemide on treatment efficacy in participants with SAnD compared to placebo (k = 8, RR 1.83; 95% CI 1.32 to 2.55, N = 1270; see <a href="./references#CD001206-fig-0051" title="">Analysis 10.1</a>; <a href="./references#CD001206-bbs2-0013" title="FahlenT , HumbleM , KoczkasC , NilssonH . Social phobia and its treatment with brofaromine, efficacy regarding social phobia symptoms and personality traits. Clinical Neuropharmacology1992;15(1 Pt B):64. FahlenT , NilssonHl , BorgK , HumbleM , PauliU . Social phobia: the clinical efficacy and tolerability of the monoamine oxidase‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study. Acta Psychiatrica Scandinavica1995;92(5):351‐8. ">Fahlen 1995</a>; <a href="./references#CD001206-bbs2-0018" title="KatschnigK , SteinMB , BullerR . Moclobemide in social phobia. A double‐blind, placebo‐controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience1997;247(2):71‐80. ">Katschnig 1997</a>; <a href="./references#CD001206-bbs2-0028" title="LottM , GreistJH , JeffersonJW , KobakKA , KatzelnickDJ , KatzRJ , SchaettleSC . Brofaromine for social phobia: a multicenter, placebo‐controlled, double‐blind study. Journal of Clinical Psychopharmacology1997;17(4):255‐60. ">Lott 1997</a>; <a href="./references#CD001206-bbs2-0037" title="NoyesRJr , MorozG , DavidsonJR , LiebowitzMR , DavidsonA , SiegelJ , et al. Moclobemide in social phobia: a controlled dose response trial. Journal of Clinical Psychopharmacology1997;17(4):247‐54. ">Noyes 1997</a>; <a href="./references#CD001206-bbs2-0038" title="OosterbaanDB , VanBalkomAJLM , SpinhovenP , vanOppenP , vanDyckR . Cognitive therapy versus moclobemide in social phobia: a controlled study. Clinical Pscyhology and Psychotherapy2001;8(4):263‐73. ">Oosterbaan 2001</a>; <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>; <a href="./references#CD001206-bbs2-0049" title="SteinDJ , CameronA , AmreinR , MontgomerySA . Moclobemide is effective and well tolerated in the long‐term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology2002;17(4):161‐70. ">Stein 2002a</a>; <a href="./references#CD001206-bbs2-0059" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO‐A inhibitor. European Neuropsychopharmacology1992;2(1):21‐9. ">Van Vliet 1992</a>), even though the evidence was low quality. There was substantial heterogeneity in effect size estimates for this outcome (Chi<sup>2</sup> = 23.57, df = 7, P = 0.001; I<sup>2</sup> = 70%). This was partly due to large medication effects for earlier, small studies (i.e. <a href="./references#CD001206-bbs2-0013" title="FahlenT , HumbleM , KoczkasC , NilssonH . Social phobia and its treatment with brofaromine, efficacy regarding social phobia symptoms and personality traits. Clinical Neuropharmacology1992;15(1 Pt B):64. FahlenT , NilssonHl , BorgK , HumbleM , PauliU . Social phobia: the clinical efficacy and tolerability of the monoamine oxidase‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study. Acta Psychiatrica Scandinavica1995;92(5):351‐8. ">Fahlen 1995</a>; <a href="./references#CD001206-bbs2-0059" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO‐A inhibitor. European Neuropsychopharmacology1992;2(1):21‐9. ">Van Vliet 1992</a>), with moderate heterogeneity evident after excluding these trials (Chi<sup>2</sup> = 8.86, df = 5, P = 0.11; I<sup>2</sup> = 44%). Evidence for efficacy of the RIMAs was still apparent after removing these two studies (k = 6, RR 1.49; 95% CI 1.17 to 1.90, N = 1165). </p> <p>Given differences in the mechanism of action for moclobemide and brofaromine and the lack of availability for the latter, we conducted a post hoc analysis for moclobemide only. There was evidence that this medication was efficacious compared to placebo (k = 5, RR 1.32; 95% CI 1.14 to 1.52, N = 1063; P &lt; 0.001). Furthermore, there was moderate‐quality evidence of a long‐term effect for moclobemide on treatment efficacy in participants with SAnD compared to placebo (k = 1, RR 1.50; 95% CI 1.12 to 2.00, N = 90; see <a href="./references#CD001206-fig-0057" title="">Analysis 10.7</a>; <a href="./references#CD001206-bbs2-0049" title="SteinDJ , CameronA , AmreinR , MontgomerySA . Moclobemide is effective and well tolerated in the long‐term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology2002;17(4):161‐70. ">Stein 2002a</a>). </p> <p>Comparisons between medication classes revealed that response to the RIMAs was smaller than that observed for the benzodiazepines (Chi<sup>2</sup> = 6.63, df = 1, P = 0.01; I<sup>2</sup> = 84.9%). </p> <p>Dropout rates due to adverse events were low in RCTs of brofaromine and moclobemide and equivalent to those observed in the placebo arms (72/83; 9%) (k = 8, RR 1.42; 95% CI 0.86 to 2.34, N = 1305; see <a href="./references#CD001206-fig-0052" title="">Analysis 10.2</a>). The evidence that was available for this outcome was of very low quality. </p> </section> <section id="CD001206-sec-0116"> <h5 class="title">Secondary outcome measures</h5> <p>There was evidence for a reduction of SAnD symptom severity on the LSAS in six studies comparing brofaromine or moclobemide to placebo (MD −12.17 points, 95% CI −23.51, −0.84 , N = 1163; see <a href="./references#CD001206-fig-0053" title="">Analysis 10.3</a>; <a href="./references#CD001206-bbs2-0018" title="KatschnigK , SteinMB , BullerR . Moclobemide in social phobia. A double‐blind, placebo‐controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience1997;247(2):71‐80. ">Katschnig 1997</a>; <a href="./references#CD001206-bbs2-0028" title="LottM , GreistJH , JeffersonJW , KobakKA , KatzelnickDJ , KatzRJ , SchaettleSC . Brofaromine for social phobia: a multicenter, placebo‐controlled, double‐blind study. Journal of Clinical Psychopharmacology1997;17(4):255‐60. ">Lott 1997</a>; <a href="./references#CD001206-bbs2-0037" title="NoyesRJr , MorozG , DavidsonJR , LiebowitzMR , DavidsonA , SiegelJ , et al. Moclobemide in social phobia: a controlled dose response trial. Journal of Clinical Psychopharmacology1997;17(4):247‐54. ">Noyes 1997</a>; <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>; <a href="./references#CD001206-bbs2-0049" title="SteinDJ , CameronA , AmreinR , MontgomerySA . Moclobemide is effective and well tolerated in the long‐term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology2002;17(4):161‐70. ">Stein 2002a</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>), although the quality of evidence was very low. We observed considerable heterogeneity for this outcome (Chi<sup>2</sup> = 77.55, df = 5, P &lt; 0.001; I<sup>2</sup> = 94%), but most disappeared after removing <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a> (Chi<sup>2</sup> = 3.14, df = 4, P = 0.53; I<sup>2</sup> = 0%), with data from the remaining five trials still supporting the efficacy of this class of medications (MD = −7.59 points, 95% CI −11.35 to −3.84). Brofaromine and moclobemide were superior to placebo on both the avoidance (k = 5, MD −5.05 points, 95% CI −7.91 to −2.18, N = 695; see <a href="./references#CD001206-fig-0053" title="">Analysis 10.3</a>; <a href="./references#CD001206-bbs2-0013" title="FahlenT , HumbleM , KoczkasC , NilssonH . Social phobia and its treatment with brofaromine, efficacy regarding social phobia symptoms and personality traits. Clinical Neuropharmacology1992;15(1 Pt B):64. FahlenT , NilssonHl , BorgK , HumbleM , PauliU . Social phobia: the clinical efficacy and tolerability of the monoamine oxidase‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study. Acta Psychiatrica Scandinavica1995;92(5):351‐8. ">Fahlen 1995</a>; <a href="./references#CD001206-bbs2-0018" title="KatschnigK , SteinMB , BullerR . Moclobemide in social phobia. A double‐blind, placebo‐controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience1997;247(2):71‐80. ">Katschnig 1997</a>; <a href="./references#CD001206-bbs2-0028" title="LottM , GreistJH , JeffersonJW , KobakKA , KatzelnickDJ , KatzRJ , SchaettleSC . Brofaromine for social phobia: a multicenter, placebo‐controlled, double‐blind study. Journal of Clinical Psychopharmacology1997;17(4):255‐60. ">Lott 1997</a>; <a href="./references#CD001206-bbs2-0038" title="OosterbaanDB , VanBalkomAJLM , SpinhovenP , vanOppenP , vanDyckR . Cognitive therapy versus moclobemide in social phobia: a controlled study. Clinical Pscyhology and Psychotherapy2001;8(4):263‐73. ">Oosterbaan 2001</a>; <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>) and fear subscale of the LSAS (k = 6, MD −5.40 points, 95% CI −8.92 to −1.88, N = 724; see <a href="./references#CD001206-fig-0053" title="">Analysis 10.3</a>; <a href="./references#CD001206-bbs2-0013" title="FahlenT , HumbleM , KoczkasC , NilssonH . Social phobia and its treatment with brofaromine, efficacy regarding social phobia symptoms and personality traits. Clinical Neuropharmacology1992;15(1 Pt B):64. FahlenT , NilssonHl , BorgK , HumbleM , PauliU . Social phobia: the clinical efficacy and tolerability of the monoamine oxidase‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study. Acta Psychiatrica Scandinavica1995;92(5):351‐8. ">Fahlen 1995</a>; <a href="./references#CD001206-bbs2-0018" title="KatschnigK , SteinMB , BullerR . Moclobemide in social phobia. A double‐blind, placebo‐controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience1997;247(2):71‐80. ">Katschnig 1997</a>; <a href="./references#CD001206-bbs2-0028" title="LottM , GreistJH , JeffersonJW , KobakKA , KatzelnickDJ , KatzRJ , SchaettleSC . Brofaromine for social phobia: a multicenter, placebo‐controlled, double‐blind study. Journal of Clinical Psychopharmacology1997;17(4):255‐60. ">Lott 1997</a>; <a href="./references#CD001206-bbs2-0038" title="OosterbaanDB , VanBalkomAJLM , SpinhovenP , vanOppenP , vanDyckR . Cognitive therapy versus moclobemide in social phobia: a controlled study. Clinical Pscyhology and Psychotherapy2001;8(4):263‐73. ">Oosterbaan 2001</a>; <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>; <a href="./references#CD001206-bbs2-0059" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO‐A inhibitor. European Neuropsychopharmacology1992;2(1):21‐9. ">Van Vliet 1992</a>). Evidence from the social subscale was low in quality. We observed moderate to substantial variability in the effects of these agents on the fear subscale (Chi<sup>2</sup> = 11.13, df = 5, P = 0.05; I<sup>2</sup> = 55%), and the evidence was very low in quality. </p> <p>We observed evidence of an effect for the reduction of depression symptoms when comparing brofaromine and moclobemide to placebo (SMD −0.28; 95% CI −0.55 to 0.00, see <a href="./references#CD001206-fig-0054" title="">Analysis 10.4</a>) in seven trials with 765 participants (<a href="./references#CD001206-bbs2-0013" title="FahlenT , HumbleM , KoczkasC , NilssonH . Social phobia and its treatment with brofaromine, efficacy regarding social phobia symptoms and personality traits. Clinical Neuropharmacology1992;15(1 Pt B):64. FahlenT , NilssonHl , BorgK , HumbleM , PauliU . Social phobia: the clinical efficacy and tolerability of the monoamine oxidase‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study. Acta Psychiatrica Scandinavica1995;92(5):351‐8. ">Fahlen 1995</a>; <a href="./references#CD001206-bbs2-0018" title="KatschnigK , SteinMB , BullerR . Moclobemide in social phobia. A double‐blind, placebo‐controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience1997;247(2):71‐80. ">Katschnig 1997</a>; <a href="./references#CD001206-bbs2-0028" title="LottM , GreistJH , JeffersonJW , KobakKA , KatzelnickDJ , KatzRJ , SchaettleSC . Brofaromine for social phobia: a multicenter, placebo‐controlled, double‐blind study. Journal of Clinical Psychopharmacology1997;17(4):255‐60. ">Lott 1997</a>; <a href="./references#CD001206-bbs2-0038" title="OosterbaanDB , VanBalkomAJLM , SpinhovenP , vanOppenP , vanDyckR . Cognitive therapy versus moclobemide in social phobia: a controlled study. Clinical Pscyhology and Psychotherapy2001;8(4):263‐73. ">Oosterbaan 2001</a>; <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>; <a href="./references#CD001206-bbs2-0059" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO‐A inhibitor. European Neuropsychopharmacology1992;2(1):21‐9. ">Van Vliet 1992</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>) on the HDRS or the MADRS. There was substantial heterogeneity in effect size estimates for this outcome (Chi<sup>2</sup> = 16.21, df = 6, P = 0.01; I<sup>2</sup> = 63%). This effect was partly due to large medication effects of two studies (<a href="./references#CD001206-bbs2-0013" title="FahlenT , HumbleM , KoczkasC , NilssonH . Social phobia and its treatment with brofaromine, efficacy regarding social phobia symptoms and personality traits. Clinical Neuropharmacology1992;15(1 Pt B):64. FahlenT , NilssonHl , BorgK , HumbleM , PauliU . Social phobia: the clinical efficacy and tolerability of the monoamine oxidase‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study. Acta Psychiatrica Scandinavica1995;92(5):351‐8. ">Fahlen 1995</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>). Evidence for efficacy of the RIMAs was not apparent after removing these studies (k = 5, RR −0.08; 95% CI −0.24 to 0.07, N = 637). </p> <p>There was no evidence of an effect for brofaromine or moclobemide compared to placebo for reducing associated disability on the work (MD −0.61 points, 95% CI −1.89 to 0.68, see <a href="./references#CD001206-fig-0055" title="">Analysis 10.5</a>), social (MD −1.14 points, 95% CI −2.32 to 0.05, see <a href="./references#CD001206-fig-0055" title="">Analysis 10.5</a>), or family subscale of the SDS (MD −0.51 points, 95% CI −1.45 to 0.44, see <a href="./references#CD001206-fig-0055" title="">Analysis 10.5</a>) in five trials with 660 participants (<a href="./references#CD001206-bbs2-0018" title="KatschnigK , SteinMB , BullerR . Moclobemide in social phobia. A double‐blind, placebo‐controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience1997;247(2):71‐80. ">Katschnig 1997</a>; <a href="./references#CD001206-bbs2-0028" title="LottM , GreistJH , JeffersonJW , KobakKA , KatzelnickDJ , KatzRJ , SchaettleSC . Brofaromine for social phobia: a multicenter, placebo‐controlled, double‐blind study. Journal of Clinical Psychopharmacology1997;17(4):255‐60. ">Lott 1997</a>; <a href="./references#CD001206-bbs2-0038" title="OosterbaanDB , VanBalkomAJLM , SpinhovenP , vanOppenP , vanDyckR . Cognitive therapy versus moclobemide in social phobia: a controlled study. Clinical Pscyhology and Psychotherapy2001;8(4):263‐73. ">Oosterbaan 2001</a>; <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>; <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a>). There was substantial and considerable heterogeneity in effect size estimates for these three scales (P &lt; 0.001, I<sup>2</sup> = 88%; P &lt; 0.001, I<sup>2</sup> = 83%; P = 0.002, I<sup>2</sup> = 65%, respectively). When we removed <a href="./references#CD001206-bbs2-0062" title="VersianiM , NardiAE , MundimFD , AlvesAB , LiebowitzMR , AmreinR . Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. British Journal of Psychiatry1992;161:353‐60. ">Versiani 1992</a> from this outcome, the findings were non‐significant for reduction of associated disability on the work, social, and family subscale of the SDS. </p> <p>We observed similar dropout rates in the medication and placebo arms for the RIMAs (k = 6, RR 0.80; 95% CI 0.60 to 1.08, N = 512; see <a href="./references#CD001206-fig-0056" title="">Analysis 10.6</a>; <a href="./references#CD001206-bbs2-0013" title="FahlenT , HumbleM , KoczkasC , NilssonH . Social phobia and its treatment with brofaromine, efficacy regarding social phobia symptoms and personality traits. Clinical Neuropharmacology1992;15(1 Pt B):64. FahlenT , NilssonHl , BorgK , HumbleM , PauliU . Social phobia: the clinical efficacy and tolerability of the monoamine oxidase‐A and serotonin uptake inhibitor brofaromine. A double‐blind placebo‐controlled study. Acta Psychiatrica Scandinavica1995;92(5):351‐8. ">Fahlen 1995</a>; <a href="./references#CD001206-bbs2-0018" title="KatschnigK , SteinMB , BullerR . Moclobemide in social phobia. A double‐blind, placebo‐controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience1997;247(2):71‐80. ">Katschnig 1997</a>; <a href="./references#CD001206-bbs2-0028" title="LottM , GreistJH , JeffersonJW , KobakKA , KatzelnickDJ , KatzRJ , SchaettleSC . Brofaromine for social phobia: a multicenter, placebo‐controlled, double‐blind study. Journal of Clinical Psychopharmacology1997;17(4):255‐60. ">Lott 1997</a>; <a href="./references#CD001206-bbs2-0038" title="OosterbaanDB , VanBalkomAJLM , SpinhovenP , vanOppenP , vanDyckR . Cognitive therapy versus moclobemide in social phobia: a controlled study. Clinical Pscyhology and Psychotherapy2001;8(4):263‐73. ">Oosterbaan 2001</a>; <a href="./references#CD001206-bbs2-0044" title="SchneierFR , GoetzD , CampeasR , FallonB , MarshallR , LiebowitzMR . Placebo‐controlled trial of moclobemide in social phobia. British Journal of Psychiatry1998;172:70‐7. ">Schneier 1998</a>; <a href="./references#CD001206-bbs2-0059" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO‐A inhibitor. European Neuropsychopharmacology1992;2(1):21‐9. ">Van Vliet 1992</a>). </p> </section> </section> <section id="CD001206-sec-0117"> <h4 class="title">Comparison 11: SARIs versus placebo</h4> <section id="CD001206-sec-0118"> <h5 class="title">Primary outcome measures</h5> <p>There were no data available to assess treatment efficacy and dropouts due to adverse events. </p> </section> <section id="CD001206-sec-0119"> <h5 class="title">Secondary outcome measures</h5> <p>There was no evidence of an effect of nefazodone compared to placebo on the reduction of total SAnD symptom severity on the LSAS (MD −6.10 points, 95% CI −16.55 to 4.35, see <a href="./references#CD001206-fig-0058" title="">Analysis 11.1</a>) in one trial with 102 participants (<a href="./references#CD001206-bbs2-0058" title="VanAmeringenM , ManciniC , OakmanJ , WalkerJ , KjernistedK , ChokkaP , et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(2):288‐95. VanAmeringenMA , ManciniCL , PipeB , OakmanJ , WalkerJR , KjernistedKD , et al. Not all serotonergic agents are created equal in social phobia: nefazodone, a placebo‐controlled trial. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR789. ">Van Ameringen 2007</a>). The evidence that was available for this outcome was of very low quality. There was also no evidence of an effect of nefazodone for reducing depression symptoms compared to placebo (k = 1, MD 0.80 points, 95% CI −2.10 to 3.70, N = 102; see <a href="./references#CD001206-fig-0059" title="">Analysis 11.2</a>) on the BDI. </p> <p>Furthermore, there was evidence that nefazodone reduced social disability compared to placebo (k = 1, MD −1.00 point, 95% CI −1.97 to −0.03, N = 102; <a href="./references#CD001206-fig-0060" title="">Analysis 11.3</a>), with no evidence of similar reductions on the work (k = 1, MD −0.90 points, 95% CI −1.87 to 0.07, N = 102; see <a href="./references#CD001206-fig-0060" title="">Analysis 11.3</a>) or family subscale of the SDS (k = 1, MD −0.20 points, 95% CI −1.06 to 0.66, N = 102; see <a href="./references#CD001206-fig-0060" title="">Analysis 11.3</a>; <a href="./references#CD001206-bbs2-0058" title="VanAmeringenM , ManciniC , OakmanJ , WalkerJ , KjernistedK , ChokkaP , et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(2):288‐95. VanAmeringenMA , ManciniCL , PipeB , OakmanJ , WalkerJR , KjernistedKD , et al. Not all serotonergic agents are created equal in social phobia: nefazodone, a placebo‐controlled trial. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR789. ">Van Ameringen 2007</a>). The data for the disability subscales were of low quality. </p> <p>The proportion of dropouts was more than twice as high in participants receiving nefazodone (15/52, 29%) compared to the placebo group (7/53, 13%), though this difference was not statistically significant (k = 1, RR 2.18; 95% CI 0.97 to 4.92; see <a href="./references#CD001206-fig-0061" title="">Analysis 11.4</a>; <a href="./references#CD001206-bbs2-0058" title="VanAmeringenM , ManciniC , OakmanJ , WalkerJ , KjernistedK , ChokkaP , et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(2):288‐95. VanAmeringenMA , ManciniCL , PipeB , OakmanJ , WalkerJR , KjernistedKD , et al. Not all serotonergic agents are created equal in social phobia: nefazodone, a placebo‐controlled trial. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR789. ">Van Ameringen 2007</a>). </p> </section> </section> <section id="CD001206-sec-0120"> <h4 class="title">Comparison 12: SNRIs compared to placebo for the treatment of SAnD</h4> <section id="CD001206-sec-0121"> <h5 class="title">Primary outcome measures</h5> <p>There was no evidence of an effect of venlafaxine on treatment efficacy in participants with SAnD compared to placebo (RR 1.30; 95% CI 0.85 to 1.99, see <a href="./references#CD001206-fig-0062" title="">Analysis 12.1</a>) in four trials with 1173 participants (<a href="./references#CD001206-bbs2-0026" title="LiebowitzMR , ManganoRM , BradwejnJ , AsnisG . A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. Journal of Clinical Psychiatry2005;66(2):238‐47. ">Liebowitz 2005a</a>; <a href="./references#CD001206-bbs2-0027" title="Liebow3149018itzMR , GelenbergAJ , MunjackD . Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry2005;62(2):190‐8. ">Liebowitz 2005b</a>; <a href="./references#CD001206-bbs2-0043" title="RickelsK , ManganoR , KhanA . A double‐blind, placebo‐controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(5):488‐96. ">Rickels 2004</a>; <a href="./references#CD001206-bbs2-0052" title="SteinMB , PollackMH , BystritskyA , KelseyJE , ManganoRM . Efficacy of low and higher dose extended‐release venlafaxine in generalized social anxiety disorder: a 6‐month randomized controlled trial. Psychopharmacology2005;177(3):280‐8. SteinMB , PollackMH , ManganoR . Long‐term treatment of generalized SAD with venlafaxine extended release. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR251. ">Stein 2005</a>). The evidence that was available for this outcome was of low quality. We observed considerable heterogeneity for this outcome (Chi<sup>2</sup> = 26.70, df = 3, P &lt; 0.001; I<sup>2</sup> = 89%). There was evidence of an effect of the SNRIs compared to the benzodiazepines (Chi<sup>2</sup> = 11.39, df = 1, P = 0.0007; I<sup>2</sup> = 91.2%) however, favouring the benzodiazepines. </p> <p>The proportion of dropouts due to adverse events was more than three times as high in participants receiving venlafaxine (109/663, 16%) compared to placebo (27/550, 5%), a statistically significant difference (k = 4, RR 3.23, 95% CI 2.15 to 4.86; <a href="./references#CD001206-fig-0063" title="">Analysis 12.2</a>). The evidence that was available for this outcome was of moderate quality. </p> </section> <section id="CD001206-sec-0122"> <h5 class="title">Secondary outcome measures</h5> <p>There was evidence of benefit for venlafaxine compared to placebo on the reduction of total SAnD symptom severity on the LSAS (k = 3; MD −11.91 points, 95% CI −16.06 to −7.76) based on moderate‐quality evidence. This outcome was calculated using a combination of endpoint (for <a href="./references#CD001206-bbs2-0043" title="RickelsK , ManganoR , KhanA . A double‐blind, placebo‐controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(5):488‐96. ">Rickels 2004</a>) and change‐from‐baseline scores (from <a href="./references#CD001206-bbs2-0027" title="Liebow3149018itzMR , GelenbergAJ , MunjackD . Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry2005;62(2):190‐8. ">Liebowitz 2005b</a> and <a href="./references#CD001206-bbs2-0052" title="SteinMB , PollackMH , BystritskyA , KelseyJE , ManganoRM . Efficacy of low and higher dose extended‐release venlafaxine in generalized social anxiety disorder: a 6‐month randomized controlled trial. Psychopharmacology2005;177(3):280‐8. SteinMB , PollackMH , ManganoR . Long‐term treatment of generalized SAD with venlafaxine extended release. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR251. ">Stein 2005</a>) across a total of 903 participants. Venlafaxine was superior to placebo on both the avoidance (k = 1, MD −4.30 points, 95% CI −8.14 to −0.46, N = 261; see <a href="./references#CD001206-fig-0064" title="">Analysis 12.3</a>) and fear subscale of the LSAS (k = 1, MD −4.00 points, 95% CI −7.68 to −0.32, N = 261; see <a href="./references#CD001206-fig-0064" title="">Analysis 12.3</a>) for a single trial providing data on these outcomes (<a href="./references#CD001206-bbs2-0043" title="RickelsK , ManganoR , KhanA . A double‐blind, placebo‐controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(5):488‐96. ">Rickels 2004</a>). The evidence on the remaining outcomes of avoidance and fear was low in quality. </p> <p>We found similar dropout rates in the medication and placebo arms for the SNRIs (k = 4, RR 0.90; 95% CI 0.76 to 1.07, N = 1224; see <a href="./references#CD001206-fig-0065" title="">Analysis 12.4</a>; <a href="./references#CD001206-bbs2-0002" title="AllgulanderC , ManganoR , ZhangJ , DahlAA , LepolaU , SjödinI , EmilienG . Efficacy of venlafaxine ER in patients with social anxiety disorder: a double‐blind, placebo‐controlled, parallel‐group comparison with paroxetine. Human Psychopharmacology2004;19(6):387‐96. ManganoR , LiebowitzMR , AllgulanderC . Comparison of venlafaxine extended release and paroxetine in short‐term treatment of SAD. New Research Abstracts. 156th Annual Meeting of the American Psychiatric Association; 2003 May 17‐22. San Francisco (CA), 2003. ">Allgulander 2004</a>; <a href="./references#CD001206-bbs2-0026" title="LiebowitzMR , ManganoRM , BradwejnJ , AsnisG . A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. Journal of Clinical Psychiatry2005;66(2):238‐47. ">Liebowitz 2005a</a>; <a href="./references#CD001206-bbs2-0027" title="Liebow3149018itzMR , GelenbergAJ , MunjackD . Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry2005;62(2):190‐8. ">Liebowitz 2005b</a>; <a href="./references#CD001206-bbs2-0052" title="SteinMB , PollackMH , BystritskyA , KelseyJE , ManganoRM . Efficacy of low and higher dose extended‐release venlafaxine in generalized social anxiety disorder: a 6‐month randomized controlled trial. Psychopharmacology2005;177(3):280‐8. SteinMB , PollackMH , ManganoR . Long‐term treatment of generalized SAD with venlafaxine extended release. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR251. ">Stein 2005</a>). </p> </section> </section> <section id="CD001206-sec-0123"> <h4 class="title">Comparison 13: SSRIs versus placebo</h4> <section id="CD001206-sec-0124"> <h5 class="title">Primary outcome measures</h5> <p>There was evidence of treatment efficacy for paroxetine, fluvoxamine, sertraline, fluoxetine, and citalopram compared to placebo in participants with SAnD (k = 24, RR 1.65; 95% CI 1.48 to 1.85, N = 4984; see <a href="./references#CD001206-fig-0066" title="">Analysis 13.1</a>; <a href="./references#CD001206-bbs2-0001" title="AllgulanderC . Efficacy of paroxetine in social phobia ‐ a single‐center double‐blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20‐50 mg or placebo for 3 months. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4. Paris, France, 1998:P.3.005. AllgulanderC . Paroxetine in social anxiety disorder: a randomised placebo‐controlled study. Acta Psychiatrica Scandinavica1999;100(3):193‐8. ">Allgulander 1999</a>; <a href="./references#CD001206-bbs2-0003" title="AsakuraS , TajimaO , KoyamaT . Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized, double‐blind, placebo‐controlled study. International Journal of Neuropsychopharmacology2007;10(2):263‐74. ">Asakura 2007</a>; <a href="./references#CD001206-bbs2-0004" title="29060/502 . Randomised, double‐blind study of paroxetine and placebo in the treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/502#rs (first received 30 September 2005). BaldwinD , BobesJ , SteinDJ , ScharwaechterI , FaureM . Paroxetine in social phobia/social anxiety disorder. Randomised, double‐blind, placebo‐controlled study. British Journal of Psychiatry1999;175(2):120‐6. SteinDJ , BerkM , ElsC , EmsleyRA , GittelsonL , WilsonD , et al. A double‐blind placebo‐controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. South African Medical Journal1999;89(4):402‐6. ">Baldwin 1999</a>; <a href="./references#CD001206-bbs2-0007" title="BlomhoffS , HaugTT , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry2001;179(1):23‐30. BlomhoffS , HaugTT , HumbleM , HallstromK , MadsbuHP , WoldJE , et al. Treatment of generalized social phobia. New Research Abstracts. 152nd Annual Meeting of the American Psychiatric Association; May 15‐20. Washington DC, 1999:NR650. HaugTT , BlomhoffS , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Exposure therapy and sertraline in social phobia: 1‐year follow‐up of a randomised controlled trial. British Journal of Psychiatry2003;182(4):312‐8. WalkerJR . The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia. Evidence‐based Mental Health2003;6(3):90. ">Blomhoff 2001</a>; <a href="./references#CD001206-bbs2-0008" title="BookSW , ThomasSE , RandallPK , RandallCL . Paroxetine reduces social anxiety in individuals with a co‐occurring alcohol use disorder. Journal of Anxiety Disorders2008;22(2):310‐8. ThomasSE , RandallPK , BookSW , RandallCL . A complex relationship between co‐occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research2008;32(1):77‐84. ">Book 2008</a>; <a href="./references#CD001206-bbs2-0011" title="DavidsonJ , Yaryura‐TobiasJ , DuPontR , StallingsL , BarbatoLM , Van derHoopRG , et al. Fluvoxamine‐controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(2):118‐25. DavidsonJR , HembyLW , BarbatoL , Van derHoopRG . Fluvoxamine controlled release for the treatment of generalized social anxiety disorder. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14;. San Juan, Puerto Rico, 2000:161. ">Davidson 2004a</a>; <a href="./references#CD001206-bbs2-0012" title="AderkaIM , McLeanCP , HuppertJD , DavidsonJRT , FoaEB . Fear, avoidance and physiological symptoms during cognitive‐behavioral therapy for social anxiety disorder. Behaviour Research and Therapy2013;51(7):352‐8. DavidsonJRT , FoaEB , HuppertJD , KeefeFJ , FranklinME , ComptonJS , et al. Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Archives of General Psychiatry2004;61(10):1005‐13. HuppertJD , SchultzLT , FoaEB , BarlowDH , DavidsonJR , GormanJM , et al. Differential response to placebo among patients with social phobia, panic disorder, and obsessive‐compulsive disorder. American Journal of Psychiatry2004;161(8):1485‐7. LedleyDR , HuppertJD , FoaEB , DavidsonJRT , KeefeFJ , PottsNLS . Impact of depressive symptoms on the treatment of generalized social anxiety disorder. Depression and Anxiety2005;22(4):161‐7. ">Davidson 2004b</a>; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0032" title="NCT00318669 . Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Social Phobia/Social Anxiety Disorder (SAD) ‐A Double‐blind, Placebo‐controlled Study‐ &lt;Phase III Study&gt; [Social Anxiety Disorder Study Of Paroxetine]. clinicaltrials.gov/ct2/show/NCT00318669 (first received 24 April 2006). ">NCT00318669</a>; <a href="./references#CD001206-bbs2-0034" title="NCT00403962 . A Randomised, Double‐Blind, Parallel‐Group, Placebo‐Controlled Fixed Dose Study Comparing the Efficacy and Safety of GW597599/Paroxetine Combination or Paroxetine Monotherapy to Placebo in Patients With Social Anxiety Disorder (SAD) [A Combination Therapy In Patients With Social Anxiety Disorder]. clinicaltrials.gov/ct2/show/NCT00403962 (first received 29 August 2005). ">NCT00403962</a>; <a href="./references#CD001206-bbs2-0033" title="NCT00397722 . Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [Treatment of patients with social anxiety disorder]. clinicaltrials.gov/ct2/show/results/NCT00397722 (first received 8 November 2006). ">NCT00397722</a>; <a href="./references#CD001206-bbs2-0017" title="KasperS , LoftH , NilR . Escitalopram in the treatment of social anxiety disorder. XII World Congress of Psychiatry; Aug 24‐9. Yokohama, Japan, 2002. KasperS , LoftH , SmithJR . Escitalopram is efficacious and well tolerated in the treatment of social anxiety disorder. New Research Abstracts. 155th Annual Meeting of the American Psychiatric Association; May 18‐23;. Philadelphia (PA), 2002. KasperS , SteinDJ , LoftH , Nil , R . Escitalopram in the treatment of social anxiety disorder: randomised, placebo‐controlled, flexible‐dosage study. British Journal of Psychiatry2005;186(3):222‐6. ">Kasper 2005</a>; <a href="./references#CD001206-bbs2-0206" title="KobakKA , GreistJH , JeffersonJW , KatzelnickDJ . Fluoxetine in social phobia: a double‐blind, placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2002;22(3):257‐62. ">Kobak 2002</a>; <a href="./references#CD001206-bbs2-0021" title="LaderM , StenderK , BurgerV , NilR . Efficacy and tolerability of escitalopram in 12‐ and 24‐week treatment of social anxiety disorder: randomised, double‐blind, placebo‐controlled, fixed dose study. Depression and Anxiety2004;19:241‐8. ">Lader 2004</a>; <a href="./references#CD001206-bbs2-0022" title="LepolaU , BergtholdtB , LambertJS , DavyKL , RuggieroL . Controlled‐release paroxetine in the treatment of patients with social anxiety disorder. Journal of Clinical Psychiatry2004;65:222‐9. ">Lepola 2004</a>; <a href="./references#CD001206-bbs2-0024" title="LiebowitzMR , SteinMB , TancerM , CarpenterD , OakesR , PittsCD . A randomized, double‐blind, fixed‐dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry2002;63(1):66‐74. ">Liebowitz 2002</a>; <a href="./references#CD001206-bbs2-0025" title="LiebowitzMR , DeMartinisNA , WeihsKL , LondborgPD , SmithWT , ChungH , et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64(7):785‐92. ">Liebowitz 2003</a>; <a href="./references#CD001206-bbs2-0027" title="Liebow3149018itzMR , GelenbergAJ , MunjackD . Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry2005;62(2):190‐8. ">Liebowitz 2005b</a>; <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a>; <a href="./references#CD001206-bbs2-0041" title="RandallCL , JohnsonMR , ThevosAK , SonneSC , ThomasSE , WillardSL , et al. Paroxetine for social anxiety and alcohol use in dual‐diagnosed patients. Depression &amp; Anxiety2001;14(4):255‐62. RandallCL , JohnsonMR , ThevosAK , SonneSC , WillardSL , ThomasSE , et al. Paroxetine improves both social anxiety and alcohol use in dual‐diagnosed patients. 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10‐14; San Juan, Puerto Rico. 2000. ">Randall 2001</a>; <a href="./references#CD001206-bbs2-0047" title="SteinMB , LiebowitzMR , LydiardRB , PittsCD , BushnellW , GergelI . Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA1998;280(8):708‐13. ">Stein 1998</a>; <a href="./references#CD001206-bbs2-0048" title="SteinMB , FyerAJ , DavidsonJR , PollackMH , WiitaB . Fluvoxamine treatment of social phobia (social anxiety disorder): a double‐blind, placebo‐controlled study. American Journal of Psychiatry1999;156(5):756‐60. ">Stein 1999</a>; <a href="./references#CD001206-bbs2-0057" title="LaneR , WalkerJ , SwinsonR , VanAmeringenM . Sertraline in generalised social phobia. 11th World Congress of Psychiatry; Aug 6‐11. Hamburg, Germany, 1999. PietersG . Sertraline was effective and well tolerated for generalised social phobia. Evidence‐based Mental Health2001;4(3):91. VanAmeringenM , OakmanJM , FarvoldenPG , ManciniC , WalkerJR , LaneRM . Predictors of sertraline response in social phobia. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14. San Juan, Puerto Rico, 2000:163. VanAmeringenMA , LaneRM , WalkerJR , BowenRC , ChokkaPR , GoldnerEM , et al. Sertraline treatment of generalised social phobia: a 20‐week, double‐blind, placebo‐controlled study. American Journal of Psychiatry2001;158(2):275‐81. VanAmeringenMA , SwinsonR , WalkerJR , LaneRM . A placebo‐controlled study of sertraline in generalized social phobia [abstract]. European Neuropsychopharmacology2000;10(Suppl 3):S335. ">Van Ameringen 2001a</a>; <a href="./references#CD001206-bbs2-0065" title="WestenbergHGM , SteinDJ , YangH , LiD , BarbatoLM . A double‐blind placebo‐controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(1):49‐55. ">Westenberg 2004</a>), though the evidence was very low in quality. There was evidence for a response to long‐term treatment with paroxetine and fluvoxamine compared to placebo in participants with SAnD (k = 4, RR 1.27; 95% CI 1.07 to 1.51, N = 806; see <a href="./references#CD001206-fig-0073" title="">Analysis 13.8</a>; <a href="./references#CD001206-bbs2-0021" title="LaderM , StenderK , BurgerV , NilR . Efficacy and tolerability of escitalopram in 12‐ and 24‐week treatment of social anxiety disorder: randomised, double‐blind, placebo‐controlled, fixed dose study. Depression and Anxiety2004;19:241‐8. ">Lader 2004</a>; <a href="./references#CD001206-bbs2-0050" title="29060/595 . A study of the maintained efficacy and safety of paroxetine versus placebo in the long‐term treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/595#rs (first received 28 September 2008). SteinDJ , VersianiM , HairT , KumarR . Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24‐week study. Archives of General Psychiatry2002;59(12):1111‐8. ">Stein 2002b</a>; <a href="./references#CD001206-bbs2-0051" title="SteinDJ , WestenbergHGM , YangH , LiD , BarbatoLM . Fluvoxamine CR in the long‐term treatment of social anxiety disorder: the 12‐ to 24‐week extension phase of a multicentre, randomized, placebo‐controlled trial. International Journal of Neuropsychopharmacology2003;6(4):317‐23. ">Stein 2003</a>), though again this conclusion was based on low quality evidence. There was moderate heterogeneity in effect size estimates for long‐term treatment response (Chi<sup>2</sup> = 7.54, df = 3, P = 0.06; I<sup>2</sup> = 60%). This was partly due to large medication effects of one study (<a href="./references#CD001206-bbs2-0050" title="29060/595 . A study of the maintained efficacy and safety of paroxetine versus placebo in the long‐term treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/595#rs (first received 28 September 2008). SteinDJ , VersianiM , HairT , KumarR . Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24‐week study. Archives of General Psychiatry2002;59(12):1111‐8. ">Stein 2002b</a>). However, evidence for efficacy of the SSRIs was still apparent after removing this study from the analysis (k = 3, RR 1.18; 95% CI 1.05 to 1.32, N = 483). </p> <p>There was evidence for a smaller response to treatment with the anticonvulsant levetiracetam (Chi<sup>2</sup> = 8.02, df = 1, P = 0.005; I<sup>2</sup> = 87.5%) compared to the benzodiazepines (Chi<sup>2</sup> = 11.58, df = 1, P = 0.0007; I<sup>2</sup> = 91.4%) and the GW876008 (Chi<sup>2</sup> = 12.28, df = 1; P = 0.0005, I<sup>2</sup> = 91.9%), although the response favoured the benzodiazepines. </p> <p>There was evidence that paroxetine and sertraline prevented relapse compared to placebo (k = 3, RR 0.34; 95% CI 0.22 to 0.50, N = 389; see <a href="./references#CD001206-fig-0067" title="">Analysis 13.2</a>; <a href="./references#CD001206-bbs2-0046" title="SteinMB , ChartierMJ , HazenAL , KroftCD , ChaleRA , CotéD , et al. Paroxetine in the treatment of generalized social phobia: open‐label treatment and double‐blind placebo‐controlled discontinuation. Journal of Clinical Psychopharmacology1996;16(3):218‐22. ">Stein 1996</a>; <a href="./references#CD001206-bbs2-0050" title="29060/595 . A study of the maintained efficacy and safety of paroxetine versus placebo in the long‐term treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/595#rs (first received 28 September 2008). SteinDJ , VersianiM , HairT , KumarR . Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24‐week study. Archives of General Psychiatry2002;59(12):1111‐8. ">Stein 2002b</a>; <a href="./references#CD001206-bbs2-0064" title="WalkerJR , VanAmeringenMA , SwinsonR , BowenRC , ChokkaPR , GoldnerE , et al. Prevention of relapse in generalized social phobia: results of a 24‐week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology2000;20(6):636‐44. WalkerJR , VanAmeringenMA , SwinsonRP , LaneRM . A 24‐week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000:NR259. ">Walker 2000</a>). </p> <p>The proportion of dropouts due to adverse events was approximately three times higher amongst participants receiving SSRIs compared to placebo. This difference was statistically significant (RR 2.59; 95% CI 1.97 to 3.39, N = 5131; see <a href="./references#CD001206-fig-0068" title="">Analysis 13.3</a>). Twelve per cent of participants across 24 RCTs who received medication withdrew prior to study endpoint. The evidence that was available for this outcome was of low quality. We found no difference in dropout rates due to treatment‐emergent side effects between the medication and control groups (RR 1.17; 95% CI 0.43 to 3.18, see <a href="./references#CD001206-fig-0074" title="">Analysis 13.9</a>) in three long‐term trials with 1274 participants (<a href="./references#CD001206-bbs2-0021" title="LaderM , StenderK , BurgerV , NilR . Efficacy and tolerability of escitalopram in 12‐ and 24‐week treatment of social anxiety disorder: randomised, double‐blind, placebo‐controlled, fixed dose study. Depression and Anxiety2004;19:241‐8. ">Lader 2004</a>; <a href="./references#CD001206-bbs2-0050" title="29060/595 . A study of the maintained efficacy and safety of paroxetine versus placebo in the long‐term treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/595#rs (first received 28 September 2008). SteinDJ , VersianiM , HairT , KumarR . Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24‐week study. Archives of General Psychiatry2002;59(12):1111‐8. ">Stein 2002b</a>; <a href="./references#CD001206-bbs2-0051" title="SteinDJ , WestenbergHGM , YangH , LiD , BarbatoLM . Fluvoxamine CR in the long‐term treatment of social anxiety disorder: the 12‐ to 24‐week extension phase of a multicentre, randomized, placebo‐controlled trial. International Journal of Neuropsychopharmacology2003;6(4):317‐23. ">Stein 2003</a>). The evidence that was available for this outcome was of very low quality.There was moderate heterogeneity in effect size estimates for this outcome (Chi<sup>2</sup> = 4.60, df = 2, P = 0.10; I<sup>2</sup> = 57%). </p> </section> <section id="CD001206-sec-0125"> <h5 class="title">Secondary outcome measures</h5> <p>There was evidence of benefit for the SSRIs compared to placebo for reducing total SAnD symptoms on the LSAS (k = 14, MD −10.14 points, 95% CI −14.05 to −6.22, N = 1990; see <a href="./references#CD001206-fig-0069" title="">Analysis 13.4</a>; <a href="./references#CD001206-bbs2-0001" title="AllgulanderC . Efficacy of paroxetine in social phobia ‐ a single‐center double‐blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20‐50 mg or placebo for 3 months. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4. Paris, France, 1998:P.3.005. AllgulanderC . Paroxetine in social anxiety disorder: a randomised placebo‐controlled study. Acta Psychiatrica Scandinavica1999;100(3):193‐8. ">Allgulander 1999</a>; <a href="./references#CD001206-bbs2-0003" title="AsakuraS , TajimaO , KoyamaT . Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized, double‐blind, placebo‐controlled study. International Journal of Neuropsychopharmacology2007;10(2):263‐74. ">Asakura 2007</a>; <a href="./references#CD001206-bbs2-0004" title="29060/502 . Randomised, double‐blind study of paroxetine and placebo in the treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/502#rs (first received 30 September 2005). BaldwinD , BobesJ , SteinDJ , ScharwaechterI , FaureM . Paroxetine in social phobia/social anxiety disorder. Randomised, double‐blind, placebo‐controlled study. British Journal of Psychiatry1999;175(2):120‐6. SteinDJ , BerkM , ElsC , EmsleyRA , GittelsonL , WilsonD , et al. A double‐blind placebo‐controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. South African Medical Journal1999;89(4):402‐6. ">Baldwin 1999</a>; <a href="./references#CD001206-bbs2-0008" title="BookSW , ThomasSE , RandallPK , RandallCL . Paroxetine reduces social anxiety in individuals with a co‐occurring alcohol use disorder. Journal of Anxiety Disorders2008;22(2):310‐8. ThomasSE , RandallPK , BookSW , RandallCL . A complex relationship between co‐occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research2008;32(1):77‐84. ">Book 2008</a>; <a href="./references#CD001206-bbs2-0011" title="DavidsonJ , Yaryura‐TobiasJ , DuPontR , StallingsL , BarbatoLM , Van derHoopRG , et al. Fluvoxamine‐controlled release formulation for the treatment of generalized social anxiety disorder. Journal of Clinical Psychopharmacology2004;24(2):118‐25. DavidsonJR , HembyLW , BarbatoL , Van derHoopRG . Fluvoxamine controlled release for the treatment of generalized social anxiety disorder. 39th Annual Meeting of the American College of Neuropsychopharmacology; Dec 10‐14;. San Juan, Puerto Rico, 2000:161. ">Davidson 2004a</a>; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0019" title="KatzelnickDJ , KobakKA , GreistJH , JeffersonJW , MantleJM , SerlinRC . Sertraline for social phobia: a double‐blind, placebo‐controlled crossover study. American Journal of Psychiatry1995;152(9):1368‐71. ">Katzelnick 1995</a>; <a href="./references#CD001206-bbs2-0206" title="KobakKA , GreistJH , JeffersonJW , KatzelnickDJ . Fluoxetine in social phobia: a double‐blind, placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2002;22(3):257‐62. ">Kobak 2002</a>; <a href="./references#CD001206-bbs2-0024" title="LiebowitzMR , SteinMB , TancerM , CarpenterD , OakesR , PittsCD . A randomized, double‐blind, fixed‐dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry2002;63(1):66‐74. ">Liebowitz 2002</a>; <a href="./references#CD001206-bbs2-0025" title="LiebowitzMR , DeMartinisNA , WeihsKL , LondborgPD , SmithWT , ChungH , et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64(7):785‐92. ">Liebowitz 2003</a>; <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a>; <a href="./references#CD001206-bbs2-0047" title="SteinMB , LiebowitzMR , LydiardRB , PittsCD , BushnellW , GergelI . Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA1998;280(8):708‐13. ">Stein 1998</a>; <a href="./references#CD001206-bbs2-0048" title="SteinMB , FyerAJ , DavidsonJR , PollackMH , WiitaB . Fluvoxamine treatment of social phobia (social anxiety disorder): a double‐blind, placebo‐controlled study. American Journal of Psychiatry1999;156(5):756‐60. ">Stein 1999</a>; <a href="./references#CD001206-bbs2-0054" title="TauscherJ , KielbasaW , IyengarS , VandenhendeF , PengX , MozleyD , et al. Development of the 2nd generation neurokinin‐1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology2010;20(2):80‐7. ">Tauscher 2010</a>), though the evidence was low in quality. There was considerable heterogeneity in effect size estimates for this outcome (Chi<sup>2</sup> = 39.61, df = 13, P &lt; 0.001; I<sup>2</sup> = 67%). This was partly due to large medication effects of <a href="./references#CD001206-bbs2-0001" title="AllgulanderC . Efficacy of paroxetine in social phobia ‐ a single‐center double‐blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20‐50 mg or placebo for 3 months. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4. Paris, France, 1998:P.3.005. AllgulanderC . Paroxetine in social anxiety disorder: a randomised placebo‐controlled study. Acta Psychiatrica Scandinavica1999;100(3):193‐8. ">Allgulander 1999</a>. Evidence for efficacy of the SSRIs was still apparent after removing this study (k = 13, RR −8.69; 95% CI −11.83 to −5.54, N = 1898). The SSRIs were superior to placebo on both the avoidance (MD −7.01 points, 95% CI −10.21 to −3.80; see <a href="./references#CD001206-fig-0069" title="">Analysis 13.4</a>) and fear subscale of the LSAS (MD −7.28 points, 95% CI −10.86 to −3.71, see <a href="./references#CD001206-fig-0069" title="">Analysis 13.4</a>) in seven trials with 1173 participants (<a href="./references#CD001206-bbs2-0001" title="AllgulanderC . Efficacy of paroxetine in social phobia ‐ a single‐center double‐blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20‐50 mg or placebo for 3 months. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4. Paris, France, 1998:P.3.005. AllgulanderC . Paroxetine in social anxiety disorder: a randomised placebo‐controlled study. Acta Psychiatrica Scandinavica1999;100(3):193‐8. ">Allgulander 1999</a>; <a href="./references#CD001206-bbs2-0003" title="AsakuraS , TajimaO , KoyamaT . Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized, double‐blind, placebo‐controlled study. International Journal of Neuropsychopharmacology2007;10(2):263‐74. ">Asakura 2007</a>; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0024" title="LiebowitzMR , SteinMB , TancerM , CarpenterD , OakesR , PittsCD . A randomized, double‐blind, fixed‐dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry2002;63(1):66‐74. ">Liebowitz 2002</a>; <a href="./references#CD001206-bbs2-0025" title="LiebowitzMR , DeMartinisNA , WeihsKL , LondborgPD , SmithWT , ChungH , et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64(7):785‐92. ">Liebowitz 2003</a>; <a href="./references#CD001206-bbs2-0047" title="SteinMB , LiebowitzMR , LydiardRB , PittsCD , BushnellW , GergelI . Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA1998;280(8):708‐13. ">Stein 1998</a>; <a href="./references#CD001206-bbs2-0060" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology1994;115(1‐2):128‐34. ">Van Vliet 1994</a>). The evidence that was available for the avoidance and fear outcomes was of low quality. There was considerable to substantial heterogeneity in effect size estimates of the avoidance and fear subscales of the LSAS (Chi<sup>2</sup> = 17.31, df = 6, P = 0.008; I<sup>2</sup> = 65%; Chi<sup>2</sup> = 24.25, df = 6, P &lt; 0.001; I<sup>2</sup> = 75%, respectively). </p> <p>We found evidence of an effect for reducing depression symptoms when comparing paroxetine, sertraline, fluoxetine, and fluvoxamine to placebo on the HAM‐D/HDRS or MADRS (k = 6, SMD −0.26; 95% CI −0.48 to −0.03, N = 960; see <a href="./references#CD001206-fig-0070" title="">Analysis 13.5</a>; <a href="./references#CD001206-bbs2-0004" title="29060/502 . Randomised, double‐blind study of paroxetine and placebo in the treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/502#rs (first received 30 September 2005). BaldwinD , BobesJ , SteinDJ , ScharwaechterI , FaureM . Paroxetine in social phobia/social anxiety disorder. Randomised, double‐blind, placebo‐controlled study. British Journal of Psychiatry1999;175(2):120‐6. SteinDJ , BerkM , ElsC , EmsleyRA , GittelsonL , WilsonD , et al. A double‐blind placebo‐controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. South African Medical Journal1999;89(4):402‐6. ">Baldwin 1999</a>; <a href="./references#CD001206-bbs2-0019" title="KatzelnickDJ , KobakKA , GreistJH , JeffersonJW , MantleJM , SerlinRC . Sertraline for social phobia: a double‐blind, placebo‐controlled crossover study. American Journal of Psychiatry1995;152(9):1368‐71. ">Katzelnick 1995</a>; <a href="./references#CD001206-bbs2-0206" title="KobakKA , GreistJH , JeffersonJW , KatzelnickDJ . Fluoxetine in social phobia: a double‐blind, placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2002;22(3):257‐62. ">Kobak 2002</a>; <a href="./references#CD001206-bbs2-0024" title="LiebowitzMR , SteinMB , TancerM , CarpenterD , OakesR , PittsCD . A randomized, double‐blind, fixed‐dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry2002;63(1):66‐74. ">Liebowitz 2002</a>; <a href="./references#CD001206-bbs2-0025" title="LiebowitzMR , DeMartinisNA , WeihsKL , LondborgPD , SmithWT , ChungH , et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64(7):785‐92. ">Liebowitz 2003</a>; <a href="./references#CD001206-bbs2-0060" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology1994;115(1‐2):128‐34. ">Van Vliet 1994</a>). There was moderate heterogeneity in effect size estimates for this outcome (Chi<sup>2</sup> = 11.05, df = 5, P = 0.05; I<sup>2</sup> = 55%), which was partly due to large medication effects of two studies (<a href="./references#CD001206-bbs2-0004" title="29060/502 . Randomised, double‐blind study of paroxetine and placebo in the treatment of social phobia. www.gsk‐clinicalstudyregister.com/study/29060/502#rs (first received 30 September 2005). BaldwinD , BobesJ , SteinDJ , ScharwaechterI , FaureM . Paroxetine in social phobia/social anxiety disorder. Randomised, double‐blind, placebo‐controlled study. British Journal of Psychiatry1999;175(2):120‐6. SteinDJ , BerkM , ElsC , EmsleyRA , GittelsonL , WilsonD , et al. A double‐blind placebo‐controlled trial of paroxetine in the management of social phobia (social anxiety disorder) in South Africa. South African Medical Journal1999;89(4):402‐6. ">Baldwin 1999</a>; <a href="./references#CD001206-bbs2-0060" title="VanVlietIM , DenBoerJA , WestenbergHG . Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine. Psychopharmacology1994;115(1‐2):128‐34. ">Van Vliet 1994</a>). Evidence for efficacy of the SSRIs was not apparent after removing these studies (k = 4, RR −0.13; 95% CI −0.28 to 0.03, N = 652). </p> <p>Futhermore, we found evidence of an effect for reducing associated disability when comparing paroxetine, sertraline, fluvoxamine and citalopram to placebo on the work (MD −0.81 points, 95% CI −1.18 to −0.45; see <a href="./references#CD001206-fig-0071" title="">Analysis 13.6</a>) and family subscale of the SDS (MD −0.45 points, 95% CI −0.75, −0.15, see <a href="./references#CD001206-fig-0071" title="">Analysis 13.6</a>), with evidence of an effect on the social subscale (MD −0.87 points, 95% CI −1.26 to −0.47, see <a href="./references#CD001206-fig-0071" title="">Analysis 13.6</a>) in five trials with 854 participants (<a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0024" title="LiebowitzMR , SteinMB , TancerM , CarpenterD , OakesR , PittsCD . A randomized, double‐blind, fixed‐dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. Journal of Clinical Psychiatry2002;63(1):66‐74. ">Liebowitz 2002</a>; <a href="./references#CD001206-bbs2-0025" title="LiebowitzMR , DeMartinisNA , WeihsKL , LondborgPD , SmithWT , ChungH , et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double‐blind, placebo‐controlled study. Journal of Clinical Psychiatry2003;64(7):785‐92. ">Liebowitz 2003</a>; <a href="./references#CD001206-bbs2-0047" title="SteinMB , LiebowitzMR , LydiardRB , PittsCD , BushnellW , GergelI . Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA1998;280(8):708‐13. ">Stein 1998</a>; <a href="./references#CD001206-bbs2-0048" title="SteinMB , FyerAJ , DavidsonJR , PollackMH , WiitaB . Fluvoxamine treatment of social phobia (social anxiety disorder): a double‐blind, placebo‐controlled study. American Journal of Psychiatry1999;156(5):756‐60. ">Stein 1999</a>). </p> <p>We observed similar dropout rates in the medication and placebo arms for the SSRIs (k = 26, RR 1.01; 95% CI 0.90 to 1.14, N = 5208; see <a href="./references#CD001206-fig-0072" title="">Analysis 13.7</a>). Findings were similar for participants who dropped out after long‐term treatment due to any cause (k = 1, RR 1.00; 95% CI 0.37 to 2.70, N = 52; see <a href="./references#CD001206-fig-0075" title="">Analysis 13.10</a>). </p> </section> </section> <section id="CD001206-sec-0126"> <h4 class="title">Comparison 14: GW876008 versus placebo</h4> <section id="CD001206-sec-0127"> <h5 class="title">Primary outcome measures</h5> <p>There was no evidence of treatment efficacy for GW876008 versus placebo (RR 0.83; 95% CI 0.58 to 1.19, see <a href="./references#CD001206-fig-0076" title="">Analysis 14.1</a>) in one trial with 250 participants (<a href="./references#CD001206-bbs2-0033" title="NCT00397722 . Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [Treatment of patients with social anxiety disorder]. clinicaltrials.gov/ct2/show/results/NCT00397722 (first received 8 November 2006). ">NCT00397722</a>), based on moderate quality evidence. </p> <p>Treatment dropouts were three times as high in participants receiving GW876008 (11/164, 7%) relative to placebo (2/88, 2%) (<a href="./references#CD001206-bbs2-0033" title="NCT00397722 . Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [Treatment of patients with social anxiety disorder]. clinicaltrials.gov/ct2/show/results/NCT00397722 (first received 8 November 2006). ">NCT00397722</a>), though this difference was not statistically significant. There was no evidence of a difference between the number of participants that dropped out due to treatment‐emergent side effects (k = 1, RR 2.95; 95% CI 0.67 to 13.02, N = 252; see Analysis 16.2) in the RCT of GW876008. The evidence that was available for this outcome was of low quality. </p> <p>The GW876008 demonstrated superiority with respect to treatment response relative to all the other medication classes that contained data from more than a single study, with the exception of the SNRI venlafaxine (Chi<sup>2</sup> = 2.49, df = 1, P = 0.11; I<sup>2</sup> = 59.8%). </p> </section> <section id="CD001206-sec-0128"> <h5 class="title">Secondary outcome measures</h5> <p>We observed similar dropout rates in the medication and placebo arms in the trial of GW876008 compared to placebo (RR 0.77; 95% CI 0.50 to 1.20, N = 252; see <a href="./references#CD001206-fig-0078" title="">Analysis 14.3</a>; <a href="./references#CD001206-bbs2-0033" title="NCT00397722 . Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [Treatment of patients with social anxiety disorder]. clinicaltrials.gov/ct2/show/results/NCT00397722 (first received 8 November 2006). ">NCT00397722</a>). </p> </section> </section> <section id="CD001206-sec-0129"> <h4 class="title">Comparison 15: NK1 receptor antagonist GR205171 versus placebo</h4> <section id="CD001206-sec-0130"> <h5 class="title">Primary outcome measures</h5> <p>There was no evidence of a superior treatment response to the NK1 receptor antagonist GR205171 than placebo in a single trial with 24 participants (RR 5.00; 95% CI 0.68 to 36.66, see <a href="./references#CD001206-fig-0079" title="">Analysis 15.1</a>; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>), based on very low quality evidence. </p> <p>No participants withdrew due to adverse events from treatment during the six‐week RCT of the NK1 receptor antagonist GR205171 (<a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-fig-0080" title="">Analysis 15.2</a>). The evidence that was available for this outcome was of moderate quality. </p> </section> <section id="CD001206-sec-0131"> <h5 class="title">Secondary outcome measures</h5> <p>We observed no evidence for an effect of the NK1 antagonist GR205171 on total LSAS symptom severity (k = 1, MD ‐0.50 points, 95% CI ‐1.35 to 0.35, N = 24; see <a href="./references#CD001206-fig-0081" title="">Analysis 15.3</a>; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>). This conclusion was based on data of very low quality. </p> <p>No participants withdrew from treatment during the six‐week RCT of the NK1 receptor antagonist GR205171 (<a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-fig-0082" title="">Analysis 15.4</a>). </p> </section> </section> <section id="CD001206-sec-0132"> <h4 class="title">Comparison 16: LY686017 versus placebo</h4> <section id="CD001206-sec-0133"> <h5 class="title">Primary outcome measures</h5> <p>There were no data available to assess treatment efficacy and dropouts due to adverse events. </p> </section> <section id="CD001206-sec-0134"> <h5 class="title">Secondary outcome measures</h5> <p>We observed no evidence for an effect of the LY686017 on total LSAS symptom severity (k = 1, MD 1.80 points, 95% CI ‐6.92 to 10.52, N = 99; see <a href="./references#CD001206-fig-0083" title="">Analysis 16.1</a>; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0054" title="TauscherJ , KielbasaW , IyengarS , VandenhendeF , PengX , MozleyD , et al. Development of the 2nd generation neurokinin‐1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology2010;20(2):80‐7. ">Tauscher 2010</a>). This conclusion was based on data of very low quality. </p> </section> </section> <section id="CD001206-sec-0135"> <h4 class="title">Comparison 17: total effect of medication versus placebo</h4> <p>There was evidence of an effect across all medication classes (k = 51, RR 1.62; 95% CI 1.46 to 1.81, N = 8564), with substantial heterogeneity across subgroups (Chi<sup>2</sup> = 42.93, df = 13, P &lt; 0.0001; I<sup>2</sup> = 69.7%). For this analysis we excluded data from two studies with additional arms of paroxetine to give preference to the least‐represented intervention in the review (i.e. GW876008 and GR205171; <a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0033" title="NCT00397722 . Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [Treatment of patients with social anxiety disorder]. clinicaltrials.gov/ct2/show/results/NCT00397722 (first received 8 November 2006). ">NCT00397722</a>). We also excluded data from <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>, a phenelzine study, and from <a href="./references#CD001206-bbs2-0027" title="Liebow3149018itzMR , GelenbergAJ , MunjackD . Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Archives of General Psychiatry2005;62(2):190‐8. ">Liebowitz 2005b</a>, a paroxetine study, to give preference to atenolol and venlafaxine (see <a href="./references#CD001206-fig-0084" title="">Analysis 17.1</a>). There was evidence that medication class explained a substantial proportion of variability in treatment efficacy when assessed across all trials providing data on this outcome (Chi<sup>2</sup> = 143.17, df = 50, P &lt; 0.00001; I<sup>2</sup> = 65%; see <a href="./references#CD001206-fig-0084" title="">Analysis 17.1</a>). </p> <p>The proportion of dropouts due to adverse events was two to three times higher across all medication classes compared to placebo (k = 45, RR 2.41; 95% CI 1.99 to 2.91, N = 8751), a statistically significant difference (P &lt; 0.001; Chi<sup>2</sup> = 49.24, df = 44, P = 0.27; I<sup>2</sup> = 11%). Nevertheless, the total proportion of dropouts due to adverse events in the medication arms (12%) is relatively low, suggesting that dropout rates may not have biased the outcomes. For this analysis we excluded data from two studies reporting data for paroxetine, as these studies also report data for the GW876008 and the NK1 receptor antagonist GR205171 (<a href="./references#CD001206-bbs2-0015" title="FurmarkT , AppelL , MichelgardA , WahlstedtK , AhsF , ZancanS , et al. Cerebral blood flow changes after treatment of social phobia with the neurokinin‐1 antagonist GR205171, citalopram or placebo. Biological Psychiatry2005;58(2):132‐42. ">Furmark 2005</a>; <a href="./references#CD001206-bbs2-0033" title="NCT00397722 . Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [Treatment of patients with social anxiety disorder]. clinicaltrials.gov/ct2/show/results/NCT00397722 (first received 8 November 2006). ">NCT00397722</a>). </p> <p>In addition, the proportion of dropouts due to any cause across both the medication and placebo groups was similar (25%) and was comparable across subgroups (Chi<sup>2</sup> = 13.31, df = 13, P = 0.42; I<sup>2</sup> = 2.3%). For this analysis we excluded data from one study with an additional arm of paroxetine to give preference to the experimental intervention, GR205171 (<a href="./references#CD001206-bbs2-0033" title="NCT00397722 . Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD) [Treatment of patients with social anxiety disorder]. clinicaltrials.gov/ct2/show/results/NCT00397722 (first received 8 November 2006). ">NCT00397722</a>; see <a href="./references#CD001206-fig-0086" title="">Analysis 17.3</a>). </p> </section> <section id="CD001206-sec-0136"> <h4 class="title">18. Subgroup analyses</h4> <p>There was evidence of differences between RCTs conducted at multiple centres versus single centres (Chi<sup>2</sup> = 7.05, df = 1, P = 0.008; I<sup>2</sup> = 85.8%; see <a href="./references#CD001206-fig-0087" title="">Analysis 18.1</a>), with larger treatment effects reported for studies conducted at single centres (k = 20, RR 2.24, 95% CI 1.67 to 3.02, N = 1332). </p> <p>There was no evidence of a difference in treatment response based on source of funding (Chi<sup>2</sup> = 1.52, df = 1, P = 0.22; I<sup>2</sup> = 34.1%; see <a href="./references#CD001206-fig-0089" title="">Analysis 20.1</a>) or the inclusion of participants diagnosed with major depressive disorder (Chi<sup>2</sup> = 1.70, df = 1, P = 0.19; I<sup>2</sup> = 41.1%; <a href="./references#CD001206-fig-0090" title="">Analysis 21.1</a>). </p> <p>Studies that involved only participants diagnosed with generalised SAnD reported smaller treatment effects (k = 26, RR 1.49, 95% CI 1.31 to 1.69, N = 5522) than trials that did not necessarily restrict inclusion to the generalised subtype (k = 27, RR 1.83, 95% CI 1.54 to 2.18, N = 3712; see <a href="./references#CD001206-fig-0088" title="">Analysis 19.1</a>). This difference was statistically significant (P &lt; 0.001). </p> </section> <section id="CD001206-sec-0137"> <h4 class="title">19. Sensitivity analyses</h4> <p>Twenty‐four parallel RCTs failed to include all of the participants randomised to the treatment groups in the responder analysis. The comparison of separate efficacy analyses in which the omitted participants were regarded as responders in either the medication or placebo groups supported the robustness of the evidence of this agent's efficacy in treating social anxiety disorder (respective results: RR 1.59, 95% CI 1.41 to 1.80, P &lt; 0. 001, N = 5437, <a href="./references#CD001206-fig-0091" title="">Analysis 22.1</a>; and RR 1.63, 95% CI 1.44 to 1.85, P &lt; 0. 001, N = 5215; <a href="./references#CD001206-fig-0092" title="">Analysis 22.2</a>). We therefore consider that missing data in these trial reports did not have a significant influence on this outcome. </p> </section> <section id="CD001206-sec-0138"> <h4 class="title">20. Publication bias</h4> <p>There is evidence of possible funnel plot asymmetry providing data on response to short‐term medication treatment, both for the SSRIs and all medications combined. Inspection of the contour enhanced funnel plots for the SSRIs (<a href="#CD001206-fig-0004">Figure 4</a>) and all of the trials (<a href="#CD001206-fig-0005">Figure 5</a>) suggests that this asymmetry is due to publication bias, as trials with less precise treatment response outcomes are more likely than their higher precision counterparts to be missing from regions of the plot representing statistically non‐significant treatment effects. Egger regression tests quantitatively confirmed this visual impression, providing evidence of possible publication bias for all of the medication trials (t = 2.8226, df = 49, P = 0.0069) and for the SSRIs (t = 2.6426, df = 22, P = 0.015). Nevertheless, trim and fill imputation of missing effect estimates from small studies with negative results continue to provide support for the efficacy of both the SSRIs (RR 1.52, 95% CI 1.35 to 1.71) and all medications (RR = 1.48, 95% CI 1.32 to 1.66) in treating SAnD. There were insufficient data to assess publication bias for the other medication classes. </p> <div class="figure" id="CD001206-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Contour enhanced funnel plot for treatment response on the CGI‐I for all medication trials  Filled circles = trial effect estimates; empty circles = trim and fill generated missing study estimates  Contours in light‐gray, gray and dark gray correspond to increasing stringent statistical boundaries (alpha = 0.1, 0.05, and 0.01, respectively). White corresponds to regions of statistical non‐significance." data-id="CD001206-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Contour enhanced funnel plot for treatment response on the CGI‐I for all medication trials<br/> Filled circles = trial effect estimates; empty circles = trim and fill generated missing study estimates<br/> Contours in light‐gray, gray and dark gray correspond to increasing stringent statistical boundaries (alpha = 0.1, 0.05, and 0.01, respectively). White corresponds to regions of statistical non‐significance. </p> </div> </div> </div> <div class="figure" id="CD001206-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Contour enhanced funnel plot for treatment response on the CGI‐I for SSRI trials  Filled circles = trial effect estimates; empty circles = trim and fill generated missing study estimates  Contours in light‐gray, gray and dark gray correspond to increasing stringent statistical boundaries (alpha = 0.1, 0.05, and 0.01, respectively). White corresponds to regions of statistical non‐significance." data-id="CD001206-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Contour enhanced funnel plot for treatment response on the CGI‐I for SSRI trials<br/> Filled circles = trial effect estimates; empty circles = trim and fill generated missing study estimates<br/> Contours in light‐gray, gray and dark gray correspond to increasing stringent statistical boundaries (alpha = 0.1, 0.05, and 0.01, respectively). White corresponds to regions of statistical non‐significance. </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001206-sec-0139" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001206-sec-0139"></div> <section id="CD001206-sec-0140"> <h3 class="title" id="CD001206-sec-0140">Summary of main results</h3> <p>We found evidence of an overall benefit of medication for treating SAnD in this review. Most evidence was for the SSRIs (i.e. paroxetine, fluvoxamine, sertraline, fluoxetine, and citalopram) and was very low in quality. Similarly, we found low‐quality evidence of efficacy for the MAOI phenelzine, the RIMAs brofaromine and moclobemide, and the benzodiazepines clonazepam and bromazepam, with moderate‐quality evidence of efficacy observed for the anticonvulsant/GABAs gabapentin and pregabalin. Conversely, there was no evidence in this review of a global clinical response to treatment for certain medication classes, including the 5HT1A partial agonists, the anticonvulsant levetiracetam, the antipsychotic olanzapine, the beta‐blockers, the NARIs, the NaSSAs, or the SNRI venlafaxine, as well as for the experimental agents GW876008 and NK1 receptor antagonist GR205171. </p> <p>This review also found evidence for an effect of the SSRIs in preventing relapse. Individuals diagnosed with SAnD who were treated with either SSRIs or the SNRI venlafaxine were more likely to withdraw from treatment due to treatment‐related adverse events. Nevertheless, the absolute proportion of individuals dropping out from treatment with these medications due to adverse events over the short term (14 weeks or less) was low (12% for SSRIs and 16% for venlafaxine). There was little evidence that any of the SSRI agents were less tolerable than any other (I<sup>2</sup> = 23%), as confirmed by a post hoc comparisons of dropout rates due to adverse events by agent (Chi<sup>2</sup> = 31.82, df = 24, P = 0.13; I<sup>2</sup> = 25%). The MAOIs and benzodiazepines appeared to be relatively well tolerated and also showed the largest treatment response (see <a href="./full#CD001206-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD001206-tbl-0007">summary of findings Table 7</a>). </p> <p>We found sufficient evidence of efficacy for reducing depression symptoms only observed for the SSRIs and RIMAs. Nevertheless, the possibility that response to treatment with these agents is entirely accounted for by their anti‐depressant effect is countered by evidence (albeit of very low quality) in this review that the SSRIs and RIMAs are effective in reducing SAnD symptoms (in addition to the MAOIs, the benzodiazepines, the SNRI venlafaxine, the antipsychotic olanzapine, and the NaSSA mirtazapine). Moreover, although trials of the MAOIs, SARIs, and benzodiazepines demonstrated evidence of efficacy of these agents in improving functioning in some domains, the SSRIs were the only medications showing a treatment effect on all three subscales (i.e. work, social, and family) of the SDS. It was on the basis of evidence such as this that the US FDA approved the SSRIs paroxetine, sertraline, and fluvoxamine for treating SAnD – the only agents that currently enjoy this status (<a href="./references#CD001206-bbs2-0167" title="BlancoC , BragdonLB , SchneierFR , LiebowitzMR . The evidence‐based pharmacotherapy of social anxiety disorder. International Journal of Neuropsychopharmacology2013;16(1):235‐49. ">Blanco 2013</a>). </p> <p>We found a response to long‐term treatment (20 to 24 weeks) with medication for the SSRIs (based on low‐quality evidence), the MAOIs (based on very low‐quality evidence), and for the RIMAs (based on moderate‐quality evidence). A similar proportion of participants withdrew due to treatment‐emergent side effects from the paroxetine, fluvoxamine, and placebo groups after long‐term treatment. Readers should exercise great caution in any inferences about the experimental agents (GW876008, the NK1 antagonist GR20517 and LY686017), more trials with each of these agents in the future may allow better comparison of classes of medication. </p> <p>For the subgroup outcomes, there was evidence that treatment response was influenced by whether RCTs took place at single or multiple centres. The size of the effect observed was also dependent on participant characteristics, with a smaller response to treatment observed in studies that restricted inclusion to participants diagnosed with generalised SAnD. Nevertheless, there was no evidence that treatment response across all medication classes varied as a function of whether trials were funded by industry or included participants diagnosed with major depressive disorder. There is also reason to believe that the effect sizes reported across all medication classes, as well as for the SSRIs, may be inflated, based on properties of the data that are consistent with publication bias. Nevertheless, the effects of medication in general and the SSRIs in particular on treatment response persist even after adjustments to account for the effect of the increased likelihood of publishing small trials if they report a positive effect of medication. </p> </section> <section id="CD001206-sec-0141"> <h3 class="title" id="CD001206-sec-0141">Overall completeness and applicability of evidence</h3> <section id="CD001206-sec-0142"> <h4 class="title">Completeness of evidence</h4> <p>Reviews of the body of evidence for pharmacotherapy of SAnD have designated SSRIs as first‐line medication agents for treating SAnD (<a href="./references#CD001206-bbs2-0159" title="BaldwinDS , AndersonIM , NuttDJ , AllgulanderC , BandelowB , DenBoerJA , et al. Evidence‐based pharmacological treatment of anxiety disorders, post‐traumatic stress disorder and obsessive‐compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology﻿2014;28(5):403‐39. [DOI: 10.1177/0269881114525674] ">Baldwin 2014</a>; <a href="./references#CD001206-bbs2-0160" title="BallengerJC , DavidsonJR , LecrubierY , NuttDJ , BobesJ , BeidelDC , et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry1998;59(Suppl 17):54–60. ">Ballenger 1998</a>; <a href="./references#CD001206-bbs2-0161" title="BandelowB , ZoharJ , HollanderE , KasperS , MollerHJ . WFSBP Task Force on Treatment Guidelines for Anxiety O‐CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive‐compulsive and posttraumatic stress disorders. World Journal of Biological Psychiatry2002;3(4):171‐99. ">Bandelow 2002</a>; <a href="./references#CD001206-bbs2-0215" title="National Institute for Health and Care Excellence. Common mental health problems: identification and pathways to care. NICE Clinical Guideline; 2011. Available from www.nice.org.uk. ">NICE 2011</a>). The current review supports the efficacy of SSRIs for short‐term treatment of SAnD. Similarly, maintenance studies demonstrate some further consolidation of clinical response to SSRIs over time. </p> <p>Importantly, although there was evidence for treatment withdrawal owing to drug‐related adverse events in the SNRI and SSRI trials, dropout rates were comparable between these medication classes. This contradicts findings in a meta‐analysis of the depression literature, which found venlafaxine to be more efficacious than SSRIs in increasing remission rates, but with a higher rate of withdrawal owing to treatment‐related adverse events (<a href="./references#CD001206-bbs2-0214" title="NemeroffCB , EntsuahR , BenattiaI . Comprehensive Analysis of Remission (COMPARE) with venlafaxine versus SSRIs. Biological Psychiatry2008;63(4):424‐34. ">Nemeroff 2008</a>). Given the frequent prescription of beta‐blockers for performance anxiety, the relative lack of empirical support for this intervention is surprising. We also found evidence of heterogeneity for the MAOIs, the RIMAs, and the SSRIs when investigating the efficacy of treatment in participants with SAnD. These differences may be partly accounted for by methodological and clinical variance but may also reflect real differences in efficacy across different medications. None of the four trials of the MAOI phenelzine provide information on the number of participants who withdrew from treatment as a result of drug‐related adverse events, against which to weigh the observed evidence for a response to treatment with this agent. There has been no investigation into the efficacy of other medication classes that may be considered for treating SAnD, such as the tricyclic antidepressants (TCAs). </p> <p>Although the SSRI trials under review used medication doses that are consistent with those advised in recent expert consensus recommendations (<a href="./references#CD001206-bbs2-0160" title="BallengerJC , DavidsonJR , LecrubierY , NuttDJ , BobesJ , BeidelDC , et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry1998;59(Suppl 17):54–60. ">Ballenger 1998</a>), there are few rigorous dose‐finding studies using fixed‐dose comparisons. The paroxetine database suggests that the dose‐response curve of SSRIs is relatively flat in SAnD, but that some participants may require higher doses (<a href="./references#CD001206-bbs2-0160" title="BallengerJC , DavidsonJR , LecrubierY , NuttDJ , BobesJ , BeidelDC , et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry1998;59(Suppl 17):54–60. ">Ballenger 1998</a>). Most SSRI studies lasted at least 12 weeks. The finding from the paroxetine database that a significant proportion of non‐responders at week 8 become responders by week 12 suggests that patients in clinical practice should be treated for a minimum period of 12 weeks before modifying treatment regimens due to medication non‐response (<a href="./references#CD001206-bbs2-0225" title="SteinDJ , SteinMB , PittsCD , KumarR , HunterB . Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo‐controlled paroxetine trials. Journal of Clinical Psychiatry2002;63(2):152‐5. ">Stein 2002c</a>). Similarly, the maintenance studies demonstrate some further consolidation of clinical response over time in SAnD. </p> <p>The negative 14‐week trial of fluoxetine raises the question of whether all SSRIs are equally effective (<a href="./references#CD001206-bbs2-0206" title="KobakKA , GreistJH , JeffersonJW , KatzelnickDJ . Fluoxetine in social phobia: a double‐blind, placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2002;22(3):257‐62. ">Kobak 2002</a>). The fluoxetine study included in this review had a relatively high placebo response rate and was not consistent with several early open‐label reports of the value of this medication in SAnD. Further work is needed to understand the differences in placebo response across the database of SAnD studies (<a href="./references#CD001206-bbs2-0117" title="OosterbaanD , VanBalkomA , Spinhoven , VanDykR . Cognitive behavior therapy versus moclobemide in social phobia. The World Psychiatric Association's (WPA) Thematic Congress; Nov. Jerusalem, 1997. ">Oosterbaan 1997</a>). In a study by <a href="./references#CD001206-bbs2-0018" title="KatschnigK , SteinMB , BullerR . Moclobemide in social phobia. A double‐blind, placebo‐controlled clinical study. European Archives of Psychiatry and Clinical Neuroscience1997;247(2):71‐80. ">Katschnig 1997</a>, for example, placebo response was higher in participants without avoidant personality disorder, in participants with a short duration of illness, and in participants with less severe illness. <a href="./references#CD001206-bbs2-0206" title="KobakKA , GreistJH , JeffersonJW , KatzelnickDJ . Fluoxetine in social phobia: a double‐blind, placebo‐controlled pilot study. Journal of Clinical Psychopharmacology2002;22(3):257‐62. ">Kobak 2002</a> found that placebo‐responders had an earlier response than medication responders and that lower severity of illness was associated with increased placebo response. These findings were similar to a recent report on two meta‐analyses where bias (i.e. reporting bias) appeared to have led to significant increases in the number of positive findings in the literature (<a href="./references#CD001206-bbs2-0219" title="RoestAM , deJongeP , WilliamsCD , deVriesYA , SchoeversRA , TurnerEH . Reporting bias in clinical trials investigating the efficacy of second‐generation antidepressants in the treatment of anxiety disorders: a report of 2 meta‐analyses. JAMA Psychiatry2015;72(5):500‐10. [DOI: doi:10.1001/jamapsychiatry.2015.15] ">Roest 2015</a>). </p> </section> <section id="CD001206-sec-0143"> <h4 class="title">Applicability of evidence</h4> <p>The outcomes of this review may be generalisable to a diverse range of settings. Studies were conducted in the USA, Europe, Japan, South Africa, and Iran, in both outpatient and inpatient settings (mainly outpatient settings). The interventions targeted both men and women across a wide age range. Differences in treatment delivery, as well as the background and training of study investigators and outcome assessors, increases the likelihood that the findings of this review are applicable to a range of countries in different income brackets. However, careful consideration should be given to the specific contexts in which the trials took place, given the lack of evidence on the availability and cost‐effectiveness of individual medications. The findings of this review will not apply equally to the full range of individuals presenting at clinics for the treatment of SAnD. RCTs included in this review were also restricted to those assessing the effectiveness of pharmacotherapy for SAnD in adults. The finding in this review that clinicians should consider medication, and in particular the SSRIs, for treating SAnD, may not apply to children. Readers are referred in this regard to another Cochrane Review on the efficacy of pharmacotherapy for anxiety disorders in children and adolescents (<a href="./references#CD001206-bbs2-0200" title="IpserJC , SteinDJ , HawkridgeS , HoppeL . Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database of Systematic Reviews2009, Issue 3. [DOI: 10.1002/14651858.CD005170.pub2] ">Ipser 2009a</a>). Most published trials of pharmacotherapy for SAnD exclude individuals with concurrent psychopathology, including substance use disorders, which are highly comorbid with SAnD. Although the limited RCT database suggests that medication may be equally effective in people with SAnD who are dependent on alcohol (<a href="./references#CD001206-bbs2-0008" title="BookSW , ThomasSE , RandallPK , RandallCL . Paroxetine reduces social anxiety in individuals with a co‐occurring alcohol use disorder. Journal of Anxiety Disorders2008;22(2):310‐8. ThomasSE , RandallPK , BookSW , RandallCL . A complex relationship between co‐occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research2008;32(1):77‐84. ">Book 2008</a>), and certain forms of comorbidity may actually be prognostic of greater treatment response (<a href="./references#CD001206-bbs2-0049" title="SteinDJ , CameronA , AmreinR , MontgomerySA . Moclobemide is effective and well tolerated in the long‐term pharmacotherapy of social anxiety disorder with or without comorbid anxiety disorder. International Clinical Psychopharmacology2002;17(4):161‐70. ">Stein 2002a</a>), firm evidence supporting conclusions regarding whether medication is indicated for these populations is currently lacking. </p> </section> </section> <section id="CD001206-sec-0144"> <h3 class="title" id="CD001206-sec-0144">Quality of the evidence</h3> <p>Twelve of the included RCTs possessed a high risk of bias related to at least one aspect of study design, with the most commonly observed weaknesses having to do with attrition bias (<a href="./references#CD001206-bbs2-0001" title="AllgulanderC . Efficacy of paroxetine in social phobia ‐ a single‐center double‐blind study of 96 symptomatic volunteers randomized to treatment with paroxetine 20‐50 mg or placebo for 3 months. 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31‐Nov 4. Paris, France, 1998:P.3.005. AllgulanderC . Paroxetine in social anxiety disorder: a randomised placebo‐controlled study. Acta Psychiatrica Scandinavica1999;100(3):193‐8. ">Allgulander 1999</a>; <a href="./references#CD001206-bbs2-0008" title="BookSW , ThomasSE , RandallPK , RandallCL . Paroxetine reduces social anxiety in individuals with a co‐occurring alcohol use disorder. Journal of Anxiety Disorders2008;22(2):310‐8. ThomasSE , RandallPK , BookSW , RandallCL . A complex relationship between co‐occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research2008;32(1):77‐84. ">Book 2008</a>; <a href="./references#CD001206-bbs2-0019" title="KatzelnickDJ , KobakKA , GreistJH , JeffersonJW , MantleJM , SerlinRC . Sertraline for social phobia: a double‐blind, placebo‐controlled crossover study. American Journal of Psychiatry1995;152(9):1368‐71. ">Katzelnick 1995</a>; <a href="./references#CD001206-bbs2-0023" title="LiebowitzMR , GormanJM , FyerAJ , CampeasR , LevinAP , SandbergD , et al. Pharmacotherapy of social phobia: an interim report of a placebo‐controlled comparison of phenelzine and atenolol. Journal of Clinical Psychiatry1988;49(7):252‐7. LiebowitzMR , SchneierF , CampeasR , GormanJ , FyerA , HollanderE , et al. Phenelzine and atenolol in social phobia. Psychopharmacology Bulletin1990;26(1):123‐5. LiebowitzMR , SchneierF , CampeasR , HollanderE , HattererJ , FyerA , et al. Phenelzine vs atenolol in social phobia: a placebo‐controlled comparison. Archives of General Psychiatry1992;49(4):290‐300. ">Liebowitz 1992</a>; <a href="./references#CD001206-bbs2-0029" title="MoghadamMNM , Atef‐VahidMK , Asgharnejad‐FaridAA , ShabaniA , LavasniF . Effectiveness of short‐term dynamic psychotherapy versus sertraline in treatment of social phobia. Iranian Journal of Psychiatry and Behavioral Sciences2015;9(2):e228. ">Moghadam 2015</a>; <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a>; <a href="./references#CD001206-bbs2-0052" title="SteinMB , PollackMH , BystritskyA , KelseyJE , ManganoRM . Efficacy of low and higher dose extended‐release venlafaxine in generalized social anxiety disorder: a 6‐month randomized controlled trial. Psychopharmacology2005;177(3):280‐8. SteinMB , PollackMH , ManganoR . Long‐term treatment of generalized SAD with venlafaxine extended release. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR251. ">Stein 2005</a>; <a href="./references#CD001206-bbs2-0058" title="VanAmeringenM , ManciniC , OakmanJ , WalkerJ , KjernistedK , ChokkaP , et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(2):288‐95. VanAmeringenMA , ManciniCL , PipeB , OakmanJ , WalkerJR , KjernistedKD , et al. Not all serotonergic agents are created equal in social phobia: nefazodone, a placebo‐controlled trial. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR789. ">Van Ameringen 2007</a>; <a href="./references#CD001206-bbs2-0064" title="WalkerJR , VanAmeringenMA , SwinsonR , BowenRC , ChokkaPR , GoldnerE , et al. Prevention of relapse in generalized social phobia: results of a 24‐week study in responders to 20 weeks of sertraline treatment. Journal of Clinical Psychopharmacology2000;20(6):636‐44. WalkerJR , VanAmeringenMA , SwinsonRP , LaneRM . A 24‐week prevention of relapse of generalized social phobia study in responders to 20 weeks of sertraline treatment. 153rd Annual Meeting of the American Psychiatric Association; May 13‐18. Chicago (IL), 2000:NR259. ">Walker 2000</a>; <a href="./references#CD001206-bbs2-0066" title="ZhangW , ConnorKM , DavidsonJRT . Levetiracetam in social phobia: a placebo controlled pilot study. Journal of Psychopharmacology2005;19(5):551‐3. ">Zhang 2005</a>). Lack of blinding for outcome assessors may also have influenced the detection of treatment effects (<a href="./references#CD001206-bbs2-0007" title="BlomhoffS , HaugTT , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. British Journal of Psychiatry2001;179(1):23‐30. BlomhoffS , HaugTT , HumbleM , HallstromK , MadsbuHP , WoldJE , et al. Treatment of generalized social phobia. New Research Abstracts. 152nd Annual Meeting of the American Psychiatric Association; May 15‐20. Washington DC, 1999:NR650. HaugTT , BlomhoffS , HellstromK , HolmeI , HumbleM , MadsbuHP , et al. Exposure therapy and sertraline in social phobia: 1‐year follow‐up of a randomised controlled trial. British Journal of Psychiatry2003;182(4):312‐8. WalkerJR . The benefits of exposure therapy alone may last longer than sertraline alone or sertraline plus exposure therapy in social phobia. Evidence‐based Mental Health2003;6(3):90. ">Blomhoff 2001</a>; <a href="./references#CD001206-bbs2-0029" title="MoghadamMNM , Atef‐VahidMK , Asgharnejad‐FaridAA , ShabaniA , LavasniF . Effectiveness of short‐term dynamic psychotherapy versus sertraline in treatment of social phobia. Iranian Journal of Psychiatry and Behavioral Sciences2015;9(2):e228. ">Moghadam 2015</a>; <a href="./references#CD001206-bbs2-0052" title="SteinMB , PollackMH , BystritskyA , KelseyJE , ManganoRM . Efficacy of low and higher dose extended‐release venlafaxine in generalized social anxiety disorder: a 6‐month randomized controlled trial. Psychopharmacology2005;177(3):280‐8. SteinMB , PollackMH , ManganoR . Long‐term treatment of generalized SAD with venlafaxine extended release. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR251. ">Stein 2005</a>; <a href="./references#CD001206-bbs2-0058" title="VanAmeringenM , ManciniC , OakmanJ , WalkerJ , KjernistedK , ChokkaP , et al. Nefazodone in the treatment of generalized social phobia: a randomized, placebo‐controlled trial. Journal of Clinical Psychiatry2007;68(2):288‐95. VanAmeringenMA , ManciniCL , PipeB , OakmanJ , WalkerJR , KjernistedKD , et al. Not all serotonergic agents are created equal in social phobia: nefazodone, a placebo‐controlled trial. 156th Annual Meeting of the American Psychiatric Association; May 17‐22. San Francisco (CA), 2003:NR789. ">Van Ameringen 2007</a>). There was also evidence for selective reporting bias in <a href="./references#CD001206-bbs2-0008" title="BookSW , ThomasSE , RandallPK , RandallCL . Paroxetine reduces social anxiety in individuals with a co‐occurring alcohol use disorder. Journal of Anxiety Disorders2008;22(2):310‐8. ThomasSE , RandallPK , BookSW , RandallCL . A complex relationship between co‐occurring social anxiety and alcohol use disorders: what effect does treating social anxiety have on drinking?. Alcoholism, Clinical and Experimental Research2008;32(1):77‐84. ">Book 2008</a>, <a href="./references#CD001206-bbs2-0036" title="NordahlHM , VogelPA , MorkenG , StilesTC , SandvikP , et al. Paroxetine, cognitive therapy or their combination in the treatment of social anxiety disorder with and without avoidant personality disorder: a randomized clinical trial. Psychotherapy and Psychosomatics2016;85(6):346–56. ">Nordahl 2016</a> and <a href="./references#CD001206-bbs2-0054" title="TauscherJ , KielbasaW , IyengarS , VandenhendeF , PengX , MozleyD , et al. Development of the 2nd generation neurokinin‐1 receptor antagonist LY686017 for social anxiety disorder. European Neuropsychopharmacology2010;20(2):80‐7. ">Tauscher 2010</a>. Even though the SSRIs were the best‐represented medication class, with 24 of the 51 RCTs contributing to the outcome of clinical response, most of these trials scored unclear for random sequence generation as well as for allocation concealment. </p> <p>Judgements of response to treatment with the SSRIs were based on evidence rated as being of very low quality. Therefore, we are very uncertain about the estimate (see <a href="./full#CD001206-tbl-0013">summary of findings Table 13</a>). The RIMAs, MAOIs, and benzodiazepines were based on evidence rated as being of low quality (see <a href="./full#CD001206-tbl-0005">summary of findings Table 5</a>; <a href="./full#CD001206-tbl-0007">summary of findings Table 7</a>), indicating that additional data from further studies may change the size of the treatment effect estimate for these medication classes, as well as our confidence in that estimate of effect. The anticonvulsants/GABAs, on the other hand, were based on evidence rated as being of moderate quality (see <a href="./full#CD001206-tbl-0002">summary of findings Table 2</a>; <a href="./full#CD001206-tbl-0012">summary of findings Table 12</a>). Further research is very unlikely to change our confidence in the estimate of treatment effect for these medication classes. The most common reasons for downgrading studies were imprecise effect estimates, low response rates, small sample size, a rating of high or unclear bias for study design (based on 50% attrition rates across groups, detection, and selective reporting bias), and inconsistency between studies (indicated by heterogeneity between the medication and placebo group). </p> <p>Variability in the number of sites contributing data reported in included studies could also have biased the results of the review. A recent meta‐analysis demonstrated that the size of treatment effect estimates are larger in single‐centre than multicentre trials, even after adjusting for sample size and various bias risk factors (<a href="./references#CD001206-bbs2-0177" title="DechartresA , BoutronI , TrinquartL , CharlesP , RavaudP . Single‐center trials show larger treatment effects than multicenter trials: evidence from a meta‐epidemiologic study. Annals of Internal Medicine2011;155(1):39–51. ">Dechartres 2011</a>). It is notable that approximately a third of the trials providing data on treatment response for this review were in single centres. Moreover, those trials were over‐represented amongst RCTs of SSRIs and in studies reporting the largest treatment effects, including more than half of the MAOI trials and both benzodiazepine RCTs. Additionally, there was a smaller treatment response in RCTs that explicitly described limiting study inclusion to people diagnosed with generalised SAnD. This finding is in agreement with the perception that the generalised SAnD subtype is more difficult to treat. It may once again have resulted in a positive bias for the MAOI, RIMA, and benzodiazepine studies in particular, given that with the exception of a single trial of phenelzine (<a href="./references#CD001206-bbs2-0016" title="HeimbergRG , LiebowitzMR , HopeDA , SchneierFR , HoltCS , WelkowitzLA , et al. Cognitive behavioural group therapy vs phenelzine therapy for social phobia: 12 week outcome. Archives of General Psychiatry1998;55(12):1133‐41. ">Heimberg 1998</a>), all of the included RCTs for these medication classes failed to specify that they restricted inclusion to the generalised subtype. </p> <p>The size of the response to acute treatment with any medication and specifically with the SSRIs may be exaggerated, as possible funnel plot asymmetry for this outcome suggests (<a href="#CD001206-fig-0004">Figure 4</a>; <a href="#CD001206-fig-0005">Figure 5</a>). Egger regression tests quantitatively confirmed the presence of small sample bias. Although small sample bias may arise from other factors besides publication bias, the absence of smaller studies with statistically non‐significant effects of treatment, as illustrated by contour‐enhanced funnel plots (<a href="#CD001206-fig-0004">Figure 4</a>; <a href="#CD001206-fig-0005">Figure 5</a>), does suggest that investigators are not publishing smaller studies that fail to detect treatment effects. </p> </section> <section id="CD001206-sec-0145"> <h3 class="title" id="CD001206-sec-0145">Potential biases in the review process</h3> <p>We conducted an extensive search for studies meeting rigorous inclusion criteria and repeatedly attempted to obtain missing data from the trial investigators. Nevertheless, there were insufficient data available to assess the extent to which selective publication may have introduced bias in the findings for medication classes besides the SSRIs. Furthermore, the post hoc addition of comparisons of the efficacy of 5HT partial agonists, anticonvulsants with or without GABAs, antipsychotics, NARIs, NaSSAs, and SARIs may have also introduced bias as a result of the small number of eligible RCTs for these medication classes (1 to 3 studies). </p> <p>The reliance on the LSAS, while considered the gold standard for measurement of SAnD symptom severity in clinical trials, represents another potential source of bias. Treatment outcomes not assessed by standardised scales such as the LSAS also deserve more attention. For example, physiological symptoms are often a source of concern for people (symptoms such as excessive sweating may for example lead to a request for surgery), and the LSAS does not specifically record these (<a href="./references#CD001206-bbs2-0172" title="DavidsonJR . Pharmacotherapy of social anxiety disorder. Journal of Clinical Psychiatry1998;59(Suppl 17):47‐51. ">Davidson 1998</a>). </p> <p>Meta‐analysis also has inherent problems (<a href="./references#CD001206-bbs2-0157" title="BailarJC3rd . The promise and problems of meta‐analysis. New England Journal of Medicine1999;337(8):559‐61. ">Bailar 1999</a>); although indirect comparison of competing interventions usually agree with direct ones (<a href="./references#CD001206-bbs2-0222" title="SongF , AltmanDG , GlennyA‐M , DeeksJJ . Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta‐analyses. BMJ2003;326(7387):472. ">Song 2003</a>), meta‐analysis is by no means a substitute for direct clinical research. Furthermore, the context of general clinical practice differs from RCTs in specialised centres in many respects, not the least being the need to treat more complex participants. In particular, conclusions about the relative efficacy of different agents from trials with different participants require confirmation in head‐to‐head comparisons. An early head‐to‐head study of clomipramine versus diazepam suggested superiority of clomipramine, but there were relatively few participants with social phobia (<a href="./references#CD001206-bbs2-0069" title="AllsoppLF , CooperGL , PoolePH . Clomipramine and diazepam in the treatment of agoraphobia and social phobia in general practice. Current Medical Research and Opinion1984;9(1):64‐70. ">Allsopp 1984</a>). The only head‐to‐head comparison of an SSRI versus moclobemide did not include a placebo control but did suggest equal efficacy and tolerability, lending caution to the findings of the current review (<a href="./references#CD001206-bbs2-0071" title="AtmacaM , KulogluM , TezcanE , UnalA . Efficacy of citalopram and moclobemide in patients with social phobia: some preliminary findings. Human Psychopharmacology2002;2002(8):401‐5. ">Atmaca 2002</a>). </p> </section> <section id="CD001206-sec-0146"> <h3 class="title" id="CD001206-sec-0146">Agreements and disagreements with other studies or reviews</h3> <p>The finding in this review of moderate to substantial variability in the response of participants with SAnD to pharmacotherapy is likely to reflect real differences in efficacy across different medication and differences brought on by trial methodology and the clinical characteristics of patients. In comparing medication classes in terms of beneficial and adverse responses to medication, the data included in this review are consistent with findings from other systematic reviews and meta‐analyses in identifying the SSRIs as first line agents for the treatment of SAnD (<a href="./references#CD001206-bbs2-0160" title="BallengerJC , DavidsonJR , LecrubierY , NuttDJ , BobesJ , BeidelDC , et al. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry1998;59(Suppl 17):54–60. ">Ballenger 1998</a>; <a href="./references#CD001206-bbs2-0161" title="BandelowB , ZoharJ , HollanderE , KasperS , MollerHJ . WFSBP Task Force on Treatment Guidelines for Anxiety O‐CaPSD. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive‐compulsive and posttraumatic stress disorders. World Journal of Biological Psychiatry2002;3(4):171‐99. ">Bandelow 2002</a>; <a href="./references#CD001206-bbs2-0162" title="BandelowB , SherL , BuneviciusR , HollanderE , KasperS , ZoharJ , et al. WFSBP Task Force on Mental Disorders in Primary Care, WFSBP Task Force on Anxiety Disorders, OCD , PTSD . Guidelines for the pharmacological treatment of anxiety disorders, obsessive – compulsive disorder and posttraumatic stress disorder in primary care. International Journal of Psychiatry in Clinical Practice2012;16:77–84. [DOI: 10.3109/13651501.2012.667114] ">Bandelow 2012</a>; <a href="./references#CD001206-bbs2-0163" title="BandelowB , MichaelisS . Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical Neuroscience2015;17(3):327‐35. ">Bandelow 2015</a>; <a href="./references#CD001206-bbs2-0166" title="BlancoC , SchneierFR , SchmidtA , Blanco‐JerezC , MarshallRD , Sanchez‐LacayA , et al. Pharmalogical treatment of social anxiety disorder: a meta‐analysis. Depression and Anxiety2003;18(1):29‐40. ">Blanco 2003</a>; <a href="./references#CD001206-bbs2-0233" title="Van derLindenGJ , SteinDJ , vanBalkomAJ . The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta‐analysis of randomized controlled trials. International Clinical Psychopharmacology2000;15(Suppl 2):15‐24. ">Van der Linden 2000</a>). The finding of efficacy for the SSRIs reported in this review is based on a considerably larger database of randomised controlled trials than in previous reviews and reports. </p> <p>This review classified medications based on their putative mechanisms of action (taken from CCMD antidepressant classification map) (<a href="./references#CD001206-bbs2-0174" title="DaviesSJ , ChampionC , DawsonS , SharpJ , ChurchillR . The Subway Map ‐ a new way to visualize antidepressant classification (a Cochrane CCDAN initiative). 14th ICGP and 19th JSNP Joint Congress; 3 October. Tsukuba, Japan, 2014:78. [Abstract P14] ">Davies 2015</a>), and they do not necessarily map onto the drug classification schemes employed in other reviews. Nevertheless, we are able to confirm the efficacy of the SSRIs, SNRIs, the RIMAs, and the anticonvulsants/GABAs. </p> <p>MAOIs, in the form of phenelzine, as well as certain benzodiazepines, are also effective in SAnD, but in view of concerns about ease of administration (e.g. MAOIs require dietary and medication restrictions) and side effects (risk of abuse with benzodiazepines seems to be highest in individuals with a history of substance abuse (<a href="./references#CD001206-bbs2-0207" title="LicataSC , RowlettJK . Abuse and dependence liability of benzodiazepine‐type drugs: GABAA receptor modulation and beyond. Pharmacology Biochemistry &amp; Behavior2008;90(1):74–89. ">Licata 2008</a>)), it does not seem reasonable to view these drugs as second‐line agents. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001206-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001206-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD001206-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001206-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Contour enhanced funnel plot for treatment response on the CGI‐I for all medication trials  Filled circles = trial effect estimates; empty circles = trim and fill generated missing study estimates  Contours in light‐gray, gray and dark gray correspond to increasing stringent statistical boundaries (alpha = 0.1, 0.05, and 0.01, respectively). White corresponds to regions of statistical non‐significance." data-id="CD001206-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Contour enhanced funnel plot for treatment response on the CGI‐I for all medication trials<br/> Filled circles = trial effect estimates; empty circles = trim and fill generated missing study estimates<br/> Contours in light‐gray, gray and dark gray correspond to increasing stringent statistical boundaries (alpha = 0.1, 0.05, and 0.01, respectively). White corresponds to regions of statistical non‐significance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Contour enhanced funnel plot for treatment response on the CGI‐I for SSRI trials  Filled circles = trial effect estimates; empty circles = trim and fill generated missing study estimates  Contours in light‐gray, gray and dark gray correspond to increasing stringent statistical boundaries (alpha = 0.1, 0.05, and 0.01, respectively). White corresponds to regions of statistical non‐significance." data-id="CD001206-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Contour enhanced funnel plot for treatment response on the CGI‐I for SSRI trials<br/> Filled circles = trial effect estimates; empty circles = trim and fill generated missing study estimates<br/> Contours in light‐gray, gray and dark gray correspond to increasing stringent statistical boundaries (alpha = 0.1, 0.05, and 0.01, respectively). White corresponds to regions of statistical non‐significance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: 5HT1A partial agonists versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: 5HT1A partial agonists versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: 5HT1A partial agonists versus placebo, Outcome 2 Adverse events (acute phase)." data-id="CD001206-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: 5HT1A partial agonists versus placebo, Outcome 2 Adverse events (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: 5HT1A partial agonists versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: 5HT1A partial agonists versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: 5HT1A partial agonists versus placebo, Outcome 4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale)." data-id="CD001206-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: 5HT1A partial agonists versus placebo, Outcome 4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Comparison 1: 5HT1A partial agonists versus placebo, Outcome 5 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Comparison 1: 5HT1A partial agonists versus placebo, Outcome 5 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparison 2: anticonvulsants/GABAs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Comparison 2: anticonvulsants/GABAs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparison 2: anticonvulsants/GABAs versus placebo, Outcome 2 Adverse events (acute phase)." data-id="CD001206-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Comparison 2: anticonvulsants/GABAs versus placebo, Outcome 2 Adverse events (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparison 2: anticonvulsants/GABAs versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Comparison 2: anticonvulsants/GABAs versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparison 2: anticonvulsants/GABAs versus placebo, Outcome 4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale)." data-id="CD001206-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Comparison 2: anticonvulsants/GABAs versus placebo, Outcome 4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Comparison 2: anticonvulsants/GABAs versus placebo, Outcome 5 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Comparison 2: anticonvulsants/GABAs versus placebo, Outcome 5 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Comparison 3: anticonvulsant levetiracetam versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Comparison 3: anticonvulsant levetiracetam versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Comparison 3: anticonvulsant levetiracetam versus placebo, Outcome 2 Adverse events (acute phase)." data-id="CD001206-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Comparison 3: anticonvulsant levetiracetam versus placebo, Outcome 2 Adverse events (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Comparison 3: anticonvulsant levetiracetam versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Comparison 3: anticonvulsant levetiracetam versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Comparison 3: anticonvulsant levetiracetam versus placebo, Outcome 4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale)." data-id="CD001206-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Comparison 3: anticonvulsant levetiracetam versus placebo, Outcome 4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Comparison 3: anticonvulsant levetiracetam versus placebo, Outcome 5 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Comparison 3: anticonvulsant levetiracetam versus placebo, Outcome 5 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Comparison 4: antipsychotics versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Comparison 4: antipsychotics versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Comparison 4: antipsychotics versus placebo, Outcome 2 Adverse events (acute phase)." data-id="CD001206-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Comparison 4: antipsychotics versus placebo, Outcome 2 Adverse events (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Comparison 4: antipsychotics versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Comparison 4: antipsychotics versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Comparison 4: antipsychotics versus placebo, Outcome 4 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Comparison 4: antipsychotics versus placebo, Outcome 4 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 2 Relapse rate." data-id="CD001206-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 2 Relapse rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 3 Adverse events (acute phase)." data-id="CD001206-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 3 Adverse events (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 4 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 4 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-005-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 5 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale)." data-id="CD001206-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 5 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-005-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-005-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 6 Reduction of functional disability." data-id="CD001206-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.6</div> <div class="figure-caption"> <p>Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 6 Reduction of functional disability. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-005-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-005-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 7 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.7</div> <div class="figure-caption"> <p>Comparison 5 Comparison 5: benzodiazepines versus placebo, Outcome 7 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-005-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Comparison 6: beta‐blockers versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0032" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Comparison 6: beta‐blockers versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Comparison 6: beta‐blockers versus placebo, Outcome 2 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale)." data-id="CD001206-fig-0033" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Comparison 6: beta‐blockers versus placebo, Outcome 2 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Comparison 6: beta‐blockers versus placebo, Outcome 3 Reduction of functional disability." data-id="CD001206-fig-0034" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Comparison 6: beta‐blockers versus placebo, Outcome 3 Reduction of functional disability. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Comparison 6: beta‐blockers versus placebo, Outcome 4 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0035" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Comparison 6: beta‐blockers versus placebo, Outcome 4 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Comparison 7: MAOIs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0036" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Comparison 7: MAOIs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Comparison 7: MAOIs versus placebo, Outcome 2 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0037" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Comparison 7: MAOIs versus placebo, Outcome 2 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Comparison 7: MAOIs versus placebo, Outcome 3 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale)." data-id="CD001206-fig-0038" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Comparison 7: MAOIs versus placebo, Outcome 3 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-007-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-007-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Comparison 7: MAOIs versus placebo, Outcome 4 Reduction of functional disability." data-id="CD001206-fig-0039" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-007-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.4</div> <div class="figure-caption"> <p>Comparison 7 Comparison 7: MAOIs versus placebo, Outcome 4 Reduction of functional disability. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-007-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-007-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-007-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Comparison 7: MAOIs versus placebo, Outcome 5 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0040" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-007-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.5</div> <div class="figure-caption"> <p>Comparison 7 Comparison 7: MAOIs versus placebo, Outcome 5 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-007-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-007-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-007-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Comparison 7: MAOIs versus placebo, Outcome 6 Clinical Global Impressions scale change item (CGI‐I) (long term)." data-id="CD001206-fig-0041" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-007-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.6</div> <div class="figure-caption"> <p>Comparison 7 Comparison 7: MAOIs versus placebo, Outcome 6 Clinical Global Impressions scale change item (CGI‐I) (long term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-007-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Comparison 8: NARIs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0042" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Comparison 8: NARIs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Comparison 8: NARIs versus placebo, Outcome 2 Adverse events (acute phase)." data-id="CD001206-fig-0043" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Comparison 8: NARIs versus placebo, Outcome 2 Adverse events (acute phase).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Comparison 8: NARIs versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0044" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Comparison 8: NARIs versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-008-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-008-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Comparison 8: NARIs versus placebo, Outcome 4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale)." data-id="CD001206-fig-0045" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-008-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.4</div> <div class="figure-caption"> <p>Comparison 8 Comparison 8: NARIs versus placebo, Outcome 4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-008-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-008-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-008-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Comparison 8: NARIs versus placebo, Outcome 5 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0046" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-008-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.5</div> <div class="figure-caption"> <p>Comparison 8 Comparison 8: NARIs versus placebo, Outcome 5 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-008-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Comparison 9: NaSSAs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0047" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Comparison 9: NaSSAs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Comparison 9: NaSSAs versus placebo, Outcome 2 Adverse events (acute phase)." data-id="CD001206-fig-0048" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Comparison 9: NaSSAs versus placebo, Outcome 2 Adverse events (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Comparison 9: NaSSAs versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0049" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Comparison 9: NaSSAs versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Comparison 9: NaSSAs versus placebo, Outcome 4 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0050" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Comparison 9: NaSSAs versus placebo, Outcome 4 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0051" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 2 Adverse events (acute phase)." data-id="CD001206-fig-0052" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 2 Adverse events (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0053" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale)." data-id="CD001206-fig-0054" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 5 Reduction of functional disability." data-id="CD001206-fig-0055" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 5 Reduction of functional disability. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-010-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-010-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 6 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0056" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 6 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-010-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-010-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 7 Clinical Global Impressions ‐ Improvement (CGI‐I) (long term)." data-id="CD001206-fig-0057" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.7</div> <div class="figure-caption"> <p>Comparison 10 Comparison 10: RIMAs versus placebo, Outcome 7 Clinical Global Impressions ‐ Improvement (CGI‐I) (long term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-010-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Comparison 11: SARIs versus placebo, Outcome 1 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0058" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Comparison 11: SARIs versus placebo, Outcome 1 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Comparison 11: SARIs versus placebo, Outcome 2 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale)." data-id="CD001206-fig-0059" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Comparison 11: SARIs versus placebo, Outcome 2 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-011-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-011-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Comparison 11: SARIs versus placebo, Outcome 3 Reduction of functional disability." data-id="CD001206-fig-0060" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-011-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.3</div> <div class="figure-caption"> <p>Comparison 11 Comparison 11: SARIs versus placebo, Outcome 3 Reduction of functional disability. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-011-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-011-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-011-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Comparison 11: SARIs versus placebo, Outcome 4 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0061" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-011-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.4</div> <div class="figure-caption"> <p>Comparison 11 Comparison 11: SARIs versus placebo, Outcome 4 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-011-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Comparison 12: SNRIs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0062" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Comparison 12: SNRIs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Comparison 12: SNRIs versus placebo, Outcome 2 Adverse events (acute phase)." data-id="CD001206-fig-0063" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Comparison 12: SNRIs versus placebo, Outcome 2 Adverse events (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Comparison 12: SNRIs versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0064" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Comparison 12: SNRIs versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-012-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-012-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Comparison 12: SNRIs versus placebo, Outcome 4 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0065" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-012-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 Comparison 12: SNRIs versus placebo, Outcome 4 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-012-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0066" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 2 Relapse rate." data-id="CD001206-fig-0067" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 2 Relapse rate.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-013-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-013-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 3 Adverse events (acute phase)." data-id="CD001206-fig-0068" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.3</div> <div class="figure-caption"> <p>Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 3 Adverse events (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-013-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-013-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 4 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0069" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.4</div> <div class="figure-caption"> <p>Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 4 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-013-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-013-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 5 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale)." data-id="CD001206-fig-0070" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.5</div> <div class="figure-caption"> <p>Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 5 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-013-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-013-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 6 Reduction of functional disability." data-id="CD001206-fig-0071" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.6</div> <div class="figure-caption"> <p>Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 6 Reduction of functional disability. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-013-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-013-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 7 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0072" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.7</div> <div class="figure-caption"> <p>Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 7 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-013-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-013-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 8 Clinical Global Impressions scale change item (CGI‐I) (long term)." data-id="CD001206-fig-0073" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.8</div> <div class="figure-caption"> <p>Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 8 Clinical Global Impressions scale change item (CGI‐I) (long term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-013-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-013-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 9 Adverse events (long term)." data-id="CD001206-fig-0074" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.9</div> <div class="figure-caption"> <p>Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 9 Adverse events (long term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-013-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-013-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 10 All‐cause dropouts (long term)." data-id="CD001206-fig-0075" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.10</div> <div class="figure-caption"> <p>Comparison 13 Comparison 13: SSRIs versus placebo, Outcome 10 All‐cause dropouts (long term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-013-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Comparison 14: GW876008 versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0076" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Comparison 14: GW876008 versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Comparison 14: GW876008 versus placebo, Outcome 2 Adverse events (acute phase)." data-id="CD001206-fig-0077" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 Comparison 14: GW876008 versus placebo, Outcome 2 Adverse events (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-014-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-014-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Comparison 14: GW876008 versus placebo, Outcome 3 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0078" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-014-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 Comparison 14: GW876008 versus placebo, Outcome 3 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-014-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Comparison 15: NK1 receptor antagonist GR205171 versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase)." data-id="CD001206-fig-0079" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Comparison 15: NK1 receptor antagonist GR205171 versus placebo, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Comparison 15: NK1 receptor antagonist GR205171 versus placebo, Outcome 2 Adverse events (acute phase)." data-id="CD001206-fig-0080" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 Comparison 15: NK1 receptor antagonist GR205171 versus placebo, Outcome 2 Adverse events (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-015-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-015-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Comparison 15: NK1 receptor antagonist GR205171 versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0081" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-015-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.3</div> <div class="figure-caption"> <p>Comparison 15 Comparison 15: NK1 receptor antagonist GR205171 versus placebo, Outcome 3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-015-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-015-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-015-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Comparison 15: NK1 receptor antagonist GR205171 versus placebo, Outcome 4 All‐cause dropouts (acute phase)." data-id="CD001206-fig-0082" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-015-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.4</div> <div class="figure-caption"> <p>Comparison 15 Comparison 15: NK1 receptor antagonist GR205171 versus placebo, Outcome 4 All‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-015-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Comparison 16: LY686017 versus placebo, Outcome 1 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms." data-id="CD001206-fig-0083" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Comparison 16: LY686017 versus placebo, Outcome 1 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Comparison 17: total effect of medication compared to placebo for the treatment of SAnD, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar) scale: no. of responders (acute phase)." data-id="CD001206-fig-0084" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 Comparison 17: total effect of medication compared to placebo for the treatment of SAnD, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar) scale: no. of responders (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-017-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-017-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Comparison 17: total effect of medication compared to placebo for the treatment of SAnD, Outcome 2 Dropout rate: adverse events (acute phase)." data-id="CD001206-fig-0085" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-017-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 Comparison 17: total effect of medication compared to placebo for the treatment of SAnD, Outcome 2 Dropout rate: adverse events (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-017-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-017-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-017-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Comparison 17: total effect of medication compared to placebo for the treatment of SAnD, Outcome 3 Dropout rate: all‐cause dropouts (acute phase)." data-id="CD001206-fig-0086" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-017-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.3</div> <div class="figure-caption"> <p>Comparison 17 Comparison 17: total effect of medication compared to placebo for the treatment of SAnD, Outcome 3 Dropout rate: all‐cause dropouts (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-017-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Subgroup analysis: multicentre versus single‐centre trials, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale: no. of responders (acute phase)." data-id="CD001206-fig-0087" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Subgroup analysis: multicentre versus single‐centre trials, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale: no. of responders (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-019-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-019-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Subgroup analysis: generalised SAnD compared to inclusive SAnD, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale: no. of responders (acute phase)." data-id="CD001206-fig-0088" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-019-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 Subgroup analysis: generalised SAnD compared to inclusive SAnD, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale: no. of responders (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-019-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-020-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-020-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Subgroup analysis: industry funding compared to no industry funding, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale: no. of responders (acute phase)." data-id="CD001206-fig-0089" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-020-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 Subgroup analysis: industry funding compared to no industry funding, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale: no. of responders (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-020-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-021-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-021-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Subgroup analysis: trials that included MDD compared to no MDD, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale: no. of responders (acute phase)." data-id="CD001206-fig-0090" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-021-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21 Subgroup analysis: trials that included MDD compared to no MDD, Outcome 1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale: no. of responders (acute phase). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-021-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-022-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-022-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Worst case versus best case: support for robustness of evidence, Outcome 1 'Worst case' lost‐to‐follow‐up analysis." data-id="CD001206-fig-0091" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-022-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22 Worst case versus best case: support for robustness of evidence, Outcome 1 'Worst case' lost‐to‐follow‐up analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-022-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001206-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/urn:x-wiley:14651858:media:CD001206:CD001206-CMP-022-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_t/tCD001206-CMP-022-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Worst case versus best case: support for robustness of evidence, Outcome 2 'Best case' lost‐to‐follow‐up analysis." data-id="CD001206-fig-0092" src="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-022-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22 Worst case versus best case: support for robustness of evidence, Outcome 2 'Best case' lost‐to‐follow‐up analysis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/media/CDSR/CD001206/image_n/nCD001206-CMP-022-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Comparison 1: 5HT1A partial agonists versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 1: 5HT1A partial agonists versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : 5HT1A partial agonists<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With 5HT1A partial agonists</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.00</b> <br/> (0.07 to 14.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the 5HT1A partial agonist group compared to the placebo group who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 1.00). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b><br/> (5 to 970) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b><br/> (5 to 975) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.00</b> <br/> (0.13 to 68.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dropout rates due to adverse events were low in the 5HT1A partial agonist group (1/30, 3%). No participants withdrew from the placebo group. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 24.3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>1.4 points lower</b> (11.61 lower to 8.81 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the 5HT1A partial agonist intervention group was 22.9 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (small sample size, few events and wide confidence interval).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (small sample size and wide confidence interval).<br/> <sup>d</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Comparison 1: 5HT1A partial agonists versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Comparison 2: anticonvulsants/GABAs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 2: anticonvulsants/GABAs versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : anticonvulsants/GABAs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With anticonvulsants/GABAs </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.60</b> <br/> (1.16 to 2.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>532<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of benefit on the number of participants with SAnD who responded to treatment (P = 0.004). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the anticonvulsant/GABA groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>221 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>353 per 1000</b><br/> (256 to 486) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>217 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b><br/> (252 to 477) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.90</b> <br/> (0.92 to 9.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>532<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dropout rates due to adverse events were high in the anticonvulsant/GABA groups (64/369, 17%) relative to placebo (9/163, 6%). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>55 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>160 per 1000</b><br/> (51 to 505) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>87 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>252 per 1000</b><br/> (80 to 795) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 71.8</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>11.50 lower</b><br/> (25.20 lower to 2.20 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the anticonvulsant/GABA intervention group was 60.3 which suggests 'moderate' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 33.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>4.60 points lower</b> (11.88 lower to 2.68 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the anticonvulsant/GABA intervention group was 29.3 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 37.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>6.90 points lower</b> (13.65 lower to 0.15 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the anticonvulsant/GABA intervention group was 31.0 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to moderate heterogeneity (I<sup>2</sup> of 56%).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>d</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>e</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Comparison 2: anticonvulsants/GABAs versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Comparison 3: anticonvulsant levetiracetam versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 3: levetiracetam versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : other anticonvulsants<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Wtih levetiracetam</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.98</b> <br/> (0.70 to 1.37) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>228<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the anticonvulsant levetiracetam groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.90). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>373 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>365 per 1000</b><br/> (261 to 511) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>266 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>261 per 1000</b><br/> (186 to 364) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.00</b> <br/> (0.81 to 4.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>235<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The proportion of dropouts due to adverse events was high in participants receiving the anticonvulsant levetiracetam (15/122, 12%) relative to placebo (6/113, 5%). There was no evidence of a difference between the number of participants that dropped out due to adverse events (P = 0.14). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>53 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>106 per 1000</b><br/> (43 to 262) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>28 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>56 per 1000</b><br/> (23 to 138) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 62.4 to 75.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>0.24 points lower</b> (15.69 lower to 15.21 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the anticonvulsant levetiracetam intervention groups ranged from 55 to 65 which suggests 'moderate' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 36.71</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>9.15 points lower</b><br/> (26.86 lower to 8.56 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the anticonvulsant levetiracetam intervention group was 27.56 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 38.71</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was<br/> <b>8.71 points lower</b> (26.02 lower to 8.60 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the anticonvulsant levetiracetam intervention group was 30.0 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>d</sup>Downgraded two levels due to very serious imprecision (small sample size, few events and wide confidence interval).<br/> <sup>e</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Comparison 3: anticonvulsant levetiracetam versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Comparison 4: antipsychotics versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 4: antipsychotics versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : antipsychotics<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With antipsychotics </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 7.00</b> <br/> (0.45 to 108.26) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>10<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the antipsychotic group compared to the placebo group who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.16). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.71</b> <br/> (0.06 to 8.90) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>12<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no difference on the number of participants who withdrew due to adverse events (P = 0.79). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>142 per 1000</b><br/> (12 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>142 per 1000</b><br/> (12 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 86.0</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>37.80 points lower</b><br/> (74.22 lower to 1.38 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the antipsychotic intervention group was 48.2 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (small sample size, few events, and wide confidence interval).<br/> <sup>d</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Comparison 4: antipsychotics versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Comparison 5: benzodiazepines versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 5: benzodiazepines versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : inpatient and outpatient settings<br/> <b>Intervention</b> : benzodiazepines<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With benzodiazepines</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 4.03</b> <br/> (2.45 to 6.65) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>132<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of a large effect on the number of participants with SAnD who responded to treatment (P &lt; 0.00001). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the benzodiazepine groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>806 per 1000</b><br/> (490 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>200 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>806 per 1000</b><br/> (490 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Relapse rate ‐ no. relapsed</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.12</b> <br/> (0.01 to 2.14) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>36<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence on the number of treatment responders who subsequently relapsed (P = 0.15). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>211 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>25 per 1000</b><br/> (2 to 451) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>211 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>25 per 1000</b><br/> (2 to 452) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.68</b> <br/> (0.21 to 13.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>96<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dropout rates due to adverse events were low in the benzodiazepine groups (2/47; 4%) and did not differ from the placebo groups (P = 0.62). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>34 per 1000</b><br/> (4 to 268) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>29 per 1000</b><br/> (4 to 223) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 61.7 to 82.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>39.75 points lower</b><br/> (71.11 lower to 8.39 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the benzodiazepine intervention groups ranged from 26.6 to 38.1 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 30.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>10.40 points lower</b> (16.08 lower to 4.72 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the benzodiazepine intervention group was 19.8 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 31.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>10.80 points lower</b> (16.62 lower to 4.98 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the benzodiazepine intervention group was 21.1 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (small sample size and wide confidence interval).<br/> <sup>d</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>e</sup>Downgraded two levels due to considerable heterogeneity (I<sup>2</sup> of 94%).<br/> <sup>f</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Comparison 5: benzodiazepines versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Comparison 6: beta‐blockers versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 6: beta‐blockers versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : inpatient and outpatient settings<br/> <b>Intervention</b> : beta‐blockers<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With beta‐blockers </b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.09</b> <br/> (0.63 to 1.88) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>97<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the beta‐blocker groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.75). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>341 per 1000</b><br/> (197 to 587) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>332 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>362 per 1000</b><br/> (209 to 624) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>c</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Comparison 6: beta‐blockers versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Comparison 7: MAOIs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 7: MAOIs versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : inpatient and outpatient settings<br/> <b>Intervention</b> : MAOIs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With MAOIs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.36</b> <br/> (1.48 to 3.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>235<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of an effect on the number of participants with SAnD who responded to treatment (P = 0.0003). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the MAOI groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>621 per 1000</b><br/> (389 to 987) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>274 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>647 per 1000</b><br/> (406 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 4.05 to 63.29</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>16.39 points lower</b><br/> (32.27 lower to 0.51 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the MAOI intervention groups ranged from 14.0 to 47.8 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 24.54</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>5.42 points lower</b><br/> (14.69 lower to 3.85 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the MAOI intervention group was 19.12 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 27.31</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>5.23 points lower</b> (13.97 lower to 3.51 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the MAOI intervention group was 22.08 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinical Global Impressions scale change item (CGI‐I)</b> :<b>no. of responders (long term)</b> </p> <p>Post‐treatment: 6 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.84</b> <br/> (1.02 to 3.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>113<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was data indicating greater efficacy over the long term on the number of participants with SAnD who responded to treatment (P = 0.04). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the MAOI groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>264 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>486 per 1000</b><br/> (269 to 880) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>263 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>484 per 1000</b><br/> (268 to 876) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to moderate heterogeneity (I<sup>2</sup> of 44%).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>d</sup>Downgraded two levels due to considerable heterogeneity (I<sup>2</sup> of 93%).<br/> <sup>e</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Comparison 7: MAOIs versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Comparison 8: NARIs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 8: NARIs versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : NARIs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With NARIs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.70</b> <br/> (0.19 to 2.54) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the NARI group compared to the placebo group who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.58). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>215 per 1000</b><br/> (58 to 782) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>308 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>216 per 1000</b><br/> (59 to 782) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.80</b> <br/> (0.12 to 63.20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Only 1 of 14 (7%) participants withdrew during 10 weeks of NARI treatment. There was no evidence for a difference in the number of participants who withdrew due to adverse events (P = 0.52). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 70.8</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>2.60 points higher</b> (15.43 lower to 20.63 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the NARI intervention group was 73.4 which suggests 'marked' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (small sample size and wide confidence interval).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (small sample size, few events and wide confidence interval).<br/> <sup>d</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Comparison 8: NARIs versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Comparison 9: NaSSAs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 9: NaSSAs compared to placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : NaSSAs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With NaSSAs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.00</b> <br/> (0.28 to 3.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>An equal number of participants (4/30, 13%) responded to treatment in both the NaSSA and placebo groups, however this difference was not statistically significant (P = 1.00). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b><br/> (37 to 484) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>133 per 1000</b><br/> (37 to 483) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 5.00</b> <br/> (0.25 to 99.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>A small proportion of participants receiving NaSSAs dropped out due to adverse events (2/30, 7%). Although, the difference was not statistically significant (P = 0.29). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b><br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 62.4 to 67.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>15.37 points lower</b><br/> (28.10 lower to 2.63 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the NaSSA intervention groups ranged from 46.3 to 54.8 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 28.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>3.90 points lower</b> (9.90 lower to 2.10 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the NaSSA intervention group was 25.0 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 33.5</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>3.70 points lower</b> (9.42 lower to 2.02 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the NaSSA intervention group was 29.8 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>d</sup>Downgraded two levels due to substantial heterogeneity (I<sup>2</sup> of 79%).<br/> <sup>e</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Comparison 9: NaSSAs versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Comparison 10: RIMAs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 10: RIMAs versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : inpatient and outpatient settings<br/> <b>Intervention</b> : RIMAs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With RIMAs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.83</b> <br/> (1.32 to 2.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1270<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of benefit on the number of participants with SAnD who responded to treatment (P = 0.0003). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the RIMA groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>254 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>465 per 1000</b><br/> (335 to 647) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>207 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>379 per 1000</b><br/> (273 to 528) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.42</b> <br/> (0.86 to 2.34) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1305<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>Dropout rates due to adverse events were low in the RIMA groups and equivalent to those observed in the placebo groups (72/83; 9%). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>69 per 1000</b><br/> (42 to 114) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>32 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>45 per 1000</b><br/> (28 to 75) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 54.4 to 79.3</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>12.17 points lower</b> (23.51 lower to 0.84 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1163<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the RIMA intervention groups ranged from 27.0 to 62.6 which suggests low to 'moderate' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 23.3 to 39.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was<br/> <b>5.05 points lower</b> (7.91 lower to 2.18 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>695<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the RIMA intervention groups ranged from 15.3 to 30.7 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 29.4 to 40.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>5.40 points lower</b> (8.92 lower to 1.88 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>724<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,e,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the RIMA intervention groups ranged from 19.1 to 33.3 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinical Global Impressions scale change item (CGI‐I): no. of responders (long term)</b> </p> <p>Post‐treatment: 1‐15 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.50</b> <br/> (1.12 to 2.00) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>90<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of a long‐term effect on treatment efficacy in participants with SAnD who responded to treatment (P = 0.006). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the RIMA group compared to the placebo group who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>575 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>862 per 1000</b><br/> (644 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>575 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>862 per 1000</b><br/> (644 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to substantial heterogeneity (I<sup>2</sup> of 70%).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>d</sup>Downgraded two levels due to considerable heterogeneity (I<sup>2</sup> of 94%).<br/> <sup>e</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>f</sup>Downgraded two levels due to moderate heterogeneity (I<sup>2</sup> of 55%).<br/> <sup>g</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Comparison 10: RIMAs versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0011"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Comparison 11: SARIs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 11: SARIs versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : SARIs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With SARIs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 71.2</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>6.10 points lower</b> (16.55 lower to 4.35 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the SARI intervention group was 65.1 which suggests 'marked' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to very serious imprecision (wide confidence interval). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 11.</span> <span class="table-title">Comparison 11: SARIs versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0012"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Comparison 12: SNRIs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 12: SNRIs compared to placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : SNRIs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With SNRIs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.30</b> <br/> (0.85 to 1.99) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1173<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the SNRI groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.22). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>374 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>486 per 1000</b><br/> (460 to 610) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>347 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>451 per 1000</b><br/> (465 to 617) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 3.23</b> <br/> (2.15 to 4.86) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1213<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The proportion of dropouts due to adverse events was more than three times as high in participants receiving SNRIs (109/663, 16%) compared to placebo (27/550, 5%), a statistically significant difference (P &lt; 0.00001). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>159 per 1000</b><br/> (106 to 239) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>49 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>158 per 1000</b><br/> (105 to 238) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from ‐22.2 to 66.0</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>11.91 points lower</b> (16.06 lower to 7.76 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>902<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the SNRI intervention groups ranged from ‐35.0 to 57.7 which suggests 'low' to 'moderate' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 32.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>4.30 points lower</b> (8.14 lower to 0.46 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the SNRI intervention group was 27.8 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 33.9</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>4.00 points lower</b> (7.68 lower to 0.32 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the SNRI intervention group was 29.9 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to considerable heterogeneity (I<sup>2</sup> of 89%).<br/> <sup>c</sup>Downgraded two levels due to very serious imprecision (wide confidence interval).<br/> <sup>d</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 12.</span> <span class="table-title">Comparison 12: SNRIs versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0013"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Comparison 13: SSRIs versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 13: SSRIs versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : inpatient and outpatient settings<br/> <b>Intervention</b> : SSRIs<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="center" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>With SSRIs</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.65</b> <br/> (1.48 to 1.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>4984<br/> (24 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,b,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence of benefit on the number of participants with SAnD who responded to treatment (P &lt; 0.00001). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the SSRI groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>317 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>523 per 1000</b><br/> (469 to 587) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>290 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>476 per 1000</b><br/> (478 to 537) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Relapse rate ‐ no. relapsed</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.34</b> <br/> (0.22 to 0.5) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>389<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>Moderate</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence that SSRIs prevented relapse compared to placebo (P &lt; 0.00001).</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>397 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>135 per 1000</b><br/> (87 to 198) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>391 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>133 per 1000</b><br/> (86 to 195) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.59</b> <br/> (1.97 to 3.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>5131<br/> (24 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The proportion of dropouts due to adverse events was approximately three times higher amongst participants receiving SSRIs compared to placebo ((P &lt; 0.00001). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>40 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>105 per 1000</b><br/> (80 to 137) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>37 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>96 per 1000</b><br/> (73 to 125) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from ‐7.8 to 69.88</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS total score) in the intervention groups was <b>10.14 points lower</b> (14.05 to 6.22 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1990<br/> (14 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the SSRI intervention groups ranged from 14.7 to 60.3 which suggests 'low' to 'moderate' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 24.2 to 34.8</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS avoidance) in the intervention groups was <b>7.01 points lower</b> (10.21 to 3.80 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1173<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS avoidance anxiety score for the SSRI intervention groups ranged from 17.09 to 26.11 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score ranged across control groups from 29.83 to 37.4</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction of anxiety symptoms (clinician‐rated: LSAS fear) in the intervention groups was <b>7.28 points lower</b> (10.86 to 3.71 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1173<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,f</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS fear anxiety score for the SSRI intervention groups ranged from 19.84 to 32.79 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Clinical Global Impressions scale change item (CGI‐I): no. of responders (long term)</b> </p> <p>Post‐treatment: 1‐4 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.27</b> <br/> (1.07 to 1.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>806<br/> (4 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>Low</b><sup>a,g</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was evidence for a response to long‐term treatment compared to placebo in participants with SAnD (P = 0.007). A RR score greater than 1 and 95% CI that does not overlap with 1 indicates that there were a statistically significantly greater number of people in the SSRI groups compared to the placebo groups who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>579 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>735 per 1000</b><br/> (619 to 874) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>584 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>742 per 1000</b><br/> (625 to 882) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (long term)</b> </p> <p>Post‐treatment: 1‐4 months</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 1.17</b> <br/> (0.43 to 3.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>1274<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>Very low</b><sup>a,h,i</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>We found no difference in dropout rates due to adverse events between the SSRI and control groups (P = 0.76). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>52 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>61 per 1000</b><br/> (23 to 166) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>50 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>58 per 1000</b><br/> (22 to 159) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI</b> : confidence interval; <b>CGI‐I</b> : Clinical Global Impressions Improvement scale; <b>LSAS</b> : Liebowitz Social Anxiety Scale;<b>RR</b>: risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality</b> : further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality</b> : further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality</b> : further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality</b>: we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup>Downgraded two levels due to moderate heterogeneity (I<sup>2</sup> of 50%).<br/> <sup>c</sup>Downgraded two levels due to very serious publication bias (t = 2.6426, df = 22, p = 0.015).<br/> <sup>d</sup>Downgraded two levels due to substantial heterogeneity (I<sup>2</sup> of 67%).<br/> <sup>e</sup>Downgraded two levels due to substantial heterogeneity (I<sup>2</sup> of 65%).<br/> <sup>f</sup>Downgraded two levels due to substantial heterogeneity (I<sup>2</sup> of 75%).<br/> <sup>g</sup>Downgraded two levels due to moderate heterogeneity (I<sup>2</sup> of 60%).<br/> <sup>h</sup>Downgraded two levels due to moderate heterogeneity (I<sup>2</sup> of 57%).<br/> <sup>i</sup>Downgraded two levels due to very serious imprecision (few events and wide confidence interval).<br/> <sup>j</sup>Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 13.</span> <span class="table-title">Comparison 13: SSRIs versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0014"> <div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Comparison 14: GW876008 versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 14: GW876008 versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : GW876008<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Comparison 14: GW876008 versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 0.83</b> <br/> (0.58 to 1.19) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>250<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the GW876008 group compared to the placebo group who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.32). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>302 per 1000</b><br/> (211 to 433) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>364 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>302 per 1000</b><br/> (211 to 433) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 2.95</b> <br/> (0.67 to 13.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>252<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>The proportion of dropouts due to adverse events was approximately three times higher amongst participants receiving GW876008 (11/164, 7%) compared to placebo (2/88, 2%), though this difference was not statistically significant (P = 0.15). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>67 per 1000</b><br/> (15 to 296) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>68 per 1000</b><br/> (15 to 299) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup> Downgraded one level due to serious imprecision (wide confidence intervals). </p> <p><sup>c</sup> Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 14.</span> <span class="table-title">Comparison 14: GW876008 versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0015"> <div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Comparison 15: NK1 receptor antagonist GR205171 versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 15: NK1 receptor antagonist GR205171 versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : NK1 receptor antagonist GR205171<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Comparison 15: NK1 receptor antagonist GR205171 versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 5</b> <br/> (0.68 to 36.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>There was no evidence of an effect on the number of participants in the NK1 receptor antagonist GR205171 group compared to the placebo group who responded 'Very Much Improved' or 'Much Improved' on the CGI‐I scale (P = 0.11). </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>417 per 1000</b><br/> (57 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>83 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>415 per 1000</b><br/> (56 to 1000) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Dropouts due to adverse events (acute phase)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No participants withdrew due to adverse events.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was 4.1</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinician‐rated: liebowitz social anxiety scale (lsas): reduction of anxiety symptoms ‐ lsas total score in the intervention groups was <b>0.5 points lower</b> (1.35 lower to 0.35 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the NK1 receptor antagonist GR205171 intervention group was 3.6 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded one level due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup> Downgraded two levels due to very serious imprecision (small sample size and wide confidence intervals). </p> <p><sup>c</sup> Response is defined as the number of participants with SAnD who responded to treatment, as assessed by the CGI‐I or similar. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 15.</span> <span class="table-title">Comparison 15: NK1 receptor antagonist GR205171 versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001206-tbl-0016"> <div class="table-heading"><span class="table-label">Summary of findings 16.</span> <span class="table-title">Comparison 16: LY686017 versus placebo for social anxiety disorder (SAnD)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Comparison 16: LY686017 versus placebo for social anxiety disorder (SAnD)</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population</b> : adults with SAnD<br/> <b>Settings</b> : outpatient settings<br/> <b>Intervention</b> : LY686017<br/> <b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Comparison 16: LY686017 versus placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean anxiety score for the control group was ‐22.59</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean clinician‐rated: liebowitz social anxiety scale (lsas): reduction of anxiety symptoms ‐ lsas total score in the intervention groups was <b>1.8 points higher</b> (6.92 lower to 10.52 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean LSAS total anxiety score for the LY686017 intervention group was ‐20.79 which suggests 'low' social phobia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup> Downgraded two levels due to serious risk of bias (concerns with randomisation procedures).<br/> <sup>b</sup> Downgraded one level due to serious imprecision (wide confidence intervals). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 16.</span> <span class="table-title">Comparison 16: LY686017 versus placebo for social anxiety disorder (SAnD)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/full#CD001206-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison 1: 5HT1A partial agonists versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 68.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 LSAS avoidance subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐11.61, 8.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐2.86, 1.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.55]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Comparison 1: 5HT1A partial agonists versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparison 2: anticonvulsants/GABAs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.16, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [0.92, 9.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.5 [‐25.20, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 LSAS avoidance subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.60 [‐11.88, 2.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 LSAS fear subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.90 [‐13.65, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.3 [‐4.78, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.78, 1.70]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Comparison 2: anticonvulsants/GABAs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Comparison 3: anticonvulsant levetiracetam versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.70, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.81, 4.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.24 [‐15.69, 15.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 LSAS avoidance subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐9.15 [‐26.86, 8.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 LSAS fear subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.71 [‐26.02, 8.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>212</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐1.33, 1.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.30, 6.76]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Comparison 3: anticonvulsant levetiracetam versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Comparison 4: antipsychotics versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.45, 108.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.06, 8.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐37.8 [‐74.22, ‐1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.27, 4.23]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Comparison 4: antipsychotics versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Comparison 5: benzodiazepines versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.03 [2.45, 6.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Relapse rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 No. relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 2.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.21, 13.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐39.75 [‐71.11, ‐8.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 LSAS avoidance subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.40 [‐16.08, ‐4.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 LSAS fear subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.80 [‐16.62, ‐4.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐3.96, 0.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Reduction of functional disability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Work subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.58 [‐6.39, ‐0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Social subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.31 [‐3.79, ‐0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Family subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>135</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.02 [‐4.26, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.41, 1.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Comparison 5: benzodiazepines versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Comparison 6: beta‐blockers versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.63, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.82 [‐1.38, 5.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Reduction of functional disability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Work subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐1.80, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Social subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐1.71, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Family subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐1.74, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.36 [0.41, 27.80]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Comparison 6: beta‐blockers versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Comparison 7: MAOIs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.36 [1.48, 3.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>218</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐16.39 [‐32.27, ‐0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 LSAS avoidance subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.42 [‐14.69, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 LSAS fear subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.23 [‐13.97, 3.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐1.11, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Reduction of functional disability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Work subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.84 [‐4.40, ‐1.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Social subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.26 [‐7.25, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Family subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐5.34, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.71, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Clinical Global Impressions scale change item (CGI‐I) (long term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>113</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [1.02, 3.33]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Comparison 7: MAOIs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Comparison 8: NARIs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.19, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.8 [0.12, 63.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [‐15.43, 20.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐2.73, 2.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.23, 3.81]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Comparison 8: NARIs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Comparison 9: NaSSAs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.28, 3.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 99.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐15.37 [‐28.10, ‐2.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 LSAS avoidance subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.90 [‐9.90, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 LSAS fear subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.70 [‐9.42, 2.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 20.90]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Comparison 9: NaSSAs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Comparison 10: RIMAs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.32, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.86, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐12.17 [‐23.51, ‐0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 LSAS avoidance subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>695</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.05 [‐7.91, ‐2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 LSAS fear subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>724</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.40 [‐8.92, ‐1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.28 [‐0.55, ‐0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Reduction of functional disability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Work subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.61 [‐1.89, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Social subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.14 [‐2.32, 0.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Family subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>660</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐1.45, 0.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.60, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Clinical Global Impressions ‐ Improvement (CGI‐I) (long term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.12, 2.00]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Comparison 10: RIMAs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Comparison 11: SARIs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.10 [‐16.55, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [‐2.10, 3.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Reduction of functional disability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Work subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.87, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Social subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐1.97, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Family subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.06, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.97, 4.92]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Comparison 11: SARIs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Comparison 12: SNRIs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.85, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.23 [2.15, 4.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>902</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐11.91 [‐16.06, ‐7.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 LSAS avoidance subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.30 [‐8.14, ‐0.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 LSAS fear subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>261</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐7.68, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Comparison 12: SNRIs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Comparison 13: SSRIs versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4984</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.48, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Relapse rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 No. relapsed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.22, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.59 [1.97, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1990</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐10.14 [‐14.05, ‐6.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 LSAS avoidance subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.01 [‐10.21, ‐3.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 LSAS fear subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.28 [‐10.86, ‐3.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Clinician‐rated: Hamilton Depression scale (HAM‐D) (or similar scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Reduction of depression symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>960</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.48, ‐0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Reduction of functional disability <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Work subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.81 [‐1.18, ‐0.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Social subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.87 [‐1.26, ‐0.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Family subscale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>854</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.75, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5208</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.90, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Clinical Global Impressions scale change item (CGI‐I) (long term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>806</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [1.07, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Adverse events (long term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.43, 3.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 All‐cause dropouts (long term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.37, 2.70]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Comparison 13: SSRIs versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Comparison 14: GW876008 versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.58, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [0.67, 13.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.50, 1.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Comparison 14: GW876008 versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Comparison 15: NK1 receptor antagonist GR205171 versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 No. of responders</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.68, 36.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐1.35, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 All‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Dropout rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Comparison 15: NK1 receptor antagonist GR205171 versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Comparison 16: LY686017 versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinician‐rated: Liebowitz Social Anxiety Scale (LSAS): reduction of anxiety symptoms <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 LSAS total score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [‐6.92, 10.52]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Comparison 16: LY686017 versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Comparison 17: total effect of medication compared to placebo for the treatment of SAnD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar) scale: no. of responders (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 5HT1A partial agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.07, 14.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Anticonvulsants/GABAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.16, 2.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Anticonvulsant levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.70, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.45, 108.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 Benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>132</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.03 [2.45, 6.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 Beta‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.63, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 MAOIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.37 [1.26, 4.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 NARIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.19, 2.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.9 NaSSAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.0 [0.28, 3.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.10 RIMAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.32, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.11 SNRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.30 [0.85, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.12 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4553</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.46, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.13 NK1 receptor antagonist GR205171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.68, 36.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.14 GW876008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.58, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Dropout rate: adverse events (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 5HT1A partial agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 68.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Anticonvulsants/GABAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>532</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [0.92, 9.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Anticonvulsant levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [0.81, 4.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.06, 8.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 Benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.68 [0.21, 13.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 NARIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.8 [0.12, 63.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 NaSSAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.0 [0.25, 99.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 RIMAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1305</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.86, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9 SNRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.23 [2.15, 4.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4965</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.56 [1.94, 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11 NK1 receptor antagonist GR205171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.12 GW876008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.95 [0.67, 13.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Dropout rate: all‐cause dropouts (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 5HT1A partial agonists</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.01, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Anticonvulsants/GABAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.78, 1.70]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Anticonvulsant levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [0.30, 6.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.27, 4.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.41, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.6 Beta‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.36 [0.41, 27.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.7 MAOIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.33 [0.71, 2.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.8 NARIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.23, 3.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.9 NaSSAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.19, 20.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.10 RIMAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>512</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.60, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.11 SARIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>105</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.18 [0.97, 4.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.12 SNRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.13 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5078</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.01 [0.89, 1.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.14 NK1 receptor antagonist GR205171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.15 GW876008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.50, 1.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Comparison 17: total effect of medication compared to placebo for the treatment of SAnD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Subgroup analysis: multicentre versus single‐centre trials</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale: no. of responders (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Single‐centre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [1.67, 3.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Multicentre</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>8274</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [1.34, 1.62]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Subgroup analysis: multicentre versus single‐centre trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Subgroup analysis: generalised SAnD compared to inclusive SAnD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale: no. of responders (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5522</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [1.31, 1.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Inclusive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3712</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.83 [1.54, 2.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Subgroup analysis: generalised SAnD compared to inclusive SAnD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Subgroup analysis: industry funding compared to no industry funding</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale: no. of responders (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6643</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.44, 1.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Non‐industry funded trials</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [1.43, 2.77]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Subgroup analysis: industry funding compared to no industry funding</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Subgroup analysis: trials that included MDD compared to no MDD</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Clinical Global Impressions ‐ Improvement (CGI‐I) or similar scale: no. of responders (acute phase) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Trials including MDD participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.77 [1.44, 2.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Trials excluding MDD participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6765</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.35, 1.70]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Subgroup analysis: trials that included MDD compared to no MDD</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0037">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001206-tbl-0038"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Worst case versus best case: support for robustness of evidence</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 'Worst case' lost‐to‐follow‐up analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Anticonvulsant levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>235</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.70, 1.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.25 [0.33, 83.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.82 [1.92, 7.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4 Beta‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.47, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.5 RIMAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.01 [1.95, 4.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6 SNRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>934</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [1.36, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3753</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.61 [1.44, 1.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8 GW876008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.57, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 'Best case' lost‐to‐follow‐up analysis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Anticonvulsant levetiracetam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.70, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Antipsychotics</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.0 [0.45, 108.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Benzodiazepines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.92 [1.98, 7.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Beta‐blockers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.55, 2.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5 RIMAs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.97 [1.93, 4.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6 SNRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>912</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.63 [1.39, 1.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7 SSRIs</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3577</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [1.46, 1.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8 GW876008</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.58, 1.19]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Worst case versus best case: support for robustness of evidence</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001206.pub3/references#CD001206-tbl-0038">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001206.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001206-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001206-note-0027">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001206-note-0025">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001206-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD001206-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pt#CD001206-note-0001">Português</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001206-note-0026">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001206\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001206\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001206\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001206\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001206\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001206.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001206.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001206.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001206.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001206.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714646780"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001206.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714646785"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001206.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d73c07d6f937f',t:'MTc0MDcxNDY0Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 